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The dopamine D2 receptor (D2R) is a G protein-coupled receptor (GPCR) that is the 
primary target of drugs treating the symptoms of Parkinson’s disease and schizophrenia. 
However, drugs acting at the D2R to manage these diseases often display efficacy for only a 
subset of their symptoms and have poor side effect profiles. Therefore, it is desirable to 
rationally design drugs that better manage disease symptoms and reduce side effects. This 
would be greatly aided by gaining a detailed understanding of the kinetic aspects of D2R ligand 
binding, signalling, regulation and trafficking. 
Differences in binding kinetics at the D2R results in varying side effect profiles between 
antipsychotics. In chapter 2, a time resolved-fluorescence resonance energy transfer 
competition kinetic ligand binding assay is optimised at the D2R. The assay is used in 
combination with D2R mutants to determine the contribution of selected residues in the 
extracellular regions of the D2R in modulating binding kinetic association and dissociation 
rates. Findings showed that different residues in this region are important determinants of 
binding kinetics in a ligand-dependent manner.   
Some agonists with slow dissociation rates have been shown to display apparent biased 
agonism at the D2R. In chapter 3, it is investigated whether the length of time an agonist binds 
the D2R influences observations of biased agonism. Within the selected panel of ligands, for 
which both binding kinetic rates and functional effects were determined, no clear relationship 
between agonist dissociation rate and apparent biased agonism could be established. 
D2R G protein signalling is regulated through phosphorylation by G protein receptor 
kinases (GRKs). In chapter 4, antibodies specific for GRK2/3 phosphorylation sites on the D2R 
were generated and characterised. A GRK2/3 phosphorylation site within intracellular loop 3 
was identified that is phosphorylated on agonist activation of the D2R.  Phosphorylation of this 
site predicts arrestin recruitment. Measurements of D2R phosphorylation were included with 
other measurements of G protein activation and receptor regulation to profile selected D2R 
agonists. 
The D2R can couple pleiotropically to G proteins of the Gαio subfamily. In chapter 5 
the kinetics of D2R mediated activation of individual Gαi/o protein subtypes was investigated. 
Increases in agonist potency were observed when the D2R activated Gαz. This was shown to 




mutation of serine 42 within the GTP binding site or co-expression with regulator of G protein 
signalling 20. 
Investigating GPCR and D2R biased agonism in the relevant cell type has been 
challenging due to the lack of molecular tools. A useful method for interrogating GPCR 
signalling functions is using bacterially derived toxins, such as pertussis toxin, to inhibit their 
coupling and then evaluate the downstream changes. In chapter 6 we developed a new pertussis 
toxin-like protein tool that can inhibit all of the Gαi/o subfamily, including Gαz. Ga subunits 
that are insensitive to the toxin were characterised to serve as tools in combination with the 
toxin.  
Finally, chapter 7 discusses the key implications of the findings in the context of the 













Publications during enrolment 
 
 
Klein Herenbrink, C., Verma, R., Lim, H. D., Kopinathan, A., Keen, A. C., Shonberg, J., 
Draper-Joyce, C. J., Scammells, P. J., Christopoulos, A., Javitch, J. A., Capuano, B., Shi, L., 
and Lane, J. R. (2019) Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic 
Aripiprazole. ACS Chemical Biology 14, 1780-1792 
 
 
Lane, J. R., Abramyan, A. M., Adhikari, P., Keen, A. C., Lee, K.-H., Sanchez, J., Verma, R. 
K., Lim, H. D., Yano, H., and Javitch, J. A. (2020) Distinct inactive conformations of the 









Thesis including published works declaration 
I hereby declare that this thesis contains no material which has been accepted for the award of 
any other degree or diploma at any university or equivalent institution and that, to the best of 
my knowledge and belief, this thesis contains no material previously published or written by 
another person, except where due reference is made in the text of the thesis.  
 
This thesis includes no original papers published in peer reviewed journals and one submitted 
publications. The core theme of the thesis is dopamine D2 receptor molecular pharmacology. 
The ideas, development and writing up of all the papers in the thesis were the principal 
responsibility of myself, the student, working within Drug Discovery Biology under the 
supervision of A/Prof. J. Robert Lane, Prof. Steven Charlton & Dr. Daniel Scott. 
  
The inclusion of co-authors reflects the fact that the work came from active collaboration 
between researchers and acknowledges input into team-based research. 
 
























unravel the role 
of GRK 
phosphorylation 

















data, wrote manuscript 
– 12.5% 
HM acquired data - 
2% 
PD acquired data, 
analysed data - 2% 
JAJ reviewed and 
edited manuscript - 
1% 
MC reviewed and 



















      
      





I have renumbered sections of submitted or published papers in order to generate a consistent 
presentation within the thesis. 
 
Student name: Alastair Charles Keen 
 
Student signature:         Date: 14/5/2020   
 
I hereby certify that the above declaration correctly reflects the nature and extent of the 
student’s and co-authors’ contributions to this work. In instances where I am not the responsible 
author I have consulted with the responsible author to agree on the respective contributions of 
the authors.  
 
Main Supervisor name: Dr. Daniel J. Scott 
 









To my primary supervisor A/Prof. J. Robert Lane, thank you so much for your consistent 
intellectual mentorship throughout the whole PhD - even when in different countries. I also 
have appreciated your kindness and the fact that you ask awesome scientific questions. 
 
To my co-supervisors Dr. Daniel J. Scott and Prof. Steven J. Charlton, thank you for your 
huge commitment and enduring support. 
 
I would like to thank my panel members, Prof. Meritxell Canals, Dr. Michelle Halls, Prof. 
MacDonald Christie and Dr. Angus Johnston, for practical advice and engaging questions at 
the many panel meetings. 
 
I greatly appreciate all our collaborators; this would never have been done without all of you. 
Dr. David Sykes for acquiring some the kinetic binding data in chapter 3. Prof. Stefan Schultz 
and his laboratory members for their expertise and data in the phosphorylation site antibody 
manuscript in chapter 4. Dr. Benjamin Capuano, Dr. Anita Yates and Dr. Timothy Fyfe for 
their insight in laboratory meetings and synthesis of compounds. I would also like to 
acknowledge Prof. Jonathan Javitch and Dr. Maria Hauge Pederson for experiments and 
guidance in chapter 6. Prof. Lei Shi for molecular modelling and discussions.  
 
I would like to acknowledge the past and present members of my immediate laboratory, Dr. 
Herman Lim, Dr. Chris Draper-Joyce, Dr. Carmen Klein-Herenbrink, Dr. Arisbel Batista 
Gondin, Dr. Julie Sanchez, Dr. Amy Chen, Dr. Srgjan Chivchiristov. Each one of these 
people have helped me tremendously both directly in laboratory techniques as well as in 
developing general research ideas. 
 
I would like to acknowledge the wider drug discovery biology colleagues and friends. Dr. 
Quynh Mai, Dr. Alice Berizzi, Dr. Eevon Moo, Dr. Sheng Yu Ang, Dr. Saori Mukaida, 
Lachlan Chlydesdale, Dr. Thomas Coudrat, Dr. Pradeep Rajeskhar, Samantha McNeill and 
the Neurogenic Mechanisms laboratory group for being great companions in this journey. 
 
I would like to acknowledge the Nottingham Cell Signalling group. Dr. Elizabeth 
Rosethorne, Dr. Maxine Roberts, Jack Lochray, Desislava Nesheva, Nicola Dijon, Dr. Chloe 
Peach, Hannah Comfort, Charles Lay, Lydia Ogrodzinski, Edward Wragg, Dr. Nick Holliday, 
Dr. Laura Kilpatrick, Dr. Mark Soave, Dr. Joelle Goulding, Prof. Steve Hill for taking me in 
and keeping my morale high all the time! 
 
The people from the Florey institute when I conducted my honours year. I have you all to 
thank for getting me started on this great journey. Prof. Ross Bathgate, Dr. Bradley Hoare, 
Dr. Kelvin Yong, Dr. Fabian Bumbak, Sharan Layfield, Tania Ferraro, Riley Cridge and Dr. 
Nick Smith.  
 
I wish to acknowledge the Wurundjeri people, the traditional custodians of the land where I 
was able to do most of my fun experiments. 
 
Finally, I would like to thank my family and friends for your support through the last four 
















β2AR – β2 adrenergic receptor 
ANOVA – analysis of variance 
ADP – adenosine diphosphate 
ACTH – adrenocorticotropic hormone 
AP-2 – adaptor protein-2 
AT1R – Angiotensin II receptor 1  
ATP – adenosine triphosphate 
BRET – bioluminescence resonance energy transfer 
cAMP – cyclic adenosine monophosphate 
CAMYEL – cAMP sensor using YFP-Epac-RLuc 
CTX – Cholera toxin 
D2R – dopamine D2 receptor 
DA - dopamine 
DAMGO - (ᴅ-Ala2, N-Me-Phe4, Gly-ol5)-enkephalin 
DNA – deoxyribonucleic acid 
DMEM – Dulbecco’s modified eagle medium 
EL/ECL – extracellular loop 
ETAR – endothelin A receptor 
FBS – Foetal bovine serum  
FSK – forskolin 
GAP – GTPase activating protein 
G protein – heterotrimeric GTP binding protein 
GDP – guanosine diphosphate 
GEF – guanine nucleotide exchange factor 
GIRK – G protein-coupled inwardly rectifying potassium channel 
GPCR – G protein coupled receptor 
GRK – G protein-protein coupled receptor kinase 
GTP – guanosine triphosphate 
HEK – human embryonic kidney 




IL/ICL – intracellular loop 
M2R – muscarinic acetylcholine receptor 2 
MAP – mitogen activated protein 
MOPR – µ opioid receptor 
NLuc – Nano-luciferase 
NT8-13 – neurotensin peptide residues 8 to 13 
NTS1R – neurotensin receptor 1 
OZITX – Gαo, Gαz and Gαi inhibiting toxin 
PBS – phosphate buffered saline 
PEI – polyethylenimine 
PTX – pertussis toxin 
RGS – regulator of G protein signalling 
RLuc – Renilla luciferase 
RNA – ribonucleic acid 
SEM – standard error from the mean 
TM – transmembrane domain 
TR-FRET – time-resolved fluorescence resonance energy transfer 








Chapter 1 – General introduction 
18 
 
1.1 G protein-coupled receptors 
1.1.1 GPCR classification and architecture 
G protein coupled receptors (GPCRs) are integral membrane proteins consisting of 
seven α-helical transmembrane domains (TMs) connected by three intracellular loops (ICL1-
3) and three extracellular loops (ECL1-3). The topology of GPCRs is such that the amino-
terminus is directed into the extracellular space and the transmembrane domains snake through 
the membrane with the carboxy-terminus oriented into the cytosol (1). GPCRs are generally 
localised to the cell surface where they serve as the main mechanism for mammals to carry 
extracellular messages across the plasma membrane and into the cell. GPCRs do this by being 
activated by diverse agonists, including neurotransmitters, peptides, hormones or light photons 
in the case of the GPCR rhodopsin, and subsequently transducing signals intracellularly via 
coupling to heterotrimeric GTP-binding (G) proteins. Due to this ability, GPCRs are harnessed 
as the targets of around 30% of currently approved therapeutics (2).  
GPCRs represent one of the largest protein superfamilies encoding over 800 different 
human proteins (3). They are classified phylogenetically into five major families that are the 
rhodopsin, secretin, adhesion, glutamate and frizzled/taste2 families (Fig.1.1) (4). Each of the 
GPCRs share common characteristics and structural features within their respective families. 
The rhodopsin family are the largest family of GPCRs within the human genome. Being the 
largest family of GPCRs, most approved GPCR drugs target the rhodopsin family (5). This 
family is generally identified by having a ligand binding site located within the TMs to bind 
small neurotransmitters or peptides (Fig. 1.1). Moreover, there are fifteen members of the 
secretin family and these can be defined by their extracellular hormone binding domain of 
around 70 amino acid residues (Fig. 1.1) (5). The secretin family GPCRs use their hormone 
binding domain to bind different agonist polypeptides such as parathyroid hormone (PTH), 
calcitonin and vasoactive intestinal polypeptide (VIP). The adhesion family earn their name by 
often binding molecules in the extracellular matrix appearing to play an adhesive role. Due to 
these functions, they usually have very long and richly glycosylated amino-termini. In addition, 
they are distinguished by a GPCR proteolytic site (GPS) motif as well as often containing 
several other common protein domains within their amino-terminus (4). The glutamate family 
differ from other GPCR families by their amino-terminal venus flytrap domain that is used to 
bind agonists and translate the signal through their cysteine-rich domain into the TMs (6). 
Another characteristic of the glutamate family is their quaternary structure as obligate dimers 
(Fig 1.1) (6). The frizzled/taste2 family consist of the smoothened receptor, the frizzed 
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receptors activated by their Wnt glycoprotein agonists and important in development, and the 
taste 2 subfamily of receptors that widely function as bitter taste receptors (5). 
 
 
Figure 1.1: Structural differences between GPCR classes.  
 
1.1.2 GPCR signalling 
Activation of a GPCR by an agonist results in a conformational change in the TM 
bundle. The most noticeable structural change upon GPCR activation is the outward movement 
of intracellular end of TM VI (Fig. 1.2A & B). TM V also moves in concert with TMVI as well 
as smaller changes and rotations in the other TMs, resulting in an opening of the intracellular 
TM core of the GPCR (7). This then permits coupling of heterotrimeric G proteins (G proteins). 
G proteins are comprised of a Gα subunit that binds guanine nucleotides and a Gβ and Gγ 
subunit that function together as a single entity. The Gα subunit is composed of an α-helical 
domain and a ras-like domain whereas the Gβ subunit contains a β-propeller domain (Fig. 
1.2B). Upon coupling, the G protein makes key interactions with the Gα’s carboxy-terminal α5 
helix extending into the intracellular TM core of the GPCR (Fig. 1.2B) (8,9). Having bound a 
heterotrimeric G protein, the GPCR then has the function of a guanine nucleotide exchange 
factor (GEF) acting on the Gα subunit of the G protein whereby the Gα subunit exchanges its 
bound guanine diphosphate (GDP) for guanine triphosphate (GTP) (Fig. 1.3). This results in 
the Gα subunit transitioning to an active conformation which dissociates from, or rearranges 
relative to, the Gβγ complex (10,11). Once active, the Gα subunit and Gβγ complex can then 
further activate downstream signalling cascades. When the G protein subunits dissociate to 
bind downstream effectors, they allow access for other heterotrimeric G proteins to the active 
GPCR again which can be activated. Furthermore, the Gα subunit has native GTPase activity 
that permits the Gα subunit to exist in an active conformation for an amount of time before its 
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GTP is hydrolysed back to GDP (Fig. 1.3). Thus, the now-inactive Gα subunit is capable of re-
associating with free Gβγ complexes. This means that the G protein heterotrimer is re-formed 
and can bind again to the active GPCR to start the signalling cycle again (for review see (12)). 
Furthermore, the G protein cycle can be accelerated by regulators of G protein signalling (RGS) 
proteins that as GTPase activating proteins (GAPs) on the active Gα subunit to increase the 
rate of GTP-hydrolysis (13). 
 
Figure 1.2: Atomic structures of an inactive GPCR, an active G protein-bound GPCR 
and an arrestin-bound GPCR. (A) Inactive structure of a GPCR – the M2R. The bottom of 
transmembrane helix VI is positioned in towards the centre of the protein occluding effector 
coupling. (PDB code: 3UON) (B) Active structure of a GPCR (the M2R) bound to a G protein 
heterotrimer. TM VI moves outwards (black arrow) upon activation, opening the intracellular 
side of the receptor. The α5 helix of the Gα subunit interacts with the intracellular core of the 
transmembrane domains of the GPCR. The M2R is bound to GαoAβ1γ2. (PDB code: 6OIK). (C) 
Active structure of the M2R bound to β arrestin-1.  TM VI is rotated outwards relative to the 
inactive structure (black arrow). The finger loop of the arrestin protein engages the intracellular 
core of the transmembrane domains of the GPCR. (PDB code: 6U1N). M2R is shown in blue 
cartoons, GαoA is shown in green cartoons, Gβ1 is shown in orange cartoons, Gγ2 is shown in 
red cartoons and β arrestin-1 is shown in purple cartoons. 
 
 




Figure 1.3: Schematic of the G protein cycle. An agonist binds and activates a GPCR. The 
active GPCR can then bind a heterotrimeric G protein. The heterotrimeric G protein consists 
of a Gβγ dimer subunit and Gα subunit that binds guanine nucleotides. The G protein is initially 
in its inactive conformation and bound to GDP. Upon G protein coupling, the GPCR promotes 
the exchange of the bound GDP for GTP and also permits the separation, or rearrangement, 
of the active GTP bound Gα subunit and the Gβγ subunit. The G protein signalling is then 
terminated when the active Gα subunit hydrolyses its GTP back to GDP and the inactive GDP 
bound Gα subunit re-associates with Gβγ. The cycle can then begin again by the inactive 
heterotrimeric G protein recoupling to the GPCR.  
 
There are a huge variety of possible heterotrimeric G protein combinations as there are 
sixteen different Gα subunits, six different Gβ subunits and twelve different Gγ subunits 
encoded in the human genome (14). The different Gα subunits are categorised into four 
subfamilies (Gαi/o, Gαs/olf, Gαq/11 and Gα12/13) and each subfamily often activates the same 
secondary messengers. The Gαs/olf subfamily activates adenylate cyclases that catalyse the 
production of cyclic adenosine monophosphate (cAMP), Gαi/o subunits inhibit adenylate 
cyclase activation which results in a reduction in cytosolic cAMP (15), an activated Gαq/11 
subunit binds to phospholipase C-β leading to an increase in intracellular Ca2+ levels (16) and 
Gα12/13 subunits cause activation of Rho guanine nucleotide exchange factors (RhoGEFs) 
which activate RhoA (17). The Gαi/o subfamily is the largest Gα subfamily, consisting of Gαi1, 
Gαi2, Gαi3, Gαo, Gαz and also the taste and visual Gα subunits; Gαgust, Gαt1 and Gαt2 (18). 
Members within the Gαi/o subfamily can be ADP-ribosylated by pertussis toxin rendering them 
unable to couple to GPCRs. However, it should be noted that Gαz is insensitive to PTX as it 
lacks the conserved cysteine substrate site (19). Moreover, after G protein activation the Gβγ 
subunit is also capable of acting on downstream effectors. For example, different Gβγ subunits 
can modulate voltage-gated calcium channels, G protein coupled inwardly rectifying potassium 
(GIRK) channels and particular adenylate cyclases (14), Overall, the specificity of a GPCR for 
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different G proteins will determine the G proteins that are activated and hence the downstream 
responses that are mediated within the cell. 
 
1.1.3 GPCR regulation and G protein independent signalling 
Once GPCRs are activated, numerous proteins are involved in regulating a GPCR’s 
signalling response over time and within distinct intracellular domains. After having coupled 
to G proteins, many GPCRs are phosphorylated on the carboxy-terminal tail or ICL3 by a 
family of serine/threonine kinases called G protein-coupled receptor kinases (GRKs) (Fig. 1.3A 
& B). There are a total of seven GRKs (GRK1-7) in the human genome with GRK2 and 3 being 
the most widely expressed in the body (20). Other serine/threonine kinases such as protein 
kinase C (PKC) can also phosphorylate some GPCRs to regulate their function.  Following 
binding and phosphorylation by a GRK, the negatively charged phosphorylation sites on the 
GPCR can be recognised by members from the arrestin family, that comprises β-arrestin-1 
(arrestin-2), β-arrestin-2 (arrestin-3) and also the visual arrestins, arrestin-1 and arrestin-4. (Fig. 
1.3C). Arrestins are structurally characterised by two domains, each containing seven β-strands 
that form curved lobes (Fig. 1.2C) (21). When arrestins are initially recruited, the 
phosphorylated carboxy-tail of the GPCR binds to a crevice within the curved amino-terminal 
domain of the arrestin. Subsequently, arrestins compete with G proteins by binding via their 
finger loop to an overlapping site located within the intracellular side of the GPCR’s TM bundle 
(Fig 1.2C) (22,23). It is through this competition and steric occlusion of G proteins that β-
arrestins earned their name on account of the initial discovery in their ability to arrest the 
signalling of the β2-adrenergic receptor (β2AR) (24). Furthermore, having bound to the GPCR, 
arrestins can serve as recruiters of the adapter protein AP-2 which can then allow access of 
clathrin to mediate budding of a clathrin-coated pit (25,26). Subsequently, dynamin is recruited 
to enable endocytosis of the GPCR by “pinching off” the clathrin coated pit from the plasma 
membrane to form an endocytic vesicle. Following this, GPCRs generally follow two distinct 
pathways: GPCRs can be trafficked from early endosomes into late endosomes and then 
lysosomes where they are degraded, or, GPCRs can enter recycling endosomes where they are 
trafficked back to the cell surface (27). While the former trafficking pathway leads to a 
sustained termination of the GPCR signal until new protein is translated, the latter trafficking 
pathway is important for rapid re-sensitisation of the GPCR. 
 




Figure 1.3: Arrestin mediated endocytosis of GPCRs. (A) GPCRs are activated upon 
agonist binding permitting their coupling to heterotrimeric G proteins producing a 
downstream signalling response. (B) GPCRs are then phosphorylated on their intracellular 
loops and carboxy-tail by GRKs. (C) Phosphorylation by GRKs allows recruitment of 
arrestins to the intracellular side that sterically hinder the coupling of G proteins. (D) 
Arrestins then allow the recruitment of the adaptor protein-2 (AP-2) followed by clathrin and 
dynamin which enable endocytosis of the GPCR. (E) GPCRs are then internalised into 
endosomes where they are either recycled back to the cell surface or it trafficked into 
lysosomes where they are degraded. 
 
GPCR trafficking is generally associated with desensitisation or re-sensitisation, 
however, trafficking can also be employed by the cell to elicit the desired signalling outcome. 
It is now appreciated that GPCRs can be trafficked to particular endocytic compartments where 
they can continue to signal from after having internalised. These observations have brought 
about the area of compartmentalised signalling at GPCRs whereby different responses may be 
elicited from a GPCR depending on the cellular localisation of the GPCR. Such 
compartmentalised signalling has been heavily investigated in regions such as endosomes, 
specific membrane microdomains and the nucleus (28-30).  
Of the different non-canonical intracellular signalling compartments, endosomes are 
the most well appreciated compartment to mediate the signalling of GPCRs. Some of the first 
evidence of endosomal G protein signalling came from observations of prolonged G protein 
dependent responses from the sphingosine-1 phosphate (S1P1) receptor, parathyroid hormone 
(PTH1) receptor and thyrotropin (TSH) receptor  (31-33). The prolonged responses mediated 
by these GPCRs were either sustained or only partially reversed after agonist washout or 
addition of a competing antagonist. Importantly, it was shown that G protein responses could 
be abolished using inhibitors of endocytosis (32). Indicating that agonist internalised GPCRs 
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can mediate responses and hence that GPCRs can have additional G protein signalling waves 
after their initial acute plasma membrane localised signalling. Furthermore, direct visual 
evidence of active GPCRs in internal endomembrane compartments has also been confirmed. 
To demonstrate this, researchers made use of nanobodies that were initially developed to 
stabilise active conformations of GPCRs for structural studies and repurposed these into 
biosensors. By tagging these different biosensors with GFP, they were able to sense the active 
state of GPCRs in live cells via fluorescence microscopy. It could be observed upon agonist 
addition that β2AR can be activated in endosomes, and, using a different nanobody, that the µ 
opioid receptor (MOPR) can be activated on endosomes and the golgi apparatus (29,34). 
Upon activation, GPCRs can also couple to other proteins to initiate G protein 
independent signalling. Some of the most intensely studied proteins involved in G protein 
independent signalling are arrestins. Once arrestins have recruited and activated, they are 
thought to be capable of scaffolding to enhance existing signalling processes or, potentially, to 
mediate their own signalling events (35,36). This arrestin-dependent signalling may often occur 
from internal endocytic compartments. Arrestins can act as signalling scaffolds to recruit and 
activate several proteins such as mitogen activated protein (MAP) kinases including 
extracellular signal related kinase (ERK) 1/2 and c-Jun N-terminal kinases (JNKs) (37). There 
are now known to be over one hundred different proteins that can interact with the non-visual 
arrestins, many of which are known cellular signalling transducers (38). Moreover, GRKs are 
activated by GPCRs and can serve as signalling molecules eliciting further effects (39). In 
addition to kinase domains, GRKs possess other domains to elicit or modify signalling. For 
example, the GRK2/3 family contain an RGS domain and pleckstrin homology (PH) domain 
that can modulate Gαq subunits and Gβγ respectively (39). 
GPCRs can exist in pre-formed complexes with scaffolding proteins and effector 
proteins, termed signallosomes, that are primed to elicit a response to an agonist. Some of the 
first evidence of GPCRs existing in a signallosome was as early as 1978 suggesting GPCR can 
complex with adenylate cyclase (40). Such signallosomes have been extensively studied at 
several GPCRs such as the dopamine D4 receptor (D4R) and the relaxin family peptide receptor 
1 (RXFP1) (41,42). There is also increasing documentation of the propensity of GPCRs to form 
homodimers, including at the dopamine D2 receptor (D2R) (43,44). GPCRs may also form 
heterodimers with other GPCRs. One of the most well studied class A GPCR heterodimers to 
date is the canonical D2R dimer consisting of the D2R and the adenosine A2A receptor (A2AR). 
Multiple levels of experimental evidence support the idea of D2R-A2AR heterodimers. Early 
work showed that activation of the A2AR modulates the affinity of ligands at the D2R; indicating 
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allosteric interactions between the two receptors (45). Subsequently, biophysical studies using 
FRET and BRET techniques further supported the existence of D2R-A2AR dimers (46). Ex vivo 
and in vivo studies have also confirmed both the presence and the functional role of D2R-A2AR 
dimers in the striatum (47,48). In addition, there has been a considerable amount of research 
into the existence and functional importance of D2R - neurotensin receptor 1 (NTS1R) 
heterodimers as well as D2R – dopamine D1 receptor (D1R) heterodimers (49-51).  
 
1.2 Ligand binding kinetics at GPCRs 
1.2.1 The importance of ligand binding kinetics 
Ligands binding a protein, such as a GPCR, have an association rate and a dissociation 
rate for the protein that are denoted kon (M-1 s-1) and koff (s-1) respectively. These two rates at 
equilibrium determine the binding affinity of the ligand for the protein, which is given by the 





   , (𝑛𝑀) 
This is the concentration of the ligand required to occupy half of the proteins (GPCRs) 
at equilibrium. Pharmacologists often use this number when describing the avidity with which 
a ligand binds to a GPCR. This is important as the affinity of a ligand lead is often increased 
through medicinal chemistry in the drug discovery process because a consequential potency 
increase in vivo is predicted. This process is commonly referred to as determining structure-
activity relationships (SAR). However, the affinity (or dissociation constant (Kd)) may be a 
poor predictor of drug action as the concentration in vivo will be in a constant flux governed 
by processes such as dosing regime, hepatic clearance and membrane absorption. Hence, the 
drug is unlikely to reach equilibrium in the target tissue or compartment (52). Therefore, a 
drug’s kinetic binding rate parameters may better predict it’s in vivo activity. Indeed, both the 
association rate and dissociation rate can shape the pharmacodynamics and micro-
pharmacokinetics of the drug (53-57).  
The dissociation rate is important as it determines the lifetime of the ligand-GPCR 
complex. The lifetime of the ligand-GPCR complex can also be termed the residence time (RT) 
of the ligand for the protein, (58) which is given by:  
(1.2) 
𝑅𝑇 =  
1
𝑘
   , (𝑠) 
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This measure is useful as a drug only elicits its effects when bound to the GPCR. The 
residence time can also be expressed as the half-life of the ligand-receptor complex (t1/2) which 
is given by ln2/koff. As mentioned above, the residence time or t1/2 may be a better predictor of 
in vivo drug efficacy. This is because at non-equilibrium conditions such as when drugs are 
rapidly cleared in the body, a drug’s action may be prolonged by having a long residence time. 
In agreement with this, the prolonged duration of action of candesartan at the angiotensin II 
receptor 1 (AT1R) is thought to be due to its slow dissociation from the receptor (59). Similarly, 
slow dissociation, or prolonged residence, time may sometimes  contribute to the sustained 
signalling of a agonists acting at their receptors (60).  
The ligand association rate is also an equally important consideration in lead 
optimisation. The association rate can contribute to rebinding, where rebinding is the ability of 
a ligand to remain in a close vicinity with the GPCR after having dissociated such that it cannot 
escape and therefore is more likely to re-associate with the receptor (54). Consequently, the 
association rate, similar to the dissociation rate, can increase the target occupancy by 
effectively prolonging the lifetime of the interaction. This occurs particularly in instances when 
rebinding effects are more pronounced in a tissue compartment that has reduced diffusion such 
as a synapse (55,61).  
1.2.2 Molecular determinants of ligand binding kinetics 
Understanding the molecular determinants of binding kinetic rates is important so that 
one can tailor a small molecule to have the desired binding kinetics. Miller and colleagues (62), 
collated data from over 2000 distinct compounds and showed that some common features 
broadly influence ligand binding kinetics at all proteins. Particularly, ligands that slowly 
associate were found to often have a slow dissociation rate. They additionally presented a 
correlation between the drug size and the residence time of the ligand-protein complex. 
However, simply increasing the molecular weight of a compound will have reduced penetration 
in vivo. Therefore, information specifically regarding the molecular determinants of each 
GPCR’s ligand kinetics are required to rationally modulate drug efficacy and potency. Yet, 
studies investigating GPCR-ligand binding have been historically dominated by performing 
mutagenesis around a proposed binding site and subsequent assessment of the equilibrium 
affinity. Although these studies have given insight into the amino acid residues that govern the 
orthosteric site, they provide no understanding of the influence these residues have on the rate 
of ligand association or dissociation. While reports investigating structure kinetics 
relationships (SKR) on drugs that bind GPCRs are increasing, only a handful of studies have 
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thoroughly explored this to date. Of note, a report investigating the binding kinetics of 
ZM241385 derivatives to the adenosine A2A receptor (A2AR), identified that some derivatives 
displayed markedly different dissociation rates while having very little change in binding 
affinity (63). Another study at the prostanoid DP2 receptor showed that the orientation of a 
hydrogen bond acceptor positioned at the tail of antagonists was critical for extending the 
dissociation rate (64). Together these studies demonstrated that association and dissociation 
rates can be adjusted based on structure. 
Technical advances have led to a rapid expansion in the number of GPCR x-ray crystal 
and cryo-electron microscopy structures being reported. These structures are only capable of 
providing static or averaged poses of the particular ligand bound. Nonetheless, the structures 
of GPCRs have provided useful data for molecular modellers to investigate the molecular basis 
of ligand binding kinetics at different GPCRs. In doing so, Dror and colleagues (65), provided 
the first evidence that GPCRs can contain an extracellular vestibule that makes initial contacts 
with the ligand before it traverses into the deep binding pocket between the TMs. This work 
also showed that the initial binding of the drug to the extracellular vestibule was enabled 
through dehydration of the residues on the extracellular vestibule. This ‘de-solvation’ presented 
the largest energy barrier to overcome for binding to occur, surprisingly larger than any 
subsequent process occurring before entry into the final binding pose. Additionally, the crystal 
structures of the muscarinic acetylcholine M2 receptor and M3 receptors (M2R and M3R) 
allowed for indirect information on ligand binding kinetics via molecular dynamics simulations 
(66,67). The two crystal structures were unable to provide a mechanism as to why tiotropium 
displays a residence time of 34.7h at the M3R but only 3.6h at the M2R (68), as the M2R and 
M3R structures exhibited a highly conserved orthosteric binding site for the co-crystallised 
antagonists. However, by using the crystal structures to perform virtual ligand dissociation 
dynamics experiments, it was observed that ECL2 of the M2R displays increased flexibility 
which allows key residues to rotate, opening an exit for tiotropium to dissociate more readily 
than at the M3R. Soon after, Tautermann et al (69) followed up these observations with more 
extensive wet lab binding experiments and molecular simulations to thoroughly map the 
residues important in determining tiotropium’s dissociation rate. 
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1.3 Biased agonism 
1.3.1 General introduction 
Biased agonism is the phenomenon of one agonist that acts to preferentially activate 
one signalling pathway more than another signalling pathway relative to another agonist at the 
same receptor (70) (Fig. 1.5). It is widely accepted that GPCRs are capable of existing in 
multiple conformational states (71,72). Hence, having this natural capability, biased ligands 
are thought to act via stabilising distinct states of the GPCR. The different conformational states 
then presumably lead to the differential coupling of heterotrimeric G proteins or other effectors 
(e.g. arrestins) and thus lead to signalling pathways being activated to different extents. 
Therefore, biased agonism can be explained through allostery at a GPCR (73) if one envisions 
a biased agonist acting allosterically to modulate a GPCR into distinct conformations that 
translate through to its “primary” intracellular G protein binding site to have different abilities 
to bind or activate G proteins and other intracellular effectors. Among some of the evidence 
showing the structural allosteric basis as the mechanism of bias are studies on the μ-opioid 
receptor (MOPR) (74), β2AR (75), AT1R (76) and the serotonin 5-HT2B receptor (77).  
The appeal of signalling bias is novel drugs can be designed which are highly targeted 
as they only activate the specific signalling pathways that are desired. For example, drugs such 
as morphine for acute pain relief target the MOPR, however their use is associated with severe 
adverse effects including respiratory depression, analgesic tolerance, hyperalgesia, 
constipation, and addiction. In the late 1990s it was shown that knockout mice that lacked the 
β-arrestin-2 (arrestin-3) subtype displayed enhanced morphine-induced analgesia but 
attenuated tolerance, respiratory depression and constipation suggesting that β-arrrestin-2 
mediated signaling underlies these adverse effects (78). This suggested when the MOPR is 
activated by these drugs, it is the signalling through arrestins that leads to these limiting side 
effects. This infers that the best pain relief drugs may be ones that are biased towards activating 
G proteins but negligibly recruit arrestins. This finding stimulated efforts to identify biased 
MOPR agonists that would activate G protein but not arrestin pathways as safer analgesics. 
One such apparent G protein biased ligand, TRV130, developed by the biotechnology company 
Trevena Inc. was reported to have an improved pre-clinical profile over morphine and 
underwent clinical trials in treating moderate to severe acute pain (79). Other biased MOPR 
agonists have been identified but remain experimental compounds (80,81).  
Recent contradictory reports, however, suggest that the abuse potential of these drugs 
is similar to morphine and that they can still cause respiratory depression and constipation (82). 
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Further, morphine was found to induce respiratory depression, constipation and withdrawal in 
a mouse in which the MOPR was replaced by a mutant MOPR that cannot activate β-arrrestin-
2 (83). Finally, a more recent study using the β-arrrestin-2 knockout mouse found that 
morphine could still cause respiratory depression in a manner indistinguishable from that 
observed for the wild-type (84). This illustrates that the clinical development of these biased 
agonists is challenging because it remains unclear how distinct downstream signalling 
pathways in different MOPR expressing cells and tissues control the therapeutic and adverse 
physiological effects of opioid analgesics. Determining which signalling pathways need to be 
activated and to what magnitude to have the desired physiological outcome is a major hurdle 
that the field faces (85). 
 
Figure 1.5: GPCR biased agonism. The balanced agonist (orange) binds the GPCR (blue), 
inducing an active conformation or conformations that lead to even relative activation of 
signalling pathways one and two. The biased agonist (red) is a chemically distinct agonist that 
binds and stimulates the same GPCR, yet, it preferentially activates signalling pathway two 
more so than pathway one (relative to the balanced agonist). By activating signalling pathways 
to different extents, the biased agonist produces a unique downstream cellular and 
physiological response. 
 
1.3.2 Quantification of biased agonism 
To determine whether an agonist displays bias, it is essential to have robust methods to 
quantify biased agonism. Measuring biased agonism is usually conducted by accurately 
detecting multiple signalling pathways in cellular assays, constructing concentration-response 
curves (Fig. 1.6A), fitting the data to a suitable model to quantify agonist action and then 
comparing to determine relative efficiency with which an agonist activates a particular pathway 
relative to another. While there are many methods for quantifying biased agonism, the most 
common is to use a method based on an operational model of agonism proposed by Black and 
Leff (86) to derive ratios of the agonists’ efficacy (τ) and functional affinity (KA), and then 
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Where, E is the pharmacological effect (or response), Em is the maximal effect (or 
maximal response) of the system, τ is termed the transducer ratio and is the agonist’s 
operational efficacy which is comprised of the receptor density ([Rt]) divided by the intrinsic 
efficacy (KE) of the agonist at the particular signalling pathway; [Rt]/KE, [A] is the agonist 
concentration, KA is the agonist’s dissociation constant for the receptor when acting at the 
particular signalling effector/pathway, and, n is the slope of the transducer function that links 
the agonist’s concentration to pharmacological effect (or response).  
The transducer slope (n) and the maximal effect (Em) are shared by all agonists. 
Therefore, parameters describing the agonist activity at a particular signalling pathway include 
both the functional affinity (KA) and the operational efficacy (τ) values. These values are 
usually, combined into a ratio called the transduction coefficient (Log(τ/KA)) (Fig. 1.6B) (87). 
Importantly, the transduction coefficients need to be normalised to a reference agonist before 
attempting to determine bias. This is because the transduction coefficient incorporates the 
differences in the coupling efficiency, cell type and signalling effector stoichiometry (system 
bias) as well as differences in the sensitivity and assay conditions (observational bias). 
Accordingly, an agonist is chosen to be the reference agonist and its transduction coefficient is 
subtracted from the agonists of interest in that particular pathway to determine their relative 
transduction coefficient (Δ Log(τ/KA)) (Fig. 1.6C). A further normalisation can then be made 
between two pathways of interest to graphically assess biased agonism as ΔΔLog(τ/KA) values 
between the two desired pathways (Fig. 1.6D).  




Figure 1.6: Biased agonism quantification based on the Black-Leff operational model. 
(A) Agonist concentration response curves are determined for two separate signalling 
pathways or endpoints. Note that agonist 1 (red) is more potent and efficacious than agonist 
2 (green) in signalling pathway 1, however, this pattern is reversed in signalling pathway 2. 
(B) Agonist concentration response curves are fit to the operational model equation described 
in detail above to determine the Log(τ/KA) values (also called transduction coefficients). (C). 
The Log(τ/KA) values of the reference agonist (shown in blue) from each signalling pathway 
are subtracted from the corresponding Log(τ/KA) values of the other agonists of interest to give 
ΔLog(τ/KA) values. (D) The ΔLog(τ/KA) values of one signalling pathway are subtracted from 
another signalling pathway to determine the ΔΔLog(τ/KA) values (also called LogBias). Shown 
here, agonist 1 is biased towards signalling pathway 1 whereas agonist 2 is biased towards 
signalling pathway 2 – importantly the bias is all relative to the reference agonist. 
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1.3.3 The influence of binding kinetics on observations of biased agonism  
A key feature of allosteric communication is the ability of one ligand to modulate the 
affinity of the other. Likewise, a change in the binding kinetics at a receptor may indicate a 
change in the conformational state of that receptor such that the ligand has a different affinity 
for this state. For example, Birdsong et al. (88) showed that after prolonged agonist exposure 
to the MOPR, the binding affinity of the receptor for agonists is increased. This suggests that 
pre-exposing the receptor to an agonist may allow intracellular effectors to couple to the 
receptor, resulting in different conformational states being stabilised. In addition, a group was 
able to decrease the rate of dissociation of ligands by titrating in the concentration of G proteins 
to a purified receptor system (89), thus showing that increasing the concentration of proteins 
which interact with the GPCR will allosterically modulate the GPCR in vitro. These studies 
indicate that the kinetics of both the agonist and the effector at the receptor have a fundamental 
part in determining the response together. While the studies showing this are relatively recent, 
the concept that ligand binding kinetics can influence efficacy is not new. Indeed, one of the 
classic models of pharmacological action is Paton’s rate “theory of drug action” (90). Paton 
used different drugs on guinea-pig intestine and observed that their response onset rate was 
proportional to the magnitude of their response. It was therefore postulated that the a drug’s 
intrinsic efficacy would be proportional to the number of agonist-receptor interactions and as 
such, dependent on the association rate (90). Contrasting with Paton’s rate theory are many 
other studies demonstrating the opposite relationship. Studies at the M3R from two separate 
groups have shown that agonists with an increased residence time display increased agonist 
efficacy assessed at multiple endpoints (91,92). Similar findings have also been observed at 
the A2AR and the α2A-adrenceptor (93,94). Additionally, the β2AR agonist C26, displayed 
higher efficacy than adrenaline and isoprenaline which was thought to be due to its extended 
residence time (95). While these reports are elegant, overall the relationship between agonist 
binding kinetics and its influence on signalling efficacy remain incomplete.  
Our group recently extended these studies from kinetic studies on efficacy to kinetic 
studies on biased agonism. Interestingly, we reported that the kinetics of agonists can also lead 
to observations of apparent biased agonism (96). This was an important step for the field 
because distinct agonist-induced conformations are generally the assumed to be the molecular 
mechanism of biased agonism when examining pharmacological data. However, without any 
direct structural evidence this assumption may be problematic because biased agonism 
observations can occur through system bias, observational bias or potentially other molecular 
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mechanisms (87). Furthermore, our finding was exemplified at the dopamine D2 receptor 
(D2R) whereby agonists with different dissociation rates, meaning different agonist-GPCR 
residence times, displayed biased agonism between different pathways in a manner that 
changed over time. Depending on the pathway being measured, agonists with a fast dissociation 
rate such as dopamine and ropinirole either displayed no change in potency over time or a 
decrease in potency over time. In contrast, agonists with slower dissociation rates such as 
bifeprunox exhibited a concomitant increase in potency over time due to an increase in receptor 
occupancy over time. Therefore, one would presume that differences in receptor occupancy 
between distinct pathways would result in bias between pathways. Yet, while the apparent bias 
emerged from slow dissociating agonists relative to fast dissociating agonists, the bias was not 
entirely due to changes in receptor occupancy over time. Therefore,  Klein-Herenbrink et al. 
(96) suggested that the interplay between the agonist binding kinetics, the kinetics of signalling 
and the kinetics of the regulatory processes all are responsible for the apparent bias. Following 
this work, other reports have followed examining the relationship between agonist binding 
kinetics and biased agonism. It appears that at some serotonin receptors arrestin recruitment, 
but not G protein mediated pathways, can be altered by changing the drugs binging kinetics 
through receptor mutagenesis (97). In addition, neuropeptide Y1 receptor biased agonists 
appear to increase the relative lifetime of the G protein with the GPCR and by doing so impart 
their G protein bias relative to arrestins (98). Overall, these reports can lead one to hypothesise 
that agonists with a slow dissociation rate or extended residence time could permit different 
effectors, such as G proteins or arrestins, to engage the receptor for different amounts of time 
through inducing a different conformational landscape in the GPCR for an extended amount 
period and thus produce biased agonism (Fig, 1.7). Certainly, more evidence is required 
including studies on more distinct ligands and pathways in order to determine whether biased 
agonism through this mechanism can occur. 




Figure 1.7: A potential mechanism of kinetic bias at a GPCR. GPCR’s can constantly 
sample multiple different conformations. Upon binding of an agonist, the agonist will induce 
the GPCR to exist in different conformational ensembles that have increased propensity to 
bind and activate downstream effectors. Agonists can have differing dissociation rates that 
determine the lifetime of the drug-receptor complex or residence time. An agonist with a slow 
dissociation rate may allow the receptor to remain in active conformations for an extended 
period as it has a long residence time. This in turn could lead to the ability of the GPCR to 
engage distinct G proteins, regulatory proteins or other effectors over time or engage these 
proteins for differing amounts of time. Subsequently, the GPCR will then explore a different 
repertoire of active conformations by engaging these proteins differently. (Figure adapted from 
Klein-Herenbrink et al. (96)).  
 
 
1.4 The dopamine D2 receptor 
1.4.1 Background 
The dopamine D2 receptor (D2R) is a constituent of a subfamily of five closely related 
GPCRs (D1-D5) within the broader rhodopsin (Class A) family of GPCRs. Receptors within 
the dopamine receptor subfamily share the monoamine dopamine as their endogenous agonist 
and thus have many similarities to other rhodopsin family monoamine receptors such as the 
adrenergic, histamine and serotonin receptors. The dopamine D1 and D5 receptors are termed 
the D1-like receptors and are coupled to the Gαs/olf subfamily of G proteins that stimulate 
adenylate cyclases. The D2-like receptors comprise the D2, D3 and D4 receptors that couple to 
Chapter 1 – General introduction 
35 
 
inhibitory Gαi/o subfamily G proteins. Interestingly, the two D1-like receptors are encoded by 
a single exon whereas the D2-like receptor genes consist of multiple exons and introns, allowing 
for translation of multiple isoforms due to alternative splicing (99). There are two splice 
variants of the D2R, termed D2 short isoform (D2SR) and D2 long isoform (D2LR), the D2SR 
lacks 29 amino acid residues in ICL3 compared to the D2LR and acts as an presynaptically 
autoreceptor (100,101). The D2R differs from most GPCRs in that it has no carboxy-terminal 
tail but instead has a very large ICL3. This large ICL3 is thought to reproduce the functions of 
the carboxy-tail in other GPCRs (102). The D2R has the widest expression in the central 
nervous system and modulates most of the effects of dopamine in the brain (103). Moreover, 
the D2R is the most intensely investigated dopamine receptor for drug discovery. The D2R is a 
key target for Parkinson’s disease, schizophrenia, restless legs syndrome, hyperprolactinaemia, 
depression, nausea and bipolar disorder (103-107).  
1.4.2 Dopamine D2 receptor expression 
The D2R has an extensive expression pattern in the central nervous system (CNS) and 
more restricted expression in the peripheral nervous system and other tissues. Of note, 
expression of the D2R has often been determined using radioligand binding or 
immunodetection, both of which are subject to cross-reactivity with other D2-like receptors. 
Nonetheless, the D2R is most abundant in the central nervous system where it is enriched in 
the striatum, the olfactory tubercle and nucleus accumbens (108,109). Within the striatum, 
D2Rs are located on medium spiny neurons (MSNs). More moderate labelling of the D2R has 
also been observed in many other brain regions including the substantia nigra pars compacta, 
olfactory bulb, superior colliculus and subthalamic nucleus (103,110). In addition, the D2R is 
expressed in smaller regions including the retina and arcuate nucleus (103). As is the case for 
all dopamine receptors, the majority of D2-like receptors are found on non-dopamine neurons 
(103,109). Moreover, Jang and colleagues (111), demonstrated in the substantia nigra pars 
compacta, that most expression of the D2R is the long isoform (D2LR) as opposed to the 
presynaptic D2SR (101). Furthermore, the D2R is also expressed in some endocrine tissues 
including the anterior pituitary and pancreatic β-cells (108,112). The D2R also appears to be 
expressed in the gut, for example, expression has been identified in the enteric nervous system 
of mice (113). Moreover, in rats, it has been determined by immunofluorescence and reverse 
transcription-polymerase chain reaction that the D2R is present in the gastric mucosa (114). 
The D2R has further been documented in the lymphocytes, implicating it in immune system 
function (115).  
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1.4.3 Dopamine D2 receptor physiological functions 
The most heavily investigated physiological functions of the D2R are those mediated 
by D2Rs expressed in different dopamine pathways in the CNS. Some examples of D2R 
functions include locomotor responses, motivation, cognition, reward behaviours, temperature 
regulation, learning and sexual behaviour. Many of these D2R functions are often overlapping 
with other dopamine receptors or dependent on their activity.  
One of the best characterised D2R functions is its role in locomotor activity. While 
locomotor activity is also regulated by the D1R and D3R, activation of the D2R has the largest 
effect (110). Specifically, activation of presynaptic D2R autoreceptors, that regulate dopamine 
release by dopaminaergic neurons, by drugs of abuse such as amphetamine and cocaine 
produce a reduction in the locomotion (103). In contrast, post-synaptic D2Rs oppose these 
functions and stimulate locomotor responses. Post-synaptic receptors generally activate 
signalling at higher concentrations than autoreceptors, therefore, locomotor activity can often 
be dependent on the concentration of the agonist. Moreover, learning and memory retention 
are also an important functions driven by the D2R. D2-like subtype selective agonists increase 
memory consolidation and subtype selective antagonists impairing this process (116). 
However, a similar relationship is also observed for the D1R. Drug reward is a neurobiological 
process associated with memory that is also influenced by the D2R. Mice lacking the D2R 
display a reduced preference to seek and consume ethanol (117). These types of process do not 
appear to be limited to addictive drugs and may be extended to general non-specific motivated 
behaviours. For example, an increase in the expression of the D2R in the nucleus accumbens is 
associated with increased motivation such as increased effort to obtain a goal (118). Moreover, 
there are a number of neuroendocrine duties of the D2R. In the pituitary, dopamine released 
from the hypothalamus acts at D2Rs on lactotrophs of the anterior pituitary to inhibit the 
production of prolactin and the subsequent lactation and developmental processes (119). 
Sexual behaviour can also be driven by the D2R through activation in the hypothalamus and 
interaction with the oxytocin system(120). Efficacious D2R agonists are well known to elicit 
hypothermia, demonstrating that the D2R regulates body temperature (110). The overarching 
roles that the receptor plays in many neurobiological and neuroendocrine functions highlights 
the reason why it has become such a common drug target. 
1.4.4 High resolution D2-like structures 
Recently there has been an explosion in the number of high-resolution structures of 
GPCRs including those of D2-like receptors. The D3R was the first dopamine receptor to have 
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its structure solved and was crystallised bound to the high affinity antagonist eticlopride (121). 
Subsequent structures were then solved of the D4R, followed by the D2R bound to risperidone 
(Fig. 1.8) (122,123). There are currently two reported structures of the D2R, with the second, 
most recent, structure solved bound to the typical antipsychotic haloperidol (123,124). These 
crystal structures revealed a very similar structure to other rhodopsin family (class A) GPCRs 
consisting of seven transmembrane domains positioned around in an anti-clockwise manner 
followed by a short helix 8 that runs parallel with the plasma membrane. Moreover, the D4R 
structure was solved at high enough resolution to visualise a conserved sodium site important 
for modulating ligand affinity and function at D2-like receptors (122). The D2-like structures 
confirmed work from previous radioligand binding and mutagenesis studies demonstrating that 
orthosteric ligands bind deep within the TM bundle. However, the structures have also aided 
further binding and molecular modelling studies to fine-tune our understanding of ligand-
receptor interactions (125,126).  
 
Figure 1.8: X-ray crystal structure of the D2R bound to risperidone. (A) Side view parallel 
to the plasma membrane of the D2R (green cartoon) bound to risperidone (magenta sticks). 
(B) Top view from the extracellular space of the D2R (green cartoon) bound to risperidone 
(magenta sticks). (PDB code: 6CM4) 
 
1.4.5 Molecular determinants of ligand binding at the dopamine D2 receptor  
Our understanding of the molecular processes that influence binding kinetics at the D2R 
is building. It is well appreciated that D2R ligands, such as dopamine, bind in the orthosteric 
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site comprising residues such as aspartate 114 located deep within the TMs (127). The 
orthosteric pocket is highly conserved among D2-like receptors, however, residues in the 
extracellular tips of the TMs and ECLs of GPCRs can form secondary binding sites and 
extracellular “vestibules” (65,67). These residues that constitute these sites are less conserved 
and hence can confer selectivity for specific ligands. While most studies investigating binding 
at the D2R have traditionally assessed effects on equilibrium affinity, an increasing number of 
studies are starting to reveal the intricacies of the whole binding and unbinding process. 
Tresadern et al (128) have investigated the influence of some physicochemical properties on 
the rate of dissociation of a large number of antagonists from the D2R. It was observed that 
increasing lipophilicity and larger molecular weight was related to slower dissociation rate 
from the receptor. Additionally, more targeted analysis on smaller sets of ligands has also been 
performed. One study examined the kinetics of a series of compounds at the D2R and suggested 
that a particular agonist-like moiety that the compounds shared was important for their fast 
dissociation rates from the D2R (129). However, this finding is only relevant for the particular 
moiety and cannot be extended to other compounds with different agonist moieties such as the 
agonist bifeprunox that is one of the slowest dissociating D2R ligands reported to date (96). 
Furthermore, Fyfe et al. (130) reported that modification of different moieties on the scaffold 
of haloperidol can significantly alter both the association and dissociation rates at the D2R. 
Together such studies have illustrated that ligands can be altered through medicinal chemistry 
to tune their D2R binding kinetics. Some studies have also started to explore the particular 
interactions ligands make with the receptor amino acid residues upon ligand binding. Early 
work by Shi and Javitch showed through substituted-cysteine accessibility that ECL2 lines the 
ligand binding site ‘crevice’ of the D2R (131). While the association and dissociation rates of 
ligands were not investigated, certain residues such as isoleucine 184 within ECL2 may be 
likely to influence binding kinetics. Interestingly, the structure of the D2R bound to risperidone 
(Fig. 1. 8) revealed a novel conformation of a tryptophan residue within ECL1 that is highly 
conserved among aminergic GPCRs. The tryptophan 100 residue was extended out over the 
top of the binding site. The tryptophan residue in this pose was suggested to be important for 
determining the residence time of risperidone (123). 
 
1.4.6 Dopamine D2 receptor G protein signalling  
The main effectors for the D2R are Gαi/o subfamily heterotrimeric G proteins. The D2R 
can activate all members of the non-visual Gαi/o family which are Gαi1, Gαi2, Gαi3, Gαo, and 
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Gαz (132,133). Downstream effects of D2R Gαi/o coupling include decreases in cAMP 
production by inhibition of adenylate cyclases (134), inhibition of P/Q-type and N-type calcium 
channels (135), activation of G protein-coupled inwardly rectifying potassium (GIRK) 
channels leading to increases in cytosolic potassium, and potentiation of stimulated arachidonic 
acid release (136).  
It is known that the D2R couples more strongly to Gαo isoforms (GαoA and GαoB) than 
the Gαi subtypes (137-139). In agreement with its G protein selectivity, the D2R is generally 
considered to elicit most of its effects in the brain through Gαo (140). Although, the method 
used to determine that Gαo coupling is the predominant form of coupling by the D2R was based 
on detecting the high affinity state of an agonist for the receptor-G protein complex. This is 
needs to be taken into consideration given that Gαo is the most plentiful G protein subtype in 
the central nervous system (141,142), such that, the experiment would be less sensitive at 
detecting other G protein subtypes expressed at lower levels. Certainly in pituitary cells it is 
appreciated that multiple Gαi/o subunits are involved in D2R mediated signalling responses such 
as inhibition of prolactin release (143). Additionally, Marcott and colleagues (144), provided 
evidence that the weaker coupling to Gαi subtypes may function to allow the D2R to display 
reduced sensitivity to dopamine in particular striatal sub-regions or cell types. While it was 
reported that multiple mechanisms likely explain differences in the kinetics of signalling 
between brain regions, the differences in signalling sensitivity in the nucleus accumbens 
relative to the dorsal striatum could be attributed to coupling to Gαo subunits in the nucleus 
accumbens compared to Gαi subunits in the dorsal striatum (144).  
In addition to Gαo and Gαi coupling, there is also evidence that the D2R can couple to 
Gαz to mediate some of its physiological effects. In contrast to other Gαi/o subtypes that are 
ubiquitously expressed, Gαz’s expression is largely specific to neuronal and some endocrine 
cell types, including regions enriched with the D2R such as the striatum and pituitary (145). 
The D2R and Gαz are also co-expressed in pancreatic islets (146,147). It has been hypothesised 
that the D2R mediates PTX-insensitive signalling through Gαz as determined by experiments 
performed on ex vivo rat pituitary tissue (148). Moreover, a well characterised behavioural 
reflex response mediated though D2R is the disruption to prepulse inhibition upon 
dopaminergic stimulation with drugs such as amphetamine (149). Interestingly, Gαz knockout 
mice display an increased disruption to prepulse inhibition upon stimulation with dopaminergic 
drugs (150). In addition, Gαz is also required for D2R mediated inhibition of dopamine release 
in the nucleus accumbans and its resultant suppression of locomotor activity (151). D2R 
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mediated adrenocorticotropic hormone (ACTH) secretion and hypothermia is also dependent 
on Gαz (151).  
1.4.7 D2R regulation and G protein-independent signalling 
Upon agonist activation of the D2R, several proteins other than G proteins are involved 
in regulating and coordinating the signalling response. The rate and magnitude of D2R G 
protein signalling can be regulated in the striatum by regulator of G protein signalling 9-2 
(RGS9-2) (152). Subsequently GRK2 and 3 are recruited and phosphorylate the receptor 
(102,153). In the case of the D2R, GRK recruitment is required for arrestin recruitment to the 
receptor although, interestingly, the phosphorylation of the receptor which occurs on ICLs has 
been shown to be not critical for arrestin recruitment (102). This observation goes against the 
current dogma within the GPCR field, as classically it is thought that arrestins recognise the 
phosphorylated serines and threonines on the receptor due to the GRK. The phosphorylation 
by GRK2 or 3 is instead thought to be important in recycling of the D2R back to the cell 
surface(102,153). Nonetheless, β-arrestin-2 is thought to be the main arrestin that binds to the 
D2R to sterically hinder G protein activation (154). The D2R is a relatively poor arrestin 
recruiter, this usually results in the receptor being recycled back to the plasma membrane 
instead of being trafficked into lysosomes for degradation. Moreover, one group has provided 
evidence of arrestin scaffolding at the D2R mediating a novel signalling cascade comprising 
protein phosphatase 2A (PP2A), Akt and GSK3 (155). In addition to agonist dependent 
regulation, heterologous desensitisation can occur at the D2R through activation of PKC (156). 
PKC can phosphorylate the receptor on intracellular loops, resulting in reduced G protein 
mediated responses and receptor trafficking. Finally, while it is beyond the scope of this thesis, 
it should be noted that many other proteins interact with the D2R to regulate or mediate their 
own signalling such as GIPC (157), NCS-1 (158,159), Spinophilin (160), Dysbindin-1 (161), 
and S100B (162). These proteins are termed dopamine receptor interacting proteins or DRIPs. 
  
1.5 The dopamine D2 receptor in Schizophrenia 
1.5.1 Dopamine hypothesis of schizophrenia 
Schizophrenia is a chronic mental illness with a prevalence of approximately 5 in 1000 
in the global population (163). The precise aetiology of the disease is poorly understood, 
however, there are a number of known risk factors involving parental age, ethnicity, birth 
issues, immune disorders, and cannabis usage (164). The disease is characterised by positive 
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symptoms such as delusion and hallucinations, negative symptoms such as social withdrawal 
and depression and cognitive symptoms including impaired working memory (165). 
The dopamine hypothesis of schizophrenia has evolved over time although broadly the 
fundamental assumption of the hypothesis is that schizophrenia is associated with a 
dysregulation of dopamine in the brain (166). Initially, antipsychotic drugs were 
extemporaneously discovered in the 1950s and found to treat the positive symptoms of the 
disease. Soon after this, the existence of dopamine receptors was starting to be established 
through work by Carlsson, Greengard and Kebabian (167-169). However, the “antipsychotic 
receptor” was not confirmed until 1976 by illustrating that the clinically used concentrations 
of all antipsychotics correlated with the concentration needed to inhibit binding of [3H] 
haloperidol to 50% in brain striatal tissue (170). This finding was made possible by the creation 
of [3H] haloperidol, that could specifically label what was later termed the dopamine D2 
receptor (171,172).  Having achieved this, the dopamine hypothesis of schizophrenia was born. 
1.5.2 Antipsychotic drugs 
Since the first antipsychotic drug, some newer and improved drugs have been approved 
yet their ability to block dopamine agonism at the D2R remains essential for robust efficacy 
(173). First generation antipsychotics are antagonists at the D2R. These first generation 
antipsychotics are largely a group of phenothiazines, of note is the first discovered 
antipsychotic chlorpromazine (174). After chlorpromazine, other first generation 
antipsychotics that were developed including ones with differing scaffolds such as the 
butyrophenone haloperidol (174). 
The first approved second generation antipsychotic was clozapine, which remains the 
gold standard treatment for schizophrenia today (175). Second generation antipsychotics are 
D2R and serotonin 5-HT2A receptor antagonists. The second generation antipsychotics have a 
reduced propensity to cause side effects such as extrapyramidal side effects due to differences 
in their binding kinetics at the D2R discussed in a following section (1.5.4) (61,176).  
The main feature of third generation antipsychotics is that they are weak partial agonists 
at the D2R (173). Although, they additionally display partial agonism at the serotonin 5-HT1A 
and 5-HT2B receptors. These antipsychotics currently include aripiprazole, cariprazine and 
brexpiprazole. These antipsychotics were originally proposed to act as dopamine stabilisers by 
functioning as agonists at the presynaptic autoreceptor but antagonists at the postsynaptic 
heteroreceptor (177). However, subsequent studies demonstrated that they act as partial 
agonists at postsynaptic receptors (178). Therefore, being partial agonists, they likely function 
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by reducing D2R signalling when there is too much dopamine released and increasing 
dopamine signalling when too little is released. In, addition the serotonin receptor agonism may 
also be advantageous through possibly boosting mood or reducing extrapyramidal side effects 
(179). Moreover, it has been suggested that the third generation antipsychotics may act through 
a mechanism involving biased agonism although this is not the current consensus in the field 
(173,180).  
1.5.3 The potential of biased agonism within the dopamine hypothesis 
The generally accepted hypothesis for pharmaceutical intervention in schizophrenia is 
that antipsychotics are antagonists or partial agonists which work by blockade of the D2R. 
However, recent work by Caron and colleagues have suggested that partial agonists that 
preferentially activate the arrestin pathways may be more efficacious. Inferring that this may 
be an example where biased agonism (or biased antagonism) may provide improved drug 
efficacy in vivo. However, the basis for arrestin biased agonism and antipsychotic efficacy is 
convoluted. Early studies showed that activation of β-arrestin-2 by the D2R in the striatum 
leads to specific dopamine-dependent behaviours in mice (181), demonstrating that not all D2R 
mediated effects in vivo are dependent on G protein cAMP/PKA. This work further developed 
into a mechanism of G protein independent activation of the Akt/GSK-3β/PP2A pathway 
whereby β-arrestin-2 recruitment by the D2R leads to deactivation of Akt which in turn 
promotes activation of GSK-3β (155,182). Additionally, it was shown that Akt protein levels 
are downregulated in patients with schizophrenia, suggesting a potential role for specifically 
pharmacologically antagonising β-arrestin-2 via D2Rs to increase Akt activity (182). Follow-
up studies by the Caron group then aligned with this hypothesis through molecular 
pharmacology by using clinically efficacious antipsychotics in mammalian cells and showing 
that they antagonise arrestin recruitment (183). However, more recent studies by the same 
group now oppose this view, whereby ligands that antagonise G protein mediated events but 
still retain the ability to recruit β-arrestin-2 are preferred. This was suggested through 
administration of an apparent arrestin-biased partial agonists in mouse models of psychosis as 
well as studies between arrestin knock-out and wild-type mouse models (184,185). Therefore, 
the relationship between arrestin bias and antipsychotic efficacy currently remains unclear. 
More recently, a separate group has investigated arrestin dependent effects at the D2R by using 
an engineered arrestin biased mutant receptor (186). Through these studies it was possible to 
discern that arrestin recruitment can independently enhance locomotion but not motivation 
behaviours. While it is unclear which downstream signalling pathways or mechanisms may be 
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involved, the work demonstrates that D2R mediated physiological effects could potentially be 
separated through biased agonism.   
 
1.5.4 The role of D2R-ligand binding kinetics in Schizophrenia 
Seminal work by Kapur and Seeman (176,187) lead to the “fast off” hypothesis for 
atypical antagonist antipsychotics at the D2R. Second generation (atypical) antipsychotics 
display less side effects such as hyperprolactinaemia, motor symptoms, and extrapyramidal 
side effects compared to first generation (typical) antipsychotics. Kapur and Seeman postulated 
that second generation antipsychotics produce less on-target side effects because they have a 
faster dissociation rate from the D2R. The fast dissociation rate of the second-generation 
antagonists then leads to a lower receptor occupancy in the striatum compared to first 
generation antipsychotics. The idea was further supported by the fact that at high doses of a 
second generation antipsychotic, which produce high receptor occupancy, on-target symptoms 
start to present akin to those of the first generation antipsychotics (188).  
Extending this work, Sykes et al (61), reassessed the both the association rate and the 
dissociation rate in regards to the side effects associated with different first and second 
generation antipsychotics. While an identical relationship was found between the dissociation 
rate and the propensity to induce hyperprolactinaemia, a different correlation emerged between 
the association rate and the tendency to cause extrapyramidal side effects (61). It was further 
suggested that this was due to rebinding of the antipsychotic inside the diffusion limited 
compartment of a synapse. 
Later investigations by Carboni and colleagues (189) took a similar approach to these 
studies to investigate the newer third generation antipsychotics. The third-generation 
antipsychotics are weak partial agonists at the D2R that include cariprazine, aripiprazole and 
brexpiperazole. Carboni et al. (189) investigated the agonist efficacy and binding kinetics in 
relation to prolactin release into the bloodstream in rats. The measurement was used as a 
surrogate to predict the likelihood of hyperprolactinamia in humans. Interestingly, they 
demonstrated with aripiprazole and several other partial agonists synthesised in-house, that 
slower dissociation of partial agonists produced a smaller increase in prolactin compared to the 
other partial agonists with similar efficacy. One key observation to come out of this study was 
that agonist maximal response did not correlate with prolactin release, suggesting that in vitro 
agonist efficacy may not be the best predictor of in vivo efficacy. Additionally, this relationship 
between kinetics for partial agonist antipsychotics was effectively the opposite of the work by 
Chapter 1 – General introduction 
44 
 
Kapur and Seeman as well as Sykes et al. with antagonist antipsychotics. This suggests then 
that the partial agonists may have a separate mechanism of action to antagonists. 
 
1.6 The dopamine D2 receptor in Parkinson’s disease 
1.6.1 Background  
Parkinson’s disease is a continual progressive neurodegenerative disorder. It is the 
second most prevalent neuropathological disorder after Alzheimer’s disease (190). The disease 
usually begins in a person’s 50s or 60s, although in rare cases early-onset Parkinson’s can occur 
before the age of 40. The high societal and economic impact of the disease is expected to grow 
substantially as the prevalence grows due to an aging global population (191). The disease is 
featured by motor symptoms including tremors, bradykinesias, muscular rigidity and reduction 
of postural balance. While in the community it is primarily thought of as a movement disorder, 
it is important to recognise that the disease is also associated with several non-motor symptoms 
including orthostatic hypotension, depression, skin conditions, anxiety, dementia, sleep 
problems and sensory impairments (192). Parkinson’s disease pathology is characterised by 
the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (193). As 
the neurons die over time this results in a loss of dopamine in the posterior striatum, where the 
dopaminergic neurons of the substantia nigra project to. It is this loss of dopaminergic tone that 
then leads to the motor symptoms observed in patients (194). This pathology is usually coupled 
with characteristic protein aggregate inclusions called Lewy bodies in certain regions of the 
brain (195).  
1.6.2 Pathogenesis 
Parkinson’s disease has been historically considered an idiopathic disorder. While it is 
still often unclear which components are responsible for initiating, spreading or worsening the 
disease, multiple environmental and genetic factors have become evident over time. Increasing 
age is the highest risk factor for the disease. This may be due in part to dopaminergic neurons 
in the substantia nigra being more susceptible to processes like mitochondrial disfunction than 
other neurons. Moreover, there are also many other triggers or risk factors including, exposure 
to some pesticides (196), brain trauma,  some bacterial and viral pathogens, changes in the gut 
microbiome (197) ethnicity, geography and sex (198).  
Specific genes were not identified as risk factors until mutations in the α-synuclein 
encoding gene SNCA were identified in a family with Parkinson’s disease in 1997 (199). 
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Shortly after identifying that mutations in α-synuclein can cause rare forms of the disease, it 
was shown that α-synuclein is a major component of Lewy bodies. This more directly linked 
the genetics to the pathogenesis because Lewy bodies are thought to be a toxic species to 
organelles. These results lead to several genome wide association studies (GWAS) and meta-
analyses to identify genetic risk factors. Now, there is an ever-increasing list of upwards of 20 
genes associated with the disease that display varying functions within the cell. The most 
common heritable form of the disease being due to genetic differences in leucine-rich repeat 
kinase 2 (LRRK2) (200,201). Other commonly associated genes are PTEN-induced kinase 1 
(PINK1) (202) and glucocerebrosidase (GBA)(203).  
1.6.3 Current treatment 
At present, pharmacological treatment mainly manages the motor symptoms of the 
disease, having efficacy towards only some of the non-motor symptoms (204). Using different 
small molecule approaches, all treatments aim to restore dopamine signalling in the striatum. 
This is managed by treatment with either L-dihydroxyphenylalanine (L-DOPA), a D2R agonist, 
a monoamine oxidase B (MAO-B) inhibitor, or a combination of these. 
L-DOPA is still the mainstay medical treatment for Parkinson’s disease (205). L-DOPA 
is converted by DOPA decarboxylase to dopamine and is the body’s natural dopamine 
precursor. Thus, in Parkinson’s treatment L-DOPA functions as a prodrug through which it can 
cross the blood brain barrier where it is then converted into dopamine to have its effect. 
Moreover, L-DOPA is usually taken in combination with a decarboxylase inhibitor such as 
carbidopa. This is to prevent conversion of dopamine outside of the brain because dopamine 
plays a dual role as a hormone in the periphery and a neurotransmitter in the brain. This then 
allows the use of lower initial doses of L-DOPA. Once treatment with L-DOPA has started, 
MAO-B inhibitors are often used in combination to enhance the effect and D2R agonists have 
also historically been used in combination. 
Taken orally or with a transdermal patch, small molecule D2R agonists cross the blood-
brain-barrier where they can act to enhance some dopamine receptor signalling in the striatum. 
These agonists generally have selectivity for the D2R and the D3R. First generation D2R 
agonists for Parkinson’s disease include lisuride, bromocriptine, pergolide and cabergoline that 
are derived from ergots. Some of these agonists have fallen out of favour due to their increased 
risk of cardiac valvular disease and fibrosis of other connective tissues (206,207). In particular, 
cabergoline and pergolide have been withdrawn from the market due to their serotonin 5-HT2B 
receptor agonism which leads to valvular pathologies (208). Bromocriptine remains a marketed 
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drug however it is mainly prescribed for other indications such as the treatment of 
hyperprolactinemia and acromegaly. Second generation agonists such as such as ropinirole, 
pramipexole, apomorphine, rotigotine and piribedil vary in structure and hence do not have the 
side effects common to some of the ergot-derived agonists. While these D2R agonists are 
generally considered to be less efficacious than L-DOPA, they can be used after L-DOPA shows 
“escape” or to delay the need for L-DOPA because they may have reduced risk for motor-
related complications such as dystonia, dyskinesia and motor fluctuations (209). Moreover, 
MAO-B inhibitors may be used for similar reasons in early stages of disease. In contrast to 
direct activation of D2Rs, MAO-B inhibitors boost dopamine signalling by permitting the 
body’s naturally produced dopamine to persist for longer in the synapse. After being released 
in the brain, dopamine is taken up by neurons or glia where it then undergoes oxidative 
deamination. MAO-B is the enzyme that is chiefly responsible for this action on dopamine 
(210). Therefore, in early stages of the disease a MAO-B inhibitor such as selegiline or 
rasagiline may be prescribed to enhance dopamine signalling in the nigrostriatal system.  
1.6.4 Scope for improving D2R targeted therapy 
It should be noted that there are numerous promising approaches targeting proteins 
other than the D2R that are being developed. However, any disease modifying therapy is only 
likely to be approved over the long term as these therapies are generally in the early clinical or 
pre-clinical stages. Some examples include drugs targeting other GPCRs (211,212), therapies 
designed to immunise against α-synuclein (213), modalities targeting other proteins such as 
LRRK2 and PINK1 (214), dopaminergic cell-based therapies (215), and gene therapies to 
restore dopamine production (216). 
In the shorter term, it may be more realistic to improve D2R targeting through detailed 
pharmacological characterisation of existing D2R agonists or through targeting the D2R via 
novel mechanisms such as biased agonism. Indeed, there is considerable scope in identifying 
the most efficacious existing drugs through post-approval research. Particularly in the case of 
the early stage of the disease where current therapeutic strategies vary, with a wide use of 
different agonists that display varying efficacies and binding kinetics. Current thinking 
suggests that the D2Rs simply need “switching on”, however we now know the agonists being 
prescribed are not equivalent. Indeed, ergot agonists are usually not prescribed by doctors 
anymore as mentioned earlier. Additionally, other D2R agonists could potentially display 
partial agonism or biased agonism with respect to dopamine. Therefore, it may be important to 
investigate the signalling properties of prescribed agonists in more detail to better understand 
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which drugs are the most efficacious or reduce side effects. In addition, investigating the 
molecular determinants of signalling and binding kinetics of D2R agonists could identify 
whether new small molecule D2R agonists can be developed with differing pharmacology to 
the currently available options. Altogether, this could improve the doctors guidelines as well 
as advise the dosing regimens of D2R agonists as it is somewhat complicated due to the existing 
drugs having different potencies (217).  
  





1.7 Scope of thesis 
The dopamine D2 receptor (D2R) is a key target for various neuropsychiatric and 
neurological diseases. However, drugs acting at the D2R for these diseases often have limited 
efficacy and poor side effect profiles. Understanding the molecular mechanisms of binding and 
signalling of the D2R, including their kinetic rates will provide the foundation for the design of 
the next generation of improved D2R-targeted drugs.  
There are quite clear differences in the binding kinetics of clinically relevant ligands 
acting at the D2R. The work of Seeman and colleagues (187,218) and later by Sykes and 
colleagues (61) has highlighted the importance of binding kinetics in the side effect profile of 
antagonist antipsychotics at the D2R. Additionally, Klein-Herenbrink and co-workers (96) as 
well as Carboni and colleagues (189), have demonstrated that the functional differences of 
agonists can sometimes be attributed to differences in their binding kinetics. In chapter 2 we 
optimise a novel time resolved fluorescence resonance energy transfer (TR-FRET) competition 
kinetic binding assay to measure unlabelled ligands binding rates. We then use mutagenesis to 
understand the influence of distinct residues in the extracellular vestibule of the D2R on the 
binding kinetics of clinically relevant antagonists and agonists. 
In Klein-Herenbrink and colleagues’ study, it was found that some slowly dissociating 
partial agonists acting at the D2R can display apparent bias relative to fast dissociating agonists 
in a manner that changes over time. Based on this work, we hypothesise that agonists with a 
slow dissociation rate and hence a longer residence time may lead to observations of biased 
agonism through potentially allowing the receptor to sample different effector bound states. In 
chapter 3, we therefore extend the work of Klein-Herenbrink and colleagues (96) with several 
different approaches. We test a greater number of agonists, including agonists that display high 
efficacy and slow dissociation from the D2R. We expand the functional assessment to multiple 
receptor-proximal events and receptor trafficking to subcellular compartments.  
Continuing with our research on the mechanisms of D2R biased agonism, we investigate 
the relationship between biased agonism and D2R phosphorylation. This is important because 
GRK phosphorylation is often thought of as the “switch point” between G protein mediated 
signalling and arrestin recruitment (219). In chapter 4, we develop novel phosphorylation-site 
antibodies that target the intracellular loops of the D2R. We then use the antibodies coupled 
with bioluminescence resonance energy transfer signalling and proximity assays to assess D2R 
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regulation and its modulation by agonists, including those that display apparent biased 
agonism. We are able to further clarify the role GRKs play in these processes. 
Through our work investigating the biased agonism in chapters 3 and 4 it is appreciated 
that the pharmacological system needs to be understood in order to determine the mechanisms 
of biased agonism observations. The D2R’s main signalling effectors are G proteins of the Gαi/o 
subfamily and it is known to promiscuously couple to multiple different Gαi/o subunits. In 
chapter 5, we therefore simplify the system and focus in on signalling only at the level of 
different G proteins. We characterise and investigate the drivers of the kinetics of agonist 
induced D2R G protein activation. We describe kinetically distinct G protein signalling waves 
that are mediated by the D2R. The kinetically distinct waves are shown to be due to a generally 
unappreciated role for the GTP hydrolysis rate of the Gα subunits in determining agonist 
responses over time. 
In chapters 3, 4 and 5 we identify that D2R biased agonism is heavily dependent on the 
system in which it is studied in. In an ideal scenario, one would study D2R biased agonism in 
a tissue or animal model that is relevant to the disease to reduce this dependence. However, 
investigating biased agonism in the relevant setting has been challenging due to the lack of 
molecular tools. Consequently, in chapter 6, the final experimental results chapter, we develop 
and characterise a new tool for helping discern, in vivo or ex vivo, the dependence of different 
Gαi/o proteins and arrestins on particular signalling responses and physiological outcomes. We 
show that this tool has the novel property of abolishing all Gαi/o signalling including Gαz. We 
further develop G protein mutants that are not inhibited by this toxin that can complement this 
tool and suggest the means in which the toolkit can be utilised. 
Overall, this thesis provides a detailed molecular understanding of the determinants of 
ligand binding kinetics and receptor function at the D2R. The findings fundamentally help to 





Towards characterisation of 
dopamine D2 receptor ligand binding 
pathways through kinetic studies on 
receptor mutants 




The dopamine D2 receptor (D2R) is a prototypical GPCR as it has been a long-standing 
target for drugs that relieve the symptoms of Parkinson’s disease and schizophrenia. Multiple 
studies have highlighted the clinical importance of drug binding kinetics at the D2R. Therefore, 
the rational design of drug binding kinetics at the D2R is desired. In order to do this, an 
understanding of the molecular interactions involved in the binding process are required. 
Recent x-ray crystal structures are not able to completely explain the molecular mechanisms 
of differing binding kinetic rates between ligands. Additionally, many amino acid residues in 
the extracellular regions of the D2R are likely quite dynamic and as such cannot be fully 
appreciated in crystal structures. Therefore, temporal studies are required to provide 
sufficiently detailed molecular insight into the binding entry and exit pathways of ligands at 
the D2R. In this study we optimise a time resolved-fluorescence resonance energy transfer 
competition kinetic binding assay at the D2R. We subsequently use the assay on some mutants 
in the extracellular regions of the D2R to determine the contribution these residues have in 
modulating binding kinetic association and dissociation rates. We show that amino acid residue 
mutations in these regions, such as Trp100EL1Ala, can alter ligand binding kinetics and that 
distinct ligands are more sensitive than others depending on the residue. Overall, these studies 
demonstrate that one can use competition kinetic binding experiments to start to understand 
the binding pathways of the D2R with molecular detail. 
  




G protein coupled receptors (GPCRs) are cell surface receptors characterised by seven 
α-helical transmembrane domains (TMs) that are connected by three extracellular loops (EL1-
3) and three intracellular loops (IL1-3). They bind agonists such as hormones, peptides and 
neurotransmitters on their extracellular side, permitting them to couple to heterotrimeric G 
proteins on their intracellular interface to transduce signals within cells. Drugs can be used to 
hi-jack GPCR signalling systems, in turn, altering cellular processes to modify the 
pathophysiology or symptoms of diseases. As a result of this, GPCRs represent the largest 
protein class of drug targets, accounting for around a third of all marketed small molecule drugs 
(220). 
Describing the relationships between small molecule leads and their GPCR target is 
essential to drug discovery efforts. To describe a particular ligands’ affinity for a GPCR, 
pharmacologists determine the dissociation constant (Kd). The dissociation constant is defined 
as the concentration of a ligand required to occupy half of the GPCRs at equilibrium. As such, 
the dissociation constant is typically determined through binding experiments such as 
saturation binding assays. Saturation binding assays are performed by mixing increasing 
concentrations of a ligand with a constant concentration of GPCR and measuring the bound 
population at equilibrium. Most studies perform these experiments due to their simplicity and 
practicality. However, a ligands’ dissociation constant for a GPCR is fundamentally comprised 
of the dissociation rate of the binding reaction (koff) divided by the association rate (kon). Indeed, 
determining the dissociation rates and association rates of ligand leads can provide a deeper 
understanding of the binding process. Binding kinetic rates can be determined by methods such 
as the one reported by Motulsky and Mahan (221) where a tracer ligand is co-added with 
increasing concentrations of a competitor ligand and tracked over time. Knowing the binding 
kinetics then allows one to incorporate these parameters when developing ligand leads in the 
drug discovery pipeline.  
It has been suggested that a drug’s binding kinetics, as opposed to its affinity, may 
better explain the in vivo efficacy in some instances (53,56). This is because a drugs’ 
concentration in the body does not reach equilibrium due to a several processes such as drug 
distribution and hepatic clearance. Therefore, effects related to a drugs’ binding kinetics can 
modulate the pharmacodynamics of the drug. For example, the slow dissociation rate of 
tiotropium at the muscarinic acetylcholine M3 receptor leads to prolonged duration of action, 
allowing for less frequent dosing compared to other chronic obstructive pulmonary disease 
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drugs (222). In addition, a fast-association rate may also produce sustained drug action due to 
an increased likelihood of rebinding (223,224), where rebinding describes the phenomenon 
whereby a drug that does not completely escape the receptor’s vicinity after its dissociation 
and subsequently rebinds (54). Therefore, there is significant scope for improvement of drugs 
by designing them with the desired binding kinetics. 
It is vital to understand the molecular basis of ligand binding kinetics at GPCRs. In 
particular, it is beneficial to understand the contribution that specific ligand-amino acid residue 
contacts have on ligand binding kinetics. Gaining knowledge on the roles of these binding 
contacts permits efforts to rationally design drugs with the desired binding kinetics. 
Consequently, a drug developed with the desired binding kinetic profile could be more 
efficacious or have a longer duration of action. Our understanding of GPCR structure has been 
greatly improved in recent years largely due to X-ray crystallography and cryo-electron 
microscopy (225). Through use of this structural data, the relationships between receptor 
structure and ligand binding kinetics have been amenable to investigations using molecular 
dynamics simulations. Dror and colleagues showed using long timescale simulations of the β2 
receptor that ligands entering the binding site first encounter a metastable site within the 
extracellular loops and the top of the transmembrane domains termed the extracellular vestibule 
(65). It is thought that when the ligand gets to this position there is a large energy barrier due 
to the significant de-wetting that occurs. Following this, the ligand can then enter the 
orthosteric site deep within the transmembrane domains. Molecular dynamics simulations on 
additional GPCRs have continued to support these observations of metastable ligand binding 
sites in the extracellular regions (126,226). Indeed, molecular dynamics simulations implicated 
the EL2 in the histamine H1 receptor and the adenosine A1A receptor as important for initial 
ligand contacts (226,227). Furthermore, a similar phenomenon has also been documented upon 
ligand exit at the adenosine A2A receptor (228). While these simulations have proven useful, 
the findings often remain to be validated by wet laboratory experiments. 
The dopamine D2 receptor (D2R) is a member of the dopamine family of GPCRs, 
consisting of the D1-like receptors (D1 and D5) and the D2-like receptors (D2, D3 and D4). The 
dopamine D1-like receptors couple to the Gαs subfamily to increase adenylate cyclase activity 
and the dopamine D2-like receptors couple to the Gαi subfamily to decrease adenylate cyclase 
activity (103). Expression of the D2R is enriched in many central nervous system regions such 
as the striatum, ventral tegmental area and substantia nigra pars compacta (109). While all 
dopamine receptors are important for many neurophysiological functions, the D2R is necessary 
for the majority of the roles of dopamine in vivo such as reward behaviours and locomotor 
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activity (229,230). The D2R is one of the most well-known GPCRs as it is the main target for 
drugs that relieve the symptoms of schizophrenia and Parkinson’s disease (231,232). Small 
molecule D2R antagonists or partial agonists are used to treat schizophrenia whereas 
efficacious agonists are used for the treatment of Parkinson’s disease. 
The importance of drug binding kinetics at the D2R has been highlighted by several 
studies. Kapur and Seeman have established the fast-off hypothesis of antipsychotic drugs 
acting at the D2R, positing that antipsychotics with fast dissociation rates have reduced side 
effects (187,218). In agreement with this hypothesis, we observe that the dissociation rate of 
an antagonist antipsychotic correlates with hyperprolactinaemia – a common side effect of 
these drugs. However, we observed that antagonists with faster association rates appeared to 
have increased likelihood of causing extrapyramidal side effects (61). Our group proposed that 
this is due to the rebinding within the diffusion limited compartment of a dopaminergic 
synapse. Moreover, the relationship between D2R agonist binding kinetics and clinical effect 
in Parkinson’s disease has not been thoroughly explored. Yet, D2R agonists with slow 
dissociation rates can also display differing functional profiles, including observations of 
biased agonism (96,189). Together, these studies indicate that ligand binding kinetics at the 
D2R may be tuned to have the desired therapeutic outcome. 
Our knowledge of the molecular determinants of binding kinetics at the D2R is still in 
its infancy. Some progress has been made towards understanding ligands’ structural elements 
that influence binding kinetics at the D2R. General trends are that higher molecular weight and 
increasing lipophilicity correlates with a slower antagonist dissociation rate at the D2R (128). 
More recently, Fyfe et al. have shown that structural modification of the scaffold of the 
antipsychotic haloperidol can yield a ligand with differing kinetics at the D2R (130). This work 
has demonstrated that ligand-receptor structure kinetic relationships can be optimised at the 
D2R. However, the interactions ligand moieties make with particular D2R amino acid residues 
upon entry and exit is largely unexplored. Traditional equilibrium binding studies coupled with 
site directed mutagenesis have established the main residues important for ligand binding such 
as Asp1143.32 that sits within the orthosteric binding pocket (233). Yet, whether a residue is 
more important for ligand association or dissociation is often unclear. For example, Shi and 
Javitch have previously shown that Ile184 within EL2 (Ile184 EL2) was important for the 
binding of 3[H]N-methylspiperone as this residue lines the top of the binding site (234). 
Whether this residue plays a role in granting access or egress of 3[H]N-methylspiperone is 
unclear.  
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There have been a number of recent reports of X-ray crystal structures of D2-like 
receptors that have helped drive investigations of ligand binding kinetics. Indeed, the first D2-
like structure of the D3R bound to eticlopride has been subsequently used to model the D2R 
and perform molecular dynamics simulations of ligand interactions on multiple occasions 
(121,125,126,235). Thomas et al. (126) used long timescale molecular dynamics simulations 
of a D2R that was based on the D3R-eticlopride structure to understand the association of two 
antipsychotics, clozapine and haloperidol. In doing so, they presented that Tyr3797.35 may be 
important for the ligand entry pathway of both ligands (126). Their simulations additionally 
indicated that haloperidol and clozapine also frequently interacted with Ile184EL2 along their 
binding entry pathway. Moreover, later structures of the D2R and D4R have also enabled 
additional molecular dynamics simulations and binding studies to improve our understanding 
of ligand entry and exit (122-124,236). In particular, Trp100EL1 was highlighted as an 
influential residue in the D2R-risperidone structure by potentially acting as a hydrophobic “lid” 
to increase the lifetime of ligands once bound (123).  
In this study, we aimed to use time resolved-fluorescence resonance energy transfer 
(TR-FRET) competition kinetic binding assays on extracellular vestibule mutants of the D2R 
to identify and characterise the roles these residues play in determining ligand binding rates. 
We identified that some residues in the extracellular vestibule are important drivers of the 
ligand binding kinetic rates. We showed that amino acid residue mutants in these regions can 
alter ligand binding kinetics in a ligand-specific manner. Generally, these residues appeared to 
alter the dissociation rate more so than the association rate. We noted that the effects of 
particular D2R residues on kinetic binding rates of different ligands cannot be easily predicted 
from the existing structural information. This study shows that TR-FRET competition kinetic 
binding represents a suitable platform for analysis of the molecular determinants of ligand 




Dulbecco’s phosphate buffered saline (DPBS), Hank’s balanced salt solution (Cat. No. 
H8264) (HBSS), pluronic acid-F127, Gpp(NH)p, Quikchange primers, risperidone, spiperone, 
haloperidol and bromocriptine were purchased from Sigma-Aldrich. Saponin was from Fluka 
(now Sigma-Aldrich). Eticlopride hydrochloride was purchased from Tocris Bioscience (Bio-
Techne Corp Ltd.) 384-well white optiplate LBS-coated were purchased from PerkinElmer. 
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Bifeprunox and aripiprazole (>95% pure) were synthesised in the Medicinal Chemistry 
department at Monash Institute of Pharmaceutical Sciences, Monash University Parkville 
Campus as described previously (96). Polyethylenimine (PEI) MW 25,000 was purchased from 
Polysciences, Inc. Clozapine-Cy5 was synthesised in the Centre for Biomolecular Sciences at 
the University of Nottingham as described previously (237). 5 x SNAP/CLIP-tag labelling 
medium (Part No. LABMED), SNAP-Lumi4-Tb (terbium cryptate, Part No. SSNPTBC) and 
fluorescent Spiperone-d2 (Part No. L0002RED) were acquired from Cisbio (PerkinElmer).  
Mutagenesis 
Quikchange technique was used to perform site directed mutagenesis. This method was 
performed using Phusion® High-Fidelity DNA polymerase (New England BioLabs). 
Quikchange was carried out using DNA template of FLAG-SNAP-D2SR encoded in a pEF5-
DEST-FRT plasmid. Primers used for the mutagenesis were as follows:  
SNAP-D2SR-L942.64A:   
Fwd; 5’-CTGGGTTGTCTACGCGGAGGTGGTAGGTGAG-3’,  
Rev: 5’-CTCACCTACCACCTCCGCGTAGACAACCCAG-3’.  
SNAP-D2SR-W100EL1A:  
Fwd; 5’-GGAGGTGGTAGGTGAGGCGAAATTCAGCAGGATTC-3’,  
Rev; 5’-GAATCCTGCTGAATTTCGCCTCACCTACCACCTCC-3’.  
SNAP-D2SR-I184EL2A:  
Fwd; 5’-CAGAACGAGTGCATCGCTGCCAACCCGGCCTTC-3’,  
Rev; 5’-GAAGGCCGGGTTGGCAGCGATGCACTCGTTCTG-3’,  
this mutant construct has been previously described by our group (235).  
SNAP-D2SR-Y3797.35A:  
Fwd; 5’-CAACATCCCGCCTGTCCTGGCGAGCGCCTTCACGTG-3’,  
Rev: 5’-CACGTGAAGGCGCTCGCCAGGACAGGCGGGATGTTG-3’.  
After Quikchange mutagenesis, the full coding region was demonstrated to be correct 
and containing the desired mutations through Sanger sequencing method by the DNA 
Sequencing Laboratory, D98 Medical School, Queens Medical Centre. 
Stable cell line production 
Generations of stably expressing mutant D2R cell lines was achieved using the Flp-In™ 
system (ThermoFisher Scientific). Mutant SNAP-D2SR constructs were transfected into 
parental Flp-In CHO-K1 cells. The parental Flp-In CHO-K1 cells were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM)/F12 supplemented with 10% FBS, 100μg/mL 
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penicillin/streptomycin and 100μg/mL zeocin. The FlpIn CHO-K1 cells were seeded into T75 
flasks to be approximately 30% confluent the following day in complete media lacking zeocin. 
The next day, the cells were transfected with pOG44 together with the mutant pEF5-DEST-
FRT-FLAG-SNAP-D2SR construct in a DNA ratio of 9:1 (w/w) using polyethylenimine (PEI). 
48 hours after transfection, selection of genomic integration by replacing the media with 
DMEM/F12 supplemented with 10% FBS, 100μg/mL penicillin/streptomycin and 700μg/mL 
hygromycin B (Corning). Cells were then expanded into T175 flasks and passaged three times 
before freezing and storing. SNAP-D2SR mutant expression was confirmed by a functional G 
protein activation assay described in detail the following chapters. previously reported Flp-In 
CHO-K1 cells stably expressing SNAP-D2SR mutants were subsequently grown in 
DMEM/F12 supplemented with 10% FBS, 100μg/mL penicillin/streptomycin and 600μg/mL 
hygromycin B. 
Terbium cryptate labelling  
Terbium cryptate labelling of SNAP-tagged receptors in live Flp-In CHO-K1 cells was 
performed identically to our previously described method in Appendix 2 (125).  
Membrane preparation 
Membrane preparations were performed on terbium cryptate labelled thawed cell 
pellets identical to our previously described method in Appendix 2 (125). 
HTRF kinetic binding assay 
The kinetic binding assay was performed almost identically to our previously described 
method, for specific details please see this work (125). This method was adapted from our 
group’s earlier publications using the same technique (61,96). Briefly, 20µL of different ligand 
cocktails diluted in Hanks Balanced Salt Solution + 20mM HEPES + 0.02% Pluronic-F127 + 
1% dimethyl sulfoxide, pH 7.4 (with KOH) was added to each well of a 384-well white bottom 
optiplate LBS coated. After incubating the ligand cocktail in the plate and the membrane 
preparation in the injector system at 37°C, the PHERAstar FS (BMG Labtech) was then set to 
inject 20µL of cell membrane preparation in the same buffer +100µM Gpp(NH)p and 50µg/mL 
saponin at 400µL/s. The HTRF filter module detected the terbium cryptate at 337nm and the 
fluorescent ligand at 665nm simultaneously. The focal height was set to 10.4mm. The 
excitation source was set to laser and the number of flashes varied between 5-9 depending on 
the particular experiment and cycle time. Integration start: 60μs, Integration time: 400μs. Cycle 
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time varied between 2-5 seconds depending on experiment. All experiments were performed a 
minimum of four times and in singlet wells. 
Data analysis  
The TR-FRET binding values were determined by dividing the 665nm (fluorescent 
ligand acceptor) channel values by the 337nm (terbium cryptate donor) channel and 
multiplying by 10,000. This was then subtracted by the non-specific binding determined in 
each experiment providing the “specific HTRF ratio x 10,000”. All laboratory data was 
analysed with the curve-fitting software GraphPad Prism 8.2 using nonlinear regression. 
To determine kinetic binding parameters of fluorescent ligands in association binding 
experiments equation (2.1) was used. In GraphPad Prism this is named as the ‘Association 
kinetics – Two or more conc. of hot.’ model. L is the fluorescent ligand - either spiperone-d2 
or clozapine-Cy5 (concentration in M). 
(2.1) 
𝑘𝑜𝑏 = [𝐿] × 𝑘𝑜𝑛 + 𝑘𝑜𝑓𝑓 
To determine the affinity of the fluorescent ligands at each mutant equation (2.2) was 






To determine the kinetic binding parameters of unlabelled competitor ligands, the data 
was fit to equation (2.3) for the kinetics of competitive binding described by Motulsky and 
Mahan (221). In GraphPad Prism this is named the ‘Kinetics of competitive binding’ model. 
Where; k1, kon of fluorescent ligand (M-1min-1); k2, koff of fluorescent ligand (min-1); k3, kon of 
unlabelled competitor ligand (M-1min-1); k4, koff of unlabelled competitor ligand (min-1); L, the 
fluorescent ligand (concentrations are in nM); I, the unlabelled competitor ligand 
(concentrations are in nM); Y, specific binding of the fluorescent ligand with the receptor 
(HTRF ratio x 10,000); X, time (minutes). 
(2.3) 
𝐾 = 𝑘 [𝐿] × 10 + 𝑘  
 
𝐾𝐵 = 𝑘3 [𝐼] × 10
−9 + 𝑘4 
 
𝑆 = (𝐾 − 𝐾 ) + 4 × 𝑘 × 𝑘 × [𝐿] × [𝐼] × 10   




𝐾𝐹 = 0.5(𝐾𝐴 + 𝐾𝐵 + 𝑆) 
 
𝐾𝑆 = 0.5(𝐾𝐴 + 𝐾𝐵 − 𝑆) 
 
𝑄 =  
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Determination of ligand kinetics at the wild-type D2R 
We initially aimed to determine the binding kinetics of several diverse ligands at the 
wild-type D2R. We subsequently aimed to assess the binding kinetics of these ligands at D2R 
mutants. Therefore, we were only able to assess a handful of ligands due to assay throughput 
constraints. Further, we selected high affinity ligands that would remain amenable to 
quantification with the assay despite a significant loss of affinity at a receptor mutant. In 
addition, we were interested in assessing agonists as well as antagonists to determine whether 
agonist efficacy may influence binding kinetic rates. We therefore selected three agonists; 
aripiprazole, bifeprunox and bromocriptine, as well as three antagonists; eticlopride, 
risperidone and spiperone (Fig. 2.1). The three agonists were chosen due to their clinical 
relevance, structural variability and variation in efficacy. Aripiprazole is the first of a novel 
class of antipsychotics that display very low levels of agonism (238). Bifeprunox is a partial 
agonist with a very slow dissociation rate that was initially under development for the treatment 
of schizophrenia but later discontinued (239). Aripiprazole and bifeprunox are both 
phenylpiperazine derivatives although they are structurally quite different from each other (Fig. 
2.1). Bromocriptine is a high efficacy agonist derived from ergots. It is prescribed for 
Parkinson’s disease and hyperprolactinemia among other indications (240). The three 
antagonists that we selected in this study were chosen based on their distinct chemotypes that 
we hypothesised may confer different D2R amino acid contacts upon binding.  In addition, we 
chose to assess eticlopride and risperidone because these antagonists had both been solved in 
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high resolution structures of D2-like receptors. This is important as it enables the first attempt 
to independently assess the accuracy of the reported structures as well as to relate accurate 
kinetic data to the static structures. Eticlopride is used primarily for research and was bound to 
the D3R in the only solved D3R crystal structure at the time of writing (121). Eticlopride has a 
similar substituted benzamide scaffold to other D2-like antagonists such as sulpiride and 
nemonapride. Risperidone is a benzisoxazole derivative that is an atypical antipsychotic and 
was reported bound to the D2R in the first D2R crystal structure (123,241). Spiperone is from 
the butyrophenone class of typical antipsychotics, a class that includes haloperidol that was 
bound in the second reported crystal structure of the D2R (124,242). 
 
Figure 2.1: Chemical structures of the D2R ligands assessed in this study. 
 
To determine the binding kinetics of our set of diverse ligands it was first necessary to 
characterise the fluorescent tracer ligands. We used two fluorescent tracers in this study; the 
high affinity tracer spiperone-d2 and a lower affinity tracer clozapine-Cy5. The binding 
kinetics of these two tracers were successfully determined using association kinetic binding 
assays at the wild type D2SR (Fig. S2.1A & B, Fig. S2.2A & B and Table 2.1). The binding 
kinetic parameters of the unlabelled ligands of interest were then obtained using the two tracers 
separately in competition kinetic binding experiments following the method of Motulsky and 
Mahan (Figure S2.1 & S2.2) (221). Importantly, the values determined with each tracer were 
in close agreement with each other (Table 2.1). Indeed, no significant differences were 
observed between the kon, koff or Kd values of unlabelled ligands when using clozapine-Cy5 as 
a tracer instead of spiperone-d2 as determined by unpaired t-test (P < 0.05). Aripiprazole, 
bifeprunox, risperidone and spiperone have previously had their binding kinetics determined 
by our group (61,96). The results here closely matched our previous results despite using 
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different fluorescent tracer ligands from our previous work. For example, bifeprunox 
dissociated slowly (2.92x10-2 min-1 using Spiperone-d2) from the D2R whereas risperidone 
dissociated at a moderate pace (8.49x10-1 min-1) (Table 2.1). Moreover, bromocriptine 
displayed the slowest association rate out of the ligands that we determined (6.69x106 M-1min-
1), whereas eticlopride displayed the fastest association rate (1.31x109 M-1min-1). Both 
bromocriptine and eticlopride also displayed relatively slow dissociation rates (Table 2.1). 
  




Table 2.1: Kinetic binding parameters of ligands at the SNAP-D2SR-WT. 
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All values are expressed as the mean ± SEM from ‘n’ number of experiments performed in 
singlet wells. aSpiperone-d2 and clozapine-Cy5 parameters were determined from association 
kinetic binding experiments. bKd and pKd values were calculated from the mean kon and koff 
values determined via competition kinetic binding experiments. 
 
 
The Trp100EL1Ala mutation markedly impacts ligand binding kinetics 
By determining the binding kinetics of several ligands at the D2R-WT, we established 
a reference dataset to then investigate the effects of mutations in extracellular vestibule 
residues. Due to the low affinity of clozapine-Cy5 it became inadequate as a tracer on mutant 
D2Rs. We ascertained that higher concentrations of clozapine-Cy5 were required when its 
affinity was reduced due to mutation of the D2R, this resulted in appreciable non-specific 
binding at these concentrations possibly through bystander FRET. The high non-specific 
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binding markedly increased the noise when acquiring temporal data (data not shown). 
Therefore, competition kinetic binding experiments were carried out using the higher affinity 
tracer spiperone-d2.   
Trp100EL1 in the D2R-risperidone structure is positioned over the top of the binding site 
suggesting that it could potentially act as a hydrophobic “lid” over the orthosteric binding site 
(Fig. 2.2A) (123). Another D2R structure, with haloperidol bound, shows disparity in its 
position of Trp100EL1 whereby it is rotated away from the orthosteric site and its sidechain 
pyrrole ring appears to make polar contacts with Ser1033.21 (superscript numbers indicate 
Ballesteros-Weinstein numbering (243)) on the very top of transmembrane domain (TM) III 
(Fig. 2.2B) (124). Trp100EL1 in this position would likely have less of an effect on ligand 
binding. Likewise, the corresponding Trp96EL1 in the closely related D3R-eticlopride structure 
is also in this position (Fig. 2.2C) (121), and the same pose of the TrpEL1 is observed in two 
separate D4R structures and other aminergic receptor structures (67,122,236,244). We therefore 
were interested in understanding what role Trp100EL1 plays in influencing ligand binding rates. 
We first assessed the effect of the Trp100EL1Ala mutation on the fluorescent tracer 
spiperone-d2. (Table 2.2). The dissociation rate of spiperone-d2 was significantly increased 
and its affinity was reduced (Fig. 2.2D). Plotting the observed association rate against the 
concentration of spiperone-d2 demonstrated that a linear relationship remained, indicating that 
the ligand-receptor binding reaction followed the law of mass action and hence spiperone-d2 
could continue to be used as a tracer on this mutant (Fig. 2.2E). Upon performing competition 
kinetic binding experiments using spiperone-d2 we observed that the mutation significantly 
reduced the affinity of all the ligands tested (Table 2.2). The three agonists; aripiprazole, 
bifeprunox and bromocriptine all displayed an accelerated dissociation rate with the largest 
change occurring on bifeprunox’s dissociation rate which increased approximately 112-fold 
(Fig. 2.2F). Moreover, bromocriptine was the only ligand to display a significantly increased 
association rate relative to that at the WT (2.5-foldΔ). In contrast to bromocriptine, the 
association rates of the antagonists eticlopride and risperidone were significantly decreased 
(eticlopride 0.17-foldΔ, risperidone 0.37-foldΔ), and spiperone’s association rate was not 
significantly changed (P = 0.057, one-way ANOVA with Dunnett’s multiple comparisons test). 
Risperidone’s dissociation rate and affinity were less attenuated relative to the other small 
molecules tested (Table 2.2 and Fig. 2.2G)). The sample size of the ligands is relatively small 
yet, overall, the loss of affinity at Trp100EL1Ala for the three agonists can be attributed to 
increases in dissociation rate, whereas for the antagonists, loss of affinity emerges from both a 
decrease in association rate and an increase in dissociation rate. 
Table 2.2: Kinetic binding parameters of ligands at SNAP-D2SR mutants. 
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All values are expressed as the mean ± SEM from ‘n’ number of experiments performed in singlet wells. aSpiperone-d2 parameters 
were determined from association kinetic binding experiments. bKd and pKd values were calculated from the mean kon and koff values 
determined with competition kinetic binding experiments. cfold change as compared to the parameters obtained at the wild type D2R 
using spiperone-d2 as a tracer. * Statistically significant (P < 0.05) from WT value determined with spiperone-d2 by one-way ANOVA 
and Dunnet’s multiple comparison’s test.
 
 
Figure 2.2: Assessment of ligand binding kinetics at the SNAP-D2SR-W100EL1A mutant. 
(A) Position of Trp100EL1 within the D2R structure (green cartoon) bound to risperidone (risp) 
(magenta sticks) (PDB code 6CM4). (B) Position of Trp100EL1 within the D2R structure (red 
cartoon) bound to haloperidol (halo) (black sticks) (PDB code 6LUQ). (C) Position of Trp96EL1 
within the D3R structure (blue cartoon) bound to eticlopride (etic) (orange sticks) (PDB code 
3PBL). (D) A representative association kinetic binding trace of increasing concentrations of 
spiperone-d2 to SNAP-D2SR-W100EL1A (experiment was performed in singlet and 
representative of 9 separate experiments).  (E) Observed association rate vs. concentration 
plot displays a linear relationship. Observed association rates were determined from one 
phase association fits at each spiperone-d2 concentration. Data represent the mean ± SEM 
(n=9). (F) A single representative competition kinetic binding trace with increasing 
concentrations of unlabelled competitor bifeprunox (representative of 8 separate experiments 
performed in singlet wells). (G) A single representative competition kinetic binding trace with 
increasing concentrations of unlabelled competitor risperidone (representative of 7 separate 
experiments performed in singlet wells).  
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The effects of the Leu942.64Ala mutation and the Trp100EL1Ala mutation show 
similarities 
Leu942.64 is positioned at the top of TM II where, in the D2R-risperidone structure, it 
appears to help coordinate Trp100EL1 over the top of the orthosteric binding site by making 
hydrophobic interactions (Fig. 2.3A) (123). In contrast, Leu942.64 in the D2R-haloperidol 
structure and Leu892.64 in the D3R-eticlopride structure do not appear to make large contacts 
with Trp100EL1 or Trp96EL1 respectively as this residue is turned away from the orthosteric site 
(Fig. 2.3A & B) (121,124). Consequently, we next examined the effects of a Leu942.64Ala 
mutation on several ligands to see whether this had related effects to the Trp100EL1Ala 
mutation.  
The Leu942.64Ala mutation significantly increased both the rate of association and 
dissociation for spiperone-d2 (Table 2.2 and Fig. 2.3D). The net effect was a reduction in 
spiperone-d2’s affinity. In competition kinetic experiments, the Leu942.64Ala mutation slowed 
the association rate of all the unlabelled antagonists while the agonists were either unchanged 
or increased in their association rate. For example, eticlopride’s association rate was 
significantly decreased by 0.31-fold (~30%), while aripiprazole’s association rate was 
unchanged (Fig. 2.3F &G). Furthermore, the effects on dissociation rate were more pronounced 
than effects on association rate. Indeed, the Leu942.64Ala mutation increased the rate of 
dissociation of all ligands tested, with the notable exception of risperidone that displayed a 
small increase that was not statistically significant. The largest increases in dissociation rate 
were observed for the agonists, all increasing more than 20-fold. On the whole, it could be seen 
that there was a broad relationship between the effects at the Leu942.64Ala mutant with those 
effects observed at the Trp100EL1Ala mutant. Dissociation rate was considerably increased for 
the agonists at Leu942.64Ala and even more so at Trp100 EL1Ala. Antagonist association rates 
were often slowed at these two residues whereas for agonists they were either unchanged or 
accelerated. 




Figure 2.3: Assessment of ligand binding kinetics at the SNAP-D2SR-L942.64A mutant. 
(A) Position of Leu942.64 within the D2R structure (green cartoon) bound to risperidone (risp) 
(magenta sticks) (PDB code 6CM4). (B) Position of Leu942.64 within the D2R structure (red 
cartoon) bound to haloperidol (halo) (black sticks) (PDB code 6LUQ). (C) Position of Leu892.64 
within the D3R structure (blue cartoon) bound to eticlopride (etic) (orange sticks) (PDB code 
3PBL). (D) A representative association kinetic binding trace of increasing concentrations of 
spiperone-d2 to SNAP-D2SR-L942.64A (experiment was performed in singlet and representative 
of 5 separate experiments).  (E) Observed association rate vs. concentration plot displays a 
linear relationship. Observed association rates were determined from one phase association 
fits at each spiperone-d2 concentration. Data represent the mean ± SEM (n=5). (F) A single 
representative competition kinetic binding trace with increasing concentrations of unlabelled 
competitor aripiprazole (representative of 4 separate experiments performed in singlet wells). 
(G) A single representative competition kinetic binding trace with increasing concentrations of 
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No large consequences in ligand binding kinetics are caused by an Ile184EL2Ala 
mutation  
We next examined the effect of an Ile184EL2Ala mutation on ligand binding kinetics. In 
the D2R-risperidone structure, Ile184EL2’s side chain extends from its short α-helix in EL2 
across to the top of the orthosteric binding pocket and interacts with Trp100 on EL1 (Fig. 2.4A, 
2.2A & 2.3A) (123). However, in the D2R-haloperidol structure Trp100EL1 is turned away and 
thus does not interact with Ile184EL2 (Fig. 2.4B and 2.3B) (124). Additionally, the IleEL2 in the 
D3R structure (Ile183EL2) is in a different pose whereby EL2 is disordered, resulting in 
Ile183EL2 being directed downwards and the Ile183EL2 backbone hydrogen bonding with 
His3496.55 (His3936.55 in D2R) (Fig. 2.4C) (121). While these interactions of Ile184EL2 would 
suggest it may be important for ligand entry and egress, the Ile184EL2Ala mutation generally 
influenced ligand kinetics the least out of all amino acid residue mutants in this study (Table 
2.2). However, very little statistically significant differences were determined between this 
mutant and the WT. For example, risperidone’s dissociation rate did not significantly change 
at the Ile184EL2Ala mutant (P = 0.39, one-way ANOVA with Dunnett’s multiple comparisons 
test). Eticlopride was the only ligand significantly affected with its dissociation rate being 
increased approximately six-fold.  
  





Figure 2.4: Assessment of ligand binding kinetics at the SNAP-D2SR-I184EL2A mutant. 
(A) Position of Ile184EL2 within the D2R structure (green cartoon) bound to risperidone (risp) 
(magenta sticks) (PDB code 6CM4). (B) Position of Ile184EL2 within the D2R structure (red 
cartoon) bound to haloperidol (halo) (black sticks) (PDB code 6LUQ). (C) Position of Ile183EL2 
within the D3R structure (blue cartoon) bound to eticlopride (etic) (orange sticks) (PDB code 
3PBL). (D) A representative association kinetic binding trace of increasing concentrations of 
spiperone-d2 to SNAP-D2SR- I184EL2A (experiment was performed in singlet and 
representative of 5 separate experiments).  (E) Observed association rate vs. concentration 
plot displays a linear relationship. Observed association rates were determined from one 
phase association fits at each spiperone-d2 concentration. Data represent the mean ± SEM 
(n=5). (F) A single representative competition kinetic binding trace with increasing 
concentrations of unlabelled competitor eticlopride (representative of 4 separate experiments 
performed in singlet wells). (G) A single representative competition kinetic binding trace with 
increasing concentrations of unlabelled competitor spiperone (representative of 5 separate 
experiments performed in singlet wells). 
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Some ligand’s association kinetics can be influenced by a Tyr3797.35Ala mutation 
Tyr3797.35 (Tyr4087.35 in D2LR) sits at the top of TM VII and makes a hydrogen bond 
with His3936.55. Broadly, Tyr3797.35 exists in two different poses in current D2-like X-ray 
crystal structures. In the D2R-risperidone structure, the Tyr3797.35 sidechain is positioned 
across towards TM VI (Fig. 2.5A)(123). Tyr3797.35 in the D2R-haloperidol structure is 
positioned with its side chain pointing in towards the orthosteric binding site and the hydroxy 
group hydrogen bonds with haloperidol (Fig. 2.5B) (124). This same pose is also observed in 
the D3R-eticlopride (Tyr3657.35) structure and other reported D4R structures (Fig. 
2.5C)(121,122,236). The position Tyr3797.35 adopts in the D2R-haloperidol structure and D3R-
eticlopride structure would in fact clash with risperidone as positioned in the D2R-risperidone 
structure. This indicates that the side chain of Tyr3797.35 is likely quite dynamic.  
Upon mutation of tyrosine 3797.35 to alanine, spiperone-d2’s association rate was 
increased. This increase was likely an effect of the attached fluorophore because unlabelled 
spiperone was unchanged in its association rate (Table 2.2 and Fig. 2.5A & B). Eticlopride 
(0.35-foldΔ) and risperidone (0.44-foldΔ) were both significantly slowed in their association 
rate at the Tyr3797.35Ala mutant. The Tyr3797.35Ala mutant significantly increased the 
association rate of bromocriptine approximately 2.6-fold (Table 2.2 and Fig. 2.5G). 
Additionally, no ligands displayed any significant differences in their dissociation rate or the 
affinity (Fig. 2.5F). Overall, Tyr3797.35 may be an important mediator of the association for 
some, but not all, agonists and antagonists. 




Figure 2.5: Assessment of ligand binding kinetics at the SNAP-D2SR-Y3797.35A mutant. 
(A) Position of Tyr3797.35 within the D2R structure (green cartoon) bound to risperidone (risp) 
(magenta sticks) (PDB code 6CM4). (B) Position of Tyr3797.35 within the D2R structure (red 
cartoon) bound to haloperidol (halo) (black sticks) (PDB code 6LUQ). (C) Position of Tyr3657.35 
within the D3R structure (blue cartoon) bound to eticlopride (etic) (orange sticks) (PDB code 
3PBL). (D) A representative association kinetic binding trace of increasing concentrations of 
spiperone-d2 to SNAP-D2SR- Y3797.35A (experiment was performed in singlet and 
representative of 5 separate experiments).  (E) Observed association rate vs. concentration 
plot displays a linear relationship. Observed association rates were determined from one 
phase association fits at each spiperone-d2 concentration. Data represent the mean ± SEM 
(n=5). (F) A single representative competition kinetic binding trace with increasing 
concentrations of unlabelled competitor bifeprunox (representative of 5 separate experiments 
performed in singlet wells). (G) A single representative competition kinetic binding trace with 
increasing concentrations of unlabelled competitor bromocriptine (representative of 4 separate 
experiments performed in singlet wells). 
 
2.4 Discussion 
In this study, we made some of the first efforts towards understanding the roles residues 
in the extracellular regions of the D2R play in determining ligand binding kinetics. We 
demonstrated that some selected amino acid residues in the extracellular regions of the D2R 
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can dramatically alter ligand binding association and dissociation in a ligand-dependent 
fashion. This suggests that small molecule drugs can be rationally designed based on particular 
metastable binding sites as they enter and exit from the D2R. Hence, medicinal chemistry of 
ligands targeting the D2R can be guided by these new contact sites identified upon entry and 
exit of the receptor in addition to the ligand contacts in the final binding pose within the 
orthosteric site as is classically done. Furthermore, we highlighted the importance of measuring 
ligand binding kinetics at GPCRs by the fact that often the association rate and/or dissociation 
rate of a ligand was altered without the affinity being altered. Therefore, these changes in 
binding would not be detected in traditional equilibrium binding assays. Moreover, through 
selecting a panel of structurally diverse ligands including antipsychotics from different classes 
and agonists with varying efficacy, we were able to show that the same mutation can influence 
the binding kinetics of agonists and antagonists in a distinct manner. Indeed, at the 
Trp100EL1Ala mutation and the Leu942.64Ala mutation, agonists’ dissociation rates were 
increased whereas for antagonists both the association rates and dissociation rates were 
negatively impacted. This may reflect distinct binding pathways between agonists and 
antagonists at the D2R or possibly different conformational equilibria or the receptor. 
Our results on the Trp100EL1Ala mutant revealed that Trp100EL1 is critical for 
determining the binding kinetics of all the six ligands that were tested. This indicates that 
Trp100EL1 is likely important for the binding of most D2R ligands. The results at this mutant 
are consistent with Wang and colleagues radioligand binding experiments reporting that 
Trp100EL1 was an important residue for prolonging the dissociation rate of risperidone and 
some additional ligands (123). Indeed, in our experiments the Trp100EL1Ala mutation had a 
larger impact on dissociation rates than association rates. Moreover, Wang and colleagues first 
singled out the Trp100EL1 residue due to the unique “lid” position it adopts in the D2R-
risperidone structure (Fig. 2.2A & 2.3A). However, out of all the ligands tested in our study, 
risperidone’s dissociation rate and its affinity were the least impacted by the Trp100EL1Ala 
mutation (koff 4.3-foldΔ, Kd 12-foldΔ). It is not clear as to why this is the case for risperidone, 
although, future assessment of additional ligands at this mutant may further our knowledge of 
the mechanisms behind this observation. Moreover, bifeprunox displayed the slowest 
dissociation rate out of the ligands tested. Interestingly, the dissociation rate of bifeprunox was 
considerably impacted (112-foldΔ) by the Trp100EL1Ala mutation. Bifeprunox is a bitopic drug 
(Fig. 2.1), therefore the fact that Trp100EL1Ala influences its dissociation to such an extent may 
be evidence for bifeprunox’s benzyl group extending out and making contacts with Trp100EL1 
that helps maintain bifeprunox in the binding site for an extended period. 
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The changes in binding kinetics at the Leu942.64Ala mutant appeared to follow a similar 
trend to the Trp100EL1Ala effects. Certainly, most ligands’ dissociation rates were significantly 
increased at the Leu942.64Ala, this was consistent with previous research showing that the 
Leu942.64Ala mutation increases the dissociation rate of nemonapride from the D2R (123). The 
two mutants having similar effects suggests that Leu942.64 and Trp100EL1 interact. Given that 
ligand dissociation rates were often impacted suggests that one of these interactions is likely to 
be Leu942.64 stabilising Trp100EL1 in a position that extends the lifetime of the drug-receptor 
complex after the ligand has bound in some manner. For Trp100EL1 to exchange between the 
position in the D2R-risperidone structure and the D2R-haloperidol structure it may have to cross 
Leu942.64. However, whether the important pose of Trp100EL1 is Trp100EL1 in its “lid” position 
as shown in the D2R-risperidone structure or the outward position in the D2R-haloperidol 
structure or a completely different pose are unclear from these experiments. What is clear is 
that Leu942.64 likely contributes through coordinating Trp100EL1 and the region is likely quite 
dynamic because ligands display differing sensitivity to these mutations. Future work 
incorporating molecular dynamics simulations would help disentangle the poses and 
interactions that occur at these residues. 
There were limited changes in the binding kinetics of each of the ligands at the 
Ile184EL2Ala mutant. The only statistically significant finding was that of an increase in 
eticlopride’s dissociation rate. This is interesting considering that the analogous Ile183EL2 in 
the D3R-eticlopride structure appears to be coordinated downwards towards the ligand relative 
to the current D2R structures (Fig. 2.4A, B & C) (121). One could speculate tentatively that 
eticlopride may direct this residue along with EL2 into a different orientation as opposed to 
other ligands. Moreover, the overall observation that there were little effects at the Ile184EL2Ala 
mutant initially appears inconsistent with previous research, for example, early work by Shi 
and Javitch (234) identified this residue as important when scanning D2R EL2 residues with 
the substituted cysteine accessibility method. In this previous work, Ile184EL2 was substituted 
for cysteine and allowed to react with methanethiosulfonate substrate derivatives. Having a 
bulky methanethiosulfonate substrate derivative attached lead to the inhibition of the binding 
of the antagonist 3[H]N-methylspiperone, indicating that the residues’ side chain is directed 
towards the binding site (234). Indeed, the position of Ile184EL2 was directly observed upon 
solving the D2R-risperidone X-ray crystal structure where it was shown to be positioned 
inwards over the orthosteric binding site (Fig. 2.4A)(123). From the crystal structure, Wang 
and colleagues suggested that Ile184EL2 was important for ligand binding kinetics by making 
contacts with Trp100EL1. However, Wang and colleagues did not observe any significant effect 
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of the Ile184EL2Ala mutation on risperidone’s dissociation rate unless the mutation was 
combined with the Leu942.64Ala mutation (123). Together this suggests that Leu942.64 is 
probably more important for the correct coordination of Trp100EL1 than Ile184EL2 is. Certainly, 
in our experiments the Ile184EL2Ala effects did not relate to those of the Trp100EL1Ala like the 
Leu942.64Ala effects did. Therefore, our data illustrates that Ile184EL2 does not play a 
substantial role in determining ligand binding kinetics even though it can line the top of the 
binding site. In agreement with this, we previously showed that the Ile184EL2Ala mutation did 
not impact the equilibrium binding affinity of aripiprazole with radioligand binding assays 
(235). Additionally, we have demonstrated in a separate study using molecular dynamics 
simulations that the EL2 of the D2R is can be disordered and has a propensity spontaneously 
unwind from its largely α-helical nature (125) (Fig. 2.4C). Accordingly, if EL2 is unwound 
then IL184EL2 may be oriented differently and hence play a less important role in ligand 
binding. In addition, it is worth noting that the chemical divergence between the isoleucine to 
alanine mutation may not have been distinct enough to notice an effect. Future research could 
assess the effects upon mutation to a polar residue.  
The data on the Tyr3797.35Ala mutant suggests that Tyr3797.35 may be important for the 
association of some antagonists. A previous molecular dynamics study provided evidence that 
Tyr3797.35 can make initial contacts with clozapine and haloperidol, allowing these ligands to 
gain entry into the extracellular vestibule before entering into their final binding pose deeper 
in the orthosteric site (126). Therefore, the results here are in agreement with these previous 
molecular dynamics simulations and that eticlopride and risperidone may have a similar 
passageway of association as that proposed for clozapine and haloperidol. It is important to 
note, however, that spiperone’s association rate was not significantly decreased even though it 
shares a butyrophenone moiety with haloperidol. The specific lack of impact on spiperone 
warrants follow up studies on additional antagonists because it indicates that not all antagonists 
follow the same entry pathway. Indeed, antagonists following different entry pathways may 
permit the fine-tuning of antagonist association rates which is an major factor for determining 
an antipsychotic’s propensity to cause extrapyramidal side effects (61). 
We have shown that understanding the role of extracellular vestibule residues in 
determining ligand binding kinetics requires extensive dynamic experiments that cannot easily 
be predicted from a stationary crystal structure. Certainly, the Ile184EL2 residue would appear 
to be important for binding of many ligands based on its position in D2R receptor structures. 
However, X-ray crystal structures reflect only a single snapshot of one binding pose of a ligand 
in the receptor. In addition, the currently available D2R structures were solved by using 
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identical constructs that harbour the same thermostabilising mutations (123,124). 
Consequently, there could be constraints in these structures that do not represent the multiple 
different conformations that the D2R can adopt. Determining D2R structures with different 
receptor constructs as well as in apo- and active-states would provide a wider picture in 
understanding the possible roles different residues play in influencing ligand entry and exit.  
We encountered some technical challenges in this study that may explain why there has 
only been a handful of reports assessing the effects mutagenesis on the ligand binding kinetics 
of GPCRs. We identified that clozapine-Cy5, that has low D2R affinity, would not be a suitable 
tracer ligand at a number of the mutants due to an inability to use it at higher concentrations. 
We also identified that differing concentrations of ligands and measurement timescales were 
often required depending on the D2R mutant. Therefore, the assay throughput is reduced owing 
to the amount of optimisation required for each mutant and ligand combination. In addition to 
this, low affinity and fast dissociating unlabelled competitor ligands could not have their 
binding kinetics determined at mutant receptors because their binding kinetics were above the 
temporal limits of assay detection (245).  
While performing competition kinetic binding experiments is excellent for aiding drug 
discovery efforts due to its ease and throughput, there is also a limitation in that the kinetic 
rates of association and dissociation are average rates of potentially multiple binding pathways. 
Hence, there may be far more complexity in the entry and exit pathways of different ligands 
that is overlooked with this approach. Fitting with this idea, the dissociation of miroviroc at the 
CCR5 was argued to be a multi-step event as it displayed a two-phase fit that indicated that 
there is possibly two receptor bound states; one with tighter binding and one that dissociates 
faster (246). Therefore, coupling the data in this study with single molecule studies or 
molecular dynamics simulations would deepen our understanding of these processes. Single 
molecule fluorescent ligand binding studies could reveal multiple different populations that 
correspond to multiple different binding pathways or processes (247). In addition, molecular 
dynamics simulations would also allow for the high-resolution visualisation of the multiple 
different binding pathways. 
In summary, we have taken the first steps towards identifying amino acid residues that 
may be important in lining the ligand entry and exit pathways of the D2R. The results in this 
study may be used towards guiding design of D2R ligands with the appropriate kinetics for the 
particular indication of interest. In addition, we have provided a framework for interrogating 
ligand binding kinetics of mutant GPCRs with TR-FRET competition kinetic binding. Hence, 
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our study here and studies following our framework will be crucial to deepening our knowledge 
of the molecular determinants of binding kinetics at GPCRs to enhance rational drug design. 
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2.5 Supplementary Materials 
Figure S2.1: SNAP-D2SR-WT membrane binding with spiperone-d2 fluorescent ligand 
tracer. (A) Representative association kinetic binding trace of increasing concentrations of 
spiperone-d2 to SNAP-D2SR-WT (n=9). (B) Observed association rate vs. concentration 
plot displays a linear relationship. Observed association rates were determined from one 
phase association fits at each spiperone-d2 concentration. Data represent the mean ± SEM 
(n=9). (C-H) Single representative competition kinetic binding traces with increasing 
concentrations of unlabelled; aripiprazole (n=8) (C), bifeprunox (n=8) (D), bromocriptine 
(n=8) (E), eticlopride (n=8) (F), risperidone (n=7) (G) and spiperone (n=8) (H). 
 
Chapter 2 – Kinetic binding studies on D2R mutants 
79 
 
Figure S2.2: SNAP-D2SR-WT membrane binding with clozapine-Cy5 fluorescent ligand 
tracer. (A) Representative association kinetic binding trace of increasing concentrations of 
clozapine-Cy5 to SNAP-D2SR-WT (n=7). (B) Observed association rate vs. concentration 
plot displays a linear relationship. Observed association rates were determined from one 
phase association fits at each clozapine-Cy5 concentration. Data represent the mean ± SEM 
(n=7). (C-H) Single representative competition kinetic binding traces with increasing 
concentrations of unlabelled; aripiprazole (n=7) (C), bifeprunox (n=7) (D), bromocriptine 







A systematic exploration of the 
relationship between agonist binding 
kinetics and observations of biased 
agonism at dopamine D2 receptor 
proximal signalling events 




In the previous chapter it was highlighted that ligands binding the D2R can have quite 
different binding kinetics. In this chapter, we investigated what differing binding kinetics of 
agonists may mean for the functional effects of those agonists. It is well appreciated that 
GPCRs, including the D2R, can elicit pluri-dimensional signalling waves mediated by different 
G proteins, regulatory proteins and other signalling effectors. Moreover, some agonists are 
capable of preferentially activating one signalling pathway over another, a phenomenon termed 
biased agonism. By selectively activating the desired pathway, harnessing biased agonism can 
potentially reduce a drugs’ on-target side effects while maintaining the therapeutic benefit. 
However, the mechanisms responsible for biased agonism are largely unknown. Establishing 
the mechanisms of biased agonism allows for the rational design of biased agonists. Therefore, 
we aimed to investigate whether the length of time an agonist binds the D2R may influence its 
signalling and manifest biased agonism. Time resolved-fluorescence resonance energy transfer 
competition kinetic binding assays were used to determine the binding kinetics of a panel of 
ligands. The agonist’s functional effects were then assessed at multiple receptor-proximal 
events including G protein activation, regulatory protein recruitment and D2R trafficking using 
bioluminescence resonance energy transfer. Responses were quantified with an operational 
model of agonism and compared to their binding kinetic parameters. Modest biased agonism 
was detected mainly between well coupled G proteins and poorly coupled regulatory proteins. 
Agonist dissociation rate did not consistently correlate with biased agonism and no clear 
relationship between agonist dissociation rate and apparent biased agonism could be 
established. Both association rate and dissociation rate may partly contribute to biased agonism 
observations. Differences in the functional affinity of agonists may be responsible for most 
observations of bias at the D2R. Overall, further studies involving a larger number of agonists 
and providing more mechanistic insight are warranted to understand whether binding 
parameters influence D2R biased agonism detection. 
  




G protein-coupled receptors (GPCRs) are the largest drug target in the world, 
accounting for approximately 30% of all marketed drugs (2). GPCRs are characterised by seven 
α-helical transmembrane domains that snake through the plasma membrane. They receive 
extracellular signals in the form of agonists such as hormones, neurotransmitters and odorants, 
that induce conformational changes in the GPCR, permitting signal transduction into the cell. 
Recent research has provided increasing examples of the multifaceted nature of GPCR 
signalling. Once activated, GPCRs can couple to heterotrimeric G proteins, consisting of a Gα 
subunit and a Gβγ obligate dimer. GPCRs can couple to multiple distinct G proteins, described 
according to the different Gα subfamilies that can act on different downstream signalling 
effectors (248). Having coupled to G proteins, GPCRs commonly bind G protein coupled-
receptor kinases (GRKs) and arrestins to regulate the G protein mediated signalling (249). In 
addition, arrestins may also act as a signalling scaffold to help elicit a distinct wave of 
signalling (250). Considerable efforts have been made to understand and harness this 
multifaceted nature of GPCR signalling in an effort to design improved drugs. This has 
spawned the notion of biased agonism. Biased agonism is the phenomenon of one agonist that 
acts to preferentially activate one signalling pathway more than another signalling pathway at 
the same receptor (70). It is widely accepted that GPCRs are capable of existing in multiple 
conformational states (71,72). Hence, having this natural capability, biased ligands are thought 
to act via stabilising distinct states of the GPCR (76). These different conformational states 
then presumably lead to the differential coupling of heterotrimeric G proteins or other effectors 
(e.g. arrestins) and thus lead to signalling pathways being activated to different extents. 
A GPCR at which biased agonism has previously been investigated is the dopamine D2 
receptor (D2R). The D2R has long been a validated therapeutic target for neuropsychiatric and 
neurological diseases. The D2R is known to promiscuously couple to all members of the Gαi/o 
family (132). While it is thought that the D2R mainly couples to the Gαo isoforms; GαoA and 
GαoB, in the brain (140), there is also strong evidence of D2R coupling to other G proteins. For 
example, the D2R may couple to a Gαi subtype (Gαi1, Gαi2 or Gαi3) in the dorsal striatum where 
the receptor has reduced sensitivity to dopamine (144). Similarly, coupling to Gαz may be 
important for D2R dependent hyperlocomotion, adrenocorticotropic hormone secretion and 
hypothermia (150,151). Furthermore, some D2R mediated behaviours may be dependent on 
arrestin scaffolding to mediate a signalling pathway distinct from those mediated by G proteins 
involving protein phosphatase 2, Akt and GSK3 (155). Therefore, by selectively biasing the 
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coupling towards different G proteins or arrestin, a D2R drug may have differential effects. For 
this reason, such drugs that display apparent bias at the D2R have already been generated 
including those that display bias between G proteins and arrestins and those that display bias 
between different G protein subtypes (184,251,252). Understanding how such agonists 
engender bias at the D2R is important because then one may be able to extend the mechanism 
to other GPCRs. If mechanisms are shared across GPCRs, such as agonists displaying a 
particular biochemical property or characteristic that is responsible for manifesting bias, then 
this would enable the rational design of biased agonists at other GPCRs, and in turn, greatly 
improve the efficiency of the drug discovery process. 
Ligand binding kinetics has long been implicated in efforts aiming to understand the 
functional effects of agonists. One of the early attempts to relate the binding kinetics to the 
action of drugs was proposed by Paton in 1961 (90). Paton’s “rate theory of drug action” was 
based on experiments with a range of ligands performed on guinea-pig ileum. It was observed 
that the magnitude of the response was proportional to the rate of the offset of the response. 
Paton concluded that a ligand must dissociate from the receptor before another ligand could 
bind and exert its effects, hypothesising that agonists act effectively as competitive antagonists 
after having induced signalling at the receptor. Hence, the theory states that agonist action is 
dependent on the number of interactions an agonist makes with the receptor. Following this, 
kinetic models have been developed based on the idea that an agonist can allosterically activate 
a GPCR that essentially acts as an enzyme to facilitate guanine nucleotide exchange on the G 
protein (253,254). It could be conceived from these models that a slower agonist dissociation 
rate may lead to higher efficacy because more productive G protein cycle events are able to 
occur before agonist dissociation. Following this logic, Sykes and colleagues were able to show 
a correlation between agonist efficacy and dissociation rate at the muscarinic acetylcholine M3 
receptor (91). Likewise, the same correlation has also been observed at the adenosine A2A 
receptor (93).  
While our laboratory did not observe any clear relationship between ligand binding 
kinetics and efficacy, we recently reported that the differing binding kinetics of agonists can 
lead to observations of apparent biased agonism (96). This was exemplified using the D2R as 
a prototypical GPCR, agonists with slow dissociation rates were shown to display biased 
agonism between distinct signalling endpoints in a manner that changed over time. The 
apparent bias emerged from slow dissociating agonists relative to fast dissociating agonists, 
and Klein-Herenbrink et al. (96) provided evidence that the interplay between agonist binding 
kinetics, the kinetics of cell signalling events and the kinetics of regulatory/desensitization 
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pathways altogether lead to apparent bias. Subsequent studies on the serotonin 5-HT2A and 5-
HT2B receptor used mutagenesis to alter the binding kinetics of agonists and by doing so, 
showed that β-arrestin-2 recruitment could be selectively modulated with minimal effects on 
G protein dependent pathways (97). Moreover, biased agonists acting at the Y1 receptor may 
impart their bias by increasing the relative residence time of the G protein with the Y1 receptor 
(98). Together these studies may indicate that agonists with a long residence time may induce 
a different conformational landscape in the GPCR for an extended amount of time and thus 
permit different effectors, such as G proteins or arrestins, to engage the receptor for different 
amounts of time, leading to biased signalling. In addition, other mechanisms may explain the 
bias observations due to differences in agonist dissociation rate. For example, Woolf and 
Linderman (255) used a kinetic two-dimensional Monte Carlo model to suggest that differently 
sized enrichment zones can be created on the plasma membrane due to differing dissociation 
rates of agonists, this in turn can result in GRK recruitment becoming partially disconnected 
from G protein signalling.  
Our groups’ previous work had some limitations that we sought to address in this study. 
Our previous research used a finite number of agonists in which all the slowly dissociating 
agonists were also partial agonists with a similar bitopic piperazine derivative structure. 
Additionally, all the higher efficacy agonists that were tested dissociated quickly from the D2R. 
Moreover, we only measured the activation of a subset of Gαi/o proteins and we measured the 
activation of downstream signalling events that may be more prone to cellular system effects 
such as cAMP inhibition, cellular impedance and ERK1/2 phosphorylation. To address these 
concerns in this study, we selected a larger panel of agonists with greater structural diversity 
and a wider range of agonist efficacy. This allowed us to draw stronger conclusions on 
relationships between agonist kinetics and particular functional measurements. In addition, we 
measured proximal signalling and regulatory events at the D2R, encompassing Gαi/o subfamily 
activation including Gαz activation, GRK2 recruitment, arrestin recruitment and D2R 
trafficking. By doing so, we allow for less kinetic steps to occur between ligand binding and 
the signalling response. We identified that while agonist dissociation rate may play a role in 
bias observations, agonist association rate may also play an equally important role – possibly 
through rebinding. Our results show that, even at proximal receptor events, high affinity 
agonists that increase in occupancy over time may display some apparent bias relative to 
agonists that have a relatively constant occupancy over time. Considering differing changes in 
agonist occupancy over time will be a critically important step for pre-clinical biased agonism 
drug discovery moving forward. 






Drugs: aripiprazole, bifeprunox, cariprazine and pardoprunox were synthesised in 
house as previously reported (96,256). Brexpiprazole was synthesised in house. Ropinirole was 
sourced from BetaPharma Shanghai. Dopamine, S-3PPP, bromocriptine, rotigotine and 
spiperone were sourced from Sigma-Aldrich Corporation. ST-836 was a generous gift from 
Thomas P. Blackburn. PPHT-Red was from Cisbio. Clozapine-Cy5 was synthesised in house 
as previously described (237). 
 
Kinetic binding assays 
The terbium labelling of receptors, fluorescent ligand binding assays, determination of 
fluorescent ligand binding kinetics, competition kinetic binding assays and data analysis were 
performed as previously described (61), also as outlined in the previous chapter and in appendix 
2. Determination of kinetic parameters for ST-836 were performed identically except that 
clozapine-Cy5 was used as the fluorescent tracer. 
 
Cell culture 
Parental Flp-In HEK 293 cells and Flp-In HEK 293 cells stably expressing the human 
D2LR were cultured in plastic T175 flasks with DMEM + 10% FBS (+ 600µg/mL G418 for 
D2LR expressing cells). Cells were split 1/10 with 1xVersene + trypsin (0.5%) every 2 days 
and were not passaged beyond 30 passages. 
 
G protein activation 
G protein activation was measured by means of a bioluminescence resonance energy 
transfer (BRET) assay that has been described earlier (132,257). The mechanism by which the 
BRET technique functions is through the ability of the pleckstrin homology domain of GRK3 
to reversibly bind free Gβγ subunits such that when the Gα subunit becomes active (GTP bound 
conformation) the Gα subunit dissociates from Gβγ and then the BRET donor; masGRK3ct-
Rluc8, binds dissociated Gβ1γ2-venus subunits – the BRET acceptor. The BRET sensors were 
adapted from earlier FRET constructs, both first published by Hollins and colleagues (258).  
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Flp-In HEK 293 cells recombinantly expressing the human D2LR were initially 
harvested and plated into 10cm dishes at a density of 2.5 million cells. 24 hours after 
transferring the cells to dishes the cells were co-transfected with the different plasmid DNA 
constructs using polyethylenimine (PEI) at a ratio of 1:6 (µg DNA: µg PEI). The following 
constructs (in pcDNA3.1) were transfected in a ratio of 1:1:1:2 (µg): masGRK3ct-Rluc8, 
venus-156-239-Gβ1, venus-1-155-Gγ2, and either Gαi1/Gαi3/GαoA /GαoB-C351I, Gαi2-C352I or 
Gαz-WT. MasGRK3ct-Rluc8, venus-156-239-Gβ1 and venus-1-155-Gγ2 constructs were kind 
gifts from Nevin Lambert (Augusta University, USA). PTX insensitive mutant Gα subunits 
and Gαz were from the cDNA resource centre, cDNA.org. The following morning, the 
transfected cells were collected from the dishes and plated into poly-D-lysine coated white-
bottom 96 well optiplates. That night, the cells were treated in their plates with pertussis toxin 
(100ng/mL) in DMEM + 10% FBS for 16 hours. The next day the plates were taken out of the 
cell culture incubator and the media was aspirated, washed with Hank’s balanced salt solution 
(HBSS) pH 7.4 and replaced with 80μL HBSS. The plate was returned to 37°C for the 
remainder of the experiment. The cells were then left to equilibrate for 15 minutes in HBSS. 
10μL of coelenterazine-h (final concentration of 5μM) was then added to the wells with an 
electronic Eppendorf multi-step pipette and the plate was incubated for another 15 minutes 
before addition of the drugs. The plate was then detected in a PHERAstar® FS microplate 
reader (BMG LABTECH GmbH, Germany). The PHERAstar® FS is equipped for 
simultaneous dual emission detection of the donor 465-505nm and acceptor 505-555nm. The 
plate was continuously measured with a 30s cycle time, 2.5 minutes occurred before addition 
of the D2LR agonist of interest using a 12 channel Eppendorf electronic multi-pipette. The 
measurements from the acceptor channel were then divided by the donor channel to determine 
the BRET ratio. The BRET ratio was then normalised with the maximal effect produced by 
dopamine set to 100%. The setup of experiments measuring the functional re-association 
kinetics of GαoB heterotrimers was kept identical up until the day of the assay with the 
exception of cells being devoid of treatment with pertussis toxin. After washing the cells with 
HBSS on the day of the assay, 140uL of HBSS was added to each well and a cocktail of 40uL 
of coelenterazine-h was co-added with 100nM ropinirole, 33nM cariprazine, 100nM 
aripiprazole, 1nM rotigotine and 100nM bifeprunox 12.5 minutes before addition of 20uL of 
spiperone to make a final concentration of 20μM. For these experiments the data was 
normalised to wells with the particular agonist followed by the vehicle set to 100%. 
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GRK2 and arrestin recruitment 
GRK2 and arrestin recruitment experiments were performed essentially the same as 
previously described by our group and others with minor modifications (96,102,259). Briefly, 
2 million Flp-In HEK 293 cells were first plated into 10cm dishes. The following day after 
transferring the cells to dishes the cells were transfected using PEI in a ratio of 1:6 (µg DNA: 
µg PEI). The cells were transfected with pcDNA3.1+ encoding human D2LR-Nluc (0.25µg). 
Then, depending on the particular assay the cells were co-transfected with the additional 
constructs as follows: For GRK2 recruitment, the cells were additionally transfected with 
GRK-venus (4µg) and pcDNA3.1+ (3.5µg). For β-arrestin-1 recruitment, the cells were 
additionally transfected with GRK2 (2µg) and YFP-β-arrestin-1 (5.5µg). For β-arrestin 2 
recruitment, the cells were additionally transfected with GRK2 (2µg) and YFP-β-arrestin 2 
(5.5µg). The following day after transfection, the cells were harvested from the dishes and 
plated into poly-D-lysine coated white-bottom 96 well optiplates. The next day after the cells 
were transferred to plates, the assay was conducted keeping the buffers, incubators and plate 
reader at 37°C. The plate was first taken out of the incubator and the media was aspirated, 
washed once with HBSS and replaced with HBSS to 80μL. The cells were then left to 
equilibrate for 15 minutes at 37°C in the HBSS before addition of 10μL of 1/100 Nano-Glo 
substrate (Promega) was added to each well of the 96 well plate with an electronic pipette. The 
plate was then left for an additionally 15 minutes at 37°C before then being measured using the 
PHERAstar® FS microplate reader (BMG LABTECH GmbH, Germany). Individual wells 
were simultaneously measured for the luminescence emission signal of the luciferase Nluc 
(465-505nm) and the acceptor fluorescent protein YFP/venus (505-555nm). The plate was 
measured at 37°C over a 30-minute time-course upon addition of each D2LR agonist with a 12-
channel electronic-pipette for quick addition of compounds. The BRET was then quantified 
identically to the G protein activation assays. 
 
Trafficking 
D2LR trafficking assays were performed using cellular compartment BRET sensors 
described by Lan and colleagues (260). Trafficking for the D2R using this method has been 
performed and characterised by another group (261). The basis of the assay requires different 
endomembrane compartments to be tagged with a yellow fluorescent protein venus to serve as 
BRET acceptor and the D2LR is tagged with Nluc to serve as BRET donor. The changes in 
BRET are then monitored to indicate movement towards or away from various compartments. 
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First, 2 million Flp-In HEK 293 cells were harvested and dispersed evenly into a 10cm dish. 
The following day after the cells had adhered, the media was changed and the cells were 
transfected with PEI:DNA complexes in a ratio of 1:6 (µg/µg). The cells were transfected in a 
dropwise manner with D2LR-Nluc (0.25µg), GRK2 (2µg), β-arrestin-2 (4µg) and either KRas-
venus (1µg), Rab5a-venus (1µg) or Rab11-venus (1µg). The following day the cells were lifted 
off the dishes and plated in poly-D-lysine coated 96 well white bottom optiplates at 100µL per 
well. The next day the assay was started and performed as described for the GRK2 and arrestin 
recruitment assays with a PHERAstar® FS plate reader at 37°C in HBSS pH 7.4. The plates 
for the trafficking experiments were measured over a one-hour time course collecting data 
simultaneously with a 465-505nm (donor) channel and a 505-555nm (acceptor) channel. The 
BRET ratio was determined by dividing the acceptor channel by the donor channel. The raw 
BRET ratio was then plotted for five independent experiments. A one phase exponential 
equation was fit to the hour-long time course data to determine the trafficking rates for each 
agonist. 
Data analysis 
Data was analysed using GraphPad prism version 8. Concentration response curves 
were fit with a three-parameter fit to determine potency and maximal effect values. For 
quantifying bias parameters, an operational model of agonism described previously was used, 
this is also outlined in the subsequent chapter in more detail (86,87). 
  





Measurement of the binding kinetics of agonists at the D2R  
We have previously determined the binding kinetics of several D2R agonists using TR-
FRET competition kinetic binding on cell membranes (96). To build on this work and obtain a 
more comprehensive panel of agonists with known binding kinetic parameters for the D2R, we 
set out to use this method again on some additional agonists. We initially characterised PPHT-
Red, the fluorescent tracer to be used for competition kinetic binding studies. In equilibrium 
saturation binding experiments, the fluorescent tracer behaved essentially as we had 
determined before (61,96); with low non-specific binding and a dissociation constant (Kd) of 
approximately 14.7 ± 1.8nM (Fig. 3.1A). The binding kinetics of PPHT-Red were then 
determined using increasing concentrations of the ligand in association kinetic binding 
experiments (Fig. 3.1B). PPHT-Red displayed an association rate (kon) of 2.3 ± 0.2 x 107 M-
1min-1 and a dissociation rate (koff) of 0.29 ± 0.02 min-1. These binding kinetic parameters also 
fit well with what we have previously described. When using the binding kinetic parameters to 
calculate an affinity (Kd =12.6 nM), this calculation agreed with the affinity that was 
determined from saturation binding at equilibrium. 
We were then able to determine the kinetics of some additional agonists through 
competition kinetic binding experiments. The binding kinetics of brexpiprazole, a relatively 
new antipsychotic drug with low agonist efficacy at the D2R, was determined (262). We 
observed that brexpiprazole displayed a high affinity for the D2R, associating very quickly and 
dissociating slowly relative to the other agonists (Table 3.1). We also determined the binding 
kinetics of bromocriptine and rotigotine, two efficacious agonists approved for the treatment 
of Parkinson’s disease (Table 3.1 & Fig. 3.1D & E)(263-265). The binding kinetics of 
bromocriptine and rotigotine varied substantially even though these two agonists are prescribed 
for the same indication. Bromocriptine dissociated quite slowly from the D2R (koff = 0.02 ± 
0.007min-1) whereas rotigotine dissociated relatively quickly (koff = 1.20 ± 0.21) (Table 3.1 & 
Fig. 3.1D & E). Additionally, we characterised a new investigational agonist for Parkinson’s 
disease – ST-836 (266). This agonist was the only ligand where the binding kinetics were 
determined with a different fluorescent tracer - clozapine-Cy5. We have previously 
demonstrated that using clozapine-Cy5 as a tracer instead of PPHT-Red in these assays leads 
to no noticeable difference in binding kinetics (237). ST-836 dissociated very rapidly from the 
D2R although it also displayed quite a fast association rate to the D2R that maintained its 
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binding affinity in the nanomolar range (Table 3.1). With these new agonists characterised, 
along with the previously characterised agonists, we then had a suite of eleven D2R agonists 
with varying binding kinetics and chemical structure (Fig. 3.1F & Table 3.1).  
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Figure 3.1: Determination of the binding kinetics of additional D2R agonists with tr-
FRET. (A) Saturation binding of SNAP-D2R membranes with the fluorescent ligands PPHT-
Red. Data represents the mean ± SEM, n=9. (B) Association kinetic binding of increasing 
concentrations of PPHT-Red to the SNAP-D2R. Data represents the mean, n=9. (C) A one 
phase association curve was fit to the binding of each concentration of PPHT-Red (shown in 
panel B) to determine the observed association rate (kobs). Each concentration of PPHT-Red 
is shown on the x-axis the kobs is plotted on the y-axis. The relationship between the two follows 
a linear relationship giving a y-intercept (koff) of 0.47 ± 0.04 min-1. Data represents the mean ± 
SEM, n=9. (D & E ) Single representative competition kinetic binding experiments with PPHT-
Red and bromocriptine (D) or rotigotine (E) are shown. (F) The binding kinetic parameters of 
agonists used in this study. Data represents the mean ± SEM. Agonists binding kinetic 




Table 3.1: Kinetic binding parameters of selected agonists for the human D2R. 
 Data are expressed as the mean ± SEM 
Agonist koff (min-1) kon (M-1 min-1) pKd 
 
Aripiprazole a 0.21 ± 0.02 1.01 ± 0.23 x 109 9.66 
Bifeprunox a 0.01 ± 0.00 1.84 ± 0.30 x 108 10.3 
Brexpiprazole 0.09 ± 0.01 1.60 ± 0.36 x 109 10.2 
Bromocriptine 0.02 ± 0.01 3.93 ± 0.52 x 107 9.40 
Cariprazine a 0.35 ± 0.05 1.27 ± 0.30 x 108 9.53 
Dopamine a 2.00 ± 0.30 3.14 ± 0.73 x 105 5.18 
Pardoprunox a 2.28 ± 0.56 1.25 ± 0.24 x 108 7.75 
Ropinirole a 2.60 ± 0.75 1.46 ± 0.46 x 106 5.73 
Rotigotine 1.20 ± 0.21 1.97 ± 0.44 x 108 8.21 
S-3PPP a 1.51 ± 0.35 3.25 ± 0.90 x 106 6.11 
ST-836 b 9.66 ± 2.81 2.42 ± 0.66 x 108 7.40 
a Determined in a previous study by our group (96). b determined using clozapine-Cy5 as the 
fluorescent tracer. 
 
Functional characterisation of agonist action over time 
We next monitored the functional effects of the panel of agonists. We used HEK 293 
cells and transiently transfected bioluminescence resonance energy transfer (BRET) sensors, 
enabling us to monitor the responses in live cells and in real time. The D2R mediated activation 
of six different inhibitory G proteins; Gαi1, Gαi2, Gαi3, GαoA, GαoB, and Gαz, was monitored 
with a sensor that measures the release of Gβγ (258). The detection method utilises the 
pleckstrin homology domain of GRK3 as a BRET donor that binds dissociated Gβγ-Venus 
subunits. Therefore, the wild type D2R and unlabelled Gα subunits are used, reducing the 
likelihood of altering the native G protein activation kinetics (257). In addition to this, we 
measured the recruitment of GRK2, β-arrestin-1 and β-arrestin-2 to the D2R. The direct 
recruitment of these three regulatory proteins was measured by tagging the D2R with a BRET 
donor (Nluc) and each one of the regulatory proteins with a BRET acceptor (YFP/Venus). In 
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general, all agonists inducing G protein activation or recruitment of regulatory proteins 
displayed signals that were sustained for over 30 minutes (Fig. S3.1-S3.11). Efficacious 
agonists, such as dopamine, produced large responses at all effectors (Fig. S3.6). Efficacious 
agonist responses were rapid and sustained when activating G proteins, however, when 
recruiting arrestins a peak followed by a smaller plateau was observed. Contrastingly, agonists 
with low efficacy, such as bifeprunox, produced weak responses over time when activating 
Gαi1, Gαi2, Gαi3 (Fig. S3.2). The greater potency and maximal effect of agonists acting at GαoA 
and GαoB relative to Gαi1, Gαi2 and Gαi3 was expected from previous studies demonstrating 
that the D2R is more efficiently coupled to these G proteins (138,139,267). Moreover, low 
efficacy agonists also very weakly induced the recruitment of GRK2, β-arrestin-1 and β-
arrestin-2 and no initial peak in recruitment was observed. 
Knowing each agonist’s binding kinetic parameters and having determined the 
functional effects over time, we then aimed to investigate how these two characteristics relate. 
We used the binding kinetic values and the different concentrations of each agonist that were 
used in our functional assays to simulate their expected receptor occupancy over time (Fig. 
3.2A, B & C). From these simulations, we observed that sub-saturating concentrations of the 
agonist had either a constant occupancy over time if the agonist dissociated quickly (e.g. 
dopamine) (Fig. 3.2A), or sub-saturating concentrations of agonist increased in occupancy over 
time if the agonist dissociated slowly (e.g. bifeprunox) (Fig. 3.2B). Therefore, we predicted 
that, when fitting concentration response curves for each measurement timepoint in our 
functional assays, agonists would either have a constant potency over time if they had a fast 
dissociation rate or they would increase in potency over time if they had a slow dissociation 
rate.  
When examining GαoA activation or β-arrestin-2 recruitment induced by the fast 
dissociating agonist dopamine, the relative responses at each concentration remained constant 
over time (Fig. 3.2D & G and Fig. S3.6). Hence, when fitting concentration response curves at 
30 second intervals over a 30-minute time course, dopamine’s potency (pEC50) remained 
constant over time for these pathways (Fig. 3.2J). Two other fast dissociating agonists, 
ropinirole and S-3PPP, had functional responses over time that fit with this pattern of agonist 
action (Fig. S3.8 & S3.10). Moreover, slow dissociating agonists including aripiprazole, 
bifeprunox, brexpiprazole, bromocriptine and cariprazine fit the expected profile whereby low 
concentrations of the agonist slowly increased in response over time, leading to an increase in 
potency over time (Fig. 3.2E, H & K and Fig. S3.1-S3.5). However, when we measured the 
functional responses of rotigotine over time, the temporal profile did not match the simulated 
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receptor occupancy (Fig. 3.2C, F, I & L & Fig. S3.9). Rotigotine had a relatively fast 
dissociation rate and hence it was expected to display a constant response at each concentration 
over time. Unexpectedly, we observed an increase in response over time for the lower 
concentrations that manifested as an increase in potency of approximately 25-fold at GαoA and 
21-fold at β-arrestin-2 (Fig. 3.2F, I & L). Additionally, pardoprunox and ST-836 also displayed 
a similar increase in potency over time to rotigotine while also having relatively fast 
dissociation rates from the D2R (Fig. S3.7 & S3.11). Overall, our temporal functional assays 
showed that potency changes over time at the D2R can usually, but not always, be predicted by 
their binding kinetics measured in membranes. 
  




Figure 3.2: Concentration-response time course characterisation of agonists acting at 
the D2R. Simulated D2R occupancy of increasing concentrations of dopamine (A), bifeprunox 
(B) and rotigotine (C) over time based on the binding kinetics determined by tr-FRET 
experiments. D2R mediated GαoA protein activation over time in response to increasing 
concentrations of dopamine (D), bifeprunox (E) and rotigotine (F). Recruitment of β-arrestin-2 
over time by the D2R upon stimulation with increasing concentrations of dopamine (G), 
bifeprunox (H) and rotigotine (I). Concentration response curves were taken at each time point 
for GαoA activation (black circles) and β-arrestin-2 recruitment (grey squares), the potency 
estimates (pEC50) were then plotted over time for dopamine (J), bifeprunox (K) and rotigotine 
(L). Data for graphs D-L represent the mean ± SEM of between 3-6 separate experiments. 
 
Slow agonist dissociation is not essential for an increase in potency over time 
We further investigated the mechanism through which rotigotine, pardoprunox and ST-
836 exhibit an increase in potency over time in a manner that was inconsistent with their fast 
dissociation rates. Given that Birdsong and colleagues (88) have shown that over time agonists 
can exhibit an increased affinity at the μ-opioid receptor, we hypothesised that the agonists 
displaying an increase in potency over time at the D2R may ‘sense’ a different conformation of 
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the receptor over time which may lead to a slowed dissociation rate in live cells. Therefore, in 
a similar experimental design as that used by Birdsong and colleagues, we decided to measure 
the functional deactivation rate of the D2R after pre-incubation with a number of agonists, 
including rotigotine. Although there are obvious differences between the experimental design 
of this assay and our measurements of ligand binding kinetics above (Fig. 3.1, Table 3.1), we 
anticipated that this would serve as a good proxy estimate of the ligand binding dissociation 
rate in our live cell assays. We performed these experiments by initially stimulating cells with 
the agonist of interest, followed by adding an antagonist at high saturating concentrations to 
prevent the agonist from re-binding once it dissociated from the D2R. Before being 
outcompeted with spiperone, agonists were incubated with the cells for 12.5 minutes - a time 
that allowed for agonists to increase in potency as well as display a robust response. This 
experiment is analogous to binding assays in which an isotopic dilution method, using a 
saturating concentration of cold ligand, is used to visualise ligand dissociation by preventing 
radioligand rebinding. In this manner, we utilised the same BRET sensor for the earlier G 
protein activation assays and were able to essentially track the rate at which the G proteins 
become inactive and re-associate. This assay was chosen because it detects activation directly 
proximal to the receptor and can be measured with high temporal resolution (132,257). When 
we performed these experiments, we observed large differences in the deactivation rates 
between the panel of agonists (Fig. 3.3A). Moreover, the rate of re-association of the G protein 
heterotrimers correlated strongly with the ligand binding dissociation rate (Fig. 3.3B) (Pearson 
r = 0.988, P=0.003). Therefore, the signalling deactivation in live cells can be directly in line 
with the binding dissociation performed in membranes. Importantly, rotigotine’s functional 
deactivation rate approximated its binding dissociation rate (Fig. 3.3B and Table 3.2). This 
suggests that the dissociation rate, at least in the case of rotigotine, is not altered at all in the 
functional assays in this study. Consequently, the increase in potency in all functional events 
over time for rotigotine, pardoprunox and ST-836 is likely not conferred through a slowed 
dissociation rate over time. 





Figure 3.3. The relationship between the agonist-specific G protein deactivation rate in 
live cells and direct ligand binding dissociation rate. D2R agonists were added to D2R 
expressing Flp-In HEK 293 cells and allowed to activate GαoB heterotrimers followed by being 
out-competed by a high concentration of the high affinity antagonist spiperone to track the rate 
of de-activation of GαoB protein signaling. (A) 100nM Bifeprunox (red squares), 100nM 
Aripiprazole (light blue circles), 33nM Cariprazine (brown diamonds) 1nM Rotigotine (pink 
triangles) and 100nM Ropinirole (orange squares) were incubated for 12.5 minutes before 
being out-competed with 20μM Spiperone. (B) Experimentally determined ligand binding 
dissociation rates (koff) plotted on the y-axis with GαoB protein re-association rate (deactivation 
– kdeact) in this study plotted on the x-axis showed a Pearson correlation with an R2 of 0.988 
(P=0.003). Data is plotted on a log10 scale for ease of visualization. 
 
 
Table 3.2: G protein deactivation rate after stimulation with different agonists. 
Data is represented as the mean ± SEM from three separate experiments. 
Agonist kdeact (min-1) 
Aripiprazole 0.085 ± 0.029 
Bifeprunox 0.005 ± 0.001 
Cariprazine 0.120 ± 0.013 
Ropinirole 15.10 ± 2.206 
Rotigotine 0.604 ± 0.104 
 
 
Quantitative assessment of agonist action at a single timepoint at proximal functional 
events 
We next wanted to quantitatively assess the different agonists’ functional responses at 
each effector. The agonists’ responses were assessed by taking a single timepoint and fitting 
concentration response curves. We chose a time of fifteen minutes after agonist stimulation to 
examine the responses because a robust window of response was maintained and most of the 
increases in potency had occurred by this time point. When assessing the activation of the 
different G proteins at 15 minutes we observed clear differences in the responses generated by 
each agonist at Gαi1, Gαi2 and Gαi3 as compared to those at GαoA, GαoB, and Gαz. As we had 
observed in the temporal responses, there were large differences in maximal effect between the 
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agonists when activating Gαi1, Gαi2 and Gαi3 but not GαoA, GαoB and Gαz. Regarding Gαi1, Gαi2 
and Gαi3 activation, known low efficacy agonists such as aripiprazole and brexpiprazole 
produced weak responses (262,268), whereas efficacious agonists such as dopamine and 
rotigotine produced more full responses (Fig. 3.4A, B & C and Table 3.3)(264). Indeed, the 
maximal Gαi2 response induced by brexpiprazole was approximately 23% that of dopamine’s 
response (Table 3.3). In contrast to the responses at Gαi1, Gαi2 and Gαi3, the activation of GαoA, 
GαoB, and Gαz produced more robust responses, with most agonists’ effects resembling a full 
agonist (Fig. 3.4D, E & F and Table 3.3). For example, brexpiprazole induced a maximal 
response at GαoA that was 89% that of dopamine’s response. Agonists were also usually more 
potent when activating GαoA, GαoB, and Gαz relative to Gαi1, Gαi2 and Gαi3. For instance, 
dopamine was approximately 10-fold more potent at activating GαoA over Gαi2 (GαoA pEC50 = 
8.32 ± 0.04 (EC50 = 4.79nM), Gαi2 pEC50 = 7.30 ± 0.03 (EC50 = 50.1nM)). The stronger 
responses at GαoA and GαoB reflect the selectivity of the D2R for these G proteins (138,139). 




Figure 3.4: Agonist activation of different G protein subtypes by the D2R. Flp-In HEK 293 
cells stably expressing the D2R were transfected with BRET sensors and the activation of Gαi1 
(A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), and Gαz (F) was monitored in the live cells in 
response to increasing concentrations of a set of agonists with varying binding kinetics and 
efficacy. All responses shown were determined 15 minutes after stimulation. Data represents 
the mean ± SEM of 4-6 separate experiments. 
 
Table 3.3: Functional parameters of various agonists abilities to induce activation of different G proteins by the D2R. 
Activation was measured 15 minutes after stimulation. Data is represented as the mean ± SEM of 4-6 separate experiments. 
 G protein α subunit 
 Gαi1 Gαi2 Gαi3 GαoA GαoB Gαz 














































































































































































































































































































































































































In the G protein cycle, a single GPCR can catalytically activate multiple G proteins that 
results in the amplification of G protein signalling (269). Arrestin and GRK recruitment by 
GPCRs does not appear to have this level of amplification. For this reason, there is often a 
reduction in the potency when measuring the recruitment of arrestins and GRKs to GPCRs 
relative to the activation of G proteins (96,270). When we assessed the recruitment of GRK2, 
β-arrestin-1 and β-arrestin-2 our data supported this notion because agonists were generally 
less potent than they were at activating G proteins (Fig. 3.5A, B & C and Table 3.4). Moreover, 
when measuring the recruitment of any of the regulatory proteins, weaker efficacy agonists 
also displayed substantial reductions in the maximal effect they induced relative to dopamine. 
For example, the aripiprazole induced maximal effects for GRK2, β-arrestin-1 and β-arrestin-
2 were all less than 20% of dopamine’s response (Table 3.4). Certainly, some partial agonists 
displayed such weak responses when recruiting GRK2 and β-arrestin-1 that a sigmoidal 
concentration response curve could not be fit to their responses accurately (Table 3.4, r2 < 0.7 
indicated by ND). The fact that weaker efficacy agonists displayed dampened maximal effects 
may reflect previously published data that, relative to other GPCRs such as the vasopressin V2 
receptor, the D2R has a weak interaction with arrestins (271,272). In the GRK2 and arrestin 
recruitment assays, dopamine induced the largest maximal response, and this robust effect 
matches previous observations in arrestin recruitment assays (270). However, rotigotine was 
the most potent agonist in these assays as well as in the G protein activation assays.  





Figure 3.5: Agonist induced recruitment of GRK2, β-arrestin-1 and β-arrestin-2 to the 
D2R. Recruitment of GRK2 (A), β-arrestin-1 (B), and β-arrestin-2 (C) to the D2R was monitored 
in live Flp-In HEK 293 cells with BRET. Concentration-response curves of different agonists 
with varying binding kinetics and efficacy at the D2R were plotted. All responses plotted were 
determined 15 minutes after stimulation. The data is presented as the mean ± SEM of 3-4 
separate experiments. 
  




Table 3.4: GRK2 and β-arrestin recruitment parameters for different agonists.  
Measurements were taken 15 minutes after stimulation. Data represents the mean ± SEM of 
3-4 separate experiments. 
 Regulatory event 
 GRK2 β-arrestin-1 β-arrestin-2 




































































































































































Having determined the potencies at G proteins and regulatory pathways we were then 
able to compare these values to our determined affinities of the agonists. It is expected that the 
potency of each compound would not match their affinity due to the intrinsic efficacy of the 
particular compound. However, we observed very large differences between potencies and 
affinities, with some potencies much higher and some lower than the respective affinity. 
Interestingly, the group of bitopic partial agonists including aripiprazole, bifeprunox, 
brexpiprazole and cariprazine all displayed functional potencies that were orders of magnitude 
lower than their binding affinities. For example, aripiprazole displayed a kinetic pKd of 9.66 
whereas its potency (pEC50) for GαoA activation and β-arrestin-2 recruitment was 7.48 and 6.94 
respectively (Table 3.3 & 3.4). The responses and potencies of these agonists largely reach 
their maximal point at the 15-minute measurement timepoint (Figure S3.1-S3.11). Therefore, 
this observation is likely not due to the agonists not reaching equilibrium with the D2R. 
Moreover, the ergot agonist bromocriptine also displayed a decrease in its potency values 
(pEC50 GαoA = 8.03, pEC50 β-arrestin-2 = 7.20) relative to its affinity (pKd = 9.40). In contrast, 
some other agonists displayed higher or similar potencies in the functional assays as comapred 
to their binding affinities, such as dopamine (pKd = 5.18, pEC50 GαoA = 8.32, pEC50 β-arrestin-
2 = 6.73) and rotigotine (pKd = 8.21, pEC50 GαoA = 9.65, pEC50 β-arrestin-2 = 8.67). In these 
cases, the higher potency in the functional assay relative to the binding affinity is likely due to 
a combination of receptor reserve, agonist efficacy and signal amplification and such 
observations are consistent with many previous studies of agonist action at GPCRs (273). 
However, the lower potency of ligands like aripiprazole as compared to their binding affinity 
cannot be reconciled with this mechanism.  Together this demonstrates that the receptor 
occupancy of an agonist required to elicit a half-maximal response can be vastly different 
between distinct D2R agonists.  
While assessing differences in either the maximal effect or potency is useful, each of 
these measures are subject to differences in both the system and the specific assay detection 
method. Different functional endpoints can have different levels of amplification due to various 
phenomenon such as the efficiency of coupling to particular downstream effectors or positive 
feedback loops. Likewise, differences in detection sensitivity or amplification depending on 
the level of detection within the signalling cascade can also introduce similar effects. Due to 
this, observations of relative changes in potency or maximal effect between different pathways 
may appear as agonist bias. However, once the signalling system and the differences in assays 
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are taken into account, such bias may be insignificant. Therefore, we were also interested in 
comparing agonist activity in an integrated manner. We did this by applying an operational 
model of agonist activity adapted from work by Black and Leff (86,87). This enabled us to 
determine individual transduction coefficients for each agonist acting at each effector (Table 
3.5). The transduction coefficient is a parameter estimated from the concentration response 
curves that is comprised of the agonists’ affinity for the receptor-effector complex (KA) and 
the efficacy of the agonist to activate that effector (τ). This analysis showed rotigotine had the 
most powerful agonist activity, having the largest transduction coefficient for all effectors 
(Table 3.5). In general, the analysis displayed larger transduction coefficients for the agonists 
at GαoA, GαoB and Gαz, indicating that these G proteins were more efficiently coupled to the 
D2R relative to other effectors. Therefore, to more accurately assess the relative activities of 
the agonists acting at each effector, the relative coupling efficiency and/or amplification of 
each signalling pathway needs to be accounted for. This was achieved by normalising the 
different transduction coefficients at each effector to that of dopamine - the reference agonist. 
Having done this, we could then observe that some agonists selectively activated some 
effectors relative to the action of dopamine. In particular, multiple agonists appeared to 
preferentially recruit either GRK2, β-arrestin-1 or β-arrestin-2 relative to their activation of 
GαoA (Table 3.6). That is, several agonists displayed statistically significant biased agonism for 
these pathways. For example, bromocriptine and rotigotine both showed a significant 
preference for the recruitment of all three regulatory proteins over GαoA.  
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Table 3.5: Agonist transduction coefficients. 
Data represents the mean ± SEM of 3-6 separate experiments. 
 Log (τ/KA) 
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Table 3.6: Relative Transduction coefficients. 
Data represents the mean ± SEM of 3-6 separate experiments. 
 ΔLog (τ/KA) 






























































































































































































































































































* Agonist’s ΔLog (τ/KA) value is significantly different from the corresponding GαoA value within 
the row, P < 0.05 Ordinary one-way ANOVA with Dunnett’s multiple comparisons test. ND – 
not determined, could not be calculated due to poor initial non-linear curve fit (r2 < 0.7). 
 
 
The majority of D2Rs in the central nervous system are thought to be coupled to Gαo 
subunits (140). In addition, more compounds displayed significant bias when using either a 
Gαo isoform or Gαz as a reference pathway compared to using one of the Gαi subunits (for 
example Gαi2). Moreover, using a Gαi subunit as a reference pathway had a similar, albeit 
reduced, pattern of bias to using GαoA or Gαz. Hence, for these reasons, we next normalised the 
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relative transduction coefficient values to the values at the reference effector GαoA to obtain 
the final values of biased agonism (Table 3.7). With these values we could construct a web of 
bias to more easily visualise biased agonism (Fig. 3.6). From this, it could be observed that 
there was minimal biased agonism between the G protein subtypes, whereas multiple agonists 
displayed apparent bias towards the recruitment of regulatory proteins and away from GαoA. 
Rotigotine, ST-836 and bromocriptine, that are quite efficacious agonists, displayed significant 
biased agonism between GαoA activation and all of GRK2, β-arrestin-1 and β-arrestin-2 (Fig. 
3.6A & B and Table 3.6 & 3.7). Moreover, multiple partial agonists at the poorly coupled 
GRK2 and β-arrestin-1 recruitment endpoints produced an inadequate signal to be able to 
robustly fit the operational model. Consequently, the transduction coefficients of some of the 
partial agonists and their resultant biased agonism values could not be determined (Table 3.5, 
3.6, & 3.7). Nonetheless, the partial agonists cariprazine and bifeprunox displayed significant 
bias between GαoA and one of the regulatory proteins. Indeed, cariprazine displayed the largest 
significant difference in relative transduction coefficients of approximately 14-fold between 
GRK2 recruitment and GαoA activation (Fig. 3.6A and Table 3.6 & 3.7). In comparison, other 
partial agonists pardoprunox and S-3PPP displayed a consistent lack of bias at each endpoint 
(Fig. 3.6B). In general, applying this straightforward method of analysis by applying an 
operational model together with suitable internal references allowed us to observe statistically 
significant apparent bias primarily, but not exclusively, between the well coupled G proteins 
and the less efficient regulatory proteins. 
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Table 5.7: Bias quantification values relative to GαoA activation. 
 Data represents the mean ± SEM of 3-6 separate experiments. 
 ΔΔLog (τ/KA) 










































































































































































































































ND – not determined, could not be calculated due to poor initial non-linear curve fit (r2 < 0.7). 
  




Figure 3.6: Web of biased agonism between the reference pathway GαoA activation and 
different functional pathways. (A) Web of biased agonism for aripiprazole, bifeprunox, 
brexpiprazole, bromocriptine and cariprazine. (B) Web of biased agonism for pardoprunox, 
ropinirole, rotigotine, S-3PPP and ST-836. Log(t/KA) values were determined for each agonist 
at each pathway 15 minutes after agonist stimulation. These values were subtracted from the 
reference agonist dopamine’s values to obtain ΔLog(τ/KA) values. The ΔLog(τ/KA) values for 
each pathway were then subtracted from theΔLog(τ/KA) values of GαoA activation to give 
ΔΔLog(τ/KA) values. The anti-logarithm (ΔΔτ/KA) of these values were then plotted to show a 
web of bias. The reference agonist dopamine is shown in black in both panels and has a 
ΔΔτ/KA value of 1 between each pathway. Filled in circles denotes where the biased agonism 
is statistically significant (P < 0.05) as determined by a one-way ANOVA between the 
ΔLog(τ/KA) values. 
 
No clear relationship between biased agonism and differences in agonist dissociation 
rate  
Having observed the most statistically significant apparent biased agonism between the 
regulatory proteins and the well coupled Gαo or Gαz proteins, we then sought to examine 
whether there is a relationship between an agonists’ dissociation rate and the bias towards a 
particular functional event. We plotted the different binding parameters we had determined 
against the biased agonism between multiple pathways detected at a single timepoint of 15 
minutes. A Spearman’s correlation was performed on these plots to assess the relationship 
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between the rank values of each parameter. We chose to perform this type of correlation 
considering the mechanisms behind the manifestation of bias are not entirely clear, such that 
one must consider the possibility that biased agonism between any two pathways may saturate 
at some point. We then examined the relationship between the binding kinetics and bias at 
GRK2 recruitment relative to GαoA activation because many agonists displayed bias between 
these two signalling events. We first performed a negative control correlation plot between this 
bias and the association rate of the agonist (Fig. 3.7A). As anticipated, we observed no 
correlation between the association rate and the bias at GRK2 recruitment relative to GαoA 
activation. Moreover, we also observed no statistically significant correlation between the bias 
towards GRK2 recruitment and the dissociation rate of the agonist (Fig. 3.7D). We next 
correlated the affinity of the agonist, again to serve as a negative control. Unexpectedly, a 
correlation was observed between agonist affinity and the bias towards GRK2 recruitment 
relative to GαoA activation (Fig. 3.7G). We next examined the bias between β-arrestin-2 
recruitment and GαoA activation. We observed no significant correlation between either the 
association rate or the dissociation rate and the bias for β-arrestin-2 recruitment relative to GαoA 
activation (Fig. 3.7B & E). However, performing a correlation between the affinity and the bias 
for β-arrestin-2 recruitment relative to GαoA activation displayed a statistically significant 
Spearman’s correlation (Fig. 3.7H). Moreover, some relatively large biased agonism was also 
observed between β-arrestin-2 recruitment and Gαz activation. When plotting the association 
rate with the bias between β-arrestin-2 recruitment and Gαz activation, no correlation was 
observed (Fig. 3.7C). In contrast, robust correlations were observed between both agonist 
dissociation rate or affinity and the bias of β-arrestin-2 recruitment relative to Gαz activation 
(Fig. 3.7F & I). In general, there was no clear relationship between bias and the dissociation 
rate of the agonist. In fact, there was a tendency for higher affinity agonists to display some 
bias towards the weakly coupled regulatory pathways such as GRK2 or β-arrestin-2 recruitment 
relative to the strongly coupled GαoA or Gαz.   




Figure 3.7: Correlation between Log(τ/KA)/LogBias and different binding parameters. 
Correlation between Log kon and the Log bias between: GRK2 recruitment and GαoA activation 
(A), β-arrestin-2 recruitment and GαoA activation (B), and β-arrestin-2 recruitment and Gαz 
activation (C). Correlation between Log koff and the Log bias between: GRK2 recruitment and 
GαoA activation (D), β-arrestin-2 recruitment and GαoA activation (E), and β-arrestin-2 
recruitment and Gαz activation (F). Correlation between pKd and the Log bias between: GRK2 
recruitment and GαoA activation (G), β-arrestin-2 recruitment and GαoA activation (H), and β-
arrestin-2 recruitment and Gαz activation (I). All Log bias values were determined at 15 
minutes after stimulation. Two-tailed nonparametric Spearman correlation was performed that 
does not assume the Log bias values to be linear with the different kinetic binding parameters. 
The Spearman’s rank correlation coefficient, r, is shown as well as the P value.   
 
Assessment of agonist induced D2R trafficking over time  
We next assessed the ability of each agonist to induce trafficking of the D2R. We again 
decided to take a BRET approach to monitor the trafficking of the D2R in live cells. The cells 
were transfected with plasmids encoding the D2R tagged on the C-terminus with Nluc to serve 
as a BRET donor and different endomembrane compartment proteins were tagged with venus 
to serve as BRET acceptors. GRK2 and β-arrestin-2 were also transfected together with the 
BRET sensors as they are known to aid the internalisation of the D2R and increase the signal 
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in these assays (261). We measured the trafficking of the D2R over time after stimulation with 
a high concentration of each agonist such that most receptors would be rapidly occupied.  
When examining the movement of the D2R away from the membrane marker KRas-
venus, we saw large differences between agonists (Fig. 3.8A & D). The efficacious agonists, 
dopamine and rotigotine produced the largest decrease in BRET ratio that plateaued 
approximately 20 minutes after stimulation. Other agonists, such as bromocriptine and 
pardoprunox produced a weaker decrease in BRET ratio however the rate of the decrease in 
BRET was similar, reaching a plateau at about 20 minutes (Fig. 3.8G & J). In contrast, the 
lower efficacy agonists such as aripiprazole and S-3PPP produced no change in BRET ratio 
from baseline. In contrast to the KRas plasma membrane sensor, we observed an increase in 
BRET over time when assessing drug induced changes in proximity to Rab5a positive early 
endosomes (Fig. 3.8B & E). Furthermore, all agonists produced some detectable change in the 
BRET ratio (Fig. 3.8H). This may indicate that because the endosomes are a smaller 
compartment relative to the plasma membrane, the stoichiometry of the Rab5a-venus donor to 
the D2R-Nluc may be more favourable for sensing small changes in the average localisation of 
the D2R. Again, the most efficacious agonists such as, dopamine and rotigotine were the most 
robust at trafficking the D2R into early endosomes. These agonists with higher efficacy tended 
to induce faster observed rates of trafficking into the Rab5a positive endosomes (Fig. 3.8K). 
The overall rate at which agonists induced trafficking into the early endosomes was similar to 
the rate that the D2R moved away from the plasma membrane. Measuring the drug induced 
changes in proximity of the D2R with recycling endosomes using the Rab11 marker, agonists 
generally produced a slow increase in BRET ratio over time (Fig. 3.8C, F, I & L). The increase 
in proximity into this recycling endosome compartment was significantly slower than the KRas 
or Rab5a marked compartments, with the BRET ratio not coming to a compete plateau within 
60 minutes for any of the agonists tested. The slow increase in BRET ratio may be indicative 
of the population of receptors slowly recycling back to the plasma membrane after having first 
been internalised. Again, efficacious agonists such as dopamine produced the largest increase 
in trafficking into this endomembrane compartment. In general, the temporal trafficking 
experiments showed marked differences in the magnitude of trafficking between agonists with 
little difference in the rate of trafficking between agonists. 




Figure 3.8: Agonist dependent trafficking of the D2R over time. (A & D) Trafficking of D2R-
Nluc away from the KRas-venus plasma membrane marker over time in response to different 
agonists. (B & E) Trafficking of D2R-Nluc towards Rab5a-venus positive early endosomes time 
in response to different agonists. (C & F) Trafficking of D2R-Nluc towards Rab11-venus 
positive recycling endosomes over time in response to different agonists. The agonist induced 
change in BRET ratio measured 60 minutes after stimulation for D2R-Nluc trafficking away 
from the KRas positive plasma membrane (G), Rab5a positive early endosomes (H) and 
Rab11 positive recycling endosomes (I). The observed rate from a one-phase exponential fit 
of agonist induced trafficking away from the plasma membrane (J), towards early endosomes 
(K) and towards recycling endosomes (L). All data represents the mean ± SEM from 5 
separate experiments. 
 
Agonist efficacy for G protein activation, GRK2 recruitment, β-arrestin-2 recruitment 
and receptor trafficking correlates 
To understand what drives agonist bias, one must determine the phenomenon that is 
responsible for differences in transduction coefficients. The parameters that underpin an 
agonists’ transduction coefficient are the efficacy (τ) and the functional affinity (KA)(86,87). 
Therefore, relative changes in the transduction coefficient can be driven by differences in either 
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of these values. Due to this duality, we therefore decided separate the transduction coefficient 
and investigate a single component separately. The functional affinity values for several 
agonists change over time in our data as their occupancy and potency changes over time. In 
addition, we did not use full concentration curves when measuring D2R trafficking and, as such, 
we were unable to determine functional affinity values for the D2R trafficking. Thus, we chose 
to focus on the estimated operational efficacy of each agonist at each pathway.  
Considering some historical models that aimed to relate efficacy to binding kinetics 
such as rate theory (90), we tested whether agonist efficacy at a particular pathway is influenced 
by either agonist association rate or dissociation rate. Hypothetically, having a slow agonist 
dissociation rate could be important to wholly elicit slow functional events including arrestin 
recruitment, whereas it may be less important for fast responses such as G protein activation. 
Consequently, some efficacy bias may emerge between fast and slow signalling events based 
on agonist dissociation rate. We therefore plotted correlations between the binding kinetic 
parameters and the Log τ values for Gαi2 activation, GRK2 recruitment and β-arrestin-2 
recruitment determined using an operational model described earlier (Fig. S3.12) (86,87). GαoA 
activation was not included in this analysis because only four agonists could have their τ values 
accurately determined due to this pathway being efficiently coupled. We observed no 
statistically significant correlation between either the association rate or the dissociation rate 
and efficacy at any signalling pathway (Fig. S3.12A-F). We also observed no correlation in the 
negative control plots examining the relationship between the agonist affinity and efficacy (Fig. 
S3.12G-I). Therefore, based on this modest panel of agonists, neither association rate nor 
dissociation rate appear to be the main drivers of efficacy for any tested D2R proximal event. 
Thus, bias observations are unlikely to be mediated by a mechanism that involves differences 
in binding kinetics driving changes in efficacy. 
We then sought to elucidate any further insights into the drivers of the efficacy (τ) 
values with the continued hope that these may in turn help to understand differences in 
transduction coefficients. Accordingly, we next aimed to identify whether our data describing 
the agonist efficacy for one signalling event could be used to help predict the agonist efficacy 
at another signalling event. To do this, we correlated the different agonist efficacies between 
each pathway. We chose to compare G protein activation values to the other events because G 
protein coupling has been the canonical function of GPCRs historically. When examining Gαi2 
activation, all ligands except the two most efficacious agonists, dopamine and rotigotine, could 
have their τ values estimated. We therefore correlated the Gαi2 activation τ value estimates with 
the other signalling events. When correlating the Log τ values of Gαi2 with GαoA, we observed 
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a statistically significant Pearson’s correlation (Fig. 3.9A). We then correlated the τ values for 
Gαi2 activation with other pathways.  Log τ values of agonists activating Gαi2, correlated with 
the Log τ values for GRK2 (Fig. 3.9B). Additionally, the Log τ values of agonists activating 
Gαi2 robustly correlated with the Log τ values for agonists in the β-arrestin-2 recruitment assay 
(Fig. 3.9C). We did not obtain full concentration response curves in the trafficking assays, such 
that we were unable to determine operational efficacy τ values. Even so, we were able to 
observe a strong correlation between the Gαi2 Log τ values and the increase in BRET when 
measuring trafficking of the D2R to Rab5a positive endosomes (Fig. 3.9D). Altogether, this 
demonstrated that the efficacy of an agonist at one D2R mediated pathway can be accurately 
predicted by measuring any other pathway. Moreover, the strong correlations may imply that 
divergence in efficacy values may not be the main mediators of bias at the D2R. 
  




Figure 3.9: Correlation of agonist Log τ values between Gαi2 activation and other 
functional pathways. (A) Correlation between agonist Log τ values for Gαi2 activation and 
Log τ values for GαoA activation. (B) Correlation between agonist Log τ values for Gαi2 
activation and Log τ values for GRK2 recruitment. (C) Correlation between agonist Log τ 
values for Gαi2 activation and Log τ values for β arrestin-2 recruitment. (D) Correlation between 
agonist Log τ values for Gαi2 activation and increase in BRET ratio for Rab5a trafficking. All 
Log τ values were determined from concentration response curves 15 minutes after 
stimulation. The Rab5a increase in BRET ratio was taken 15 minutes after agonist addition 
with a saturating concentration. For each panel a Pearson correlation was performed, the 




The concept of biased agonism suggests that a drug’s on-target side effects can be 
reduced while maintaining its therapeutic activity. Therefore, new drugs may be developed that 
have improved therapeutic windows through harnessing biased agonism (274). While this 
offers great potential, the mechanisms of biased agonism are not entirely clear. Consequently, 
biased agonism drug discovery efforts have relied on inefficient means such as complex high 
throughput screens that require multiple drug concentrations and signalling endpoints 
(251,275,276). Such approaches leave the probability of obtaining a biased agonist to chance 
and only explore a fraction of the total chemical space available. Understanding how biased 
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agonism materialises would allow for the rational design of biased agonists. This would greatly 
aid biased agonist drug discovery by reducing the time and costs associated with the process. 
In our previous research we identified a mechanism that may explain some biased 
agonism observations. We determined that some agonists that slowly dissociate from the D2R 
can display bias between proximal signalling measurements and downstream measurements 
(96). We concluded that this observation is due to the interplay between the differences in the 
kinetics of binding and the kinetics of signalling. In particular, bias was observed when 
comparing an upstream or transient signalling endpoint with one further downstream, and when 
the measurement of each pathway was taken at different timepoints. While this finding helped 
move forward views on biased agonism, we did not comprehensively explore the kinetic effects 
on all G protein subtypes, regulatory proteins such as arrestins, and receptor trafficking. In the 
present study, we aimed to further explore this by determining whether differences in agonist 
dissociation rate may contribute to apparent biased agonism when assessed at diverse proximal 
functional events.  
We were able to demonstrate that the dissociation rate of the agonist is likely not the 
sole determinant of biased agonism observations at proximal events at the D2R. We achieved 
this by taking a range of agonists with varying binding kinetics and structure, quantifying bias 
at multiple proximal events, and correlating the bias with the agonist dissociation rate. A 
correlation was observed between the dissociation rate in only one instance. Furthermore, we 
additionally performed the same correlations with the association rate and the affinity. In 
reality, the affinity of the agonist appeared to correlate more strongly than did the dissociation 
rate. Importantly, affinity is a composite of association rate and dissociation rate. Therefore, 
this may suggest that large differences in association rate, dissociation rate or a combination of 
both, may lead to observations of bias by some means. 
It could be reconciled that our results altogether provide preliminary evidence for a 
mechanism by which higher affinity agonists display bias through an increase in receptor 
occupancy over time. In our temporal functional assays, not only did we observe increases in 
potency over time for the slow dissociating agonists such as bifeprunox, but we also observed 
that some other agonists displayed an increase in potency over time. In particular, we observed 
that rotigotine, pardoprunox and ST-836 increased in potency over time in a manner that was 
inconsistent with their fast dissociation rate (Fig. S3.7, S3.9 & S3.11). We verified that 
rotigotine had a fast dissociation rate by measuring the deactivation of G proteins (Fig. 3.3) 
and a separate group has also determined that rotigotine dissociates from the D2R faster than 
aripiprazole and cariprazine through radioligand binding (277). Under further examination of 
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the properties of rotigotine, pardoprunox and ST-836, it can be seen that these agonists very 
rapidly associate with the D2R. This property is important because, along with the receptor 
density and factors influencing ligand diffusion, agonist association rate is also a major 
determinant of ligand rebinding (54,224). In this case ligand rebinding describes the action of 
a ligand, having dissociated from the receptor, remains in the close vicinity to the receptor and 
as such revisits the receptor binding site or another receptor site nearby. The plausibility of 
rebinding occurring in this study is supported by reports of the antagonist [3H]-spiperone 
displaying D2R rebinding characteristics in assays with a similar setup, and also, that many 
D2R ligands are likely to display rebinding propensity in vivo (61,278,279) . Therefore, we 
speculate that fast associating agonists, including rotigotine, pardoprunox and ST-836, may be 
rebinding in our assays leading to sub-saturating concentrations of the agonist increasing in 
receptor occupancy over time and in turn producing an increase in potency over time. 
The results in the present study agree with our previous work when re-examining the 
data. As mentioned earlier, our previous research led us to conclude that agonists with slow 
dissociation rates increased in potency over time that lead to apparent bias (96). We had not 
previously considered that association rate may also play a role in this process. Our group’s 
publication reported that bifeprunox was by far the slowest dissociating ligand in the study, 
however, it did not actually display any more bias than cariprazine or aripiprazole (96). The 
affinity and association rate of cariprazine, aripiprazole and bifeprunox are in a similar range 
and this may explain why differences in the magnitude of bias between the two ligands was 
not observed. In the case of cariprazine, aripiprazole and bifeprunox, both the association rate 
and dissociation rate may be partly involved. Therefore, increases in potency either through 
slow dissociation or through rebinding due to a fast association rate may explain these 
observations of bias.  
Moving forward, it would be useful to attempt to extend this mechanism to other 
datasets using additional GPCRs. One GPCR where bias has been extensively investigated is 
the angiotensin II receptor 1 (AT1R). There may be a similar trend for the AT1R as it appears 
that apparent biased agonists such as DVG and SII have reduced receptor affinity relative to 
the high affinity reference agonist angiotensin II (280,281). However, for most GPCRs, there 
is a lack of large datasets that include both ligand affinity and biased agonism. Additionally, 
there is often no consensus on which ligands are definitively biased. For example, initial reports 
suggested that PZM21 displayed G protein bias at the µ opioid receptor, however this was not 
supported by any statistically significant biased agonism when quantified (82). Future studies 
could design experiments to further explore this idea at other GPCRs. 
Chapter 3 – Biased agonism and binding kinetics at the D2R 
120 
 
While there was a trend for high affinity agonists to display bias relative to the low 
affinity reference agonist dopamine, the biased agonism was repeatedly observed towards the 
poorly coupled effectors and away from the well coupled effectors. Such bias was observed 
between the most efficiently coupled Gαo or Gαz proteins and poorly coupled GRK2, β-
arrestin-1 or β-arrestin-2. The fact that the bias routinely occurs in the same direction suggests 
that either each biased agonist is biasing the receptor in a similar fashion or that biased agonism 
is hard-wired by the system. By using a reference agonist together with the Black and Leff 
operational model we were able to reduce system bias by accounting for any differences in 
receptor reserve between pathways. However, we cannot completely rule out system bias if 
there are very large and irregular patterns of amplification in a particular pathway (282). As a 
theoretical example, continual increases in receptor occupancy may result in amplified 
increases in response in one pathway through mechanisms such as positive cooperativity or 
positive feedback until the response is saturated for one pathway, while having no effect at 
another pathway. This could result in relative differences in response if one agonist is much 
higher efficacy than another agonist as smaller occupancy levels may still lead to a very large 
response. Indeed, Onaran and colleagues (283) have demonstrated that using the Black and 
Leff operational model of agonism to determine ligand bias can result in a higher number of 
false positives than other methods. Moreover, when we did observe bias, there was appreciable 
noise in our final bias calculations resulting in some nonuniform bias patterns. For example, 
bifeprunox displayed statistically significant bias between GαoA and β-arrestin-2, however, 
bifeprunox’s transduction coefficient at GRK2 and β-arrestin-1 was not determined due to a 
poor signal in these assays. Therefore, it is unclear whether bifeprunox would display bias at 
GRK2 or β-arrestin-1 if there was a robust window in these assays. Similarly, ropinirole 
displayed very subtle bias at β-arrestin-1 relative to GαoA. However, no statistically significant 
bias was observed at β-arrestin-2 relative to GαoA. This makes interpretations of the data 
difficult because β-arrestin-1 and β-arrestin-2 would be expected to share similar patterns of 
recruitment due to their very high sequence identity (284).  
It should be noted that while our goal was to investigate the mechanisms of bias at the 
D2R, this task became challenging due to the underwhelming amount of bias that materialised. 
Having BRET as the sole detection technique and using identical buffers, detection times and 
temperatures, we expected to reduce the amount of observational bias. Nevertheless, we did 
not expect to observe few ligands displaying bias and the fold change in bias generally being 
less than 10-fold. In addition, we did not predict that there would be almost no statistically 
significant bias between G protein subtypes. GPCR-G protein selectivity is common, hence, if 
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an agonist induces different conformational states then one could envisage that these different 
states may have G protein selectivity as well. In agreement with this concept, apparent bias 
between G protein subtypes at the D2R has been observed before between Gαi1 and GαoA (252). 
Furthermore, G protein subtype bias has been identified at other GPCRs such as the dopamine 
D1 receptor and the free fatty acid 2 receptor (285,286). The reasons why we do not widely 
observe G protein subtype bias cannot yet be explained.  
We were able to investigate the drivers of agonist efficacy at the D2R. While rate theory 
advocates for association rate being proportional to efficacy (90), we did not observe this with 
our dataset. Other groups have also observed the opposite of rate theory, whereby slow 
dissociation leads to increased efficacy (91,93). However, we again did not see any correlation 
between dissociation rate and efficacy. It is important to note here that some ligands within the 
dataset have been through a drug discovery process that may have selected for increased or 
decreased agonist efficacy. Indeed, weak partial agonists are the preferred agonists for 
schizophrenia whereas efficacious agonists are desired for Parkinson’s disease (287). 
Nonetheless, we also compared the agonist efficacy between all the endpoints. Each endpoints’ 
Log τ showed a robust correlation with Gαi2 activation (Fig. 3.9). This matches another report 
at the µ opioid receptor where efficacy between G protein mediated signalling, arrestin 
recruitment and internalisation all correlated (288). While the number of agonists tested in our 
study is not totally all-encompassing, our results nevertheless indicate that the ligand-specific 
properties that determine intrinsic efficacy at the D2R are in fact identical at all signalling 
pathways. This has implications for targeting the D2R because it suggests that the relative 
maximal effects may be quite challenging to separate based on the agonist. That is, the strong 
correlation of Log τ values between all pathways may indicate that bias observations (as 
determined by relative Log(τ/KA) values) may only be able to be driven by KA values and not 
τ values at the D2R. Thus, further insight into how KA values can differ would be important to 
move the field forward. A possible mechanism explaining the manifestation of differences in 
KA values that in turn engenders bias may be through agonists having different affinities for 
the GPCR when bound to different effectors. This mechanism has been proposed by Strachan 
and colleagues (76), through designing AT1R fusion proteins of AT1R-Gαq and AT1R-β-
arrestin-2, they were able to demonstrate that biased agonists have a tighter binding affinity for 
the fusion protein consisting of the effector in which they are biased towards whereas balanced 
agonists displayed no preference.  
In summary, our study suggests that differences in the binding affinity of agonists may 
explain some observations of biased agonism. The mechanism accounting for why agonist 
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affinity appears to sometimes correlate with bias between well coupled G proteins and poorly 
coupled regulatory proteins may in part be due to increases in receptor occupancy over time. 
Future research may seek to investigate whether differences in affinity relate to bias at other 
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3.5 Supplementary Materials 
 
 
Figure S3.1: Measurement of aripiprazole induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 5 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
4 separate experiments. 




Figure S3.2: Measurement of bifeprunox induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 5 separate experiments.Recruitment over time 
of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 4 
separate experiments. 
 




Figure S3.3: Measurement of brexpiprazole induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 5 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
4 separate experiments. 
 




Figure S3.4: Measurement of bromocriptine induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 5 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
3 separate experiments. 
 




Figure S3.5: Measurement of cariprazine induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 4 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
4 separate experiments. 
 




Figure S3.6: Measurement of dopamine induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 6 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
3 separate experiments. 
 




Figure S3.7: Measurement of pardoprunox induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 5 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
3 separate experiments. 




Figure S3.8: Measurement of ropinirole induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 4 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
4 separate experiments. 
 




Figure S3.9: Measurement of rotigotine induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 5 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
4 separate experiments. 
 




Figure S3.10: Measurement of S-3PPP induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 5 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
3 separate experiments. 
 




Figure S3.11: Measurement of ST-836 induced G protein activation and regulatory 
protein recruitment. Activation over time of Gαi1 (A), Gαi2 (B), Gαi3 (C), GαoA (D), GαoB (E), 
Gαz (F). Data represents the mean + SEM from 4 separate experiments. Recruitment over 
time of GRK2 (G), β arrestin-1 (H) and β arrestin-2 (I). Data represents the mean + SEM from 
3 separate experiments. 




Figure S3.12: Correlations between Log(τ) values at different endpoints and different 
binding parameters. Correlation of the Log kon with the Log τ for: Gαi2 activation (A), GRK2 
recruitment (B), β arrestin-2 recruitment (C). Correlation of the Log koff with the Log τ for: Gαi2 
activation (D), GRK2 recruitment (E), β arrestin-2 recruitment (F). Correlation of the pKd with 
the Log for: Gαi2 activation (G), GRK2 recruitment (H), β arrestin-2 recruitment (I).F All τ 
values were determined at 15 minutes after stimulation. Two-tailed nonparametric 
Spearman correlation was performed that does not assume the τ values to be linear 
with the different kinetic binding parameters. The Spearman’s rank correlation 
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The dopamine D2 receptor (D2R) is the target of drugs used to treat the symptoms of 
Parkinson’s disease and schizophrenia. D2R G protein signalling is regulated through 
phosphorylation by G protein receptor kinases (GRKs) and interaction with arrestins. In 
addition, D2R arrestin mediated signalling has been shown to have physiological functions 
distinct from those of G protein mediated pathways. Recent studies have explored the action 
of pathway biased agonists as an avenue for the development of improved antipsychotic 
treatments. Despite this interest, relatively little is known about the patterns of D2R receptor 
phosphorylation that might control these processes. Antibodies that selectively bind 
intracellular phosphorylation sites have proved useful tools to investigate such mechanisms at 
other GPCRs. Herein we generate and characterise the first antibodies specific for GRK2/3 
phosphorylation sites on the D2R. We identify a phosphorylation site in ICL3 that is 
phosphorylated by GRK2/3 on agonist activation of the D2R. Phosphorylation of this site 
predicts arrestin recruitment.   We incorporate measurements of D2R phosphorylation with 
other measurements of G protein activation and receptor regulation to profile selected D2R 
agonists including putative biased agonists. These studies demonstrate the utility of these 
phospho-site-specific antibodies to investigate D2R regulation, and as part of the 
characterisation of biased agonists at the D2R. 
  





The catecholamine neurotransmitter dopamine (DA) is involved in many physiological 
processes in the central nervous system (CNS) such as cognition, motor control and reward 
(289). DA effects are mediated by 5 members of the G protein-coupled receptor (GPCR) 
superfamily. The dopamine D1 and D5 receptors (D1R & D5R) are coupled to stimulatory G 
proteins (Gs or Golf) whereas the D2-like DRs (D2R, D3R, D4R) are coupled to inhibitory G 
proteins (Gi/o/z). Dysregulation of dopamine signalling is associated with many CNS disorders 
and the D2R is a validated drug target in neurology and psychiatry. D2R agonists are used to 
treat the symptoms of Parkinson’s disease, whereas D2R antagonism is a necessary property of 
all clinically used antipsychotics(290).  
G protein signalling is rapidly desensitized by phosphorylation of the receptor by GPCR 
kinases (GRKs) followed by the recruitment of arrestins to the phosphorylated receptor(24). 
This inhibits G protein-signalling and leads to receptor internalization, dephosphorylation and 
recycling of receptors to the cell surface or trafficking to lysosomes for degradation. GRKs 2 
and 3 primarily mediate agonist stimulated D2R phosphorylation (291,292) and over-
expression of GRK2 has been shown to enhance D2R arrestin recruitment(293). The D2R lacks 
the long C-terminal tail that is the site of GRK phosphorylation for many GPCRs. Mutagenesis 
studies from Namkung and colleagues identified eight serine/threonine (Ser/Thr) residues that 
are phosphorylated by GRK2/3 and a further five residues that are phosphorylated by protein 
kinase C (PKC) within intracellular loop (ICL) 3(294). A subsequent study by Cho and 
colleagues identified additional residues in ICL2 and 3 that appear to be important for PKC-
meditated desensitisation of the D2R (292). 
In addition to their role in receptor regulation, arrestins may act as scaffolding proteins 
to initiate signalling pathways (295). Indeed, while Gαi/o/z G protein signalling appears to be 
responsible for many of the physiological consequences of D2R activation, a -arrestin-2-
mediated signalling cascade involving protein phosphatase 2A, Akt (PKB) and glycogen 
synthase 3 may also have an important physiological role (155,296). A global -arrestin-2 
knockout displayed a reduction in DA dependent locomotor activity (155). Two studies that 
used the expression of mutant D2Rs, compromised either in the ability to recruit -arrestin-2 
or to activate G protein signalling relative to the other signalling process, in D2R-expressing 
medium spiny neurons (D2R-MSNs), provided evidence that D2R-arrestin signalling is 
sufficient for normal locomotor activity but not incentive motivation (297,298). Elimination of 
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-arrestin-2 specifically in D2-MSNs reduced locomotor responses and blunted cocaine reward 
(299). Together these data suggest that D2R -arrestin-2 signalling may mediate physiological 
functions distinct from those controlled by D2R Gi/o protein signalling (300). ‘Biased agonism’ 
describes a phenomenon whereby different ligands stabilise distinct conformations of a single 
receptor such that they differentially engage distinct signalling effectors (301). By exploiting 
this concept, one may be able to develop signalling pathway-specific drugs that display a 
greater level of cell type or tissue specificity (302). Therefore, if the therapeutic and deleterious 
side effects of a drug are mediated through a single receptor, as is the case for antipsychotics 
at the D2R, then biased agonists may provide an approach to avoid such “on-target” side effects. 
Both arrestin and G protein biased ligands have been identified for the D2R (293,303). 
Intriguingly, the action of one series of arrestin-biased ligands both to attenuate amphetamine-
induced hyperlocomotion and avoid catalepsy was diminished by global knockout of -
arrestin-2 (293). 
Together these studies highlight D2R phosphorylation by GRK2/3 as a key step in 
modulating downstream to control distinct physiological responses to dopamine. We and others 
have shown that antibodies specific to phosphorylated residues of GPCRs are particularly 
useful in unravelling the complexities of such regulatory processes and in particular the 
hierarchy of phosphorylation patterns or barcodes (304-306). In this study we develop and 
characterise the first GRK phosphorylation site (phospho-site)-specific antibodies for the D2R 
and identify a site that is phosphorylated by GRK2 in response to D2R agonists. We compare 
the action of a number of agonists, including putatively biased agonists, at triggering receptor 





DNA for the long splice variant of the hD2R was generated via artificial synthesis and 
cloned into pcDNA3.1 by imaGenes. The coding sequence for an amino-terminal HA-tag was 
added.  
 




Peptide sequences used for generating phosphosite-specific antibodies against 
individual phosphorylated forms of the long splice variant of the D2R are shown in Table 4.1, 
including a phosphorylation-independent antiserum targeting a proximal epitope in the D2R 
third intracellular loop. After HPLC purification, the respective peptides were coupled to 
keyhole limpet haemocyanin. The conjugates were mixed 1:1 with Freund´s adjuvant and 
injected into groups of three rabbits (5095-5097) for anti-pT287/288 antibody production, 
(5098-5100) for anti-pT293/S296 antibody production, (5101-2103) for anti-pS317/T318 
antibody production, and (5104-5106) for anti-D2R antibody production. The rabbits were 
injected at 4-week intervals. The serum was obtained 2 weeks after immunizations, beginning 
with the second injection. Specificity of the antisera was tested using dot blot analysis. 
Antibodies were affinity-purified against their immunizing peptide, immobilized using the 
SulfoLink kit (Thermo Scientific), for subsequent analysis. Anti-GRK2 (sc-562), anti-GRK3 
(sc-563), anti-GRK5 (sc-518005) and anti-GRK6 (sc-566) antibodies were purchased from 
Santa Cruz Biotechnology. The anti-HA IgG CF488A antibody (SAB4600054) was obtained 
from Sigma-Aldrich, anti-HA IgG CF640R antibody (20240) was purchased from Biotium and 
the anti-rabbit IgG HRP-coupled antibody (7074) was obtained from Cell Signaling.  
 
Table 4.1: D2R peptide sequences used for generation of phospho-site-specific 
antisera. List of peptide sequences used for generating phosphosite-specific antibodies 
against individual phosphorylated forms of the D2R and a phosphorylation-independent 
antiserum targeting the D2R at the proximal part of the third intracellular loop.  
Antiserum Name Sequence used for immunization 
Amino acid position 
in human D2 
receptor 
T287/S288 EMLSS-T(p)-S(p)-PPER 282-292 
T293/S296 PPER-T(p)-RY-S(p)-PIPP 289-300 










Terguride (ab144611) was obtained from Abcam. Aripiprazole (SML-0935), PMA 
(P8139) and pergolide mesylate (P8828) were purchased from Sigma-Aldrich. Apomorphine 
hydrochloride (2073), MLS1547 (6171), ropinirole (3680), quinpirole hydrochloride (1061), 
dopamine hydrochloride (3548), cabergoline (2664), bromocriptine mesylate (0427), forskolin 
(1099), SCH23390 (0925), PTX (3097), haloperidol hydrochloride (0931), L-741,626 (1003) 
and roxindole (1559) were obtained from Tocris. UNC9994 (A16087) was purchased from 
AdooQ® Bioscience. Lambda-phosphatase (P0753S) was obtained from Santa Cruz. 
Compound 101 (HB2840) was obtained from Hello Bio. Terguride, PMA, forskolin, L-
741,626, aripiprazole, pergolide, apomorphine, MLS1547, ropinirole, cabergoline, 
bromocriptine, haloperidol, roxindole, UNC9994 and compound 101 are DMSO-soluble and 
all the other mentioned compounds are water-soluble.  
 
Cell culture and transfection 
Human embryonic kidney 293 (HEK293) cells were obtained from the German 
Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen; DSMZ). Cells were cultured in Dulbecco´s modified 
Eagle´s medium (DMEM), supplemented with 10% fetal bovine serum, 2 mM L-glutamine 
and 100 U/ml penicillin/streptomycin at 37 °C and 5% CO2. HEK293 cells were stably 
transfected with TurboFect (ThermoFisher Scientific). Cells stably expressing HA-hD2 
receptor were selected in medium supplemented with 400 µg/ml geneticin and cells stably 
transfected with HA-hD2 receptor and GIRK-eGFP were selected in medium supplemented 
with 400 µg/ml geneticin and 300 µg/ml hygromycin. To increase the number of HEK293 cells 
stably expressing HA-hD2 receptor or HA-hD2 receptor in combination with GIRK-eGFP, 
fluorescence-activated cell sorting was used as described previously (305,307). 
 
Small interfering RNA (siRNA) silencing of gene expression 
Chemically synthesized double-stranded siRNA duplexes (with 3-dTdT overhangs) 
were purchased from Qiagen for the following targets: GRK2 (5-
AAGAAAUUCAUUGAGAGCGAU-3), GRK3 (5-AAGCAAGCUGUAGAACACGUA-
3), GRK5 (5’-AAGCAGTATCGAGTGCTAGGA-3’) and GRK6 (5’-
AACACCUUCAGGCAAUACCGA-3’) and from GE Dharmacon a non-silencing RNA 
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duplex (5-GCUUAGGAGCAUUAGUAAA-3 and 3-UUUACUAAUGCUCCUAAGC-5). -
HEK293 cells stably expressing HA-hD2 receptor were transfected with 150 nM siRNA for 
single transfection or with 100 nM of each siRNA for double transfection for 3 days using 
HiPerFect. All experiments showed target protein abundance reduced by 80%.  
 
Western blotting analysis  
HEK293 cells stably expressing the HA-hD2R were plated onto poly-L-lysine-coated 
60-mm dishes and grown for 2 days to 80% confluency. Cells were treated with agonists or 
antagonists and subsequently lysed with detergent buffer (50 mM Tris-HCl, pH 7.4; 150 mM 
NaCl; 5 mM EDTA; 10 mM NaF; 10 mM disodium pyrophosphate; 1% Nonidet P-40; 0.5% 
sodium deoxycholate; 0.1% SDS) in the presence of protease and phosphatase inhibitors. 
Where indicated, cells were preincubated with GRK2/3 inhibitor compound 101 or D2 receptor 
antagonists for 30 min before agonist treatment. HA-tagged hD2 receptors were enriched using 
anti-HA-agarose beads after 30 min centrifugation at 4 °C. Samples were inverted for 2 hours 
at 4 °C. Where indicated, cell lysates were dephosphorylated with lambda protein phosphatase 
(Santa Cruz) for 1 hour at 30 °C. Following sample washing, proteins were eluted using SDS 
sample buffer for 30 min at 50 °C. Protein separation was performed on 7.5% or 12% SDS-
polyacrylamide gels. After electroblotting, membranes were incubated with 0.1 µg/ml 
antibodies to pT287/S288 (5095), pT293/S296 (5099) or pS317/T318 (5102) overnight at 4 °C. 
Enhanced chemiluminescence detection (ECL) was used to detect bound antibodies (Thermo 
Fisher Scientific). Subsequently, blots were stripped and reprobed with the phosphorylation-
independent antibody to the D2 receptor (5106) to ensure equal loading of the gels.  
 
G protein activation assay 
The G protein activation assay was performed based on a previously reported  
bioluminescence resonance energy transfer (BRET) detection method (257,308). Initially, 
2,500,000 Flp-InTM HEK 293 cells stably expressing the human D2LR were harvested into 
10cm dishes. 24 hours after harvesting cells, the cells were transfected with cDNA constructs 
using linear polyethylenimine (PEI) in a ratio of 1μg DNA: 6μg PEI. Cells were transfected 
with pcDNA3.1 encoding the following constructs: 1μg venus-1-155-Gγ2, 1μg venus-156-239-
Gβ1, 1μg masGRK3ct-Nluc and 2μg of either Gαi1-C351I or GαoA-C351I. 24 hours after 
transfection the cells were harvested from dishes and plated into poly-D-lysine coated Greiner 
white 96-well TC treated plates. The cells were left to adhere for approximately 8 hours and 
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then treated with 100ng/mL pertussis toxin overnight. The following day the plate was taken 
out of the incubator, washed once with Hank’s balanced salt solution (HBSS) pH 7.4 and left 
to equilibrate in HBSS 37°C for 30 minutes before BRET detection. 10 minutes prior to 
addition of agonist, 10μL of Nano-Glo substrate (Promega) was added to each well with a 
multi-step pipette (final dilution 1 in 1000). BRET was then measured using a PHERAstar FS 
microplate reader (BMG LABTECH). Luminescence was measured with the BRET1 plus filter 
for the emission signal of Nluc (445-505nm) and venus (505-565nm) simultaneously. 
Measurements were taken 10 minutes after agonist addition. The counts from the venus 
acceptor (505-555nm) was then divided by the donor Nluc (465-505nm) counts to give a BRET 
ratio. BRET ratios were then normalised to percent of the dopamine induced maximal 
responses where indicated. 
 
Membrane potential assay 
Membrane potential change was measured as previously described (309). HEK293 
cells stably expressing the HA-hD2and R GIRK-eGFP transfected HEK293 cells were plated 
into 96-well plates. After washing with Hank´s balanced salt solution (HBSS), buffered with 
20 mM HEPES (pH 7.4, containing 1.3 mM CaCl2; 5.4 mM KCl; 0.4 mM K2HPO4; 0.5 mM 
MgCl2; 0.4 mM MgSO4; 136.9 mM NaCl; 0.3 mM Na2HPO4; 4.2 mM NaHCO3; 5.5 mM 
glucose) cells were incubated with membrane potential dye (FLIPR Membrane Potential kit 
BLUE, Molecular Devices) for 45 min at 37 °C. Final used injection volume of compounds 
and vehicle was 20 µl. The initial volume in the wells was 180 µL (90 µL buffer plus 90 µL 
dye) and 20 µL of compound was added to the cells resulting in a final volume in the well of 
200 µL and a 1:10 dilution of the compound. Therefore, the compounds were prepared at 10x 
concentrations. Compounds or buffer were injected after a baseline reading for 60 sec and 
measurements were accomplished at 37 °C using a FlexStation 3 microplate reader (Molecular 
Devices). After data normalization to the baseline, the buffer-only trace for each corresponding 
data point was substracted.  
 
GRK2 and β-arrestin-2 recruitment 
GRK2 and β-arrestin-2 recruitment assays were measured by means of BRET detection. 
The BRET assays previously reported by our group (310) and by others (311) were improved 
by utilising NanoBRET technology. Flp-In™ HEK 293 cells were initially harvested and 
transferred into plastic 10cm2 dishes (Corning®) in DMEM + 10% FBS at a density of 
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2,000,000 cells. 24 hours after transferring the cells to dishes, the cells were transfected using 
linear polyethylenimine (PEI) in a 1:6 ratio of DNA:PEI (μg). For GRK2 recruitment, 0.25μg 
hD2LR-NLuc, 4μg GRK2-Venus and 3.5μg pcDNA3.1 were transfected. For β-arrestin-2 
recruitment, 0.25μg hD2LR-NLuc, 2μg GRK2 (untagged) and 5.5μg YFP-β-arrestin-2 were 
transfected. Approximately 30 hours after transfection the cells were harvested from the dishes 
and plated into poly-D-lysine coated Greiner white 96-well TC treated plates in DMEM + 10% 
FBS. Approximately 20 hours after cells were transferred to plates, the plate was washed with 
HBSS pH 7.4 and replaced with 80μL HBSS. The cells were then left to equilibrate for 30 
minutes at 37°C before agonist addition. 10 minutes prior to agonist addition, 10μL of Nano-
Glo Luciferase Assay Substrate (Promega) diluted in HBSS was added to each well with a 
multi-step pipette (final concentration 1 in 1000). Changes in BRET were then detected 10 
minutes after agonist addition in a PHERAstar FS microplate reader (BMG LABTECH) set to 
37°C. Individual wells were measured for the luminescence emission signal of NLuc (465-
505nm) and Venus/YFP (505-555nm) simultaneously. Data was analysed by taking the counts 
from the acceptor Venus/YFP (505-555nm) and dividing by the donor NLuc (465-505nm) 
counts to give a BRET ratio. The BRET ratio is baseline-normalised to vehicle wells as well 
as 100% defined as the maximal BRET ratio obtained by stimulation with dopamine or 
quinpirole where indicated. 
 
Data Analysis 
ImageJ 1.47v software was used for quantification of protein bands detected on western 
blots. GraphPad Prism 5 software was used for data analyzation. Densitometry of every protein 
band was carried out with Image J. We used the same area size to perform densitometry for 
every protein band from the same experiment for every phosphorylation site as well as the total 
receptor. Accordingly, an equally sized empty area from the blot/film was measured to subtract 
this value as background signal from every measuring point. Finally, phosphorylation signals 
were normalized to the total receptor (phosphorylation-independent antibody; D2R). SCR-
controls were defined as 100% and phosphorylation of every target protein was calculated as 
percentage phosphorylation in comparison to the respective control. Statistical analysis was 
carried out with one-way ANOVA followed by Bonferroni correction. P values <0.05 were 
considered statistically significant.  
 




The development of novel phospho-site-specific antibodies for the D2R 
We set out to develop G protein-coupled receptor kinase (GRK) phospho-site-specific 
antibodies for the hD2R. Previous work identified putative GRK2 phosphorylation sites within 
the intracellular loops of the D2R using site-directed mutagenesis coupled with auto-
radiography(292,294). In particular, Namkung and colleagues identified several GRK2 sites in 
the rat D2LR (rD2LR) including Thr287, Ser288, Thr293 and Ser317(294). Note that in the 
human D2LR Ser317 is positioned next to another putative GRK site, Thr318, that is substituted 
for Asn in rD2LR (Fig. S4.1). Taking this work into consideration, we synthesised phospho-
peptides corresponding to regions within ICL3 of the hD2R (Table 4.1, Fig. 4.1A, Fig. S4.1) 
and used them to raise phospho-site-specific antibodies for the hD2R, targeting 
pThr287/pSer288, pThr293/pSer296 and pSer317/pThr318 (Fig. 4.1A). In addition to raising 
antibodies to distinct phospho-sites we also raised antibodies to a spatially separate region of 
ICL3 to serve as a hD2R loading control antibody (Table 4.1, Fig. 4.1A). All sites are conserved 
in the long (D2LR) and short (D2SR) isoforms of the D2R. 
When used in western blot experiments, all the antibodies detected the hD2R, showing 
a diffuse band at approximately 72 kDa consistent with preceding studies of N-terminally 
glycosylated D2Rs(312). While previous work suggested that Thr287, Ser288, and Thr293 are 
GRK2 phosphorylation sites(294), we were unable to detect significant agonist-induced 
changes in phosphorylation with the pThr287/pSer288 antibody or the pThr293/pSer296 
antibody (Fig. 4.1B). The pThr287/pSer288 and pThr293/pSer296 antibody recognition was 
phosphorylation dependent because the binding was lost when samples were treated with λ-
phosphatase (Fig. 4.1C). This indicates that these sites are likely to be constitutively 
phosphorylated. The antibody recognising pSer317/pThr318 showed a large increase in 
binding when cells were stimulated with the D2R-selective agonist quinpirole, and this agonist-
induced phosphorylation was lost when samples were treated with λ-phosphatase (Fig. 4.1B & 
C), or with the D2R antagonists haloperidol or L741,626 (Fig. S4.2). 
 




Figure 4.1: Characterisation of phospho-site-specific D2R antibodies. (A) Schematic 
representation of the long splice variant of the human dopamine D2 receptor (hD2RL). All 
potential phosphate acceptor sites in the third intracellular loop are indicated (gray). 
T287/S288, T293/S296 and S317/T318 were targeted for the generation of phospho-site-
specific antibodies and the epitope used for generating a phosphorylation-independent 
antibody (D2RL) is indicated by a black line. (B) HEK293 cells stably expressing HA-tagged 
D2R were either untreated (-) or treated (+) with 1 µM quinpirole for 10 min at 37C. Cells were 
lysed and immunoblotted with the anti-pT287/288 antibodies (5095-5097), anti-pT293/S296 
antibodies (5098-5100) anti-pS317/T318 antibodies (5101-5103) or anti-D2R antibodies 
(5104-5106), respectively. Blots are representative, n=3. (C) Characterisation of phospho-site-
specific antibodies directed against T287/S288, T293/S296 and S317/T318 using -
phosphatase. Cells described in (B) were either untreated (-) or treated (+) with 1 µM 
quinpirole for 10 min at 37C. Lysates were then either incubated (+) or not (-) with -
phosphatase and immunoblotted with the phospho-site-specific antibodies to pT287/S288 
[5095], pT293/S296 [5099], or pS317/T318 [5102]. Blots were stripped and re-probed with the 
phosphorylation-independent antibody to D2R [5106] as a loading control. Blots are 
representative, n=3. Molecular mass markers (kDa) are indicated, left.  
 
 
GRKs 2 & 3 phosphorylate Ser317/Thr318 and enhance β-arrestin-2 recruitment 
Ser317 has been shown to be phosphorylated by GRK2 in the rD2R (294). We next 
wanted to confirm that phosphorylation of Ser317/Thr318 in the hD2R is also orchestrated by 
GRK2/3. No phosphorylation of Ser317/Thr318 was detected when cells were stimulated with 
either phorbol 12-myristate 13-acetate (PMA) or forskolin, that lead to activation of protein 
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kinase C (PKC) and protein kinase A (PKA) family members, respectively (Fig. 4.2A). 
Treatment of cells with the ATP-competitive inhibitor of GRK2 and 3, compound 101 
(cmpd101) (313), led to a concentration-dependent decrease in quinpirole-induced 
phosphorylation of Ser317/Thr318 (Fig. 4.2B). We used siRNA to confirm the GRK subtypes 
involved in phosphorylation of Ser317/Thr318. Transfection of siRNA directed at GRK2 
significantly reduced Ser317/Thr318 phosphorylation, as did siRNA directed at GRK3 (Fig. 
4.2C). Co-transfection of cells with the siRNAs directed at GRK2 and GRK3 together had a 
synergistic effect in decreasing the phosphorylation of Ser317/Thr318 further as compared to 
each siRNA alone (Fig. 4.2C). Moreover, experiments transfecting siRNA directed at the other 
ubiquitously expressed GRKs; GRK5 and GRK6, had no effect on agonist-induced 
phosphorylation (Fig. 4.2C and D). Finally, overexpression of GRK2 increased the 
phosphorylation of Ser317/Thr318 in response to quinpirole (Fig. S4.3). Together these data 
confirm that GRK2 or 3 activity is required for agonist-induced phosphorylation of 
Ser317/Thr318. 
In the prevalent model of arrestin recruitment to GPCRs, GRK-mediated 
phosphorylation of intracellular serine and threonine residues drives this process by increasing 
the affinity of arrestins for the GPCR(24,314). Having shown that GRK2 or 3 mediate agonist-
dependent phosphorylation of Ser317/Thr318, we next investigated the role GRK2-mediated 
phosphorylation plays in β-arrestin-2 recruitment to the D2R. β-arrestin-2 recruitment assays 
were performed with or without GRK2 overexpression (Fig. 4.2E & F). Quinpirole-induced β-
arrestin-2 recruitment was enhanced upon GRK2 overexpression. Pre-treatment of cells 
overexpressing GRK2 with compound 101 significantly reduced β-arrestin-2 recruitment 
(vehicle control Emax = 100.00 ± 0.91, compound 101 Emax = 28.89 ± 0.90, (mean ± SEM), 
P<0.0001, Extra sum-of-squares F-test) (vehicle control pEC50 = 7.29 ± 0.02 , compound 101 
pEC50 = 6.89 ± 0.07, (mean ± SEM), P<0.0001, Extra sum-of-squares F-test) (Fig. 4.2E). In 
cells expressing endogenous levels of GRK2, a more subtle but statistically significant 
reduction in maximal effect was observed on treatment with compound 101 (vehicle control 
Emax = 33.58 ± 1.33, compound 101 Emax = 29.09 ± 0.98 (mean ± SEM), P=0.0041, Extra sum-
of-squares F-test) (vehicle control pEC50 = 6.83 ± 0.08 , compound 101 pEC50 = 6.82 ± 0.05, 
(mean ± SEM) (Fig. 4.2F). Together these data demonstrate that there are both GRK2/3 
phosphorylation -dependent and -independent components of β-arrestin-2 recruitment to the 
hD2R.  





Chapter 4 – New phospho-antibodies for the D2R 
149 
 
Figure 4.2:  GRK2 and GRK3 mediate phosphorylation at Ser317/Thr318 and enhance 
β-arrestin-2 recruitment. (A) HEK293 cells stably expressing HA-hD2LR were stimulated with 
1 µM quinpirole, 1 µM PMA or 10 µM forskolin for 10 min at 37 °C. Cell lysates were 
immunoblotted with anti-pS317/T318 [5102] antibody. Blots were stripped and reprobed for 
D2R [5106] to confirm equal loading of the gel. Blots are representative, n=3. (B) Cells 
described in (A) were pre-incubated with either vehicle (DMSO; control (-)) or the GRK2/3-
specific inhibitor compound 101 (cmpd 101) at the indicated concentrations for 30 minutes at 
37 °C, then treated with water (-) or 1 µM quinpirole for 10 min at 37 °C. Lysates were 
immunoblotted as described in (A). Blots are representative, n=3. (C and D)  Cells described 
in (A) were transfected with siRNAs targeting GRK2, GRK3, or GRK2 and GRK3 (GRK2/3) or 
a scrambled control (SCR) (C) or with siRNAs targeting GRK5, GRK6 or GRK5 and GRK6 
(GRK5/6) or a scrambled control (SCR) (D). 72 hours post-transfection, cells were stimulated 
with 1 µM quinpirole for 10 min at 37 °C and cell lysates were immunoblotted as described in 
(A). Blots were stripped and reprobed for D2R. Densitometry analysis, shown above the blots, 
was normalized to the signal obtained in SCR-transfected cells, which was set to 100%. Data 
are mean  SEM from five to six independent experiments. (*p<0.05 vs. SCR by one-way 
ANOVA with Bonferroni post-test). (E and F) β-arrestin-2 recruitment to the D2R in the 
presence and absence of over expressed GRK2. FlpIn™ HEK 293 cells were transfected with 
cDNA encoding hD2LR-Nluc, YFP-β-arrestin-2, and either GRK2 (E) or pcDNA3.1 control (F) 
as described in the methods section. Transfected cells were then preincubated with either 
vehicle (DMSO) or 30µM cmpd 101 for 30 minutes at 37°C before stimulation with increasing 
concentrations of quinpirole for 10 minutes before BRET detection at 37°C.  Data represents 
mean ± SEM from 3-4 separate experiments and are normalised to the maximal effect of 
quinpirole in the presence of GRK2 overexpression. 
 
 
Ser317/Thr318 phosphorylation occurs rapidly after D2R activation 
As Ser317/Thr318 is phosphorylated by GRK2/3 (Fig. 4.2), we next monitored GRK2 
recruitment to the hD2R in live cells using BRET. GRK2 was rapidly recruited to the D2R, 
within one minute of dopamine addition, and the recruitment remained sustained over time 
(Fig. 4.3A).  We next used the pSer317/pThr318 antibody to monitor the time-course of D2R 
phosphorylation at these residues following application of the agonist quinpirole (1µM) and 
observed rapid and sustained phosphorylation over time, with maximal signal obtained within 
2.5 minutes (Fig. 4.3B). The kinetic profile of Ser317/Thr318 phosphorylation, then, is rapid 
and occurs on a timescale similar to that of GRK2 recruitment.  





Figure 4.3: Time-course of GRK2 recruitment and Ser317/Thr318 phosphorylation. (A) 
Agonist-stimulated GRK2 recruitment to the D2R over time. Flp-In™ HEK 293 cells were 
transfected with hD2LR-NLuc and GRK2-Venus. Dopamine-induced recruitment of GRK2-
Venus was measured for 30 minutes at 37°C. The baseline-corrected increase in BRET ratio 
over time is plotted. Data represents mean ± SD (grey shading) of three separate experiments. 
(B) Agonist stimulated Ser317/Thr318 phosphorylation of the D2R over time. HEK 293 cells 
stably expressing HA-hD2LR were exposed to 1 µM quinpirole for the indicated times at 37 °C; 
lysates were immunoblotted with antibody to pSer317/Thr318 [5102]. Blots were stripped and 
re-probed for D2R. Blots are representative, n=4. 
 
 
D2R agonists vary broadly in their ability to stimulate the recruitment of GRK2, 
phosphorylation of Ser317/Thr318 and recruitment of β-arrestin-2 
Our pSer317/pThr318 antibody is a novel tool with which to measure agonist dependent 
GRK2/3 mediated phosphorylation of the D2R and complements our BRET assays to measure 
GRK2 and β-arrestin-2 recruitment. We next used these tools to measure the ability of 12 
structurally distinct D2R agonists to initiate these processes. This selection included the 
efficacious agonists pergolide, cabergoline, bromocriptine, ropinirole, apomorphine that are 
used clinically to treat Parkinson’s disease and hyperprolactinaemia. We also included the 
partial agonists roxindole, terguride and the antipsychotic aripiprazole as well as ligands that 
have previously been described as G protein (MLS1547) and arrestin (UNC9994) biased 
agonists(293,303). We have previously shown that the binding kinetics of D2R agonists can 
influence comparisons of agonist effect across measurements of different signalling endpoints 
(310). This effect is driven, to an extent, by measurements of agonist action at different 
signalling endpoints at distinct timepoints. To negate this effect, the agonist induced regulatory 
effects were all measured ten minutes after stimulation to allow comparison across all assays. 
There was a wide range in the maximal response of agonists to induce GRK2 recruitment to 
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the D2R (Fig. 4.4A, Table 4.2). Interestingly, DA produced a larger maximal effect than all 
other agonists tested. We used Schild analysis to determine whether the larger response induced 
by dopamine was due to action at endogenously expressed dopamine D1-like receptor subtypes 
using the selective D1-type antagonist SCH23390. Increasing concentrations of this antagonist 
caused a dextral shift of the DA concentration-response curve with no decrease of Emax. Schild 
analysis of these data gave a Schild slope of approximately unity (1.10 ± 0.04), indicating that 
SCH23390 inhibits a response mediated by a single receptor type, and an affinity that was 
consistent with the reported affinity of SCH23390 for the D2R (pA2= 6.28 ± 0.06, Fig. S4.4A 
and B). Thus, it appears that, with respect to GRK2 recruitment, DA displays superior efficacy 
to all other tested agonists. 
Quinpirole, apomorphine, ropinirole and cabergoline showed robust GRK2 recruitment 
to 50-60% that of dopamine (Fig. 4.4A & Table 4.2). Bromocriptine and roxindole behaved as 
less efficacious partial agonists. The antipsychotic and weak partial agonist aripiprazole, 
stimulated GRK2 recruitment very poorly such that an accurate measurement of maximal effect 
or potency could be determined. Surprisingly, both the previously reported G protein-biased 
agonist (MLS1547) and the arrestin biased agonist (UNC9994) induced GRK2 recruitment 
with similar low potency and efficacy (26.1% and 13.3% of DA, respectively at a concentration 
of 10 M (Fig. 4.4A & Table 4.2). Roxindole and terguride also displayed weak partial agonist 
efficacy in this assay (Emax 24% and 7% of DA, respectively) 
We next determined the level of Ser317/Thr318 phosphorylation induced by the twelve 
different agonists (Fig. 4.4B, Table 4.2). In general, the ability of the various agonists to 
stimulate GRK2 recruitment largely predicted their relative ability to induce phosphorylation 
at Ser317/Thr318 at saturating concentrations. For example, efficacious agonists such as 
dopamine and quinpirole produced robust phosphorylation whereas roxindole promoted 
phosphorylation to a lesser degree. To quantify this phosphorylation responses, we performed 
densitometry analysis in which the intensity of the pSer317/pThr317 bands were normalised to 
the corresponding intensity of the total D2R bands. The relative effect of a saturating 
concentration (10 M) of each agonist was then normalised relative to DA. Together these 
analyses allowed us to plot the concentration-dependent increases in Ser317/Thr318 
phosphorylation for each agonist. DA displayed higher intrinsic efficacy relative to all other 
agonists consistent with the GRK2 recruitment data and while observed potencies were 
generally lower for Ser317/Thr318 phosphorylation as compared to GRK2 recruitment the 
order of potencies was consistent (Fig. 4.4A & B, Table 4.2). Importantly, no significant 
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phosphorylation could be detected after treatment with aripiprazole, MLS1547 or UNC9994 as 
compared to the control condition (Fig. 4.4B). This is in line with the very low efficacy shown 
by these ligands in the GRK2 recruitment above.  
Next, we evaluated β-arrestin-2 recruitment to the D2R for the 12 agonists. Of note, β-
arrestin-2 recruitment assays were performed in the presence of GRK2 to enable us to observe 
both the GRK2 phosphorylation dependent and independent components that we previously 
distinguished (Fig. 4.2E & F). The maximal effects observed for β-arrestin-2 recruitment 
followed a very similar trend to that observed for GRK2 recruitment and Ser317/Thr318 
phosphorylation (Fig. 4.4C, Table 4.2). The more efficacious agonists dopamine, quinpirole 
and apomorphine produced robust responses whereas partial agonists such as aripiprazole 
produced weaker responses. DA was more potent in this assay as compared to our 
measurements of GRK2 recruitment or Ser317/Thr318 phosphorylation and all other agonists 
followed this trend, indicating. Surprisingly, the arrestin biased agonist UNC9994 displayed 
only modest β-arrestin-2 recruitment and a reduced maximal effect (23.3 ± 3.3 % DA Emax, 
Table 4.2) relative to previously reported values in a similar assay (>50 % Quinpirole Emax) 
(293). We subsequently assessed β-arrestin-2 recruitment in the absence of overexpression of 
GRK2. In these experiments, however, stimulation with a concentration of up to 10 M 
UNC9994 could not be distinguished from the vehicle control (Fig. S4.7)., In summary, the 
ability of agonists to stimulate GRK2 recruitment and Ser317/Thr318 phosphorylation predicts 
their efficacy to drive -arrestin-2 recruitment, in agreement with the canonical model of 
GPCR regulation. The pSer317/pThr318 antibody is, therefore, a useful tool with which to 
measure the action of D2R agonists to activate these regulatory events. 
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Figure 4.4: Agonist-induced GRK2 recruitment, Ser317/Thr318 phosphorylation and β-
arrestin-2 recruitment. (A) Agonist-induced GRK2 recruitment to the D2R. FlpIn™ HEK 293 
cells were transfected GRK2-Venus and hD2LR-Nluc. GRK2 recruitment was measured by 
BRET 10 minutes after agonist addition at 37°C. Data is presented as the increase in BRET 
ratio normalised to vehicle (0%) and the maximal effect of dopamine (100%). Data represents 
the mean ± SEM of 3-6 separate experiments performed in duplicate. (B) HA-hD2R expressing 
HEK293 cells were either stimulated with vehicle (solvent) or quinpirole, dopamine, pergolide, 
ropinirole, apomorphine, cabergoline, bromocriptine, terguride, roxindole, aripiprazole, 
MLS1547 or UNC9994 at concentrations ranging from 10-9 to 10-5 M for 10 min at 37 °C. 
Lysates were immunoblotted with antibody to pS317/T318 [5102]. Blots were stripped and 
reprobed for D2R. Blots are representative, n=3-4. (C) Densitometry analysis of Western blots. 
pS317/pT318 signals were normalised to the total D2R signal and expressed as a percentage 
of the signal detected when cells were stimulated with 10 M dopamine. These data are 
presented as concentration response curves. (D) Agonist-induced β-arrestin-2 recruitment to 
the D2R. FlpIn™ HEK 293 cells were transfected with hD2LR-Nluc, GRK2 and YFP-β-arrestin-
2. β-arrestin-2 recruitment was measured by BRET 10 minutes after agonist addition at 37°C. 
Data is presented as the increase in BRET ratio normalised to vehicle (0%) and the maximal 
effect of dopamine (100%). Data represents the mean ± SEM of 3-6 separate experiments 
performed in duplicate. 
 
 
Table 4.2:  Potency and maximal effect estimates for agonists activating different D2R 
pathways. 
Responses were analysed using a three-parameter fit. Values represent the mean ± SEM. 
Agonist pSer317/pThr318 GRK2 β-arr-2 
 pEC50 Emax pEC50 Emax pEC50 Emax 
Dopamine 6.40 ± 0.45 100 ± 7 6.84 ± 0.04 100.0 ± 2.1 7.13 ± 0.05 100.0 ± 2.3 
Apomorphine 7.42 ± 0.10 84 ± 3 7.68 ± 0.09 56.2 ± 2.1 7.85 ± 0.05 81.2 ± 1.7 
Aripiprazole ND ND ND ND 6.23 ± 0.25 10.3 ± 1.5 
Bromocriptine 6.84 ± 0.25 57 ± 2 7.18 ± 0.06 38.7 ± 1.1 7.10 ± 0.05 66.3 ± 1.3 
Cabergoline 7.38 ± 0.25 61 ± 2 8.36 ± 0.07 54.4 ± 1.4 8.29 ± 0.04 83.7 ± 1.2 
MLS1547 ND ND 5.20 ± 0.27 26.1 ± 7.8 5.59 ± 0.13 33.6 ± 3.8 
Pergolide 7.73 ± 0.46 79 ± 2 7.67 ± 0.06 50.8 ± 1.2 7.83 ± 0.04 76.7 ± 1.3 
Quinpirole 7.06 ± 0.17 83 ± 0.6 7.13 ± 0.04 62.9 ± 1.2 7.38 ± 0.03 88.6 ± 1.2 
Ropinirole 6.77 ± 0.22 77 ± 2 6.72 ± 0.07 59.1 ± 2.0 6.99 ± 0.04 76.8 ± 1.4 
Roxindole 7.52 ± 0.09 10 ± 0.6 8.73 ± 0.15 24.3 ± 1.3 8.83 ± 0.07 41.0 ± 1.0 
Terguride ND ND 8.10 ± 0.24 7.4 ± 0.7 8.33 ± 0.09 18.9 ± 0.6 
UNC9994 ND ND 5.45 ± 0.31 13.3 ± 3.8 5.63 ± 0.18 23.0 ± 3.3 
ND – Not determined: unable to be determined due to insufficient response to allow accurate 




A putative arrestin-biased agonist displays robust activity in measurements of G protein 
signalling 
Two agonists previously described as arrestin and G protein-biased agonists both acted 
as low efficacy partial agonists at these regulatory endpoints. It was important, then, to extend 
our analysis to test the ability of these agonists to activate G protein-mediated pathways. We 
measured Gαi1 and GαoA G protein activation using BRET sensors that monitor the dissociation 
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of the Gβγ subunit from the Gα subunit (308,315). All agonists induced robust activation of 
Gαi1 (Fig. 4.5A & Table 4.3). Aripiprazole, roxindole and terguride acted as partial agonists 
for Gαi1 activation whereas most of the other agonists showed maximal responses equivalent 
to that of dopamine. Surprisingly, UNC9994, the arrestin biased agonist, displayed robust 
partial agonism in this assay (81.6% dopamine response) with a similar low potency to that 
observed in the -arrestin-2 recruitment assay (Fig. 4.5A & Table 4.3). The D2R is 
preferentially coupled to Gαo G proteins (316). Accordingly, in the GαoA activation assay, all 
agonists displayed a similar maximal response to dopamine and an increase in potency relative 
to that observed when Gαi1 activation was measured (Fig. 4.5B & Table 4.3).  
Finally, we measured activation of G protein inwardly rectifying potassium (GIRK) 
channels as a readout of the activation of Gαi/o G proteins using a membrane potential sensitive 
dye (309)(Fig. S4.5). In this case all agonists displayed the same maximal response as 
dopamine with the exception of terguride which acted as a partial agonist. In addition, while 
the relative order of potencies for the various agonists was consistent with that obtained in the 
G protein activation assays, aripiprazole, MLS1547 and UNC9994 displayed low potencies in 
this assay such that the maximal response was not obtained at the highest (1M) concentration 
used for each agonist (Fig. 4.5C & Table 4.2).  
Overall, all agonists displayed a similar relative trend in their responses in each of the 
three G protein-dependent signalling measurements. In addition, our observations were largely 
consistent with previous reports of agonist action, for example apomorphine is known to be a 
potent and efficacious agonist (317) and induced robust responses in all three G protein 
signalling endpoints and in measurements of receptor regulatory events. In contrast, 
aripiprazole is known to be a low efficacy agonist and behaved as such in all assays with the 
exception of the highly amplified GαoA activation assay (318,319). Interestingly, UNC9994, 
that was previously reported to be an arrestin biased agonist unable to activate G protein 
responses or antagonise G protein signalling stimulated by dopamine (293,320), acted as a 
weak partial agonist in measurements of both G protein activation and receptor regulation. 
Furthermore, we found that pre-treatment of cells with UNC9994 antagonised GIRK channel 
activation or pSer317/Thr318 down to a level consistent with its maximal effect in each assay 
(Fig. S4.6) These observations are in agreement with a previous study that characterised 
UNC9994 measuring GIRK channel activation in frog oocytes expressing the hD2R(321).  




Figure 4.5. D2R mediated activation of Gαi1, GαoA and GIRK channels by distinct 
agonists. FlpIn™ HEK 293 cells stably expressing hD2LR were transfected with BRET 
sensors for (A) Gαi1 activation and for (B) GαoA activation as described in methods. Agonist 
responses were determined after 10 minutes at 37°C. The response is plotted as the increase 
in BRET ratio normalised to the vehicle control (0%) and the maximal response produced by 
dopamine defined as 100%. The data in (A) and (B) represent the mean ± SEM for 3-6 
separate experiments performed in duplicate.  (C) GIRK channel activation using a membrane 
potential kit. Data represents mean ± SEM performed in duplicate.  




Table 4.3:  Potency and maximal effect estimates for agonists activating different D2R 
pathways. 
Responses were analysed using a three-parameter fit. Values represent the mean ± SEM. 
Agonist Gαi1 GαoA GIRK 
 pEC50 Emax pEC50 Emax pEC50 Emax 
Dopamine 7.50 ± 0.09 100.0 ± 3.5 8.63 ± 0.08 100.0 ± 2.6 8.70 ± 0.06 100.0 ± 2.5 
Apomorphine 8.10 ± 0.07 103.6 ± 2.5 9.07 ± 0.06 98.6 ± 1.9 9.13 ± 0.08 110.0 ± 3.5 
Aripiprazole 6.21 ± 0.17 67.5 ± 6.9 6.64 ± 0.08 97.6 ± 3.8 6.53 ± 0.11 54.6 ± 4.5 
Bromocriptine 7.07 ± 0.08 115.0 ± 4.1 7.84 ± 0.05 103.7 ± 2.0 7.38 ± 0.08 104.7 ± 4.3 
Cabergoline 8.13 ± 0.16 109.8 ± 6.5 8.80 ± 0.05 102.7 ± 1.7 9.01 ± 0.08 104.0 ± 3.4 
MLS1547 5.71 ± 0.20 123.9 ± 19.5 6.68 ± 0.08 106.5 ± 4.4 6.25 ± 0.08 129.3 ± 15.4 
Pergolide 7.73 ± 0.17 112.3 ± 7.3 8.73 ± 0.07 96.7 ± 2.3 9.28 ± 0.07 97.9 ± 2.7 
Quinpirole 7.81 ± 0.10 119.3 ± 4.6 8.93 ± 0.05 97.4 ± 1.5 8.98 ± 0.05 104.9 ± 2.1 
Ropinirole 7.33 ± 0.13 98.01 ± 5.2 8.55 ± 0.13 93.9 ± 3.7 8.23 ± 0.07 94.4 ± 3.4 
Roxindole 8.19 ± 0.12 86.6 ± 4.2 9.04 ± 0.04 90.7 ± 1.1 9.26 ± 0.06 89.7 ± 2.2 
Terguride 7.76 ± 0.18 66.2 ± 4.6 8.36 ± 0.05 100.1 ± 1.6 8.05 ± 0.08 53.3 ± 2.1 
UNC9994 5.74 ± 0.21 81.6 ± 13.4 6.55 ± 0.08 98.0 ± 4.1 ND ND 
ND – Not determined: unable to be determined due to insufficient response to allow accurate 
fitting of the model.  
 
 
Analysis of signalling data using an operational model of agonism allows quantitative 
evaluation of bias between G protein and regulatory events 
In general, our data suggests that the actions of the various agonists appeared, relative 
to each other, consistent across the various G protein-mediated and regulatory pathways. 
However, such qualitative comparisons of agonist action across different pathways can be 
confounded by system bias resulting from, for example, the relative efficiency with which each 
pathway is coupled to the receptor. Accordingly, we employed a more quantitative approach 
to determine the relative action of each agonist at each pathway by fitting our concentration 
response data to an operational model of agonism (322). Using this model, we can determine a 
transduction coefficient (τ/KA) that is a composite of the affinity of the agonist for the receptor-
effector complex (KA) and the efficacy with which the agonist acts at that effector (τ) (Table 
4.2). We then subtracted the values obtained for each agonist with the values obtained by 
dopamine to compare the relative transduction coefficients of agonists between pathways 
(Dlog[τ/KA]), Fig. 4.6 & Table 4.4). The transduction coefficients of apomorphine, 
aripiprazole, quinpirole, MLS1547, pergolide and ropinirole were not significantly different 
across the different signalling and regulatory endpoints, noting that the operational model could 
not be fitted to data describing the action of MLS1547 to stimulate GRK2 recruitment or 
pSer317/pThr318 likely due to the inefficient coupling of these pathways and the low affinity 
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and efficacy of this compound. No significant difference was seen across all regulatory 
endpoints measured for any of the compounds, illustrating that measurement of one of these 
steps (GRK2 recruitment, pSer317/pThr318 or -arrestin-2 recruitment) is likely to predict 
relative agonist action at the others. Moreover, for all agonists, there was no significant 
difference between the normalised transduction coefficient obtained in the Gi1 activation 
assay and any of the regulatory pathways. However, we did observe differences between the 
GoA activation or GIRK activation and the regulatory events for the agonists bromocriptine 
(GRK2 recruitment, pSer317/pThr318 and -arrestin-2 recruitment), carbergoline (GRK2 and 
-arrestin-2 recruitment), terguride (GRK2 and -arrestin-2 recruitment)  and pergolide 
(pSer317/Thr318 and -arrestin-2 recruitment versus GoA activation, Fig. 4.6, Table 4.4). In 
all cases, relative to the action of dopamine, these agonists were more efficient at activating 
the regulatory pathways (Fig. 4.6). While most of these differences were subtle (< 5-fold), 
bromocriptine displayed a 13-fold and 8-fold preference for GRK2 and -arrestin-2 recruitment 
over GIRK activation, respectively. Of particular note, however, is that two agonists previously 
described as arrestin biased (UNC9994) and G protein biased (MLS1547) did not display these 
profiles in our hands. UNC9994 acts as a low efficacy partial agonist at all pathways, displaying 
robust agonist action at more efficiently coupled pathways such as GoA activation but barely 
detectable action at less efficiently coupled endpoints such as pSer317/pThr318 or -arrestin-
2 recruitment. MLS1547 was able to stimulate both G protein activation and -arrestin-2 
recruitment. Our analysis revealed that this ligand does not display bias between these two 
endpoints. 




Figure 4.6: Relative transduction coefficients (ΔLog (τ/KA)) for agonists to activate D2R 
pathways. Concentration response curves for each endpoint were fit to an operational model 
of agonism to determine (Log (τ/KA)), this was normalised relative to dopamine to determine 
the relative transduction coefficient (ΔLog (τ/KA), Table 4.4). Analysis of these data using a 
one-way ANOVA with Dunnet’s post hoc test revealed significant differences between the 
relative transduction coefficient, normalised to that of dopamine, determined for each agonist 
in the Go assay as compared to that obtained in the other signalling and regulatory endpoints 
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Table 4.4: Estimates of transduction coefficients and relative transduction coefficients for agonists activating D2R signalling pathways. 
Responses were determined and analysed using an operational model of agonism. Values represent the mean ± SEM.  
Agonist Log (τ/KA) ΔLog (τ/KA) 
 Gαi1 GαoA GIRK GRK2 pS317/pT318 β-arr-2 Gαi1 GαoA GIRK GRK2 pS317/pTr18 β-arr-2 
Dopamine 7.42 ± 0.14 8.68 ± 0.09 8.57 ± 0.06 6.90 ± 0.05 6.55 ± 0.18 7.19 ± 0.03 0.00 ± 0.20 0.00 ± 0.12 0.00 ± 0.09 0.00 ± 0.07 0.00 ± 0.07 0.00 ± 0.05 
Apomorphine 8.08 ± 0.12 9.09 ± 0.07 9.06 ± 0.07 7.55 ± 0.07 7.38 ± 0.18 7.87 ± 0.04 0.66 ± 0.19 0.42 ± 0.11 0.49 ± 0.10 0.65 ± 0.09 0.85 ± 0.09 0.69 ± 0.05 
Aripiprazole 6.02 ± 0.19 6.66 ± 0.06 6.10 ± 0.22 5.01 ± 0.52 ND 5.86 ± 0.25 -1.40 ± 0.23 -2.02 ± 0.11 -2.47 ± 0.23 ND ND -1.33 ± 0.25 
Bromocriptine 7.18 ± 0.11 7.93 ± 0.06 7.35 ± 0.06 6.94 ± 0.10 6.79 ± 0.17 7.09 ± 0.05 -0.24 ± 0.18 -0.75 ± 0.11 -1.23 ± 0.09 0.05 ± 0.11 0.24 ± 0.11 -0.10 ± 0.06 
Cabergoline 8.18 ± 0.10 8.89 ± 0.06 9.16 ± 0.14 8.22 ± 0.07 7.25 ± 0.17 8.31 ± 0.03 0.76 ± 0.17 0.22 ± 0.10 0.59 ± 0.15 1.32 ± 0.09 0.70 ± 0.19 1.13 ± 0.05 
MLS1547 5.91 ± 0.10 6.81 ± 0.06 6.43± 0.11 ND ND 5.46 ± 0.11 -1.51 ± 0.17 -1.87 ± 0.10 -2.14 ± 0.12 ND ND -1.73 ± 0.11 
Pergolide 7.83 ± 0.11 8.73 ± 0.06 9.18 ± 0.12 7.53 ± 0.08 7.21 ± 0.13 7.85 ± 0.04 0.41 ± 0.18 0.05 ± 0.11 0.61 ± 0.14 0.64 ± 0.19 0.66 ± 0.09 0.67 ± 0.05 
Quinpirole 8.00 ± 0.11 8.94 ± 0.06 8.95 ± 0.07 7.06 ± 0.07 7.02 ± 0.11 7.44 ± 0.03 0.58 ± 0.18 0.27 ± 0.11 0.38 ± 0.10 0.48 ± 0.18 0.48 ± 0.18 0.25 ± 0.05 
Ropinirole 7.21 ± 0.11 8.50 ± 0.07 8.45 ± 0.11 6.63 ± 0.07 6.63 ± 0.14 7.03 ± 0.04 -0.21 ± 0.18 -0.17 ± 0.11 -0.12 ± 0.13 -0.27 ± 0.09 0.09 ± 0.19 -0.16 ± 0.05 
Roxindole 8.08 ± 0.13 8.95 ± 0.06 9.31 ± 0.11 8.36 ± 0.13 6.17 ± 1.16 8.69 ± 0.07 0.67 ± 0.19 0.28 ± 0.10 0.74 ± 0.13 1.46 ± 0.14 -0.37 ± 1.2 1.51 ± 0.08 
Terguride 7.52 ± 0.18 8.40 ± 0.06 7.87 ± 0.12 7.54 ± 0.32 ND 7.99 ± 0.14 0.10 ± 0.23 -0.27 ± 0.11 -0.71 ± 0.14 0.64 ± 0.33 ND 0.81 ± 0.14 
UNC9994 5.64 ± 0.18 6.57 ± 0.06 5.75 ± 0.08 ND ND 5.44 ± 0.15 -1.78 ± 0.23 -2.11 ± 0.10 -2.82 ± 0.10 ND ND -1.75 ±0.15 





GPCR phosphorylation by GRKs is a key process for the regulation of most GPCRs by 
promoting arrestin binding and, thus, inhibition of G protein mediated signalling. Arrestin 
mediated signalling has been shown to mediate distinct physiological processes downstream 
of the D2R and arrestin-biased agonists have been proposed as an avenue for the development 
of more efficacious antipsychotic drugs (300). Antibodies raised against GPCR 
phosphorylation sites have been useful tools with which to understand the hierarchical and 
sequential pattern of multisite phosphorylation upon agonist stimulation (323,324). In this 
study we developed and characterised phospho-site-specific antibodies for the D2R against 
predicted phosphorylation sites within ICL3 and used them to provide an insight into the role 
GRK phosphorylation plays in D2R regulatory processes and how it is controlled by chemically 
distinct agonists including those thought to have pathway-biased actions. One of these 
antibodies revealed an increase in Ser317 and Thr318 phosphorylation upon agonist activation 
mediated by GRK2/3. Comparison of these data with measurements of GRK2 and arrestin 
recruitment revealed that the relative efficacy of all tested agonists at the level 
pSer317/pThr318 can predict their efficacy at these other regulatory processes. A challenge 
associated with measuring these regulatory processes is that such measurements often entail 
the overexpression of one or more regulatory proteins that are modified with a fluorescent tag 
such as those used in BRET assays. This may alter the stoichiometry of the different protein 
components associated with downstream signalling and may be particularly problematic if one 
wants to compare agonist action across different signalling pathways as is often done in studies 
aimed at identifying biased agonists. In this regard, the measurement of Ser317/Thr318 
phosphorylation can be used in both heterologous expression systems and native tissue without 
the need for the over-expression of modified proteins. Importantly, the antibodies described in 
the present study recognise phospho-sites present in both D2SR and D2LR. This is particularly 
relevant when considering future studies that use these antibodies in tissues or primary neuronal 
cultures as it will allow the detection of phosphorylation of both, pre- and post-synaptic 
receptors. 
Two other antibodies developed in this study recognised two additional sites, 
pThr287/pSer288 and pThr293/pSer296, that appear to be constitutively phosphorylated. The 
role of this constitutive phosphorylation is unclear. Interestingly, GRK2/3 phosphorylation has 
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been shown to play a role in post-endocytic trafficking and re-sensitisation (291,294,325) and 
Thr287, Ser288, and Thr293 have been identified as GRK2 phosphorylation sites important for 
post-endocytic trafficking (294). Interestingly, while Ser317 is conserved in humans and 
rodents, Thr318 is absent in both mice (Mus musculus) and rats (Rattus norvegicus) suggesting 
there may be species differences in the patterns of GRK phosphorylation. Moreover, other 
kinases have been shown to regulate D2Rs (326,327), for example PKC has been demonstrated 
to phosphorylate the D2R and regulate function through heterologous desensitisation (327,328). 
An antibody that recognizes a PKC phospho-site in ILC3 of the D2R has previously been 
described that, surprisingly, shows differences in phosphorylation between D2SR and D2LR 
(329). It should be noted that we observed significant arrestin recruitment in the presence of a 
GRK2/3 inhibitor, meaning that this process can occur independently of Ser317/Thr318 
phosphorylation. Future efforts to develop phospho-antibodies targeting other GRK and PKC 
sites, in combination with receptor mutants in which such phosphorylation sites are removed, 
will allow us to understand better the broader temporal pattern of D2R phosphorylation and 
how it might modulate D2R signalling. 
Recent interest in understanding GPCR regulatory processes such as arrestin 
recruitment has been driven, to some extent, by the appreciation that arrestin-mediated 
signalling may drive distinct physiological processes to those mediated by G protein signalling 
and that one may be able to selectively modulate these processes using biased agonists. GRK 
phosphorylation has been proposed to be the key event that controls the balance between G 
protein- and arrestin-mediated signalling. It is suggested that the unique phosphorylation 
pattern, or barcode, that can then lead to distinct downstream signalling through a mechanism 
that involves altered β-arrestin recruitment and/or stabilisation of distinct β-arrestin 
conformations (330).  There has been a surge of interest in D2R biased agonists over the last 
decade driven by their potential as novel, safer, treatments for schizophrenia and Parkinson’s 
disease (293,331-337). In this study we tested a range of agonists and compared their relative 
ability to stimulate Ser317/Thr318 phosphorylation to other measures of D2R activation 
including measurements of G protein signalling and arrestin recruitment. We included two 
ligands that have been described as biased agonists, the G protein-biased agonist MLS1547 
(331) and the arrestin-biased agonist UNC9994 (293). In addition, the atypical antipsychotic 
aripiprazole was initially described as a D2R partial agonist, but subsequent studies suggested 
it may act as a biased agonist (338,339). Initial reports using MLS1547 suggested that it is a G 
protein biased agonist that acts as an agonist to activate G protein pathways but antagonises 
the arrestin pathway (331). In our hands, stimulation with MLS1547 results in recruitment of 
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β-arrestin-2 as well as GRK2 recruitment and our analysis revealed no bias between G protein 
activation and β-arrestin-2 recruitment. In agreement with this finding, MLS1547 has 
previously been shown to induce recruitment of β-arrestin-2 (340), and produce some 
internalisation in striatal neurons (341), a process that is usually mediated through arrestins. 
UNC9994 was initially described as an arrestin biased agonist, acting as a robust partial agonist 
for β-arrestin-2 recruitment but with no apparent activity at G protein signalling pathways 
(293,342). In this present study, however, we found that even in the presence of over-expressed 
GRK2 UNC9994 promoted modest recruitment of β-arrestin-2 with both lower maximal effect 
and potency than that reported in its initial characterisation (293). Consistent with this 
observation, UNC9994 showed no detectable phosphorylation of Ser317/Thr318 and induced 
only very weak GRK2 recruitment. Furthermore, in the absence of GRK2 overexpression 
UNC9994 did not stimulate β-arrestin-2 recruitment. Together these data suggest that 
UNC9994 has low efficacy for GRK2 phosphorylation, GRK2 recruitment and β-arrestin-2 
recruitment. Surprisingly, we found that UNC9994 also acted as a weak partial agonist in G 
protein activation BRET assays as well as in an assay measuring G protein mediated GIRK 
channel activation. These observations match previous work by Ågren and co-workers in 
experiments measuring GIRK channel opening in frog oocytes (321). Analysis of our data to 
derive bias factors revealed that UNC9994 does not display bias between G protein and arrestin 
pathways relative to dopamine. Together these data are difficult to reconcile with the initial 
characterisation of UNC9994 as an arrestin biased agonist. Finally, we also found that 
aripiprazole did not display bias between G protein signalling and any of the regulatory 
processes such as arrestin recruitment. In original studies that identified MLS1547 and 
UNC9994 as biased agonists (293,331), no agonism was detected in the ‘unfavoured’ pathway 
and, thus, no quantitative measurement of bias could be made whereas in our studies we 
observed sufficient efficacy in all pathways to enable the quantification of their effect. The 
difference between these observations likely stems from differences in the sensitivity of the 
assays used to detect the different endpoints. These results, therefore, are not necessarily 
contradictory but instead illustrate how experimental conditions and cellular context can 
influence measurements of agonist action, particularly for very low efficacy partial agonists. 
Our study illustrates how the measurement of the action of putative biased agonists at multiple 
steps of a signalling pathway may provide further insight into their mechanism of action, 
particularly if the different endpoints are associated with different levels of amplification.  
Measuring this process by using phosphorylation-site specific antibodies, will likely be an 
effective approach to identify and characterise such ligands. 
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Beyond their potential therapeutic value, biased agonists that display a preference for 
one pathway over another can be extremely useful tools with which to interrogate the role of 
distinct downstream signals in a particular physiological process. In this regard, the utility of 
such biased agonists as tools is entirely dependent on the robustness of the pathway bias that 
they display. MLS1547 and UNC9994 have both been used to interrogate the contribution of 
arrestins and G proteins to D2R mediated physiological effects (185,293,300,342,343). The 
interpretation of the above studies that used these drugs as tool compounds should now be 
revisited considering our data that shows that neither UNC9994 or MLS1547 are biased 
agonists.  
The ability of all ligands to stimulate Gαi1 activation predicted their effect in the three 
regulatory endpoints. This observation agrees with β-arrestin recruitment being somewhat 
dependent on G protein activation through release of Gβγ that binds the pleckstrin homology 
domain of GRK2/3 recruiting it to the plasma membrane, leading to receptor phosphorylation 
and  β-arrestin recruitment (344-346). Gαo, however, has been proposed to be the primary G 
protein that the D2R is coupled to in vivo(347). While the relative action of the agonists 
dopamine, apomorphine, aripiprazole, quinpirole, ropinirole and roxindole, as well as the 
biased agonists UNC9994 and MLS1547 are consistent between Gαo activation and the 
regulatory endpoints, this is not the case for bromocriptine, cabergoline, terguride and 
pergolide. These agonists display a preference for the regulatory pathways as compared to Gαo 
activation. These agonists are used clinically to treat hyperprolactinaemia and/or Parkinson’s 
disease and, intriguingly, all have an ergoline scaffold. It is not apparent how this bias profile 
might influence their therapeutic effect, but this observation certainly warrants further 
investigation. 
In summary, we have developed the first antibodies specific for GRK phosphorylation 
sites on the D2R. We identify one phosphorylation site (pS317/pT318) within ICL3 that is 
phosphorylated on agonist activation of the D2R. The action of agonists to phosphorylate this 
site predicts their relative action at arrestin recruitment suggesting that phosphorylation of this 
site is important for arrestin binding to the D2R. We incorporate measurements of pS317/pT318 
with other measurements of G protein activation and receptor regulation to profile a number of 
D2R agonists including putative biased agonists. Our findings, in the light of the interest in G 
protein independent signalling, show the utility of measurements of receptor phosphorylation 
as part of such characterisations. 
 








This work was supported by the Deutsche Forschungsgemeinschaft grants SFB/TR166-
TPC5 and SCHU924/18-1 to S.S and National Health and Medical Research Council 
(NHMRC) Project Grant APP1049564 to J.R.L. 
  
Author contributions 
AM, SS, ACK, JRL designed experiments. AM, HM, PD, ACK acquired the data. AM, 
HM, PD, ACK, JRL analysed the data. AM, ACK, JRL wrote the manuscript. SS, JRL, JAJ, 
MC reviewed and edited the draft.  
 
Conflict of Interest 
The authors declare that they have no conflict of interest. 
  




4.5 Supplementary Materials 
 
 
            214(HUMAN)                                         263 
DRD2_HUMAN  IVLRRRRKRV NTKRSSRAFR AHLRAPLKGN CTHPEDMKLC TVIMKSNGSF 
DRD2_PANTR  IVLRRRRKRV NTKRSSRAFR AHLRAPLKGN CTHPEDMKLC TVIMKSNGSF 
DRD2_BOVIN  IVLRRRRKRV NTKRSSRAFR ANLKAPLKGN CTHPEDMKLC TVIMKSNGSF 
DRD2_RAT    IVLRKRRKRV NTKRSSRAFR ANLKTPLKGN CTHPEDMKLC TVIMKSNGSF 
DRD2_MOUSE  IVLRKRRKRV NTKRSSRAFR ANLKTPLKGN CTHPEDMKLC TVIMKSNGSF 
 
            264                                                313 
DRD2_HUMAN  PVNRRRVEAA RRAQELEMEM LSSTSPPERT RYSPIPPSHH QLTLPDPSHH 
DRD2_PANTR  PVNRRRVEAA RRAQELEMEM LSSTSPPERT RYSPIPPSHH QLTLPDPSHH 
DRD2_BOVIN  PVNRRRVEAA RRAQELEMEM LSSTSPPERT RYSPIPPSHH QLTLPDPSHH 
DRD2_RAT    PVNRRRMDAA RRAQELEMEM LSSTSPPERT RYSPIPPSHH QLTLPDPSHH 
DRD2_MOUSE  PVNRRRMDAA RRAQELEMEM LSSTSPPERT RYSPIPPSHH QLTLPDPSHH 
 
            314                                                362 
DRD2_HUMAN  GLHSTPDSPA KPEKNGHAKD .HPKIAKIFE IQTMPNGKTR TSLKTMSRRK 
DRD2_PANTR  GLHSTPDSPA KPEKNGHAKD .HPKIAKIFE IQTMPNGKTR TSLKTMSRRK 
DRD2_BOVIN  GLHSTPDSPA KPEKNGHAKT VNPKIAKIFE IQSMPNGKTR TSLKTMSRRK 
DRD2_RAT    GLHSNPDSPA KPEKNGHAKI VNPRIAKFFE IQTMPNGKTR TSLKTMSRRK 
DRD2_MOUSE  GLHSNPDSPA KPEKNGHAKI VNPRIAKFFE IQTMPNGKTR TSLKTMSRRK 
 
            363      373 
DRD2_HUMAN  LSQQKEKKAT Q 
DRD2_PANTR  LSQQKEKKAT Q 
DRD2_BOVIN  LSQQKEKKAT Q 
DRD2_RAT    LSQQKEKKAT Q 
DRD2_MOUSE  LSQQKEKKAT Q 
 
Figure S4.1: Multiple amino acid sequence alignment of mammalian D2LR intracellular 
loop three. Primary amino acid sequence alignment of intracellular loop three for Homo 
sapiens (Human), Pan troglodytes (Chimpanzee), Bos Taurus (Bovine), Rattus norvegicus 
(Rat) and Mus musculus (mouse). Phosphosite-specific antibody sites (T287/S288, 
T293/S296 and S317/T318) are highlighted in grey. T318 is not present in rat or mouse D2R. 
Sequence absent from the short isoform (D2SR) is highlighted in yellow. Alignment was 
performed using Clustal Omega version 1.2.4. 
 
 




Figure S4.2: Antagonist-selective inhibition of quinpirole-induced phosphorylation and 
G protein signaling. (A) Reversal of quinpirole-induced hyperpolarization by haloperidol 
using a fluorescence-based membrane potential assay. After baseline recording for 60 sec, 
HEK293 cells stably expressing HA-hD2 receptor and GIRK-eGFP were exposed to 1 µM 
quinpirole and 240 sec later, 10 µM haloperidol was added, yielding a final molar 
quinpirole/haloperidol ratio of 1:10. Shown are representative results from one of four 
independent experiments performed in triplicate. Vehicle-induced changes in fluorescence 
signal (background) were subtracted. (B) Stably HA-hD2 receptor expressing HEK293 cells 
were preincubated (+) or not (-) with 50 µM haloperidol or L-741,626 for 30 min at 37 °C, then 
treated with vehicle (water (-)) or with 1 µM quinpirole (+) for 10 min at 37 °C. Cell lysates were 
then immunoblotted with anti-pS317/T318 antibody. Blots were stripped and reprobed for 
D2R. Blots are representative, n=3.  
 
 
Figure S4.3: D2 receptor phosphorylation is increased by GRK2 overexpression. 
HEK293 cells stably expressing HA-hD2 receptor were transfected with GRK2 plasmid or 
empty vector (MOCK) for 48 hours. After stimulation with 1 µM quinpirole, 10 µM MLS1547, 
10 µM UNC9994 or 10 µM aripiprazole for 10 min at 37 °C, lysates were immunoblotted with 
anti-pS317/T318 antibody. Blots were stripped and reprobed for D2R to confirm equal loading 
of the gel. Densitometry, above the blots, was normalized to those in MOCK-transfected cells, 
which were set to 100%. Data are mean  SEM from seven independent experiments. 
(*p<0.05 vs. MOCK by one-way ANOVA with Bonferroni post-test).  







Figure S4.4: Schild analysis of the effect of SCH23390 on dopamine-induced GRK2 
recruitment. (A) Recruitment of GRK2-Venus to the D2R-Nluc in response to dopamine with 
30 minutes prior treatment of increasing concentrations of the dopamine D1-type receptor 
selective antagonist SCH23390. Schild slope = 1.01 ± 0.03, pA2 = 6.28 ± 0.06 (mean ± SEM) 
(Analysis using a global fit to the Gaddum/Schild EC50 model with prism 8.1.2) (B) Schild plot 
linear regression analysis. Slope = 1.10 ± 0.04, pA2 = 6.06 ± 0.08. Data is presented as the 















Figure S4.5: Establishment of the membrane potential assay. (A, B) HEK293 cells stably 
expressing the HA-hD2 receptor and GIRK-eGFP were stimulated with quinpirole at the 
indicated concentrations. (C) Cells described in (A and B) were either not treated or treated 
with 300 ng/ml PTX for 24 hours and then stimulated with 1 µM quinpirole after baseline 
recording for 60 sec. (D) Cells described in (A and B) were treated with 1 µM quinpirole and 
subsequently either not treated or treated with 10 µM SCH23390 for 10 min. Shown are 
representative results of four independent experiments performed in quintuple (mean  SEM) 
for dose-response curves and four to five independent experiments performed in duplicate 
(mean  SEM) for experiments with PTX and SCH23390. Relative changes in fluorescence 
signal were shown. Background signal (vehicle-induced changes in fluorescence signal) were 
subtracted from agonist-induced changes at each given concentration. Fitting was performed 
using a Levensberg-Marquardt Iteration algorithm using a four-parameter nonlinear regression 
to obtain concentration-response curves with OriginPro software. 
 




Figure S4.6: Inhibition of quinpirole-induced phosphorylation and G protein signaling. 
(A) Stably expressing HA-hD2R HEK293 cells were preincubated (+) or not (-) with 5 µM 
MLS1547, UNC9994 or aripiprazole for 30 min at 37 °C, then treated with vehicle (water (-)) 
or with 1 µM quinpirole (+) for 10 min at 37 °C. Cell lysates were then immunoblotted with anti-
pSer317/Thr318 antibody. Blots were stripped and reprobed for D2R. Blots are representative, 
n=3. (B, C, D) After baseline recording for 60 sec, HEK293 cells stably expressing HA-hD2R  
and GIRK-eGFP were exposed to 1 µM quinpirole and 240 sec later, (A) 10 µM MLS1547, (B) 
10 µM UNC9994 or (C) 10 µM aripiprazole was added, yielding a final molar 
quinpirole/MLS1547, quinpirole/UNC9994 or quinpirole/aripiprazole ratio of 1:10. Shown are 
representative results from one of four independent experiments performed in triplicate. 






Evidence for kinetically distinct 
dopamine D2 receptor G protein 
signalling waves






The dopamine D2 receptor (D2R) is a G protein-coupled receptor that activates members of 
the Gαi family of heterotrimeric G proteins. We sought to investigate the kinetics of D2R mediated 
activation of individual Gαi protein subtypes to provide a further understanding of the biochemical 
processes that govern the ability of the D2R to activate a particular G protein. We used genetically 
encodable bioluminescence resonance energy transfer-based sensors to monitor either G protein 
activation or relative concentrations of cAMP in live cells. When the D2R was stimulated with 
ropinirole, the D2R robustly activated Gαo and Gαz proteins more so than Gαi1, Gαi2 and Gαi3. 
Ropinirole induced the activation of all G proteins tested at a significantly faster observed rate than 
the rate produced by the D2R agonist antipsychotic aripiprazole. Moreover, the efficient activation of 
Gαz by the D2R was shown to be dependent on the slow GTP hydrolysis rate of Gαz. The slow GTP 
hydrolysis rate lead to an accumulation of active Gαz over time when activated by the D2R, resulting 
in increased agonist potency over time. The increased potency over time was abolished by either 
mutation of serine 42 within the GTP binding site or co-expression with RGS20. Overall, we 
demonstrate that G protein mediated responses by the D2R are largely controlled over time by the 
efficacy and binding kinetics of the agonist as well as the GTP hydrolysis rate of the Gα subunit. 
 
  






G protein-coupled receptors (GPCRs) are integral membrane proteins that transduce cellular 
signals from a diverse range of extracellular stimuli such as neurotransmitters, hormones and light. 
Therapeutic exploitation of the ability of GPCRs to transduce such signals has been achieved by 
designing small molecule binders that can consequently control cellular and physiological outcomes 
in disease, thus GPCRs represent the largest class of drug targets (348).  
GPCRs respond to stimuli by coupling to and activating heterotrimeric G proteins. 
Heterotrimeric G proteins are comprised of an α subunit (Gα) that binds guanine nucleotides and a β 
and γ subunit that act together as a dimer (Gβγ). In the G protein cycle, GPCRs function as guanine 
nucleotide exchange factors (GEFs) by means of inducing a conformational change in the G protein 
such that the Gα subunit exchanges bound guanine diphosphate (GDP) for guanine triphosphate 
(GTP). This results in Gα dissociation, or rearrangement relative to, the Gβγ subunit (10,11). Once 
active, the Gα subunit and Gβγ complex can then further activate downstream signalling cascades. 
The signalling is then terminated by the Gα subunit’s native GTPase activity that permits the Gα 
subunit to exist in an active conformation before hydrolysis of the γ-phosphate of GTP, converting it 
to GDP. The inactive Gα subunit then re-associates with free Gβγ and is able to couple to the GPCR 
and start the cycle again (12). 
Despite there being over 800 GPCRs in humans, there are only sixteen genes encoding 
different Gα subunits for GPCRs to transduce signals through. The Gα subunits are categorised into 
four subfamilies (Gαi, Gαs, Gαq and Gα12) depending on their sequence homology. Gα subunits within 
the same subfamily often activate similar effectors. For example, the Gαi subfamily members 
commonly act to inhibit adenylate cyclases and activate G protein-coupled inwardly-rectifying 
potassium (GIRK) channels (349,350). Because of the restriction in variety of G proteins and 
downstream effectors, it is thought that GPCRs coordinate a distinct cellular response through 
discriminating between different G proteins over space and time. One specialised example of spatial 
coordination is in the retina where activation of Gαt leads to a large portion of  Gαt translocating from 
the rod outer segment to rod intracellular compartments (351). This translocation away from the 
receptor serves as a means of light adaptation, permitting the retina to work at higher levels of light 
than usual. Understanding the molecular mechanisms of how GPCRs can process extracellular stimuli 
and coordinate such a response has been a significant focus of the field.  
GPCR signalling can be tuned through activation by agonists with differing efficacy. Ligand 
efficacy describes the intrinsic ‘power’ of an agonist to elicit a cellular response in relation to its 
receptor occupancy (352). While an agonist with high efficacy might robustly activate all responses, 
an agonist with low efficacy may only poorly activate responses that are less efficiently transduced 





by the receptor. Moreover, agonist binding kinetics can shape the texture of the response over time 
because the association and dissociation rate are responsible for determining the receptor occupancy 
at any given time. For example, an agonist with slow dissociation from the receptor will often slowly 
increase its receptor occupancy over time, leading to an increase in potency over time. Interestingly, 
agonist efficacy and binding kinetics do not appear to be completely independent from each other. 
Agonist binding kinetics has been proposed to play a role in influencing agonist efficacy and biased 
agonism at some GPCRs (91,93,95-97,353).  
The dopamine D2 receptor (D2R) is a GPCR that mediates many of the effects of the 
catecholamine dopamine in the central nervous system. The D2R has been the subject of intense study 
because it is a target for several neuropsychiatric and neurological disorders (104-107). Due to these 
investigations, there is a wealth of knowledge and pharmacological tools for the D2R such that it can 
serve as a good model for investigating GPCR signalling. The D2R can couple pleiotropically to the 
non-visual G proteins of the Gαi subfamily (Gαi1, Gαi2, Gαi3, Gαo & Gαz) upon activation. In the 
brain, the D2R is thought to mainly couple to the Gαo isoforms (140). However, when specifically 
examining the nucleus accumbens, where the D2R displays reduced sensitivity to dopamine, it is 
thought that D2R coupling to Gαo may be reduced relative to Gαi1, Gαi2 or Gαi3 subtype coupling 
(144). Additionally, there is also evidence that the D2R couples to Gαz, based on Gαz knockout studies 
in mice and experiments in rat primary tissue cultures (148,150,151).  
Here, we investigated the kinetics of D2R G protein coupling in live cells. We reconstituted 
the D2R signalling system with single Gα subunits to assess the activation of individual subunits in 
real time. We observed differences in maximal effect values and observed rates of activation when 
assessing the different agonists and G proteins. Potency estimates changed differently over time 
depending on the agonist and the G protein α subtype. We were able to attribute the changes in 
potency to disparities in either the agonist dissociation rate or the rate of GTP hydrolysis of the G 
protein. In doing so, we were able to determine the main molecular determinants responsible for 




Ropinirole (>98% pure) was purchased from BetaPharma Co. Ltd. (Wujiang, China). 
Aripiprazole was synthesised as previously described and shown to be >95% pure (256). Spiperone 
was purchased from Sigma-Aldrich Pty Ltd (Castle Hill, NSW, AUS). Coelenterazine-h was 
purchased from Nanolight Technologies a division of Prolume Ltd. (Pinetop, AZ, USA). 96-well 





CulturPlates were purchased from PerkinElmer (Beaconsfield, UK). Dulbecco’s Modified Eagle 
Medium (DMEM), Hanks Balanced Salt Solution (HBSS), foetal bovine serum (FBS), trypsin, Flp-
InTM 293 cells, pertussis toxin, geneticin® (G418 Sulfate) and the PierceTM BCA Protein Assay Kit 
were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Mini-PROTEAN® TGX 
Stain-FreeTM Gels and Immun-Blot® Low Fluorescence PVDF membranes were purchased from 
Bio-Rad (Hercules, CA, USA). Anti-Gαz rabbit polyclonal antibody #3904S and anti-β-actin mouse 
monoclonal antibody #3700 were purchased from Cell Signalling Technology, Inc. (Danvers, MA, 
USA). Anti-rabbit 800CW #926-32211 and anti-mouse 680RD #926-68070 IRDye® goat polyclonal 
antibodies were purchased from LI-COR (Lincoln, NE, USA).  
Plasmids encoding masGRK3ct-Rluc8, venus-1-155-Gγ2 and venus-156-239-Gβ1 were a 
generous gift from Prof. Nevin Lambert (Augusta University, GA, USA). pcDNA3L-6xHis-
CAMYEL plasmid encoding the BRET sensor was purchased from ATCC (Manassas, VA, USA). 
pcDNA3.1+ encoding human cDNA of D2LR, Gαi1-C351I, Gαi2-C352I, Gαi3-C351I, GαoA-C351I, 
GαoB-C351I, Gαz, Gβ5s, RGS9-2 and RGS20 were purchased from the cDNA Resource Centre 
(Bloomsberg, PA, USA). 
 
Mutagenesis 
Mutations were introduced into pcDNA3.1+ encoding wild-type Gαz or Gαi2-C352I at amino 
acid position 42 using the Phusion Site-Directed Mutagenesis Kit (Thermo Fisher Scientific). Primers 
were purchased from Integrated DNA Technologies (Baulkam Hills, NSW, AUS).  
Primers are as follows;  
Gαz->S42G;  
forward: 5’-CTCCTGCTGGGCACCGGAAACTCAGGCAAGAG-3’ 
reverse: 5’- CTCTTGCCTGAGTTTCCGGTGCCCAGCAGGAG-3’.  
Gαi2-C352I->G42S; 
forward: 5’-CTGCTGTTGGGTGCTAGCGAGTCAGGGAAGAG-3’ 
reverse: 5’-CTCTTCCCTGACTCGCTAGCACCCAACAGCAG-3’.  
Mutagenesis was confirmed by Sanger sequencing of the open reading frame (AGRF, 
Melbourne, AUS). 
 
Cell culture and transfection 
Creation and culture of stable cell line-Cells stably expressing the wild type D2LR were 
generated by initially harvesting 500,000 Flp-InTM 293 cells into a T25 flask. The following day cells 





were transfected with 1ug of pcDNA3.1+ hD2LR. The cells were then cultured in DMEM 10% FBS 
and left to divide to reach 50% confluency in a T75 flask before selection with 600ug/ml G418. After 
selection, live single cells were then sorted into 96 well plates via fluorescence activated cell sorting 
(FACS). Individual cells were then cultured to obtain separate colonies and a single colony was 
selected based on [3H] spiperone radio-ligand binding, and functional receptor detection with the 
cAMP production inhibition assay. Flp-InTM 293 cells stably expressing the wild type D2LR were then 
aliquoted and frozen for later culturing in DMEM 10% FBS 600μg/mL G418. Cells were split 1 in 
10 with 0.5% trypsin in Versene every 2-3 days and were not used past 30 passages. 
Transfection for signalling assays and western blotting-2,500,000 Flp-InTM 293 cells stably 
expressing the D2LR were harvested into 10cm dishes. 24 hours after harvesting cells, the DNA 
constructs were mixed in 250uL PBS and linear polyethylenimine (PEI) was mixed in a separate tube 
of 250uL PBS in a ratio of 1ug DNA: 6ug PEI. The DNA-PBS mix was then combined with the PEI-
PBS mix, vortexed and incubated at room temperature for 10 minutes. In the incubation time, the 
media was removed from the cell culture dishes and replaced with 10mL DMEM +10% FBS 
containing penicillin (100U/mL) and streptomycin (100ug/mL). The DNA-PEI-PBS mix was then 
added drop-wise on top of the cell media and the dishes were returned to the incubator. 
 
G protein activation assay 
The G protein activation assay was based on a BRET detection method that has been 
previously reported (257,258). Initially, Flp-InTM 293 cells stably expressing the D2LR were 
transfected as described above with pcDNA3.1 encoding the following constructs: 1μg venus-1-155-
Gγ2, 1μg venus-156-239-Gβ1, 1μg masGRK3ct-Rluc8 and 2μg of either Gαi1-C351I, Gαi2-C352I, 
Gαi3-C351I, GαoA-C351I, GαoB-C351I, Gαz, Gαz-S42G, Gαi2-G42S-C352I or empty vector control. 
For the G protein activation assays where RGS proteins were also transfected, cells were transfected 
with 1μg venus-1-155-Gγ2, 1μg venus-156-239-Gβ1, 1μg masGRK3ct-Rluc8, 2μg of the Gα subunit 
of interest, 1μg Gβ5s and 1μg of either pcDNA3.1+, RGS9-2 or RGS20. 24 hours after transfection, 
the cells were harvested from dishes and plated into poly-D-lysine coated white 96 well CulturPlates. 
The cells were left to adhere for approximately 8 hours and then treated with 100ng/mL pertussis 
toxin overnight. The following day the plate was taken out of the incubator, washed once with Hank’s 
balanced salt solution (HBSS) pH 7.4 and left to equilibrate in HBSS 37°C for 30 minutes before 
BRET detection. 15 minutes prior to addition of agonist, coelenterazine-h was added to each well 
with an electronic multi-step pipette to make a final concentration of 5μM. For experiments using 
PDBu, 333nM PDBu was added 10 minutes before addition of ropinirole. BRET was then measured 
in a LUMIstar Omega microplate reader (BMG LABTECH). Individual well luminescence was 





measured for the emission signal of RLuc8 (445-505nm) and venus (505-565nm) simultaneously. 
For slow temporal assays, measurements were conducted in ‘plate mode’ at a cycle time of 30 seconds 
with five cycles occurring before manual addition of agonist or spiperone with a 12 channel multi-
pipette. For fast temporal assays, the plate was measured in ‘well mode’ with a measurement interval 
time of 60 milliseconds and a baseline established for 10 seconds before automated injection of 20μL 
agonist or spiperone at 430μL/s. The counts from the venus acceptor (505-555nm) was then divided 
by the donor Rluc8 (465-505nm) counts to give a BRET ratio. The BRET ratio values were then 
subtracted by the vehicle control values to give ∆BRET ratio. 
 
cAMP inhibition assay 
Flp-InTM 293 cells stably expressing the D2LR were transfected with 3μg of pcDNA3L-6xHis-
CAMYEL and 2μg of either pcDNA3.1+ encoding Gαi2-C352I, GαoA-C351I, Gαz, Gαz-S42G or 
empty vector control. 24 hours later the cells were harvested and transferred into poly-D-lysine coated 
white 96 well CulturPlates. Approximately 8 hours after the cells were transferred to plates, the cells 
were treated with 100ng/mL pertussis toxin overnight. The following day the cells were washed once 
with HBSS (pH 7.4, 37°C) and left to equilibrate in HBSS for 30 minutes before taking luminescence 
measurements. Addition of coelenterazine-h to make a final concentration of 5μM was carried out 15 
minutes before agonist addition. Cells were then treated with 10μM forskolin 10 minutes before 
addition of increasing concentrations of agonist and detecting BRET at the indicated times. For 
experiments using spiperone to out-compete ropinirole, coelenterazine-h and ropinirole (100nM final 
concentration) were co-added 18 minutes before addition of 20μM spiperone. BRET was detected at 
37°C measuring luminescence at 445-505nm (RLuc) and 505-565nm (venus) simultaneously using a 
LUMIstar Omega microplate reader (BMG LABTECH). Plates were measured in ‘plate mode’ at a 
cycle time of 30 seconds with a baseline of 5 cycles established before addition of agonist or 
spiperone. Counts from the 505-555nm channel were then divided by the 465-505 channel to give a 
BRET ratio. The ratios were then baseline normalised whereby wells treated with 10uM forskolin 
were set to 0% and vehicle treated wells set to 100%. 
 
Western blotting analysis 
While plating transfected cells for G protein activation assays or cAMP inhibition assays the 
cells were also plated into Corning® Costar® 6 well plates. On the same day as performing signalling 
assays, protein samples were prepared from the cells for later blotting. Cells were washed with PBS 
and harvested in 1mL Versene. Cells were spun at 350g for 5 minutes at 4°C and supernatant was 





removed. The cell pellet was then lysed in RIPA buffer (150mM NaCl, 1%NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50mM Tris-HCl, pH8.0, cOmpleteTM protease inhibitor) and left to shake 
gently on ice for 30 minutes. The sample was then spun at 15,000g for 10 minutes at 4°C, the 
supernatant was kept and stored at -80°C for analysis. Protein concentration was determined by BCA 
assay and 30μg of protein in SDS-loading buffer (4% SDS, 10% β-mercaptoethanol, 20% glycerol, 
0.004% bromophenol blue, 0.125M Tris-HCl) was loaded for separation by SDS-PAGE (4-15% 
gradient gel). Samples were transferred onto Immun-Blot® Low Fluorescence PVDF membranes 
using a Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad). Membranes were then blocked with 5% 
BSA in PBS 0.1% Tween 20 for 1 hour followed by overnight incubation with the primary antibody 
at 4°C. The Gαz and β-actin antibodies were used at a 1:1000 dilution and the Gαz antibody was raised 
against an epitope separate from the mutagenesis site. The membranes were then washed in PBS 0.1% 
Tween 20 and incubated with either anti-rabbit 800CW or anti-mouse 680RD secondary antibodies 
used at a dilution of 1:10,000 for 1 hour at 25°C. The membranes were then washed again in PBS 




Concentration response curves were fit with the log(agonist) vs. response (three parameter) 
equation and functional rates were determined by fitting a one-phase association or decay in 
GraphPad Prism 7.02. All data was analysed by first pooling the experimental replicates together 




Monitoring G protein activation at the D2R 
To investigate D2R mediated activation of different G proteins in live cells we used a 
genetically encoded bioluminescence resonance energy transfer (BRET) sensor (Fig. 5.1A)(258). The 
BRET sensor monitors Gβγ release by utilising the pleckstrin homology domain of GRK3 (GRKct) 
that binds free Gβγ upon dissociation from the Gα subunit. While there are several methods for 
detection of G protein activation, this assay allows use of wild-type GPCRs and Gα subunits, hence 
it can be universally applied to any GPCR and Gα subunit. In addition, previous studies have 
demonstrated that the assay provides a robust signal-to-noise ratio and high temporal resolution 
(132,354).  





We used Flp-In HEK 293 cells stably expressing the long isoform of the D2R (Flp-In-293-
D2LR) and transiently transfected the BRET sensor together with pertussis toxin (PTX) insensitive 
Gαi subfamily proteins or wild-type Gαz (that is natively PTX insensitive) followed by treatment with 
PTX to abolish any signal from endogenous Gαi coupling. The D2R agonist ropinirole was used to 
probe G protein activation due to dopamine suffering from oxidation (355) and a potential lack of 
selectivity for dopamine D2 type receptors over endogenously expressed adrenergic receptors (356). 
In addition, ropinirole is a useful reference as it displays similar efficacy and binding kinetics to 
dopamine at the D2R (96,357). Upon stimulation of Flp-In-293-D2R cells with ropinirole, we detected 
activation of all Gα proteins known to couple to the D2R, including Gαz (Fig. 5.1B). The measured 
responses 15 minutes after stimulation with increasing concentrations of ropinirole fit well to a 
sigmoidal concentration-response curve. Ropinirole was approximately 10-fold more potent at 
activating GαoA, GαoB and Gαz subunits compared to Gαi2, and 5-fold more potent than at Gαi1 and 
Gαi3 (Fig 5.1C-E, Fig S5.1A-C & Table 5.1).  Additionally, ropinirole-induced activation of GαoA, 
GαoB and Gαz subunits produced a larger maximal effect (given as change in BRET ratio) compared 
to Gαi1, Gαi2 and Gαi3 subunits (Fig. 5.1B-E, Fig S5.1A-C & Table 5.1). While it has been 
demonstrated that the D2R preferentially activates GαoA subunits over Gαi1, Gαi2 and Gαi3 (139), the 
potency and maximal effect of ropinirole in the Gαz condition suggest that the D2R is also efficiently 
coupled to this G protein.  
Some studies using [35S]GTPγS binding assays to detect G protein coupling have failed to 
detect activation of some or all of Gαi1, Gαi2 and Gαi3 upon stimulation of the D2R with partial 
agonists (137-139). Therefore, we next stimulated the Flp-In-293-D2R cells with the partial agonist 
antipsychotic aripiprazole. Aripiprazole induced activation of Gαi1, Gαi2 and Gαi3 with approximately 
half the maximal effect of ropinirole, and induced activation of GαoA, GαoB and Gαz with responses 
almost equal to ropinirole’s maximal effect (Fig. 5.1B-E, Fig S5.1A-C & Table 5.1). Detection of 
aripiprazole-induced responses at Gαi1, Gαi2 and Gαi3 suggest that the BRET-based G protein 
activation assay has superior sensitivity for detecting G protein coupling compared to the [35S]GTPγS 
binding assays used in previous studies. 







Figure 5.1: G protein activation assay accurately measures differences in agonist responses 
over time at the D2R. (A) Diagram of the detection method for G protein activation by the D2R. D2R 
activation of Gαi/o/zGβγ-venus heterotrimers induces a conformational change in the G protein that 
results in Gαi/o/z exchanging its bound GDP for GTP and dissociation of the Gβγ-venus subunit. The 
myristoylated and RLuc8-tagged pleckstrin homology domain of GRK3 reversibly binds free Gβγ-
venus subunits such that when the Gα subunit is inactive (GDP bound) it can outcompete the GRK3 
domain for Gβγ, yet once the Gα subunit becomes active (exchanges GDP for GTP) the Gα subunit 
dissociates from Gβγ. (B) Quantification of increases in BRET ratio in response to 2.5 minutes of 
stimulation with 10μM ropinirole (orange bars) or 10μM aripiprazole (grey bars) for cells transfected 
with the G protein activation sensor together with the indicated Gα subunit or Gα-free control. (C, D 
& E) Concentration response curves of cells transfected with cDNA encoding the G protein activation 
sensor together with Gαi2 (panel C), GαoA (panel D) or Gαz (panel E) measured at 15 minutes in 
response to increasing concentrations of ropinirole (orange circles) or aripiprazole (grey squares). 
(F, G & H) Potency changes over 30 minutes of Gαi2 (panel F), GαoA (panel G) or Gαz (panel H) 
activation plotted as pEC50 parameter values estimated from concentration response curves fitted at 
each measurement interval after stimulation of increasing concentrations of ropinirole (orange 
circles) or aripiprazole (grey squares). All values are expressed as mean ± SEM from 5-9 separate 





experiments performed in single wells. Students unpaired t test was used to test for statistical 
significance between ropinirole and aripiprazole induced maximal values in panel B. *P<0.05, ** 
P<0.01, *** P<0.001.  
 
 
Table 5.1: Ropinirole and aripiprazole induced dissociation of various G proteins by the D2R. 
Potency (pEC50) and maximal effect (Emax – BRET units) parameter values represent the mean ± 
SEM from 5-9 separate experiments determined 15 minutes after stimulation 
 Ropinirole Aripiprazole 
Gα subunit pEC50 Emax pEC50 Emax 
Gαi1 6.95 ± 0.09 a 8.44 ± 0.34 x10-2 a 7.14 ± 0.12 4.40 ± 0.23 x10-2 b 
Gαi2 6.56 ± 0.06 9.95 ± 0.30 x10-2 7.28 ± 0.18 b 3.64 ± 0.28 x10-2 b 
Gαi3 6.90 ± 0.07 a 7.45 ± 0.26 x10-2 a 7.19 ± 0.13 4.27 ± 0.23 x10-2 b 
GαoA 7.65 ± 0.04 a 13.97 ± 0.25 x10-2 a 7.41 ± 0.08 12.76 ± 0.43 x10-2 a, b 
GαoB 7.54 ± 0.08 a 13.18 ± 0.45 x10-2 a 7.47 ± 0.09 12.05 ± 0.42 x10-2 a 
Gαz 7.83 ± 0.04 a 13.37 ± 0.20 x10-2 a 7.23 ± 0.05 b 12.19 ± 0.28 x10-2 a, b 
a Significantly different (P<0.05) from corresponding Gαi2 value within the column as determined by 
one-way analysis of variance with Dunnett’s multiple comparisons test 
b Significantly different (P<0.05) from corresponding ropinirole parameter value within the row as 
determined by student’s t-test 
 
 
Temporal patterns of G protein activation change depending on the agonist and the Gα 
subunit 
Having accurately detected G protein activation, we then analysed agonist action over time 
by fitting concentration response curves to the data at each measurement interval over a time-course 
of 30 minutes (Fig. S5.2). We were then able to plot potencies (pEC50) values over time to compare 
ropinirole and aripiprazole at each G protein (Fig. 5.1F-H, Fig. S5.1D-F). We have previously 
demonstrated that aripiprazole displays a fast association rate and a slow dissociation rate for the D2R 
such that upon addition of aripiprazole, the equilibrium between the bound and free species of the 
D2R will slowly be reached (96). Therefore, the potency in a functional assay is expected to increase 
over time as the occupancy of aripiprazole at the receptor increases. As predicted, aripiprazole 
displayed a large increase in potency over time for each of the different G proteins. In contrast, 
ropinirole is a fast dissociating agonist such that binding at the D2R will rapidly reach equilibrium. In 
agreement with ropinirole’s binding kinetics at the D2R, the potency for Gαi1, Gαi2, Gαi3, GαoA and 
GαoB activation remained constant over time. However, ropinirole displayed a 10-fold increase in 
potency over time at Gαz. Additionally, aripiprazole displayed a larger increase in potency over time 
for Gαz than any other Gα subunit, suggesting a ligand-independent difference at the level of the Gαz 
G protein. This was surprising as G protein activation is thought to occur on the millisecond-second 
timescale and thus might be expected to be limited by the rate of agonist binding to the D2R (11).  





Gα subunit-specific cAMP inhibition reflects G protein activation 
The Gαi subfamily proteins, including Gαz, inhibit the production of cAMP by binding to and 
negatively modulating adenylate cyclases. This property allowed us to investigate if any downstream 
consequences result from the different temporal patterns seen at the level of G protein activation. 
Measurements of relative intracellular cAMP concentrations in Flp-In-293-D2R cells were 
determined with a conformational BRET sensor based on Epac1 (Fig. 5.2A) (358). We used the same 
rationale as the G protein activation assay to measure G protein-specific signalling whereby the G 
protein cDNA (PTX insensitive Gαi subunits or wild-type Gαz) was transfected together with the 
BRET sensor followed by overnight treatment with PTX. Gαi2 was used as a representative subunit 
for the Gαi1, Gαi2 and Gαi3 subunits, and GαoA was used as a representative of the GαoA and GαoB 
isoforms. Similar to the G protein activation assay, we observed that ropinirole was more potent at 
stimulating GαoA and Gαz mediated cAMP inhibition than Gαi2 (Fig. 5.2B, D & F & Table 5.2). 
Aripiprazole also showed maximal responses closer to ropinirole at GαoA and Gαz but produced 
approximately half the maximal effect of ropinirole when measuring Gαi2 dependent cAMP 
inhibition. Measuring potency over time showed that aripiprazole increased in potency over time for 
each of the three Gα subunits, consistent with its binding kinetics to the D2R (Fig. 5.2C, E & G). We 
then observed an increase in ropinirole’s potency for Gαz-dependent cAMP inhibition but not for Gαi2 
or GαoA. Accordingly, all measurements of D2R mediated cAMP inhibition closely matched the G 
protein activation assay, confirming that the observed temporal signalling patterns are dependent on 
the agonist as well as the G protein. The cAMP measurements also confirmed that the pattern of 
changing potency over time was not an artefact associated with the methods or plasmid constructs 
used in the G protein activation assay. 






Figure 5.2: cAMP assay reports on individual G protein signalling kinetics. (A): Schematic of 
the intracellular cAMP detection method. Agonist activation of the D2R results in coupling to Gαi/o/z 
subunits that inhibit the production of forskolin stimulated cAMP. The relative amount of cAMP within 
the live cells is then detected by the BRET-based cAMP sensor – CAMYEL, that undergoes a 
conformational change upon binding to cAMP resulting in increased proximity of the Rluc and venus 
allowing for more efficient non-radiative energy transfer. Cells were transfected with the particular 
PTX-insensitive Gα subunit of interest and treated with PTX to measure the cAMP inhibition 
mediated through the single Gα species. (B, D & F) cAMP production inhibition concentration 
response curves of Flp-In-293-D2R cells transfected with cDNA encoding the cAMP BRET sensor 





together with Gαi2 (B), GαoA (D) or Gαz (F) measured at 15 minutes in response to increasing 
concentrations of ropinirole (orange circles) or aripiprazole (grey squares). (C, E & G) Potency 
changes over 30 minutes of Gαi2 (C), GαoA (E) or Gαz (G) dependent cAMP production inhibition 
plotted as pEC50 parameter values estimated from concentration response curves fitted at each 
measurement interval after stimulation of increasing concentrations of ropinirole (orange circles) or 
aripiprazole (grey squares). All values are expressed as mean ± SEM from 4-7 separate experiments 
performed in duplicate wells.  
 
 
Table 5.2: Ropinirole and aripiprazole induced G protein-dependent cAMP inhibition by the 
D2R. 
Potency (pEC50) and maximal effect (Emax – % Forskolin inhibition) parameter values represent the 
mean ± SEM from 4-7 separate experiments determined 15 minutes after stimulation 
 Ropinirole Aripiprazole 
Gα subunit pEC50 Emax pEC50 Emax 
Gαi2 7.01 ± 0.02 80.0 ± 0.7 6.63 ± 0.10 b 44.5 ± 2.3 b 
GαoA 7.79 ± 0.03 a 75.7 ± 0.8 6.95 ± 0.06 a, b 72.1 ± 2.1 a 
Gαz 7.69 ± 0.05 a 82.2 ± 1.6 6.738 ± 0.05 b 76.8 ± 1.8 a 
a Significantly different (P<0.05) from corresponding Gαi2 value within the column as determined by 
one-way analysis of variance with Dunnett’s multiple comparisons test 
b Significantly different (P<0.05) from corresponding ropinirole parameter value within the row as 
determined by student’s t-test 
 
 
Observed G protein activation rate at the D2R is influenced by agonist efficacy 
We next investigated the differences in G protein activation kinetics between ropinirole and 
aripiprazole on a faster timescale. To perform these experiments, we used a high concentration of the 
agonist that was calculated, using rate constants determined from our previously published binding 
experiments (96), to occupy >95% of receptors within 1.5 seconds. Upon injection of ropinirole, we 
observed that Gαi2, GαoA and Gαz were all activated on a millisecond-second timescale consistent 
with what has been previously proposed for GPCR activation (Fig 5.3A, B & C) (359). Ropinirole-
induced GαoA activation was approximately 3-fold faster and 6-fold faster than ropinirole-induced 
activation of Gαi2 and Gαz respectively (Table. 5.3). Stimulation with aripiprazole produced rates of 
activation for each G protein that were all considerably (>6-fold) slower than the ropinirole-induced 
rates (Gαi2, GαoA & Gαz P<0.0001, student’s t test), highlighting that a key determinant of the 
observed G protein activation rate at the D2R is agonist efficacy. Furthermore, while ropinirole 
displayed 3-fold slower activation of Gαi2 compared to GαoA, the rates of activation of these two G 
proteins induced by aripiprazole was similar (Table 5.3). Moreover, aripiprazole produced a smaller 
total increase in BRET for Gαi2, consistent with its partial agonist action as detected by the 
concentration response curves measured at a later timepoint (Fig 5.1.). Therefore, activation of Gαi2 
by aripiprazole displays a unique temporal pattern whereby activation occurred almost as fast as 
observed for GαoA, but it only produces a partial response. 






Figure 5.3: Differences in observed G protein activation rates in response to saturating 
concentrations of ropinirole and aripiprazole.  (A) D2R mediated Gαi2 activation response upon 
injection of 100μM ropinirole (orange circles) or 10μM aripiprazole (grey squares) over 50 seconds. 
All values represent the mean ± SEM (grey shading indicates error bars) of 5 separate experiments 
(ropinirole) or 3 separate experiments (aripiprazole). (B) D2R mediated GαoA activation response 
upon injection of 100μM ropinirole (orange circles) or 10μM aripiprazole (grey squares) over 50 
seconds. All values represent the mean ± SEM (grey shading indicates error bars) of 5 separate 
experiments (ropinirole) or 3 separate experiments (aripiprazole). (C) D2R mediated Gαz activation 
response upon injection of 100μM ropinirole (orange circles) or 10μM aripiprazole (grey squares) 
over 50 seconds. All values represent the mean ± SEM (grey shading indicates error bars) of 6 
separate experiments (ropinirole) or 3 separate experiments (aripiprazole). (D) Ropinirole (orange 
bars) and aripiprazole (grey bars) stimulated D2R dependent G protein activation rates determined 
by one phase association curve fit of the responses shown in panels A, B & C. Rate values are 
represented as mean ± SEM. Students unpaired t test was used to determine statistical significance 
between rates induced by ropinirole and aripiprazole. *** P<0.001. 
 
 
Table 5.3: Observed G protein activation rates induced by ropinirole and aripiprazole 
Kobs (s-1) values are determined from 3-6 separate experiments 
Gα subunit Ropinirole Aripiprazole 
Gαi2 6.18 ± 0.12 x10-1 9.46 ± 0.14 x10-2 b 
GαoA 16.79 ± 0.63 x10-1 a 1.36 ± 0.01 x10-1 a, b 
Gαz 2.79 ± 0.05 x10-1 a 2.27 ± 0.02 x10-2 a, b 
a Significantly different (P<0.05) from corresponding Gαi2 value within the column as determined by 
one-way analysis of variance with Dunnett’s multiple comparisons test 
b Significantly different (P<0.05) from corresponding ropinirole value within the row as determined 
by student’s t-test 
 
 





Gαz remains active for an extended period 
High concentrations of ropinirole produced a rapid response at Gαz (Fig. 5.3C), yet low 
concentrations of ropinirole produced responses that slowly increased over several minutes (Fig. S5.2, 
Panel C). This increase in response over time for low concentrations of agonist resulted in an increase 
in the potency of ropinirole over time. Furthermore, saturating concentrations of ropinirole produced 
a slower activation rate for Gαz compared to Gαi2 and GαoA. Our previous ligand binding experiments 
revealed that the dissociation rate of ropinirole from the D2R is fast such that this increase in potency 
over time cannot be related to an increase in receptor occupancy over time (96). Furthermore, this 
increase in potency is specific to Gαz as no change in the potency of ropinirole is observed at the other 
Gα subunits. Thus, this difference must relate to a difference in the signalling properties of Gαz 
compared to the other Gαi subfamily G proteins. It is known that recombinant Gαz purified from 
Escherichia coli displays a slow basal GTP hydrolysis rate when compared to other Gα subunits (19). 
We therefore hypothesized that once active, Gαz may slowly hydrolyse its bound GTP in live cells, 
and thus remain in the active state for an extended period. This in turn would cause the active species 
of Gαz to accumulate over time. The active species could make multiple interactions with effector 
proteins which may effectively amplify the signalling response. This would then result in an increase 
in potency over time as the active Gαz species accumulates.  
We first tested whether Gαz remained active for an extended period by pre-stimulation with 
ropinirole followed by addition of a high concentration of the high affinity antagonist spiperone to 
rapidly stop the activation of the D2R upon ropinirole dissociation. Upon addition of spiperone, Gαz 
remained active for approximately 56-fold longer than GαoA, and 37-fold longer than Gαi2 as 
measured by a decrease in the BRET signal between Gβγ-venus and GRKct-Rluc8 (Table 5.4, Fig. 
5.4A & B). We observed the same pattern when using the CAMYEL biosensor to measure changes 
in intracellular cAMP; the downstream rate of cAMP increase upon addition of spiperone in the Gαz 
transfected condition was also significantly slower than that observed in the Gαi2 and GαoA conditions 
(P=0.0001 & P<0.0001 respectively, one-way ANOVA) (Table 5.4, Fig. 5.4C & D). Together these 
data indicate that, after activation, the Gαz subunit remains in the active state for a longer time as 
compared to the other Gαi subunits. However, the rate of inhibition of the Gαi2 and GαoA signals 
observed upon addition of spiperone were slower in the cAMP assay as compared to the rates detected 
using the direct G protein activation sensors. This suggests that the limiting step, at least for Gαi2 and 
GαoA-dependent cAMP inhibition lies at the level of adenylate cyclase whereas for Gαz, it lies at the 
level of the G protein. 






Figure 5.4: Gαz exhibits an extended lifetime in the active state. (A) G protein deactivation of 
Gαi2 (orange circles), GαoA (grey squares) and Gαz (black triangles) over time. Flp-In-293-D2R cells 
transfected with the BRET sensor and specific Gα subunit were incubated for 18 minutes with 333nM 
ropinirole followed by injection with 20μM spiperone (antagonist) and changes in BRET were 
measured over time. All values represent mean ± SEM (light grey shading indicates error bars) of 4 
separate experiments (GαoA) or 6 separate experiments (Gαi2 & Gαz) performed in triplicate wells. 
(B) G protein deactivation rates for Gαi2 (orange bar), GαoA (grey bar) and Gαz (black bar) determined 
by one phase decay curve fit of the responses shown in panel A. Rate values are represented as 
mean ± SEM. (C) Increase in intracellular cAMP concentration due to deactivation of Gαi2 (orange 
circles), GαoA (grey squares) and Gαz (black triangles) over time. Flp-In-293-D2R cells transfected 
with the BRET sensor and the Gα subunit of interest were incubated for 18 minutes with 100nM 
ropinirole followed by injection with 10μM spiperone (antagonist) and changes in BRET were 
measured over time. All values represent mean ± SEM (light grey shading indicates error bars) of 3 
separate experiments performed in triplicate wells. (D) Rates of Gα specific increase in intracellular 
cAMP concentration for Gαi2 (orange bar), GαoA (grey bar) and Gαz (black bar) determined by one 
phase decay curve fit of the responses shown in panel C. Rate values are represented as mean ± 
SEM. A one-way analysis of variance with Dunnett’s multiple comparisons test was used to 
determine statistical significance between deactivation rates of Gαi2 and either GαoA or Gαz. ** 
P<0.01, *** P<0.001. 
 
 
Table 5.4: G protein deactivation rates determined by spiperone competition experiments 
Values are determined from 3-6 separate experiments 
 G protein sensor cAMP sensor 
Gα subunit Kdeact (s-1) t½ (s) Kdeact (s-1) t½ (s) 
Gαi2 17.24 ± 0.18 x10-2 5.8 7.72 ± 0.34 x10-3 129.5 
GαoA 26.40 ± 0.29 x10-2 a 3.8 9.89 ± 0.35 x10-3 a 101.2 
Gαz 4.68 ± 0.08 x10-3 a 213.9 3.39 ± 0.07 x10-3 a 294.6 
a Significantly different (P<0.05) from corresponding Gαi2 value within the column as determined by 
one-way analysis of variance with Dunnett’s multiple comparisons test 
 
 





The unique signalling pattern of Gαz is dependent on serine 42 
Many nucleotide binding proteins contain a conserved phosphate binding loop (P-loop) motif 
(360). For heterotrimeric G proteins in particular, it has been demonstrated through structural and 
biochemical studies on Gαi1, that a highly conserved glycine residue within the P-loop is required for 
the fast hydrolysis of GTP (Table 5.5) (361). Gαz is unique among the heterotrimeric G proteins, as 
it possesses a serine residue at this position (Ser42) (Table 5.5). Accordingly, we postulated that 
mutation of Ser42 to the glycine present in all other heterotrimeric G proteins will increase the G 
protein turnover kinetics in live cells. In our G protein activation assay, the S42G mutation lead to a 
modest 2-fold increase in the observed rate of activation upon stimulation with a saturating 
concentration of ropinirole (Kobs = 5.90 ± 0.17 x 10-1 s-1, Fig. 5.5A & B), while the expression levels 
of the Gαz-S42G mutant were similar to wild-type (Fig. 5.5C). Moreover, the deactivation rate was 
increased by approximately 20-fold (Kdeact = 9.99 ± 0.01 x 10-2 s-1, (Fig. 5.5D & E), consistent with 
the hypothesis that serine 42 indeed governs the slow GTP hydrolysis rate of Gαz. This provides 
further evidence that it is not agonist dissociation rate from the D2R that likely determines the rate of 
Gαz deactivation but, rather, the rate of GTP hydrolysis.  
We then tested the effect of the S42G mutation on G protein activation response over time to 
increasing concentrations of ropinirole. Strikingly, this mutation completely abolished the increase in 
potency over time upon activation with ropinirole (Fig. 5.5G). Furthermore, the potency and maximal 
effect of ropinirole at Gαz-S42G was significantly decreased when measured 15 minutes after 
stimulation (Fig. 5.5F) (pEC50 = 7.27 ± 0.04, Emax = 8.884 ± 0.13 x 10-2 BRET units) (P<0.0001 & P 
<0.0001 respectively, student’s t-test) as compared to that observed at Gαz wildtype (pEC50 = 7.83 ± 
0.04 , Emax = 13.37 ± 0.20 x10-2 BRET units). Thus, the slow rate of GTP hydrolysis by Gαz is required 
for the increase in potency of ropinirole over time and may contribute to the higher potency observed 
at Gαz compared to Gαi2 observed at later time-points.  
 








G protein Position Sequence 
Gαz 40 G T S N S G K S 
Gαi2 40 G A G E S G K S 
GαoA 40 G A G E S G K S 
Gαq 46 G T G E S G K S 
Gα12 64 G A G E S G K S 
Gαs 47 G A G E S G K S 
H-Ras 10 G A G G V G K S 
Ran 17 G D G G T G K T 
RhoA 12 G D G A C G K T 
Arf1 24 G L D A A G K T 






Figure 5.5: Mutation of serine 42 to glycine confers fast Gαi2 kinetics to Gαz. (A) D2R mediated 
G protein activation of Gαz-WT (orange circles) and Gαz-S42G (grey squares) over time. Flp-In-293-
D2R cells transfected with the BRET sensor and Gαz-WT or Gαz-S42G were injected with 100μM 
ropinirole and changes in BRET were measured over time. All values represent mean ± SEM (grey 
lines indicate error bars) of 6 separate experiments performed in triplicate wells. (B) D2R mediated 
G protein activation rates for Gαz-WT (orange bar) or Gαz-S42G (grey bar) determined by one phase 
decay curve fit of the responses shown in panel A. Rate values are represented as mean ± SEM. 
(C) Expression levels of the different transfected Gαz subunits in G protein activation assays were 
determined by western blotting. A representative western blot is shown from cell lysates of 3 
experiments. (D) G protein deactivation of Gαz-WT (orange circles) and Gαz-S42G (grey squares) 
over time. Flp-In-293-D2R cells transfected with the BRET sensor and Gαz-wt or Gαz-S42G were 
incubated for 18 minutes with 333nM ropinirole followed by injection with 20μM spiperone 
(antagonist) and changes in BRET were measured over time. All values represent mean ± SEM 
(light grey lines indicate error bars) of 6 (Gαz-WT) or 4 (Gαz-S42G) separate experiments performed 
in triplicate wells. (E) G protein deactivation rates the Gαz-WT (orange bar) or Gαz-S42G (grey bar) 
determined by one phase decay curve fit of the responses shown in panel D. Rate values are 
represented as mean ± SEM. (F) Concentration response curves for D2R mediated activation of Gαz-
WT (orange circles) or Gαz-S42G (grey squares) measured 15 minutes after addition of increasing 
concentrations of ropinirole. (G) Potency changes over 30 minutes of Gαz-WT (orange circles) or 
Gαz-S42G (grey squares) activation plotted as pEC50 parameter values estimated from concentration 
response curves fitted at each measurement interval after stimulation of increasing concentrations 
of ropinirole. All values in panels F & G represent mean ± SEM of 4 separate experiments performed 





in duplicate wells. Students unpaired t test was used to determine statistical significance between 
rates of Gαz-WT and Gαz-S42G. *** P<0.001. 
 
Next, we performed cAMP assays using cells expressing either Gαz-WT or Gαz-S42G. Similar 
to our observations in the G protein activation assay, we observed that the potency of ropinirole 
remained constant over time when the S42G mutant was expressed, while the potency increased in 
the presence of the WT G protein. Comparing concentration response curves obtained at a 15-minute 
timepoint we found that ropinirole displayed a statistically significant decrease in potency (pEC50 = 
6.95±0.1318, P=0.00015, student’s t test) and maximal effect (Emax =65.44±4.014 % FSK induced 
cAMP inhibition, P=0.0013, student’s t test) when Gαz-S42G was expressed as compared to the Gαz-
WT condition (Fig. 5.6A & B). Expression levels of Gαz-S42G were comparable to wild-type in this 
assay (Fig. 5.6C). These data support our findings in the G protein activation assay; illustrating how 




Figure 5.6: Mutation of serine 42 abolishes potency increase when measuring Gαz-dependent 
cAMP inhibition. (A) cAMP production inhibition concentration response curves of Flp-In-293-D2R 
cells transfected with cDNA encoding the cAMP BRET sensor together with Gαz-WT (orange circles) 
or Gαz-S42G (grey squares) measured at 15 minutes after stimulation with increasing concentrations 
of ropinirole. (B) Potency changes of Gαz-WT (orange circles) or Gαz-S42G (grey squares) 
transduced cAMP production inhibition plotted as pEC50 parameter values estimated from 
concentration response curves fitted at each measurement interval after stimulation of increasing 
concentrations of ropinirole. Values in A & B represent mean ± SEM of 7 (Gαz-WT) or 4 (Gαz-S42G) 
separate experiments performed in duplicate wells. (C) Expression levels of the different transfected 
Gαz subunits in cAMP production inhibition assays were determined by western blotting. A single 
representative western blot is shown from three separate experiments. 
 
A mutation that decreases the GTP hydrolysis rate of Gαi2 confers changes in agonist potency 
over time. 
To demonstrate the relationship between GTP hydrolysis rate and time-dependent changes in 
agonist potency we replaced the conserved glycine residue within the P-loop of Gαi2 with a serine 





residue that is present in Gαz. We hypothesized that this mutation would confer a Gαz-like slow GTP 
hydrolysis rate that would in turn cause an increase in ropiniroles’ potency over time. Indeed, 
estimates of potency increased over time in the Gαi2-G42S condition and no increase in ropiniroles’ 
potency was observed in the WT Gαi2 condition (Fig. 5.7B). This potency increase was analogous to 
ropinirole induced activation of wild type Gαz - albeit on a faster timescale (Fig. 5.7B). When 
measuring the G protein activation response after 15 minutes, the G42S mutation within the P-loop 
of Gαi2 increased ropiniroles’ potency by over 10-fold as well as increasing the maximal effect (pEC50 
= 7.64 ± 0.05, Emax = 11.11 ± 0.22 x 10-2 BRET units) (Fig. 5.7A). Moreover, the rate of signal decay 
after competition of ropinirole with spiperone was slowed by approximately 20-fold (Kdeact = 8.31 ± 
0.30 x 10-3 s-1) compared to wild type Gαi2 (Fig. 5.7C & D). In summary, upon replacement of glycine 




Figure 5.7: Mutation of glycine 42 to serine in Gαi2 increases the active lifetime of the G 
protein. (A) Concentration response curves for D2R mediated activation of Gαi2-WT (orange circles) 
or Gαi2-G42S (grey squares) measured 15 minutes after addition of increasing concentrations of 
ropinirole. (B) Potency changes over time of Gαi2-WT (orange circles) or Gαi2-G42S (grey squares) 
activation plotted as pEC50 parameter values estimated from concentration response curves fitted at 
each measurement interval after stimulation of increasing concentrations of ropinirole. All values in 
panel A & B represent mean ± SEM of 3 separate experiments performed in duplicate wells. (C) G 
protein deactivation of Gαi2-WT (orange circles) or Gαi2-G42S (grey squares) over time. Flp-In-293-
D2R cells transfected with the BRET sensor and Gαi2-WT or Gαi2-G42S were incubated for 18 
minutes with 333nM ropinirole followed by injection with 20μM spiperone (antagonist) and changes 
in BRET were measured over time. All values represent mean ± SEM (light grey lines indicate error 
bars) of 6 (Gαi2-WT) or 3 (Gαi2-G42S) separate experiments performed in triplicate wells. (D) G 





protein deactivation rates of Gαi2-WT (orange bar) or Gαi2-G42S (grey bar) determined by one phase 
decay curve fit of the responses shown in panel C. Students unpaired t test was used to determine 
statistical significance between deactivation rates of Gαi2-WT and Gαi2-G42S. *** P<0.001. 
 
 
Co-expression of RGS proteins alters agonist potency over time  
Having identified that the GTP hydrolysis rate of the Gα subunit is crucial in determining the 
agonist response over time, we were then interested in investigating the temporal effects that RGS 
proteins could have on the D2R mediated responses. RGS proteins selectively bind to activated Gα-
GTP subunits acting as GTPase-activating proteins (GAPs) to increase the Gα subunits’ rate of GTP 
hydrolysis (362,363). By doing this, the RGS protein speeds up the rate of G protein deactivation 
within the G protein cycle. It is well appreciated that RGS proteins functioning in this manner can 
dampen the potency at a G protein-dependent signalling endpoint. Extending this, we wanted to 
determine the effect that RGS proteins have on the increase in agonist potency over time that we 
observe when measuring Gαz activation. We therefore performed G protein activation assays where 
we co-expressed RGS9-2 or RGS20. RGS9-2 is an RGS9 splice variant that is strongly co-localised 
with the D2R in the striatum where it regulates some D2R functions (364,365). RGS20 is a member 
of the RGS-Z family of RGS proteins; RGS17, RGS19 and RGS20, that selectively act on Gαz (366-
369).  
When assessing the responses 15 minutes after ropinirole stimulation, we observed that 
RGS9-2 and RGS20 had different effects depending on the Gα subunit being activated. When Gαi2 
was activated, the maximal effect was significantly decreased in the presence of both RGS9-2 and 
RGS20 (Fig. 5.8A & Table 5.6). RGS20 also significantly reduced the potency of Gαi2 activation by 
approximately half a log-unit, while the small reduction in potency caused by RGS9-2 was not 
statistically significant. Measuring GαoA activation, we observed that both the maximal effect and the 
potency were significantly reduced by RGS9-2 and RGS20 (Fig. 5.8B & Table 5.6). Although, GαoA 
activation was more impacted in the presence of RGS9-2 than it was by RGS20. The largest effect 
we observed by any RGS protein acting on a Gα subunit was the potency decrease induced by RGS20 
on Gαz (Gαz-pcDNA pEC50 = 7.88 ± 0.05, Gαz-RGS20 pEC50 = 6.81 ± 0.04, mean ± SEM). RGS20 
decreased the potency by approximately 10-fold, and also decreased the maximal effect of the 
response. Contrasting this, RGS9-2 had no effect on Gαz activation relative to the pcDNA control 
(Fig. 5.8C & Table 5.6).  
We next assessed the effect of RGS9-2 and RGS20 on potency estimates over time. Gαi2 and 
GαoA displayed altered potencies in the presence of either RGS9-2 and RGS20, however their 
potencies remained constant over time (Fig. 5.8D & E). This suggests that the Gαi2 and GαoA systems 





quickly come to a condition that resembles a steady state. Furthermore, activation of Gαz in the 
pcDNA control condition displayed a large increase in potency over time that was consistent with our 
earlier experiments. The co-expression of RGS9-2 had no effect on this increase in potency. In 
contrast, however, in the presence of RGS20, the potency of ropinirole in the Gαz activation response 
did not increase in potency over time (Fig. 5.8F). This implies that GTP hydrolysis rate of Gαz was 
increased by RGS20, thus inhibiting the large accumulation of the active Gα-GTP species that 
mediates the increase in agonist potency in the control condition. 
 
Figure 5.8: RGS protein co-expression alters D2R mediated Gαi2, GαoA and Gαz activation 
responses over time. (A, B & C) Gαi2 (A), GαoA (B) and Gαz (C) activation responses mediated by 
the D2R 15 minutes after stimulation with increasing concentrations of ropinirole in the presence of 
transfected pcDNA control (orange circles), RGS9-2 (grey squares) or RGS20 (black triangles). Data 
represents the mean ± SEM of 3 separate experiment for all. (D, E & F) Potency (pEC50 parameter) 
values plotted over time after stimulation with ropinirole for Gαi2 (D), GαoA (E) and Gαz (F) activation 
in the presence of pcDNA control (orange circles), RGS9-2 (grey squares) or RGS20 (black 
triangles). Concentration response curves were determined at each timepoint as shown in panels A, 
B and C and the pEC50 values were taken and plotted over time. Data represents the mean ± SEM 
from 3 separate experiments for each data set. Gβ5s was co-transfected in all conditions for 









Table 5.6: Ropinirole induced activation of G proteins by the D2R in the presence of RGS 
proteins. 
Potency (pEC50) and maximal effect (Emax – BRET units) parameter values were determined 15 
minutes after ropinirole stimulation and represent the mean ± SEM from 3 separate experiments  
 
Gα subunit 
pcDNA RGS9-2 RGS20 
pEC50 Emax pEC50 Emax pEC50 Emax 
Gαi2 7.01 ± 0.04 8.79 ± 0.14 
x10-2 
6.80 ± 0.05 5.86 ± 0.12 
x10-2 b 
6.52 ± 0.07 
b 
7.03 ± 0.20 
x10-2 b 
GαoA 7.86 ± 0.06 
a 
10.75 ± 
0.20 x10-2 a 
7.28 ± 0.03 
a, b 
8.58 ± 0.08 
x10-2 a, b 
7.43 ± 0.03 
a, b 
9.96 ± 0.11 
x10-2 a, b 
Gαz 7.88 ± 0.05 
a 
9.79 ± 0.16 
x10-2 a 
7.88 ± 0.04 
a 
9.58 ± 0.11 
x10-2 a 
6.81 ± 0.04 
a, b 
8.54 ± 0.13 
x10-2 a, b 
 
a Significantly different (P<0.05) from corresponding Gαi2 value within the column as determined by 
one-way analysis of variance with Dunnett’s multiple comparisons test 
b Significantly different (P<0.05) from corresponding ‘pcDNA condition’ parameter value within the 




A particular focus of the GPCR drug discovery field has been to ascertain how specific GPCRs 
can transmit unique intracellular signals while only activating a handful of communal effectors. In 
the present study, we reconstituted the D2R with individual Gαi proteins in live cells to assess the G 
protein signalling in a temporal manner. Stimulation with two different agonists yielded varying G 
protein signalling profiles depending on the agonist efficacy and binding kinetics to the D2R. In 
addition, G protein signalling was also highly dependent on the biochemical properties of the specific 
G protein α subunit. In this manner, we observed a D2R-Gαz signalling wave that was kinetically 
distinct from Gαi or Gαo signalling.  
The slow amplification of D2R-Gαz signalling, manifesting as an increase in potency over 
time, occurs by a mechanism involving the slow GTP hydrolysis rate of Gαz that leads to an 
accumulation of the active Gαz-GTP species over time. Indeed, ropinirole and aripiprazole, when 
activating Gαz, increased in potency over time approximately 10- and 140-fold respectively. Such an 
increase in the potency of ropinirole and aripiprazole can only partly be attributed to the relatively 
slow dissociation rate from the D2R of the latter and this mechanism could not explain the behaviour 
of ropinirole, a fast dissociating agonist. By rapidly ‘switching off’ the D2R with an antagonist, we 
were able to monitor the deactivation rate of the different G protein subunits. This revealed that 
Gαz slowly deactivates in live cells. This slow deactivation of Gαz has been observed before 
(354,370). We were able, through both mutagenesis of the P-loop as well as a secondary approach 
using co-expression with RGS20, to demonstrate that the slow deactivation of Gαz and the increase 
in agonist potency over time are due to its slow GTP hydrolysis rate. This was confirmed by 





conferring the slow GTP hydrolysis rate into Gαi2 via mutagenesis, that conferred an increase in 
potency over time similar to that observed at Gαz.  
Our data demonstrate that the slow GTP hydrolysis rate of Gαz occurs in live cells, implying 
that this characteristic may serve a physiological role. Indeed, the Ser42 residue of Gαz that we 
demonstrate confers this slow hydrolysis rate is within the P-loop motif of the G protein subunit. 
As a key determinant of the GTPase activity, the P-loop has significant evolutionary pressure on it, 
hence, it is highly conserved across all G proteins. Therefore, it must be evolutionarily favourable to 
harbour a G protein within an organisms’ genome that has a slow deactivation rate for some particular 
function(s). We postulate that Gαz may be upregulated and coupled to by GPCRs when a slow 
signalling pattern is desired as opposed to a fast signalling response. This may be a logical purpose 
for Gαz considering that Gαz has similar downstream effectors to the other Gαi subfamily members 
and as such would not elicit a distinct biochemical response. Indeed, a previously suggested function 
of Gαz has been that the sustained signalling pattern of Gαz could be useful in regulating the slow 
control of the circadian clock by GPCRs such as GPR176 (371-373). Additionally, the expression of 
Gαz mRNA in mice appears to be upregulated perinatally and decreases over time into adulthood 
(374). Therefore, the slow G protein signalling via Gαz coupling to the D2R may be dependent on 
developmental stage. Furthermore, studies have shown unique patterns of Gαz expression in 
intracellular compartments (375-377). In addition to being localised to the plasma membrane, Gαz in 
Purkinje cells was shown to be localised to the outer membrane of the nuclear envelope, the 
endoplasmic reticulum and microtubules (375). It has further been determined that Gαz in the sciatic 
nerve can transport from the axon to the soma (retrograde axonal transport)(376,377). This leads one 
to hypothesise that the slow deactivation rate of Gαz may allow GPCR-activated Gαz to translocate 
from the plasma membrane to intracellular compartments for a sustained period to serve a distinct 
signalling role. Of course, this all must be considered in the context of RGS protein expression as our 
data illustrates that RGS20 can act on D2R-activated Gαz to increase the turnover rate. Thus, Gαz may 
behave as a fast cycling G protein when co-expressed with specific RGS proteins or exist as a slow 
cycling G protein when no such RGS proteins are present. It is possible then, that the relative 
expression of Gαz and its cognate RGS proteins may allow for fine tuning of temporal responses 
downstream of Gαi/o/z coupled GPCRs in individual tissues. 
The relative potency and maximal effect values suggest that perhaps there is an 
underappreciated role for the D2R to signal through Gαz in vivo. This contrasts with the most accepted 
view, that the D2R predominantly exerts its’ in vivo effects through the Gαo isoforms (140). Certainly, 
in line with this historical view, our data showed that the D2R couples more efficiently to GαoA and 
GαoB isoforms than to Gαi1, Gαi2 and Gαi3 as previously reported (139). However, our concentration-





response curves demonstrated that the D2R can be as efficiently coupled to Gαz as it is to the Gαo 
isoforms. While it was previously known that the D2R can couple to Gαz (378), the selectivity of the 
D2R for all the Gαi subunits had not been quantitatively assessed in the same system. This selectivity 
pattern implies that the D2R may couple to Gαz natively. Furthermore, the evidence supporting Gαo 
as the main G protein transducer for the D2R is largely based around one study by Jiang and colleagues 
(140). They reported that high affinity agonist binding at the D2R was not present in membranes 
prepared from the brains of Gαo knockout mice but it was present in the Gαi1, Gαi2 and Gαi3 knockouts 
(140). Importantly, there are some limitations of this work: First, this study did not specifically 
investigate Gαz coupling. Second, Gαo is likely the most prevalent subunit in the brain and as such its 
effects are more easily measured than the other Gα subunits (141,142). Third, this direct agonist 
binding measurement provides an indication of agonist affinity for the receptor-G protein complex 
and as such, does not account for the proposed signal amplification associated with the longer lifetime 
of the active GTP-bound Gαz G protein. Our data suggests that it is this step that contributes to the 
relatively high potency of agonists when the D2R is coupled to Gαz. Thus, Gαz may have an 
unappreciated role in D2R signalling that would not be detected by such an approach. D2R-Gαz 
coupling in vivo can be supported by data demonstrating that Gαz is required for some D2R mediated 
responses. For example, Van Den Buuse and colleagues (150), demonstrated that either amphetamine 
or apomorphine induced disruption of prepulse inhibition is enhanced in Gαz knockout mice. The 
disruption of prepulse inhibition in mice induced by amphetamine and apomorphine is a D2R 
dependent process (149,379). Therefore, this is direct evidence that D2R signalling through Gαz may 
play a role in sensorimotor gating. Moreover, in mice lacking Gαz, the D2-type selective agonist 
quinpirole is less effective at decreasing locomotor responses, inhibiting dopamine release in the 
nucleus accumbens, eliciting hypothermia and increasing plasma adrenocorticotropic hormone 
(ACTH) (151). Additionally, Gαz may couple to the D2R in neuroendocrine systems. For example, 
Gαz has been postulated to play a role in D2R mediated inhibition of prolactin release from rat 
pituitary lactotrophs (148).  
Having identified molecular and cellular evidence for a unique D2R-Gαz signalling wave, 
future studies could aim to investigate this in vivo and with additional GPCRs. Whole mouse genetic 
knockout studies have suggested a role for D2R-Gαz signalling in the brain (150,151). This may be a 
crude approach to investigate the dependence of Gαz in some D2R mediated behaviours. Given that 
we now recognise an important functional difference of Gαz in its slow GTPase activity, a more 
targeted approach to investigate Gαz could be to use gene editing technologies to alter the GTPase 
activity of Gαz in vivo. D2R-dependent behaviours could then be assessed to understand the role the 
slow GTP hydrolysis rate plays. Additionally, both the D2R and Gαz have separately been studied for 





their role in metabolism. The D2R and Gαz are expressed in pancreatic beta cells where they can 
modulate glucose-stimulated insulin secretion (146,147). Therefore, it could be worthwhile 
investigating whether the D2R can couple to Gαz in such a system. Furthermore, given that the distinct 
D2R-Gαz signalling wave we observed is in fact largely independent of the properties of the D2R, 
other Gαz coupled receptors are worth investigating such as the serotonin, opioid, melatonin and α-
adrenergic receptors (378,380-382). It would be of importance to determine whether an increase in 
potency over time is also observed upon activation of Gαz by these GPCRs. 
Detailed measurement of agonist-stimulated D2R-mediated G protein activation kinetics 
revealed that a saturating concentration of ropinirole stimulated activation of all tested Gα subunits 
with an observed rate that was statistically faster than aripiprazole stimulation. This is consistent with 
previous studies of GPCRs in which increasing agonist efficacy has been associated with faster 
nucleotide exchange rates (383,384) as well as observed G protein dissociation rates (385). The data 
in this study, although confined to just one high efficacy and one partial agonist, is in agreement with 
such a relationship between G protein heterotrimer dissociation rate and agonist efficacy at the D2R. 
Moreover, we found some nuances in the different agonist induced observed activation rates. Indeed, 
aripiprazole disproportionately activated Gαi2 at a faster observed rate relative to GαoA or Gαz subunits 
as compared to ropinirole’s relative rate of activation of these subunits. It is important to understand 
that this observed rate is a multiple of the rates within the G protein cycle and not simply dependent 
on the GEF ability of the agonist bound D2R. Consequently, we hypothesise that this faster relative 
rate of aripiprazole acting at Gαi2 is due to the G protein cycle being less perturbed by aripiprazole, 
and therefore, it finds a new equilibrium more quickly. In line with this, aripiprazole displayed a 
lower maximal effect when activating Gαi2 relative to ropinirole when compared to GαoA or Gαz 
activation. Our estimated deactivation rate of Gαz was about 50-fold slower than GαoA, whereas a 
previous study documented Gαz as having a 200-fold slower GTP hydrolysis rate (19). While the two 
assay readouts are different, the deactivation rate is entirely dependent on the GTPase rate. We believe 
this discrepancy may reflect differing experimental conditions in our BRET experiments as compared 
to the previous GTP hydrolysis assays (19). The experiments in this study, were performed in live 
mammalian cells at 37°C compared to the GTP hydrolysis assays performed at 30°C on Gαz purified 
from E.coli (19). Furthermore, being in live cells, our assays may be impacted by regulatory proteins 
within the cell and also the relative concentrations of all the signalling components within the system. 
We transfected constant amounts all components however it is difficult to have identical expression 
and localisation between the different transfection conditions. While the components within the GTP 
hydrolysis assays can be tightly controlled, the assays will be more influenced by the buffer 
conditions that can influence the G proteins differently. 





‘Perfect’ biased agonism describes an observation where an agonist acting at a particular 
receptor can activate one signalling pathway while entirely avoiding activating another pathway 
whereas other non-biased agonists might display activity at all pathways. Such observations can be 
confounded by so called system bias. In this case a weak partial agonist might have robust activity at 
a particularly well coupled signalling endpoint but no measurable activity at a less efficiently coupled 
endpoint. While previous studies have suggested that ‘perfect’ biased agonism can occur at the D2R, 
our measurements of the responses of the weak partial agonist aripiprazole are not consistent with 
this notion. To date the majority of studies investigating both agonist efficacy and G protein 
selectivity at the D2R have used [35S]GTPγS binding assays to measure G protein activation (19,386). 
[35S]GTPγS assays have often failed to detect activation of either Gαi1, Gαi2 or Gαi3 by the D2R when 
stimulated with partial agonists even when overexpressing G proteins or using receptor-G protein 
fusions (137-139), inferring that some agonists can selectively activate Gαo isoforms without 
activating Gαi subunits. In contrast, we could detect robust responses induced by the weak partial 
agonist aripiprazole in the live cell BRET assay. We attribute this to the increased sensitivity in the 
new BRET assay as opposed to older methods. It would be interesting, therefore, to reassess such 
historical observations of bias using this more sensitive approach. 
In conclusion, we showed that kinetically distinct G protein signalling waves transduced by 
the D2R are determined by the nature of the agonist and the G protein. Agonists acting at the D2R can 
induce distinct signalling patterns based on their efficacy and binding kinetics. On the other hand, we 
identified that the GTP hydrolysis rate of the G protein is crucial in determining the temporal 
response. In particular, we observed a distinct signalling wave mediated by Gαz due to its 
considerably slower GTPase activity than all other Gα subunits. These findings bring increased 
importance to D2R-Gαz coupling as it may serve as a novel signalling platform to coordinate a unique 
response from the D2R. 
 





5.5 Supplementary Materials 
 
Figure S5.1: G protein activation of Gαi1, Gαi3 and GαoB over time by the D2R. (A, B & C) 
Concentration response curves of cells transfected with the G protein activation sensors together 
with Gαi1 (A), Gαi3 (B) or GαoB (C) measured at 15 minutes in response to increasing concentrations 
of ropinirole (orange circles) or aripiprazole (grey squares). (D, E & F) Potency changes over 30 
minutes of Gαi1 (D), Gαi3 (E) or GαoB (F) activation plotted as pEC50 parameter values estimated from 
concentration response curves fitted at each measurement interval after stimulation of increasing 
concentrations of ropinirole (orange circles) or aripiprazole (grey squares). All values are expressed 
as mean ± SEM from 5 separate experiments performed in single wells. 
 







Figure S5.2: Examples of G protein activation increase in BRET responses over time used for 
potency estimates. (A, B & C) Ropinirole induced D2R G protein activation responses over 30 
minutes at Gαi2 (A), GαoA (B) or Gαz (C). (D, E & F) Aripiprazole induced D2R G protein activation 
responses over 30 minutes at Gαi2 (D), GαoA (E) or Gαz (F). All values are expressed as mean ± 






A pertussis toxin-like protein tool for 










Heterotrimeric G proteins are the main effector for G protein coupled receptors, including the 
D2R. Consequently, understanding G proteins’ functions is key to understanding how signalling 
responses and physiological effects of GPCRs emerge. A useful method for interrogating G proteins’ 
functions has been to use bacterially derived AB5 toxins, such as pertussis toxin, to inhibit their 
coupling and then evaluate the downstream changes. In chapter 3, some of the largest apparent biased 
agonism was observed between the well coupled G protein; Gαz, and the poorly coupled regulatory 
proteins. Additionally, we identified in chapter 5 that Gαz mediates a distinct signalling wave from 
the D2R that is slow and sustained. Together these results advocated for further investigations of D2R-
Gαz signalling. However, Gαz signalling has been historically neglected due to a lack of inhibitor 
tools available to study it. Therefore, in the present chapter we develop a new pertussis toxin-like tool 
that can inhibit Gαi subfamily G proteins, including Gαz. In addition, we characterise Gα subunits 
that are insensitive to the toxin to serve as tools in combination with the toxin. Used in the appropriate 
manner these tools will aid our laboratories’ studies on D2R-Gαz coupling. In addition, these tools 
should prove useful to the wider communities’ general GPCR-Gαi and GPCR-Gαz signalling studies.  
  






Heterotrimeric guanine nucleotide-binding proteins (G proteins) are signalling transducers 
that link cell surface receptors to intracellular effectors. Heterotrimeric G proteins are localised to the 
intracellular side of the plasma membrane where they can be activated by G protein-coupled receptors 
(GPCRs). Agonists such as a neurotransmitters, hormones, odorants or light can induce a 
conformational change in the transmembrane domains of GPCRs (7). This allows the G protein to 
couple to the GPCR, activate and then act on effectors downstream such as adenylate cyclases, 
phospholipase C isotypes and ion channels (387-389). 
Heterotrimeric G proteins consist of a Gα subunit that has a guanine nucleotide-binding 
domain, as well as a Gβ and Gγ subunit that function as an obligate dimer. The Gα subunit is 
responsible, to a large degree, in determining the specificity of the interaction with the activated 
GPCR. Upon coupling, an important interaction is made between the carboxy-tail of the Gα and the 
intracellular side of the active GPCR (8,9). Following this, the G protein becomes active by the Gα 
subunit exchanging bound guanosine diphosphate (GDP) for guanosine triphosphate (GTP) and 
dissociating from, or rearranging relative to the Gβγ dimer (10,390). Having dissociated, the Gα and 
Gβγ subunits are then able to act on downstream effectors (387-389). 
Gα subunits consist of four subfamilies (Gαs, Gαi, Gαq and Gα12) based on sequence similarity. 
The functions of the Gα subunits can be broadly generalised based on their subfamily classification. 
The stimulatory Gαs subfamily stimulates adenylate cyclases to produce cyclic adenosine 
monophosphate (cAMP), in contrast, inhibitory Gαi subunits are able to inhibit adenylate cyclases 
(349,387). The Gαq subfamily activates phospholipase C-β leading to increases in cytosolic Ca2+, and 
the Gα12 subfamily can activate Rho family GTPases that regulate cytoskeletal processes (388,391). 
However, the intricate functions of the individual subunits within each subfamily is far more complex 
than this. Understanding the details of how each subunit interacts with and regulates specific effectors 
is central to our comprehension of basic cellular signalling systems. Likewise, it is important to 
determine the role each individual Gα subunit plays in controlling particular physiological processes.   
One inhibitory Gα subunit of interest is Gαz because it displays some divergent characteristics. 
Gαz is a Gαi subfamily member that was identified in 1988 (392,393), just prior to the Gαq and Gα12 
subfamilies (394,395). It was shown that Gαz has a slow GDP-GTP exchange rate, slow GTP 
hydrolysis rate, unique Mg2+ dependence, and a restricted pattern of expression (19,147,392,393). 
Despite these unique biochemical characteristics, only a handful of reports have shed light on the 
functions of Gαz. While Kimple and colleagues have built a body of knowledge around Gαz’s role in 
the pancreas (147,396-398), , the functions of Gαz in other tissues largely remain elusive. This neglect 
of Gαz may be due to the lack of molecular tools for investigating its function. 





AB5-type toxins have been attractive tools for the interrogation of mechanisms of signalling. 
AB5 toxins are virulence factors commonly secreted by pathogenic bacterial species. The toxins are 
characterised by a hetero-hexameric structure consisting of a single A subunit and pentameric ring of 
B subunits. The A subunit is an enzymatically active subunit that acts on a host protein within the cell 
to modulate the hosts’ behaviour. The B subunits are responsible for recognition of host cell receptors 
on the cell surface, aiding in cellular entry. AB5 toxins can have a varied functions on their targets to 
modulate host cell behaviour such as protease activity (399), RNA N-glycosidase activity (400) and 
NAD+-dependent ADP-ribosylation (401). While there are many AB5 toxins with a range of host 
protein targets, there are currently only a few of known interest to the G protein signalling field. 
Cholera toxin (CTX) acts on the Gαs subfamily and renders Gαs subunits constitutively active (402). 
Pasteurella multicoda toxin (PMT) has been identified to deamidate members of the Gαi, Gαq and 
Gα12 family, rendering them constitutively active (403). Pertussis toxin (PTX), from Bordetella 
pertussis, the organism responsible for whooping cough, can actively ADP-ribosylate the members 
of the Gαi subfamily, except for Gαz (404). The ADP-ribosylation by PTX occurs on a cysteine 
residue near the carboxy-tail of Gαi subunits, rendering them incapable of coupling to GPCRs. Cell 
signalling researchers have exploited the actions of CTX and PTX for decades to identify the Gα 
subunits responsible for certain cell signalling and phenotypic phenomena.  
A recent publication by Littler and colleagues (405), reported the identification and structural 
characterisation of a novel PTX-like protein derived from a uropathogenic Escherichia coli. The toxin 
has an active A subunit homologous to PTX and has maintained a similar overall structural fold (Fig. 
S6.1A &B). When using Gαi2 as a substrate in vitro, the novel toxin was shown to have a distinct site 
of ADP-ribosylation from that of PTX (405). The toxin ADP-ribosylated an asparagine residue eight 
amino acids from the carboxy tail, as well as a lysine residue ten amino acids from the carboxy tail. 
Interestingly, the toxins’ asparagine site - approximately one turn below PTXs’ cysteine site - is 
conserved across several heterotrimeric Gα subunits, suggesting that the toxin may have broader 
substrate specificity than PTX (Fig. 6.1A & B).  
In the present study, we demonstrate that the newly described toxin can inhibit the coupling 
of all Gαi subfamily members tested, including Gαz. Thus, we refer to it as GαO, GαZ and GαI 
inhibiting ToXin, or in short; OZITX. Additionally, we show that OZITX abolishes all Gαi subfamily 
mediated downstream inhibition of cAMP production. The active A subunit also remains functional 
upon transfection into mammalian cells, allowing for experiments without the need for toxin 
expression and purification. Moreover, we generate members of the Gαi subfamily that are OZITX 
insensitive, and hence, can serve as tools in combination with OZTIX treatment. Overall, we believe 
OZITX will be a useful molecular tool in the future. 







Figure 6.1: Identification of Gα carboxy-tail amino acid residues that are putatively ADP-
ribosylated by OZITX. (A) Amino acid sequence alignment of carboxy-termini residues of 
heterotrimeric Gα proteins. Cysteine residues ADP-ribosylated by PTX are indicated in red. Putative 
lysine and asparagine residues ADP-ribosylated by OZITX identified by Littler and colleagues(405) 
are indicated in yellow. The asparagine residue that is a putative substrate is conserved across many 
Gα subunits. (B) The location of OZTX’s and PTX’s substrate amino acid sites within a GPCR-G 
protein complex. The structure of rhodopsin bound to Gαi1β1γ2 is depicted in cartoon (PDB code 
6CMO). Rhodopsin is shown in dark blue, Gαi1 in light blue, Gβ1 in green and Gγ2 in light green. The 
carboxy-terminal Cys351 residue ADP-ribosylated by PTX is shown in red spheres. Lys345 and Asn347, 
the putative residues ADP-ribosylated by OZITX, are highlighted in yellow spheres. Graphic 




Polyethylenimine (PEI), Linear (MW 25,000) was purchased from Polysciences, Inc. 
Ropinirole was purchased from BetaPharma (Shanghai) Co. Ltd. DAMGO ((ᴅ-Ala2, N-Me-Phe4, 
Gly-ol5)-enkephalin)) was purchased from Mimotopes. SKF83822, neurotensin residues 8-13 (NT8-
13), (-)-quinpirole hydrochloride (#1061), Acetylcholine chloride (#A2661), D-glucose (#G8270) 
and pertussis toxin (PTX) were purchased from Sigma-Aldrich. Isoproterenol (#1747) and 
endothelin-1 (#1160) was purchased from Tocris Bioscience (Bristol, UK). Coelenterazine-h was 
purchased from both NanoLight™ Technology and Dalton research molecules (#50303-86-9). 
Forskolin was purchased from Cayman Chemicals (#11018). Nano-Glo® luciferase assay system, 
containing the furimazine substrate, was purchased from Promega. Purified OZITX (EcPltAB) 
protein was a generous gift from Travis Beddoe, La Trobe University. 
 






pcDNA3.1(+) encoding human constructs of: long isoform of the dopamine D2 receptor 
(D2LR), μ opioid receptor (MOPR), dopamine D1 receptor (D1R), neurotensin receptor 1 (NTS1R), 
M1 muscarinic acetylcholine receptor (M1R), β2-adrenergic receptor (β2AR), endothelin A receptor 
(ETAR), Gαi1, Gαi2, Gαi3, GαoA, GαoB, Gαz, GαsS, GαsL, Gαolf, Gαq, Gα11, Gα14, Gα15-EE, Gα12 and 
Gα13 were from the cDNA Resource Centre (cDNA.org). pcDNA3L-His-CAMYEL was purchased 
from ATCC (ATCC MBA-277). masGRK3ct-Nluc, masGRK3ct-Rluc8, venus-1-155-Gγ2 and venus-
156-239-Gβ1 were from Nevin Lambert, Augusta University. pCAGGS-Ric8A and pCAGGS-Ric8B 
were from Asuka Inoue, Tohoku University. The active S1 subunit of OZITX (EcPltAB) was codon-
optimized, synthesized and inserted into pcDNA3.1+. OZITX resistant mutations were made in Gαi1, 
Gαi2, Gαi3, GαoA GαoB and Gαz using site directed mutagenesis. Primer sequences that were used for 
the mutagenesis can be found in Table 6.1.  
Table 6.1: Primers for mutagenesis to create OZITX resistant Gα subunits. 














OZITX resistant mutations were made by changing the eighth-last amino acid to an alanine 
(indicated in red) by using site-directed mutagenesis with the reverse primers used to the right, the 
alanine mutation change is shown in red and restriction site chosen in blue (XhoI) or green (XbaI). 
The constructs were inserted into pcDNA3.1+ with KpnI and XhoI or XbaI as indicated. 
 
Cell culture 
HEK293T cells were purchased from ATCC (CRL-3216). HEK293A ΔGα-all CRISPR/Cas 
knockout cells and HEK293A ΔGαi/o CRISPR/Cas knockout cells were a generous gift from Asuka 
Inoue, Tohoku University. HEK293T cells, HEK293A ΔGα-all cells and HEK293A ΔGαi/o cells were 
cultured in T175 flasks with Dulbecco’s Modified Eagle Medium (DMEM) + GlutaMAXTM-I (Gibco, 
Invitrogen, Paisley, UK) with 10% foetal bovine serum (Corning #35-010) and 1% 





penicillin/streptomycin (Corning #30-002). All Cells were grown in a humidified incubator in 5% 
CO2 at 37°C and sub-cultured at a ratio of 1/10-1/20. 
 
Transfection 
Briefly, cells were harvested from T175 flasks and plated into 6 well Nunc™ tissue culture 
plates at a density of 500,000 cells per well. The following day the media was removed and replaced 
with fresh media and transfected using PEI as the transfection reagent. The correct amounts of PEI 
and DNA were added to the buffer separately before mixing together, incubating for 20 minutes, and 
then adding dropwise on top of the cells in the fresh media.  
For the G protein activation assays where the toxin was added exogenously: The HEK293A 
ΔGα-all CRISPR knockout cells were transfected using PEI in a ratio of 6:1 PEI:DNA (w/w) in PBS. 
The cells were transfected with a cDNA mixture consisting of: 0.143µg GPCR, 0.286µg Gα, 0.143µg 
Gβ1-venus, 0.143µg Gγ2-venus, 0.143µg masGRK3ct-Nluc and 0.143µg Ric8A or Ric8B or 
pcDNA3.1. The chaperone Ric8A was transfected together with Gα14 and Gα15 and Ric8B was 
transfected with Gαolf.  
For the cAMP BRET assays where the toxins were exogenously added: The HEK293A ΔGαi/o 
CRISPR knockout cells were transfected using PEI in a ratio of 6:1 PEI:DNA (w/w) in PBS. The 
cells were transfected with a cDNA mixture consisting of: 0.143µg D2LR, 0.286µg 
Gαi2/GαoA/Gαz/pcDNA3.1 and 0.429µg CAMYEL sensor. 
Assays where the active A subunits of the toxins were transiently transfected had the 
following conditions: HEK293T cells were used and transfected using PEI in a ratio of 1.5 PEI: 1 
DNA (w/w) mixed in 150mM NaCl.  For the G protein activation assays the cells were transfected 
with Gβ1, Venus-Gγ2 and masGRKctRluc8 as well as the Gα subunit of interest together with a 
receptor suited for the specific G protein class and the chaperone proteins Ric8A for Gα14 and Gα15 
and Ric8B for Gαolf. For the cAMP production inhibition assays the cells were transfected with the 
CAMYEL sensor (ATCC MBA-277). For arrestin recruitment MeNArc assays (406), the cells were 
transfected with a membrane-anchor fused to the N-terminus of NanoLuc and β-arrestin-2 fused to 
the C-terminus, together with GRK2, D2R and either the active subunit of PTX (PTX-S1), OZITX 
(OZITX-S1) or pcDNA3.1+ as a control.  
 
G protein activation 
G protein activation was measured using a BRET assay that monitors Gβγ release(257,258). 
The HEK293A ΔGα-all cells were first transfected as described earlier and the following day the cells 





were harvested and transferred into white 96 well CulturPlates (PerkinElmer) in DMEM +10% FBS. 
In the conditions where the cells were treated with OZITX or PTX, the cells were left to adhere before 
being treated in the 96 well plate 16-20 hours before performing the assay. The G protein activation 
assays were then performed approximately 24 hours after plating out the transfected cells. The media 
in each well was aspirated, washed with Hank’s balanced salt solution pH7.4 (HBSS), replaced with 
HBSS and then kept at 37°C for the remainder of the assay. Furimazine was added with a multi-
stepper pipette 15 minutes before agonist addition and left to equilibrate. The agonist was then added, 
and cells were incubated in a LUMIstar Omega (BMG Labtech) plate reader. The BRET 
measurements were then taken 2.5 minutes after agonist addition. Simultaneous dual emission filters 
were used in the LUMIstar Omega for detection of the luciferase at 445-505nm and venus at 505-
565nm, all measured at 37°C. For G protein activation assays where the toxin active A subunit cDNAs 
were transfected, the same protocol was followed with some exceptions: HEK293T cells were used 
instead of CRISPR/Cas gene editied cells, DPBS + 5mM glucose was used as the assay buffer, 96 
well black-white iso plates were used, and the plate was detected five minutes after agonist 
stimulation in a Pherastar FS (BMG Labtech). After acquiring the data, the ratio of the venus emission 
channel was then divided by the luciferase emission channel to determine the BRET ratio. The 
vehicle-subtracted raw BRET ratio (drug induced increase in BRET) is plotted for the G protein 
activation assay data.  
 
cAMP production inhibition 
The cAMP production inhibition assays’ principle is based on the ability of a genetically 
encoded conformational BRET sensor to detect the relative concentrations of intracellular 
cAMP(358). Initially, the transfected HEK293A ΔGαi/o cells were harvested and transferred into 
white 96 well CulturPlates in DMEM +10% FBS 24 hours after the transient transfection. When the 
cells were treated with OZITX or PTX, this occurred in the 96 well plate after adherence and about 
18 hours before the assay. Next, the cAMP inhibition assays were performed the following day after 
plating out the transfected cells and toxin or control treatment. On the day of the assay, the plate 
media was aspirated, washed once with HBSS pH 7.4 and replenished with HBSS pH 7.4 and then 
held at 37°C for the rest of the experiment. 5μM coelenterazine-h was added 15 minutes before 
agonist addition. 10µM Forskolin was added 10 minutes before agonist addition and the readings 
were then continuously taken in the live cells. Bioluminescence was detected on a LUMIstar Omega 
set to 37°C. Simultaneous dual emission filters were used for the BRET donor at 445-505nm and the 
acceptor at 505-565nm. The ratio of the acceptor channel was then divided by the donor channel to 
determine the BRET ratio. The data was then baseline-corrected to the vehicle control wells over 





time. A slightly modified protocol was followed for the assays where the active subunit cDNAs of 
the toxins were transfected: HEK293T cells were used instead of the HEK293A ΔGαi/o cells, 96 well 
black-white isoplates were used, DPBS +5mM glucose was used as the assay buffer, a higher 
concentration of 30μM forskolin was used and this was co-added with the coelenterazine-h ten 
minutes prior to the addition of the agonist. The plate was then detected 20 minutes after agonist 
addition in a PHERAstar FS.  
 
Arrestin recruitment 
D2R mediated β-arrestin-2 recruitment to the plasma membrane was conducted using the split 
luciferase complementation-based assay – MeNArC (406). HEK293T cells were co-transfected with 
multiple constructs as described earlier in the methods section. The cells were transfected with; D2R, 
GRK2, a membrane-anchor fused to the N-terminal half of NanoLuc, β-arrestin-2 fused to the C-
terminal half of NanoLuc and either the active subunit of PTX (PTX-S1), OZITX (OZITX-S1) or 
pcDNA3.1+ as a control. 48 hours after transfection the cells were washed with DPBS (Corning #21-
031-CV), resuspended in DPBS +5 mM Glucose and seeded out into a 96 well black-white iso plate 
(Perkin-Elmer). Five minutes after the addition of 5µM coelenterazine-h, the D2R agonist quinpirole 
was added and luminescence was read after 20 minutes in a Pherastar FS (BMG Labtech).  
 
Data analysis 
GraphPad Prism 8 was used for data analysis and performing statistical tests. Figures 




OZITX treatment abolishes GPCR mediated activation of all Gαi subfamily members, 
including Gαz 
Gαz displays divergent biochemistry and a more restricted expression profile compared to the 
other Gαi members (19,392,393). The significance of these characteristics, however, has not been 
realised partly due to the lack of molecular biological tools for Gαz. We hypothesised that OZITX 
may serve as one such tool to investigate Gαz because we observed that Gαz possesses a conserved 
Asn348 residue eight amino acids from the carboxy tail that is thought to be ADP-ribosylated by 
OZITX (Fig. 6.1A) (405). Consequently, we sought to determine whether OZITX inhibits Gαz 





coupling to GPCRs. To achieve this, we used a previously described NanoBRET assay that measures 
the release of Gβγ subunits from the Gα subunits upon activation of the heterotrimer (Fig. 6.2A) 
(257,258). While this assay provides a method for rapidly assessing G protein activation, the signal 
can potentially be partially contaminated by endogenously expressed Gα subunits in the cells 
(257,354). We therefore, adapted the assay for use in newly edited HEK293A CRISPR/Cas ΔGα-all 
cells whereby all the Gα subunits had been genetically knocked out (408). This allowed us to quickly 
monitor the Gβγ release from the activation of one particular Gα subtype of interest that had been 
exogenously transfected.  
The dopamine D2 receptor (D2R) was used as a prototypical Gαi subfamily coupled receptor 
to assess the effect of OZITX treatment on Gαi protein activation. The D2R is an ideal GPCR to use 
for these experiments as it promiscuously couples to all of the Gαi subfamily, including Gαo isoforms 
and Gαz (186,267). Cells transiently expressing the D2R were pre-incubated with PTX or OZITX 
followed by stimulation with the D2-like receptor selective agonist ropinirole (409). When doing this, 
it was observed that OZITX completely blocked the activation of Gαi1, Gαi2, Gαi3, GαoA and GαoB 
(Fig. 6.2B). This finding demonstrates that OZITX can function essentially the same as PTX - a 
finding that was in fact previously reported by Littler and colleagues (405). We extended our studies 
to see the effect of OZITX treatment on Gαz activation. As predicted from the carboxy-tail Asn348 
residue within Gαz, the D2R was incapable of activating Gαz upon ropinirole stimulation of cells that 
were pre-incubated with OZITX (Fig. 6.2B). In contrast, Gαz was insensitive to inhibition by pre-
treatment of cells with PTX, consistent with the absence of the required cysteine substrate site residue 
(Fig. 6.1A).  
Next, the same set of experiments was performed with another Gαi/o/z coupled GPCR; the μ 
opioid receptor (MOPR). Cells expressing the MOPR were pre-incubated with either OZITX or PTX 
and then stimulated with the agonist DAMGO (Fig. 6.2C). OZITX again inhibited coupling to each 
of the Gαi subunits completely, including Gαz. (Fig. 6.2C). This showed that OZITX does not 
discriminate between GPCRs when inhibiting G protein activation and thus may serve as a universal 
GPCR tool. We then sought to further characterise the toxin by measuring the activation of Gαi2 by 
the D2R after exposure to OZITX at different timepoints. Gαi2 activation decreased with increasing 
time of OZITX exposure until Gαi2 activation was completely abolished approximately sixteen hours 
after the addition of OZITX (Fig. 6.2D). This is consistent with the characteristics of PTX and hence 
suggests that OZITX, like PTX, would be best utilised in the laboratory by incubating with the cells 
overnight.  
 






Figure 6.2: Activation of members of the Gαi subfamily in the presence of OZITX and PTX. (A) 
Representation of the BRET sensors used for detection of G protein activation. Cells are transfected 
with DNA encoding a GPCR, Gα, venus156-239-Gβ1, venus1-155-Gγ2 and masGRK3ct-Nluc. The 
Gαβγ heterotrimer is activated through agonist binding to the GPCR. Active Gα exchanges the bound 
GDP for GTP and the Gα and Gβγ-venus dissociates. Free Gβγ-venus is bound by masGRK3ct-
Nluc that serves as a BRET donor resulting in non-radiative energy transfer from Nluc to venus in 
the presence of the substrate furimazine. (B) D2R mediated activation of Gαi subfamily members in 
the presence of OZITX or PTX. Cells were pre-treated with either vehicle (black), OZITX (blue) or 
PTX (red) for 24 hours. Cells were then stimulated with 1μM ropinirole for 2.5 minutes followed by 
BRET detection. Data represents the mean drug induced increase in BRET ratio from vehicle ± SEM 
from 3-6 independent experiments. (C) MOPR mediated activation of Gαi subfamily members in the 
presence of OZITX or PTX. Cells were pre-treated with either vehicle (black), OZITX (blue) or PTX 
(red) for 24 hours. Cells were then stimulated with 1μM DAMGO for 2.5 minutes followed by BRET 
detection. Data represents the mean drug induced increase in BRET ratio from vehicle ± SEM from 
3 independent experiments. In (B) and (C), * represents where the response is significantly different 
(P < 0.05) from the respective vehicle toxin untreated control condition (black bar) as determined by 
a one-way ANOVA with Dunnett’s multiple comparisons test. (D) Time course of OZITX treatment 
on G protein activation. HEK 293 ΔGα-all cells were transfected with cDNA encoding the D2LR, Gαi2 
and G protein activation sensors. Cells were pre-treated with OZITX for the indicated times. BRET 
was measured 2.5 minutes after stimulation with 1µM ropinirole (blue open circles) or vehicle (blue 
filled circles). The basal BRET ratio prior to agonist stimulation has been subtracted to give the drug 
induced ΔBRET ratio. Data represents the mean ± SD from three separate experiments. * represents 
where the response is significantly different (P < 0.05) from the respective pcDNA control condition 
as determined by one-way ANOVA with Dunnett’s multiple comparisons test. 
 
 





Gαi2, GαoA and Gαz mediated cAMP production inhibition is inhibited by OZITX 
Cell surface receptor signalling is commonly amplified in the subsequent steps down the 
signalling cascade to increase the cells’ sensitivity to extracellular stimuli. We wanted to confirm that 
OZITX also blocks the signalling at later stages in the cascade because a negligible response at the 
level of G protein activation could manifest as a larger signal further downstream. We therefore, 
assessed the effect of OZITX treatment on the downstream endpoint of intracellular cAMP since the 
Gαi subfamily are well-known to bind and inhibit adenylate cyclases (349,410). The intracellular 
cAMP levels were then monitored using CAMYEL; an intramolecular conformational BRET sensor 
based on EPAC (358). In these experiments, we used HEK293A cells that harboured a genetic 
knockout of all the Gαi subfamily members using CRISPR/Cas (HEK293A CRISPR/Cas ΔGαi). 
Individual Gαi subunits of interest were then transfected into the cell background to monitor their 
ability to inhibit cAMP production. The cells were then treated with forskolin to stimulate adenylate 
cyclase, resulting in an increase in the levels of cAMP. This was then followed by treatment with 
ropinirole to stimulate the D2R, leading to activation of the Gαi subunit of interest. Importantly, in 
the absence of a transfected Gα subunit, there was no detectable drug-induced inhibition of cAMP 
production, as observed by a lack of an increase in BRET ratio (Fig. 6.3A). When Gαi2 or GαoA were 
transfected, stimulation of the D2R produced a decrease in relative cAMP levels (indicated by an 
increase in BRET ratio) and this was completely abolished in cells treated with OZITX (Fig. 6.3B & 
C). In addition, cells transfected with Gαz also produced a decrease in cAMP, albeit to a slightly 
smaller amount, and this was again blocked in the presence of OZITX (Fig. 6.3D). This indicates that 
OZITX mediated ADP-ribosylation entirely occludes the Gαi protein members from coupling thus 
wholly preventing any downstream signalling. 
  







Figure 6.3: OZITX’s effect on Gαi2, GαoA and Gαz mediated inhibition of cAMP production. 
Inhibition of forskolin stimulated cAMP production was detected in live cells using CAMYEL; a 
conformational BRET sensor based on EPAC. HEK 293 ΔGαi/o CRISPR cells were transfected with 
DNA encoding the D2R, CAMYEL and either (A) pcDNA3.1+ control, (B) Gαi2, (C) GαoA or (D) Gαz. 
Transfected cells were then incubated with either vehicle (black) or OZITX (blue) for 24 hours. Cells 
were then pre-stimulated with 10µM forskolin for 10 minutes before stimulation with either vehicle 
control (filled circles) or 1μM ropinirole (open circles). Data was baseline corrected to the cells not 
treated with OZITX or ropinirole and is shown as the mean ± SEM from four separate experiments. 
Values were deemed significantly different using an unpaired student’s t-test. * represents P<0.05.  
 
OZITX does not ablate Gαs, Gαq or Gα12 subfamily coupling  
In addition to the Gαi subfamily, the asparagine residue eight amino acids upstream of the 
carboxy-terminus is also conserved across some other Gα members (Fig. 6.1A). We therefore sought 
to further assess the substrate selectivity of OZITX as it could potentially be used as a tool to inhibit 
activation of a wider range of Gα subunits. We first measured the Gαs subfamily activation after 
treatment with OZITX to serve as a negative control because the Gαs subfamily possess a histidine 
residue instead of an asparagine in this position. This was performed using the well-established Gαs 
coupled receptor, the dopamine D1 receptor (D1R) together with the D1-type selective agonist 
SKF83822 for activation (411-414). Indeed, overnight incubation with OZITX did not inhibit Gαs or 
Gαolf activation by the D1R which was in line with our predicted mechanism of OZITX action (Fig. 
6.4A). 
Next, we measured the activation of the Gαq subfamily proteins using the Gαq coupled 
neurotensin receptor 1 (NTS1R)(415,416). Gαq, Gα11, and Gα14 but not Gα15 possess an asparagine 
residue as their eighth last amino acid such that one would expect only the former three subunits to 
be substrates for OZITX and hence not be activated by NTS1R in the presence of OZITX (Fig. 6.1A). 





Upon stimulation of the NTS1R with a truncated version of the endogenous agonist neurotensin 
(neurotensin residues 8-13 (NT8-13)), OZITX pre-treatment was incapable of completely inhibiting 
activation of any of the Gαq members (Fig. 6.4B). OZITX had no effect on Gαq, Gα11 or Gα15 although 
Gα14 activation was partially decreased (vehicle control = 0.0840, OZITX treated = 0.0644, 
P=0.0012, one-way ANOVA with Dunnett’s multiple comparisons test).  
Moreover, both members of the Gα12 subfamily; Gα12 and Gα13, also harbour the putative 
asparagine site as their eighth-last amino acid (Fig. 6.1A). Consequently, we proceeded to assess the 
action of OZITX on the Gα12 subfamily. We used the NTS1R for activation again because it is known 
to also be capable of coupling to the Gα12 subfamily (417). While we were successful in detecting 
robust activation of Gα12 and Gα13 by the NTS1R, there was no inhibitory effect on the activation of 
either subunit when the cells were treated with OZITX (Fig. 6.4C). Taken together, despite the 
presence of the Asn residue with the Gαq and Gα12 subfamilies, no detectable inhibitory action was 
observed with the exception of Gα14 at which only partial inhibition was observed.  






Figure 6.4: Gαs, Gαq and Gα12 subfamily activation in presence of OZITX and PTX. (A) 
Activation of Gαs subfamily members by D1R in the presence of OZITX and PTX. (B) Activation of 
Gαq subfamily members by NTS1R in the presence of OZITX and PTX. (C) Activation of Gα12 
subfamily members by NTS1R in the presence of OZITX and PTX. HEK 293 ΔGα-all CRISPR cells 
were transfected with cDNA encoding the particular GPCR and Gα together with the G protein 
activation sensors as described the methods. The cells were pre-treated with either vehicle (black), 
OZITX (blue) or PTX (red) for 24 hours before stimulation with the GPCR agonists 100nM SKF83822 
(D1R) / 1μM NT8-13 (NTS1R) for 2.5 minutes followed by BRET detection. The data is represented 
as the mean drug induced increase in BRET ratio from vehicle control ± SEM from 3-5 separate 
experiments. * represents where the OZITX or PTX treated condition is significantly different (P < 
0.05) from the vehicle treated condition (black) as determined by a one-way ANOVA with Dunnett’s 
multiple comparisons test. 
 





The active A subunit of OZITX can be transfected into mammalian cells to act as an inhibitor 
In order to treat cells with AB5 toxin protein complexes both expression and purification of 
this toxin is required (405). We therefore sought to determine if this process could be circumvented 
when using OZITX in order to increase its accessibility to laboratories. Accordingly, we tested 
whether the toxin would be functional upon transfection of the cDNA encoding the active A subunit 
on its own (OZITX-S1). Indeed, the active A subunit of PTX alone can be transiently expressed to 
act this way (418,419). The cDNA sequence of OZITX-S1 was codon optimised for high expression 
in human cells and ligated into pcDNA3.1+. The plasmid encoding OZITX-S1 was then co-
transfected with the CAMYEL sensor into HEK293T cells to assess its effect in a cAMP production 
inhibition assay. Upon activation of the D2R with the agonist quinpirole, cells that were transfected 
with the pcDNA control showed a concentration-dependent decrease in intracellular cAMP levels, 
whereas this response was completely blocked in cells transfected with the positive control PTX-S1 
cDNA as well as the OZITX-S1 cDNA (Fig. 6.5A). This effect indicates that all endogenously 
expressing Gαi subunits were ADP-ribosylated by transfected OZITX-S1 consistent with the action 
of the purified toxin described above. Having identified that transfected OZITX-S1 is functional, we 
then further monitored the activation of the other Gα subfamilies in OZITX-S1 transfected cells in 
order to confirm our previous results using treatment of the complete OZITX protein complex (Fig. 
S6.2 & Fig. 6.4). Indeed, OZITX-S1 transfection was ineffective in abolishing activation of Gαs, Gαq 
and Gα12 subfamilies (Fig. S6.2). 
We next were interested in assessing the effect of OZITX on arrestin recruitment to GPCRs. 
This is of importance considering many studies seeking to detect arrestin-dependent signalling do so 
by using PTX under the assumption that all Gαi mediated signalling is blocked (420-426). We 
reasoned that OZITX may be more appropriately used in such situations given that PTX is an 
imperfect tool in such instances when the cells of interest express Gαz and the GPCR of interest is 
coupled to this G protein. Accordingly, we examined the effect of OZITX on agonist-induced β-
arrestin-2 (also termed arrestin-3) recruitment to the D2R using a new MeNArC assay. We found that 
OZITX-S1 had a negligible effect on β-arrestin-2 recruitment to the D2R, akin to the effect of 
transfected PTX-S1 (Fig. 6.5B). This illustrates that OZITX may be a useful tool to completely inhibit 
all Gαi subfamily members while permitting the assessment of arrestin-dependent signalling. 






Figure 6.5: Effect of transfected cDNA encoding OZITX and PTX on cAMP inhibition and β-
arrestin-2 recruitment. (A) D2R mediated cAMP inhibition in the presence of OZITX and PTX cDNA. 
cAMP inhibition was performed after transfection of the either a pcDNA3.1+ control (black open 
circles), OZITX active subunit (OZITX-S1) (blue open circles), or PTX active subunit (PTX-S1) (red 
open circles) together with the D2R and CAMYEL as described in methods. Cells were pre-treated 
with 30μM forskolin 5 minutes before stimulation with increasing concentrations of quinpirole 
followed by BRET detection. Data represents the mean ± SEM of eight separate experiments. (B) 
Recruitment of β-arrestin-2 to the D2R in the presence of OZITX and PTX cDNA.  β-arrestin-2 
recruitment was performed after transfection of the either a pcDNA3.1+ control (black open circles), 
OZITX active subunit (OZITX-S1) (blue open circles), or PTX active subunit (PTX-S1) (red open 
circles).  β-arrestin-2 recruitment was measured in response to increasing concentrations of 
quinpirole using the MeNArC split luciferase complementation assay as outlined in the methods. 
Data represents the mean ± SEM of four separate experiments. 
 
Gαi subunits can be made OZITX insensitive 
Understanding the actions of a single Gαi subtype has historically been challenging because 
there are usually multiple Gαi members expressed within any given cell type. A method that has 
permitted the investigation of a single Gαi subunit is to use cells expressing a PTX insensitive Gαi 
mutant in combination with PTX pre-treatment of the cells (427). This uncouples any endogenously 
expressed PTX sensitive Gαi subunits and allows GPCR mediated activation of only the PTX 
insensitive mutant of interest. Appreciating this, we followed the same rationale by attempting to 
generate OZITX insensitive Gαi mutants in the hope of increasing the scope of OZITX applications. 
To render the Gαi/o/z subunits insensitive to OZITX, we replaced the asparagine eight amino acids 
from the carboxy-terminus to an alanine (Gαi1-N347A, Gαi2-N348A, Gαi3-N347A, GαoA-N347A, 
GαoB-N347A and Gαz-N348A)  as this was previously identified as the most likely substrate site using 
mass spectrometry (Fig. 6.1A) (405). We then performed G protein activation assays using the D2R 
to activate each Gαi mutant in the presence or absence of PTX-S1 or OZITX-S1 (Fig. 6.6 & Fig. 
S6.3). In contrast to the activation of the wild-type Gαi3, GαoA and Gαz that are all abolished by 
OZITX (Fig. 6.6A, B & C), activation of Gαi3-N347A, GαoA-N347A and Gαz-N348A were OZITX 
insensitive (Fig. 6.6D, E & F). Additionally, it was observed that the N347A/N348A mutation did 
not impact the PTX sensitivity of the Gαi subunits (Fig. 6.6D, E &F). Likewise, the well-known PTX 





insensitive mutation (C351I) introduced into Gαi3 and GαoA, did not disturb the ability of OZITX to 
act on them (Fig. 6.6G & H). Having identified that the N347A/N348A mutation renders these Gαi 
members insensitive to OZITX without perturbation, the mutations were also extended into the 
remaining Gαi subunits and validated (Fig. S6.3).  
 
Figure 6.6: OZITX sensitivity of Gαi subfamily carboxy tail Asn347/348 mutants. (A) Gαi3-WT 
activation, n=4-11. (B) GαoA-WT activation, n=4. (C) Gαz-WT activation, n=5-6. (D) Gαi3-N347A 
activation, n=4. (E) GαoA-N347A activation, n=4. (F) Gαz-N347A activation, n=6-8. (G) Gαi3-C351 
activation, n=4-9. (H) GαoA-C351 activation, n=4. The G protein activation assay was performed on 
WT, Asn347Ala/Asn348Ala (putative OZITX site) and Cys351Ile (PTX insensitive) mutants. Cells 
were transfected with the D2R, the particular Gα mutant, the G protein activation sensors and either 
a pcDNA3.1+ control (black open circles), OZITX-S1 cDNA (blue open circles) or PTX-S1 cDNA (red 
open circles). Cells were then stimulated with increasing concentrations of quinpirole before BRET 




PTX and CTX have been useful tools in GPCR signalling research to interrogate signalling 
pathways responsible for particular physiological processes. Here we have demonstrated a new tool 
for the inhibition of GPCR mediated activation of the Gαi subfamily, including Gαz, through the use 
of a recently identified PTX-like protein - OZITX. OZITX has a distinct substrate site from that of 
PTX, enabling it to act on Gαz in addition to all the PTX sensitive Gα subunits. The unique substrate 





site was shown to be an asparagine residue eight amino acids from the carboxy-tail, yet, harbouring 
the asparagine residue was insufficient in rendering the Gαq and Gα12 subfamilies sensitive to OZITX. 
Moreover, we showed that the transfected OZITX-S1 subunit is functional in mammalian cells, 
allowing for a more economical method of intracellular inhibitor delivery. Using this method of 
delivery, we finally showed that mutation of the Asn347 or Asn348 substrate site within Gαi subunits 
maintains their ability to couple to GPCRs while engendering them insensitive to OZITX.  
While OZITX inhibits the other Gαi subunits, we showed that OZITX can be used for the total 
prevention of GPCR-Gαz signalling. Used in this fashion, OZITX is a tool distinct from all the prior 
methods that have been used to interrogate Gαz signalling. Previous studies have relied on inventive 
strategies to inhibit Gαz signalling such as; overexpression of Gαz-specific RGS proteins (147), Gαz-
directed siRNA (428), and Gαz de-activation via PKC phosphorylation (148). However, these 
approaches do not completely block all activation of Gαz. This property is crucial for reliable results 
because any amplification in the signal transduction system may mask the partial inhibition that 
occurred upstream. Therefore, an ideal molecular tool can completely block all signalling via the 
pathway of interest. Genetic knockouts of the gene that encodes Gαz have been used for this reason 
(150,396). The genetic knockout approach is more robust than the earlier described methods, 
however, it is technically challenging compared to OZITX treatment. Additionally, OZITX can be 
used in a more acute manner by overnight treatment whereas gene-editing technologies provide 
greater time for compensatory mechanisms by the cell potentially leading to uncertain results. While 
a complete genetic knockout may be advantageous in some circumstances, post-translational 
modification is likely to have less off-target cellular effects because it occurs at a later stage - the 
level of the protein. 
Our results suggest that OZITX could serve as a replacement to PTX in most experimental 
paradigms aimed at interrogating Gαi/o/z signalling moving forward. One of the early demonstrations 
of PTX’s utility was to aid in identifying the Gαi subfamily by distinguishing it from the Gαs 
subfamily (349). PTX was shown to block the inhibitory effect that Gαi proteins have on adenylyl 
cyclases, thus building evidence for a separate Gα species with distinct functionality to Gαs. Since 
then, PTX has been widely used with the same rationale, that is, to differentiate GPCR responses 
mediated by Gαi proteins from other signal transducers (429). However, it has been known for 
decades that it is imperfect due to its lack of action on Gαz (392,393). We have now shown that this 
contrasts with OZITX, we determined that it can inhibit Gαz in addition to inhibiting Gαi1, Gαi2, Gαi3 
and the Gαo isoforms. Considering this, it should be recognised that the replacement of PTX by 
OZITX will occur assuming OZITX also inhibits the visual and taste Gα subunits; Gαt1, Gαt2 and 
Gαgust. We have not evaluated whether OZITX inhibits the coupling of these Gα subunits in the 





present study. One would expect ADP-ribosylation by OZITX to occur on Gαt1, Gαt2 and Gαgust since 
they harbour an asparagine as their eighth-last amino acid residue in addition to having high sequence 
homology to the other Gαi subunits.  
While OZITX is expected to often replace PTX, one would consider that PTX will not become 
redundant because the reasons for using PTX will evolve. There are likely be cases where PTX is still 
required due to its contrast in Gα specificity. For example, disentangling the functions of Gαz from 
the other Gα subunits will require both the use of PTX and OZITX. Indeed, performing an experiment 
with an OZITX treated, a PTX treated and an untreated condition in parallel, would enable the 
signalling mediated by Gαz, PTX sensitive Gαi subunits and toxin insensitive Gα subunits to be 
separately measured. 
OZITX lacked the ability to abolish the coupling of the Gαq and Gα12 subfamily, despite the 
Gαq and Gα12 subfamilies carrying the conserved asparagine substrate site in their carboxy α-helix. 
OZITX only had a small effect on Gα14 activation and there was a lack of any effect on all the 
remaining Gαq and Gα12 subunits. This result complicated our predicted mechanism of action as we 
had presumed that the conserved asparagine residue was the main determinant for OZITX specificity. 
In line with our thinking, PTX can act on all the Gα subunits that contain the Cys351/352 substrate site. 
Certainly, our initial results supported this mechanism because the Gαs subfamily was not inhibited 
and it does not possess an asparagine in the appropriate position for ADP-ribosylation. However, our 
results together suggested that Gα14 is a very poor substrate for OZITX and that the Gαq and Gα12 
subfamilies are not the target of OZITX. Curiously, these findings can be explained when considering 
prior literature reporting that swapping the five carboxy-terminal residues of Gαi2 or GαoA onto Gαq 
does not produce a Gα subunit that is sensitive to PTX, even though the modified Gαq contains the 
required cysteine residue four amino acids from the carboxy-termini (430). This indicates that 
carrying the required substrate amino acid site alone is not enough to render the a Gα subunit sensitive 
to the PTX-like protein. In the case of OZITX, this hypothesis could be further supported by 
determining whether introducing the conserved asparagine residue into the Gαs subfamily has any 
effect on the subfamilies’ OZITX insensitivity. Furthermore, our results using OZITX together with 
previous findings using PTX would imply that the site of ADP-ribosylation is distinct from the 
binding recognition site of the PTX-like protein. Future studies could investigate the structural basis 
for the recognition of specific Gα subunits by OZITX and PTX. 
It was determined that the OZITX-S1 cDNA can be transfected for a more practical and 
economical approach to inhibit Gαi/o/z signalling as compared to use of the purified toxin. This means 
that the whole protein complex does not need to be expressed and purified, instead obtaining DNA 
that encodes the active A subunit is adequate. Previous studies have demonstrated that transfected 





PTX-S1 can be used to reduce the time and cost associated with acquiring the purified protein 
(418,419). Indeed, this suggests that most ADP-ribosylating active subunits from PTX-like proteins 
will remain functional when transfected. Furthermore, we also demonstrated that using transfected 
OZITX does not prevent β-arrestin-2 recruitment to the D2R. Accordingly, OZITX may be used as a 
method for blocking any unwanted Gαi subfamily signalling when seeking to exclusively assess 
arrestin-dependent signalling. 
We showed that Gαi subunits can be made OZITX insensitive through an N347A/N348A 
mutation in the eighth-last amino acid position. Further studies may seek to check the alanine mutant 
and, if required, potentially swap the alanine with another residue that continues to prevent ADP-
ribosylation while more closely matching the biochemistry of the wild type protein. Mutations like 
this have previously been generated for the PTX insensitive Gαi subunits by changing the initially 
discovered PTX insensitive C351G/C352G mutation to the preferred C351I/C352I mutation (431). 
Nonetheless, the OZITX insensitive mutants can serve as a useful tool in combination with OZITX 
treatment to investigate single Gαi proteins in an endogenous Gαi null background. Building on this, 
OZITX insensitive Gα mutants and PTX insensitive mutants could be complementary to each other. 
For example, it could be of use to transfect both an OZITX insensitive Gα mutant and a PTX 
insensitive Gα mutant into the same cells and either treat with OZITX or PTX to assess the effect of 
one subunit in identical cellular conditions.  
Moreover, it was interesting that in our hands, mutation of the Asn347/348 residue alone was 
sufficient to render Gαi1, Gαi2 and Gαi3 resistant to OZITX. This is because these Gα subunits contain 
a lysine residue as their tenth-last amino acid (Lys345/346) that was suggested to be a site for OZITX 
by Littler and colleagues (Fig. 6.1A) (405). These results may suggest that this Lys345/346 site is a poor 
secondary substrate site that is very minimally ADP-ribosylated. Alternatively, another scenario may 
be that ADP-ribosylation of the Lys345/346 site may have no effect on the G protein coupling ability. 
However, this is less probable given that the Lys345/346 site would appear to have quite close proximity 
to the GPCR upon coupling. 
Finally, we have helped support the overarching idea that there is continuing value in the 
characterisation and use of novel AB5 toxins as laboratory tools. Host-pathogen arms races are 
hotspots of molecular evolution that result in proteins with extraordinary functionality. This is 
exemplified in the diversity of ADP-ribosylating AB5 toxins. At present, an unknown number of these 
toxins remain as a large untapped resource. Some ADP-ribosylating AB5 toxins that have been well 
characterised, such as PTX and CTX, have been widely used as tools in G protein signal transduction 
research. Here, we have now validated the use of OZITX and hence, it can be added to the ADP-





ribosylating AB5 protein tool kit. Indeed, OZITX will be particularly useful when investigating 
aspects of Gαz signalling.  
 
  










OZITX_S1      -------------------MLKMFILFLISFSWYANATDFVYRVDSRPPEEIFRDGFRSH 41 
PTX_S1        MRCTRAIRQTARTGWLTWLAILAVTAPVTSPAWADDPPATVYRYDSRPPEDVFQNGFTAW 60 
                                  :  .   : * :*  :    *** ******::*::** :  
 
OZITX_S1      GFNRNLQQHLRGDSCAAGSRDSAFIATTTSLIET--YN---------IARQYYSSSGFHG 90 
PTX_S1        GNNDNVLDHLTGRSCQVGSSNSAFVSTSSSRRYTEVYLEHRMQEAVEAERAGRGTGHFIG 120 
              * * *: :** * ** .** :***::*::*   *  *            *   .:. * * 
 
OZITX_S1      RLYRYRIRANNIFYPIQPSV-NYLTQRGITFSG-FERIMMREQNEIVAVEHIPGENIVEA 148 
PTX_S1        --YIYEVRADNNFYGAASSYFEYVDTYGDNAGRILAGALATYQSEYLAHRRIPPENIRRV 178 
                * *.:**:* **    *  :*:   * . .  :   :   *.* :* .:** *** .. 
 
OZITX_S1      VELTYDRFNSQVSDGPGTTNARYVPGSTFVNPGVIPQLVVPTVSVRERINAFGSLISACF 208 
PTX_S1        TRVYHNGITG-ETTTTEYSNARYVSQQTRANPNPYTSRR-SVASIVGTLVRMAPVIGACM 236 
              ..: :: :..  :     :*****  .* .**.   .    ..*:   :  :. :*.**: 
 
OZITX_S1      ALKGVRRD---------GLNKRATYYEPEFYDARGVLKEIIK 241 
PTX_S1        ARQAESSEAMAAWSERAGEAMVLVYYESIAYSF--------- 269 
              * :.   :         *     .***   *.           
Figure S6.1: Structural comparison of OZITX-S1 and PTX-S1. (A) Amino acid sequence 
alignment of OZITX-S1 and PTX-S1 active subunits. Sequences were aligned with Clustal Omega 
version 1.2.4. ‘*’ represents a completely conserved residue. ‘:’ represents a conserved residue (>0.5 
in the Gonnet PAM 250 matrix). ‘.’ represents a weakly conserved residue (≤0.5 and >0 in the Gonnet 
PAM 250 matrix). (B) Structural superimposition of OZITX-S1 and PTX-S1 active subunits. OZITX-
S1 is depicted in blue cartoon (PDB code: 4Z9C). PTX-S1 is depicted in red cartoon (PDB code: 
1PRT). The toxins are presented in the oxidised state; the state whereby the A subunit is bound to 
the B subunits. The B subunits have been removed for clarity.  
 






Figure S6.2: Gαs, Gαq and Gα12 subfamily activation upon transfection of OZITX active 
subunit. (A) β2AR activation of GαsS, GαsL and Gαolf, n=4-7. (B) M1R activation of Gαq, Gα11, Gα14 
and Gα15, n=6. (C) ETAR activation of Gα12 and Gα13, n=7. HEK 293T cells were transfected with 
cDNA encoding the particular GPCR, the Gα, the G protein activation sensors and either pcDNA3.1+ 
control (black), OZITX-S1 cDNA (blue) or PTX-S1 cDNA (red) as described in the methods. 48 hours 
after transfection the BRET assay was performed, stimulation of the cells was carried out by adding 
the agonists isoproterenol (β2AR) / acetylcholine (M1R) / endothelin 1 (ETAR) for 5 minutes followed 
by BRET detection. The data is represented as the mean ± SEM drug induced increase in BRET 










Figure S6.3: OZITX Resistant mutants of Gαi1, Gαi2 and GαoB can be engineered. (A) Activation 
of Gαi1-WT, Gαi1-N347A and Gαi1-C351I, n=4-8. (B) Activation of Gαi2-WT, Gαi2-N348A and Gαi2-
C352I, n=4-7. (C) Activation of GαoB-WT, GαoB-N347A and GαoB-C352I, n=4-6. G protein activation 
was performed in the presence of either transfected pcDNA3.1+ control (black), OZITX-S1 cDNA 
(blue) and PTX-S1 cDNA (red). HEK 293 cells were transfected with the Gα mutant subunit of 
interest, G protein activation sensors, the D2R and either a pcDNA3.1+ control, OZITX-S1 cDNA or 
PTX-S1 cDNA. Cells were then stimulated with quinpirole and the drug induced increase in BRET 
ratio baseline subtracted from the vehicle wells is represented. Data is shown as the mean ± SEM. 
* represents the response is significantly different from the respective pcDNA (non-toxin transfected) 











 More clinically approved small molecules target GPCRs than any other protein family 
(2,432). Before the approval of a GPCR drug, lead molecules are selected for in a drug discovery 
process that is typically based on equilibrium estimates of affinity and potency.  However, a drug’s 
concentration in the body is usually in a constant state of change due to multiple physiological 
processes such as drug distribution, dosing regime, tissue absorption, hepatic metabolism and 
excretion (53,54). Therefore, this drug discovery process may be an inefficient means because a 
drug’s binding kinetic rates for the GPCR can often better predict its efficacy in vivo (52,55,56,60). 
The D2R is one such GPCR where ligand binding kinetics has been related to clinical 
outcomes. The D2R is a target to treat many neuropsychiatric and neurological disorders (103,433). 
D2R antagonist kinetics are thought to be important for determining the side effect profile of 
antipsychotic drugs (61,187,218). In the case of D2R agonists, differing binding kinetics has been 
linked to distinct functional effects including some observations of apparent biased agonism (96,189). 
However, the precise mechanisms as to how these findings arise are largely unclear.  
Given that G protein signalling, regulation by GRKs, desensitisation and trafficking of the 
D2R all occur over different timescales (96,102,153,261,434), the lifetime of the agonist-receptor 
complex could differently influence the ability of effectors to bind and function in these processes. 
Therefore, the primary hypothesis of this thesis was to determine whether differences in the residence 
time (or dissociation rate) of D2R agonists can function as a mechanism to manifest biased agonism. 
Before examining this however, we first wanted to determine whether ligands could have their 
binding kinetics rationally modulated. We aimed to do this by determining different ligand’s amino 
acid interactions along their binding pathway into the pocket of the D2R. After having investigated 
these first two aims, we appreciated that to wholly understand the mechanisms of biased agonism, 
one must first understand the drivers of the signalling systems. We consequently developed secondary 
questions in this area. We aimed to ascertain the role GRK regulation plays in determining bias, and 
also, the influence G protein signalling kinetics has on shaping agonist action.  
We made many key findings addressing the aims outlined in the above paragraph. Firstly, we 
observed that amino acid residue mutants in the extracellular regions of the D2R can alter ligand 
binding kinetic rates in a ligand-specific manner. This was encouraging as it suggests that in the future 
ligands can have their structure logically modified to tune their binding kinetics. When next assessing 
the primary aim of this thesis however, we observed no clear relationship between the agonist 
dissociation rate (or residence time) and biased agonism. The results were somewhat hampered by 
the small amount of statistically significant biased agonism that we observed. Nonetheless, we 
revealed that regulation by GRK2/3 phosphorylation is directly proportional to agonist efficacy in 
any D2R response. Suggesting that GRK biased “switching” between G protein responses and arrestin 





scaffolding may be unlikely at the D2R. We then showed that the G protein Gαz can produce a distinct 
signalling wave by the D2R that is largely independent of the properties of the agonist but instead 
dependent on the hydrolysis rate of Gαz. We therefore had thoroughly examined D2R biased agonism 
in vitro. We next wanted to take steps to examine D2R bias in a more relevant context. One of the key 
challenges to further investigate D2R biased agonism phenomena in relevant cells or tissues is how 
to isolate and measure G protein versus arrestin signalling or indeed signalling from specific G protein 
subunits given the promiscuity of the D2R to activate all inhibitory G proteins. Therefore, we 
developed the pertussis toxin-like protein OZITX to inhibit all of the D2R mediated Gαi/o subfamily 
signalling, including Gαz. 
Showing that each ligand’s binding kinetics can be differently influenced by particular amino 
acid residues in the extracellular vestibule may be an important step for D2R drug discovery. For 
example, in Chapter 2 we were able to show that Trp100ECL1 and Leu942.64 had dramatic effects on 
the dissociation rate of most tested ligands although, risperidone appeared to be less influenced than 
others. The extracellular vestibule is generally less conserved between GPCRs and as such can offer 
receptor subtype selectivity (65). Consequently, we may be able to rationally design D2R drugs 
through medicinal chemistry such that they can make the sought-after interactions with extracellular 
vestibule residues. These interactions would tune the binding kinetics of the ligand while the ligand 
remains selective for the D2R receptor subtype. If the ability of a D2R agonist to activate particular 
signalling pathways is indeed related to its residence time, then one might be able to rationally 
modulate the agonist kinetics as a mechanism to design biased D2R drugs. However, our functional 
data in Chapter 3 and 4 do not support that such pathway bias can be achieved in this way. 
Nonetheless, there is a strong link between antagonist dissociation rate and the propensity to cause 
extrapyramidal side effects (61,187,218). Indeed, the “gold standard” treatment for schizophrenia 
remains as the second generation antagonist clozapine and not the third generation partial agonist 
antipsychotics (175,435). Therefore, developing antagonists with an even better binding kinetics 
profile than clozapine may be possible in the future.  
It would be exciting to extend these studies in Chapter 2 by performing assessments on a 
larger set of ligands as well as a larger number of D2R mutants to get coverage of the complete ligand 
binding site and pathway. Before doing this however, it would be necessary to develop the assay to a 
point where large-scale high throughput determinations of ligand binding kinetics can be conducted. 
Sykes and colleagues have shown that the injection time of the receptors with the cocktail of tracer 
and unlabelled competitor is very important for accurately determining binding kinetics rates with 
this assay (245). Additionally, the instrument detection cycle time that determines the temporal 
resolution is also crucial for determining fast dissociating ligands (245). Currently, each mutant and 





ligand combination require careful optimisation in order to be able to acquire meaningful rate 
constants. Having done this, it could then be coupled with molecular dynamics simulations to wholly 
understand the binding entry and exit pathways of D2R ligands.  
In Chapter 3, we observed no clear relationship between the agonist’s binding kinetics and 
their biased agonism (of the panel of agonists that were tested). This was the primary result of the 
thesis that we set out to determine. This was achieved by assessing correlations between the binding 
kinetics and the relative transduction coefficients (ΔLog τ/KA) from an operational model of agonism 
(86,87). While some correlations were observed between affinity estimates and biased agonism, the 
results were largely uncertain in regard to the mechanism behind this. However, we can make some 
definitive conclusions from our findings. Paton’s rate theory argues for a positive relationship 
between the association rate and the efficacy of an agonist (90). We saw no relationship between any 
binding kinetic parameters and efficacy. This means that we can rule out rate theory or the opposite 
of rate theory (anti-rate theory - efficacy mediated by dissociation rate). Some recent reports suggest 
that anti-rate theory may explain efficacy at the M3R and A2AR as shown by a correlation between 
agonist dissociation rate and efficacy (91,93). However, based on our results at the D2R we suspect 
that this is a not a common property shared between all GPCRs. Furthermore, in the examples of the 
the M3R and A2AR, human selection in the drug discovery process may have selected for high 
affinity/potency and consequently, slower dissociating agonists, as well as selected for increased 
efficacy. Therefore, the results showing anti-rate theory at these receptors could potentially be due to 
this selective pressure.  
This also highlights a potential limitation in our study related to human selection. Klein-
Herenbrink et al (96) showed that apparent biased agonism occurs between slowly dissociating 
agonists and fast dissociating agonists at the D2R. Yet, all the slowly dissociating agonists in their 
study were low efficacy partial agonists (96). Therefore, in our study we deliberately incorporated 
both low efficacy (third generation antipsychotics) and high efficacy drugs. This reduced a 
confounder in our study and provided a wider range of efficacy to draw correlations. However, by 
potentially selecting compounds based on their efficacy we may have artificially influenced our 
correlations. Future work could seek to investigate this further by performing correlations where less 
human intervention is involved. We tested eleven separate compounds when the D2R has a whole 
library of agonists available to assess because it is such a popular drug target. Therefore, selecting a 
larger and a random sample of ligands with D2R activity may be a better approach. Similarly, future 
work could not only perform similar experiments on larger numbers of ligands but could also do this 
in a completely “receptor naïve” manner. This means, performing a large screen of a number of 
ligands with unknown efficacy at the D2R. If millions of compounds could be screened and a panel 





have agonism at the D2R, then determining their transduction coefficient and determining their 
binding kinetics with identical methods to the ones we describe here could test this. This would mean 
that a random sample of agonists is selected with varying structure and efficacy. 
In Chapters 3 and 4 only very minimal biased agonism is observed. Almost no biased agonism 
is observed between G protein subunits in Chapter 3 and no statistically significant biased agonism 
is reported for the putative biased agonists MLS1547 and UNC9994 in Chapter 4 (184,251). When 
looking back through the examples of bias at the D2R our data here appears to follow a similar pattern 
that has occurred over the years: In 2002, dihydrexidine was the first reported biased agonist at the 
D2R (436,437). However, this ligand is generally no longer under investigation as a biased agonist, 
and, in fact, it was recently reported as a D1R biased agonist (285). Further, S-3PPP was reported 
soon after as another biased agonist at the D2R. This compound was reported as a “protean agonist” 
through GTPγS binding with different G proteins showing that it lacked the ability to activate some 
poorly coupled Gαi/o subunits (138,139). Subsequent BRET-based G protein activation assays that 
exhibit increased sensitivity have demonstrated that S-3PPP is capable of activating G proteins and 
is better defined as a partial agonist (96). Next, aripiprazole was identified as a biased agonist referred 
as “functionally selective” before biased agonism was the commonly recognised term (438,439) . 
Aripiprazole displayed bias for arachidonic acid release compared to MAPK activity (438).  Again 
aripiprazole was proven to act more so as a partial agonist than a biased agonist with more sensitive 
assays and also applying a model of agonist action to account for system bias (440). Moreover, 
UNC9975 and UNC9994 were identified as arrestin biased agonists and MLS1547 was said to be G 
protein biased (184,251). We here observe no statistically significant bias for these compounds. 
Interestingly, from literature it would appear that the order with which the putative biased agonists 
are reported aligns with their efficacy (dihydrexidine > S-3PPP > aripiprazole > UNC9994). This 
likely indicates that as more sensitive assay techniques were developed, weaker responses could be 
detected and agonists that originally displayed no activity in a particular pathway appear to act as 
partial agonists. Whether this pattern continues in the future will be fascinating to see. 
If one can expect that a biased D2R agonist found today will likely be re-characterised as a 
partial agonist in the future due to more sensitive laboratory techniques and more modern analytical 
approaches, then where does this leave D2R drug discovery? And what role does this have in the 
future for the pharmacological management of psychiatric and neurological diseases? For D2R drug 
discovery, it leaves two obvious options moving forwards; firstly, to go back to more traditional 
methods of small molecule drug discovery or, secondly, to harness system bias (system bias will be 
discussed in later paragraphs). In terms of going back to more traditional methods of pharmacology, 
this means focussing on classic parameters such as efficacy, binding kinetics rates and selectivity. 





Therefore, for targeting the D2R in schizophrenia, the best approach will be to design drugs that are 
antagonists with a fast dissociation rate from the D2R and the appropriate receptor selectivity profile. 
Overall current guidelines should advocate for the use of clozapine as opposed to the approval and 
use of any existing reported biased agonist in the treatment of schizophrenia symptoms. For targeting 
the D2R in diseases where agonism is wanted, then the ideal amount of efficacy should be determined 
based on the particular indication. Regarding Parkinson’s disease, the results in this thesis show that 
dopamine is the most efficacious agonist when measuring regulatory responses. Given that L-DOPA 
is considered the most efficacious treatment clinically, this likely suggests that higher agonist efficacy 
in vitro corresponds to higher efficacy in vivo. Therefore, agonists could be developed that are higher 
efficacy than dopamine as an attempt to create even more efficacious drugs for the treatment of 
Parkinson’s disease. In terms of current treatment for Parkinson’s, the results in this thesis would 
suggest that L-DOPA should remain first line treatment, rotigotine also appears to offer superior 
agonist efficacy to other agonists and as such may be a good alternative to L-DOPA. 
This pattern also appears to match biased agonism studies for at least some other GPCRs. 
Indeed, a similar pattern to the one we observe at the D2R also seems to emerge when examining the 
history of biased agonism at the MOPR (441). The first reports of biased agonists later turned out to 
be partial agonists when further scrutinised (441). In addition,  subsequent purported biased agonists 
such as PZM21, actually have never been shown to display any statistically significant biased 
agonism when using the Black/Leff operational model to quantify the bias (80,82). Moreover, the 
angiotensin II type-I receptor (AT1R) may follow a similar narrative. The first reported biased agonist 
at the AT1R; [Sar1, Ile4, Ile8] Angiotensin II  or SII - was reported to be arrestin biased and lack any 
ability to stimulate the G protein dependent responses IP accumulation and [35S]GTPγS binding 
(442). Later, SII has proven to be a partial agonist at G protein mediated pathways and direct G protein 
activation (281,443). The discrepancies in these results may reflect the increased sensitivity of the 
BRET assays used in later studies investigating SII. Further, it would be fascinating to observe 
whether this pattern occurs for reported biased agonists at other GPCRs as their signalling pathways 
and pharmacology become better characterised. If this pattern continues to emerge then it will be 
clear that the field needs to revise early stage GPCR drug discovery pipelines to workflows that focus 
less heavily on biased agonism. 
In Chapters 3 and 4 we observe apparent bias between some agonists. Ligand bias, system 
bias and observational bias are the three main drivers of bias observations. It is commonplace to 
assume that these can be separated by using methods that the field has developed such as reference 
agonists and reference pathways. However, this may be more challenging that initially thought. 
Certainly, in our studies in this thesis it is often not clear which type of bias we are observing and 





whether it could be a combination of the three types. We therefore propose that the three bias 
mediators may overlap or be dependent on each other (Fig. 7.1). 
 
Figure 1. Biased agonism components may not be separated. 
 
In our studies in Chapter 3 and 4 the statistically significant bias was generally detected 
between similar pathways and in the same direction. That is, we observed bias between a well coupled 
G protein pathways and a poorly coupled regulatory pathway and the biased agonism was usually 
directed towards the regulatory pathway. Therefore, this apparent bias is either due to all ligands 
acting in a similar manner or potentially the system is hard-wired to disproportionately amplify one 
pathway more than another. If this is system bias, then it is interesting as it may still be able to be 
harnessed. For example, Marcott and colleagues (144) have proposed that the D2R couples to Gαo in 
the nucleus accumbens and Gαi in the dorsal striatum. The D2R more efficiently couples to Gαo than 
Gαi such that all agonists are effectively full agonists at Gαo whereas partial agonism can be observed 
at Gαi (shown in Chapters 3, 4 and 5) (139,267). Therefore, by using either a full agonist or a partial 
agonist, the dorsal striatum will be activated to a different extent but the nucleus accumbens will have 
similar activity depending on the agonist. 
Another example where system bias could be employed without the need for ligand bias is at 
the D1R. A report by Yano et al (285) reveals agonists acting at the D1R that display bias at Gαs 
relative to Gαolf. The D1R has broad expression in the brain, the authors highlight Gαolf has the widest 
expression in the striatum whereas Gαs is expressed in the cortex and other brain regions (444). 
Therefore, the biased agonists are able to achieve brain region selectivity. However, system bias could 
have already been harnessed to achieve at least some tissue selectivity. It is shown that the D1R 
preferentially couples to Gαs relative to Gαolf (285). Agonists with lower efficacy display more robust 
responses and increased potencies at Gαs. Therefore, if it is desired to selectively target D1R signalling 
in the striatum then it can be achieved with a partial agonist, whereas if wanting to target both brain 
regions, a full agonist could be used. 





We observed in both Chapter 3 and Chapter 4 that ergot agonists at the D2R displayed bias. 
This was unexpected particularly considering we carried along previously reported biased agonists in 
Chapter 4, with their bias being overshadowed. While the ergot agonists share common structural 
similarities, it is not entirely clear how this bias emerged. It requires further investigation into how 
this may manifest. 
In Chapter 5 we were able to convincingly show that an increase in potency at Gαz is due to 
its slow GTP hydrolysis rate which leads to an accumulation of the active Gαz-GTP species over time. 
Based on this work, we propose that the D2R temporal responses may be regulated depending on Gαi/o 
protein expression patterns (Fig. 7.2). At a neuronal synapse, dopamine is released and then rapidly 
taken up by dopamine transporters and broken down by MOA-B. Dopamine has a rapid dissociation 
rate from the D2R (96). Therefore, as dopamine is taken up, the dopamine will leave the receptor and 
the receptor will be rapidly deactivated. If a Gαi or Gαo subtype is expressed, then the G protein signal 
will be rapidly switched off as the G protein hydrolyses the bound GTP. Yet, if Gαz is expressed the 
it will continue to be active for several minutes (Fig. 7.2). Moreover, if there is sustained dopamine 
release or activation by exogenous agonists such as those in the treatment of Parkinson’s disease, then 
arrestins may couple to sterically occlude G protein coupling and turn off the signal. Similarly, Gαz 
will have already coupled and, based on our data in Chapter 5, it will again remain active in live cells 
for several minutes. We believe this model is highly plausible based on work in knockout mice 
demonstrating many D2R dependent behaviours are altered and additionally that the D2R has been 
suggested to couple to the Gαz in rat pituitary tissues (148,150,151). However, the model needs to be 
considered in light of RGS proteins that regulate G proteins responses such as RGS9-2, known to 
regulate the D2R in some instances (152). Furthermore, if this model does hold true this could also 
be a situation where natural system bias is harnessed. 






Figure 7.2: Identification of a novel D2R G protein signalling wave and a new toxin for its 
inhibition. Dopamine is released from a neuron and can bind postsynaptic D2Rs. This leads to a 
rapid yet short period of activation of the D2R as dopamine dissociates and is then taken up by 
dopamine transporters and/or broken down by MOA-B. The D2R can produce a short and sharp 
signalling wave upon coupling to Gαi or Gαo subunits as their GTP hydrolysis rates are fast and thus 
will be deactivated shortly after the receptor deactivates. In contrast, Gαz coupling will produce a 
sustained signalling wave due to its slow GTP hydrolysis rate even though dopamine has dissociated 
from the D2R and the D2R is no longer active. This slow and sustained Gαz signalling wave may 
produce distinct physiological effects. Moreover, PTX is able to act on Gαi/o proteins to inhibit the 
rapid signalling wave produced by these proteins whereas the newly characterised OZITX can block 
these proteins in addition to the Gαz signalling, providing a new tool to study this largely unexplored 
signalling. 
 
Finally, in Chapter 6 we were able to demonstrate that a new AB5 toxin – OZITX , could 
completely abolish Gαz activation and Gαz dependent cAMP inhibition. Thus, this is the first pan 
Gαi/o inhibitor that importantly acts on Gαz (Fig. 7.2). OZITX can be used by the scientific community 
in many ways. Of relevance to the work in Chapter 5, OZITX could be used in combination with PTX 
to disentangle D2R signalling through Gαz from D2R signalling through other Gαi/o subunits. 
Additionally, OZTX can be used as a replacement for PTX when it is used to block Gαi/o signalling 
to assess arrestin dependent signalling. PTX is commonly used in this manner even though it lacks 
the ability to block Gαz (426). Any study that has not recognised that Gαz signalling is a potential 
contaminant should be re-assessed in this context.  Furthermore, the Chapter also presents the idea 
that AB5 toxins are underutilised tools. Some of the first work describing G protein signalling relied 





heavily on the use of AB5 toxins such as PTX and CTX (349). These tools are underappreciated 
because they completely abolish coupling due to the covalent modifications that they make on the G 
protein. Other peptide and small molecule inhibitors for Gαq/11 and Gαs/olf are available, however, 
their inhibition is dependent on the concentration of the inhibitor that can be achieved within the cell 
(445,446). 
The use of BRET as a detection technique in Chapters 2, 3, 4 and 5 provides several 
advantages. These include high sensitivity, moderate throughput, ability to measure temporally, 
perform experiments at physiological temperatures and measure in live cells. Yet, BRET sensors 
generally require over-expression of the sensors. This may alter the stoichiometry of the interactions 
between effectors in some cases. This is as a potential limitation when examining biased agonism. 
However, this is likely not a major issue within the thesis because any over expression of the effectors 
should bias the signalling allosterically towards that pathway such that when assessing biased 
agonism the bias may be larger than in native cells. Very little biased agonism was observed in this 
research and therefore this effect is likely not a contributor. 
In conclusion, the studies presented here provide a detailed kinetic insight into D2R ligand 
binding, activation and regulation. Further, we propose a novel D2R Gαz signalling wave and we 
provide the first tool to entirely abolish Gαz activation – a pan Gαi/o acting toxin. Overall, the findings 
















1. Rosenbaum, D. M., Rasmussen, S. G. F., and Kobilka, B. K. (2009) The structure and 
function of G-protein-coupled receptors. Nature 459, 356-363 
2. Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., and Gloriam, D. E. 
(2017) Trends in GPCR drug discovery: new agents, targets and indications. Nature 
reviews Drug discovery 16, 829 
3. Fredriksson, R., Lagerström, M. C., Lundin, L.-G., and Schiöth, H. B. (2003) The G-protein-
coupled receptors in the human genome form five main families. Phylogenetic analysis, 
paralogon groups, and fingerprints. Molecular pharmacology 63, 1256-1272 
4. Schiöth, H. B., and Fredriksson, R. (2005) The GRAFS classification system of G-protein 
coupled receptors in comparative perspective. General and comparative endocrinology 
142, 94-101 
5. Lagerstrom, M. C., and Schioth, H. B. (2008) Structural diversity of G protein-coupled 
receptors and significance for drug discovery. Nat Rev Drug Discov 7, 339-357 
6. Kniazeff, J., Prézeau, L., Rondard, P., Pin, J.-P., and Goudet, C. (2011) Dimers and 
beyond: The functional puzzles of class C GPCRs. Pharmacology & therapeutics 130, 9-25 
7. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) 
Requirement of rigid-body motion of transmembrane helices for light activation of 
rhodopsin. Science (New York, N.Y.) 274, 768-770 
8. Sullivan, K. A., Miller, R. T., Masters, S. B., Beiderman, B., Heideman, W., and Bourne, H. 
R. (1987) Identification of receptor contact site involved in receptor–G protein coupling. 
Nature 330, 758 
9. Hamm, H. E., Deretic, D., Arendt, A., Hargrave, P. A., Koenig, B., and Hofmann, K. P. 
(1988) Site of G protein binding to rhodopsin mapped with synthetic peptides from the 
alpha subunit. Science (New York, N.Y.) 241, 832-835 
10. Digby, G. J., Lober, R. M., Sethi, P. R., and Lambert, N. A. (2006) Some G protein 
heterotrimers physically dissociate in living cells. Proceedings of the National Academy of 
Sciences 103, 17789-17794 
11. Bünemann, M., Frank, M., and Lohse, M. J. (2003) Gi protein activation in intact cells 
involves subunit rearrangement rather than dissociation. Proceedings of the National 
Academy of Sciences 100, 16077-16082 
12. Luttrell, L. M. (2008) Reviews in Molecular Biology and Biotechnology: Transmembrane 
Signaling by G Protein-Coupled Receptors. Molecular Biotechnology 39, 239-264 
13. Dohlman, H. G., and Thorner, J. (1997) RGS proteins and signaling by heterotrimeric G 
proteins. Journal of Biological Chemistry 272, 3871-3874 
14. Khan, S. M., Sleno, R., Gora, S., Zylbergold, P., Laverdure, J. P., Labbe, J. C., Miller, G. J., 
and Hebert, T. E. (2013) The expanding roles of Gbetagamma subunits in G protein-
coupled receptor signaling and drug action. Pharmacological reviews 65, 545-577 
15. R K Sunahara, C W Dessauer, a., and Gilman, A. G. (1996) Complexity and Diversity of 
Mammalian Adenylyl Cyclases. Annual Review of Pharmacology and Toxicology 36, 461-
480 
16. Exton, J. H. (1996) Regulation of Phosphoinositide Phospholipases by Hormones, 
Neurotransmitters, and Other Agonists Linked to G Proteins. Annual Review of 
Pharmacology and Toxicology 36, 481-509 
17. Worzfeld, T., Wettschureck, N., and Offermanns, S. (2008) G12/G13-mediated signalling in 
mammalian physiology and disease. Trends in pharmacological sciences 29, 582-589 
18. Milligan, G., and Kostenis, E. (2006) Heterotrimeric G‐proteins: a short history. British 
journal of pharmacology 147, S46-S55 
19. Casey, P. J., Fong, H. K., Simon, M. I., and Gilman, A. G. (1990) Gz, a guanine nucleotide-
binding protein with unique biochemical properties. Journal of Biological Chemistry 265, 
2383-2390 
20. Gurevich, E. V., Tesmer, J. J. G., Mushegian, A., and Gurevich, V. V. (2012) G protein-
coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacology & 






21. Gurevich, V. V., and Gurevich, E. V. (2019) The structural basis of the arrestin binding to 
GPCRs. Molecular and cellular endocrinology  
22. Kang, Y., Zhou, X. E., Gao, X., He, Y., Liu, W., Ishchenko, A., Barty, A., White, T. A., 
Yefanov, O., and Han, G. W. (2015) Crystal structure of rhodopsin bound to arrestin by 
femtosecond X-ray laser. Nature 523, 561-567 
23. Staus, D. P., Hu, H., Robertson, M. J., Kleinhenz, A. L., Wingler, L. M., Capel, W. D., 
Latorraca, N. R., Lefkowitz, R. J., and Skiniotis, G. (2020) Structure of the M2 muscarinic 
receptor–β-arrestin complex in a lipid nanodisc. Nature 579, 297-302 
24. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1990) beta-
Arrestin: a protein that regulates beta-adrenergic receptor function. Science (New York, 
N.Y.) 248, 1547-1550 
25. Ferguson, S. S. G., Downey, W. E., III, Colapietro, A.-M., Barak, L. S., and et al. (1996) 
Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor 
internalization. Science (New York, N.Y.) 271, 363 
26. Goodman, O. B., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., 
Keen, J. H., and Benovic, J. L. (1996) [beta]-Arrestin acts as a clathrin adaptor in 
endocytosis of the [beta]2-adrenergic receptor. Nature 383, 447-450 
27. Jean-Alphonse, F., and Hanyaloglu, A. (2011) Regulation of GPCR signal networks via 
membrane trafficking. Molecular and cellular endocrinology 331, 205-214 
28. Cattaneo, F., Parisi, M., Fioretti, T., Esposito, G., and Ammendola, R. (2016) Intranuclear 
Signaling Cascades Triggered by Nuclear GPCRs. J Cell  
29. Irannejad, R., Tomshine, J. C., Tomshine, J. R., Chevalier, M., Mahoney, J. P., Steyaert, J., 
Rasmussen, S. G., Sunahara, R. K., El-Samad, H., and Huang, B. (2013) Conformational 
biosensors reveal GPCR signalling from endosomes. Nature 495, 534-538 
30. Navratil, A. M., Bliss, S. P., Berghorn, K. A., Haughian, J. M., Farmerie, T. A., Graham, J. 
K., Clay, C. M., and Roberson, M. S. (2003) Constitutive localization of the gonadotropin-
releasing hormone (GnRH) receptor to low density membrane microdomains is necessary 
for GnRH signaling to ERK. Journal of Biological Chemistry 278, 31593-31602 
31. Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., and Seuwen, K. (2009) 
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 
receptors. Nature chemical biology 5, 428-434 
32. Ferrandon, S., Feinstein, T. N., Castro, M., Wang, B., Bouley, R., Potts, J. T., Gardella, T. 
J., and Vilardaga, J.-P. (2009) Sustained cyclic AMP production by parathyroid hormone 
receptor endocytosis. Nature chemical biology 5, 734-742 
33. Calebiro, D., Nikolaev, V. O., Gagliani, M. C., De Filippis, T., Dees, C., Tacchetti, C., 
Persani, L., and Lohse, M. J. (2009) Persistent cAMP-signals triggered by internalized G-
protein–coupled receptors. PLoS Biol 7, e1000172 
34. Stoeber, M., Jullié, D., Lobingier, B. T., Laeremans, T., Steyaert, J., Schiller, P. W., 
Manglik, A., and von Zastrow, M. (2018) A genetically encoded biosensor reveals location 
bias of opioid drug action. Neuron 98, 963-976. e965 
35. Wehbi, V. L., Stevenson, H. P., Feinstein, T. N., Calero, G., Romero, G., and Vilardaga, J.-
P. (2013) Noncanonical GPCR signaling arising from a PTH receptor–arrestin–Gβγ 
complex. Proceedings of the National Academy of Sciences 110, 1530-1535 
36. Gutkind, J. S., and Kostenis, E. (2018) Arrestins as rheostats of GPCR signalling. Nature 
Reviews Molecular Cell Biology 19, 615-616 
37. Miller, W. E., and Lefkowitz, R. J. (2001) Expanding roles for β-arrestins as scaffolds and 
adapters in GPCR signaling and trafficking. Current opinion in cell biology 13, 139-145 
38. Xiao, K., McClatchy, D. B., Shukla, A. K., Zhao, Y., Chen, M., Shenoy, S. K., Yates, J. R., 
and Lefkowitz, R. J. (2007) Functional specialization of β-arrestin interactions revealed by 
proteomic analysis. Proceedings of the National Academy of Sciences 104, 12011-12016 
39. Evron, T., Daigle, T. L., and Caron, M. G. (2012) GRK2: multiple roles beyond G protein-
coupled receptor desensitization. Trends in pharmacological sciences 33, 154-164 
40. Tolkovsky, A. M., and Levitzki, A. (1978) Coupling of a single adenylate cyclase of two 






41. Halls, M. L. (2012) Constitutive formation of an RXFP1-signalosome: a novel paradigm in 
GPCR function and regulation. British journal of pharmacology 165, 1644-1658 
42. Spooren, A., Rondou, P., Debowska, K., Lintermans, B., Vermeulen, L., Samyn, B., 
Skieterska, K., Debyser, G., Devreese, B., Vanhoenacker, P., Wojda, U., Haegeman, G., 
and Van Craenenbroeck, K. (2010) Resistance of the dopamine D4 receptor to agonist-
induced internalization and degradation. Cellular Signalling 22, 600-609 
43. Guo, W., Shi, L., and Javitch, J. A. (2003) The fourth transmembrane segment forms the 
interface of the dopamine D2 receptor homodimer. Journal of Biological Chemistry 278, 
4385-4388 
44. Lane, J. R., Donthamsetti, P., Shonberg, J., Draper-Joyce, C. J., Dentry, S., Michino, M., 
Shi, L., López, L., Scammells, P. J., and Capuano, B. (2014) A new mechanism of allostery 
in a G protein–coupled receptor dimer. Nature chemical biology 10, 745-752 
45. Ferre, S., Von Euler, G., Johansson, B., Fredholm, B. B., and Fuxe, K. (1991) Stimulation 
of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in 
rat striatal membranes. Proceedings of the National Academy of Sciences 88, 7238-7241 
46. Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., De Benedetti, P., Goldberg, S. R., Neve, 
K., Fuxe, K., Agnati, L. F., and Woods, A. S. (2003) Adenosine A2A-dopamine D2 receptor-
receptor heteromerization qualitative and quantitative assessment by fluorescence and 
bioluminescence energy transfer. Journal of Biological Chemistry 278, 46741-46749 
47. Trifilieff, P., Rives, M.-L., Urizar, E., Piskorowski, R. A., Vishwasrao, H. D., Castrillon, J., 
Schmauss, C., Slättman, M., Gullberg, M., and Javitch, J. A. (2011) Detection of antigen 
interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A 
receptor complexes in the striatum. Biotechniques 51, 111-118 
48. Fenu, S., Pinna, A., Ongini, E., and Morelli, M. (1997) Adenosine A2A receptor antagonism 
potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-
hydroxydopamine-lesioned rats. European journal of pharmacology 321, 143-147 
49. Koschatzky, S., Tschammer, N., and Gmeiner, P. (2011) Cross-receptor interactions 
between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of 
dopaminergics. ACS chemical neuroscience 2, 308-316 
50. Borroto-Escuela, D. O., Ravani, A., Tarakanov, A. O., Brito, I., Narvaez, M., Romero-
Fernandez, W., Corrales, F., Agnati, L. F., Tanganelli, S., Ferraro, L., and Fuxe, K. (2013) 
Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor 
heteromers. Biochemical and Biophysical Research Communications 435, 140-146 
51. Dziedzicka-Wasylewska, M., Faron-Górecka, A., Andrecka, J., Polit, A., Kusmider, M., and 
Wasylewski, Z. (2006) Fluorescence studies reveal heterodimerization of dopamine D1 and 
D2 receptors in the plasma membrane. Biochemistry 45, 8751-8759 
52. Guo, D., Hillger, J. M., IJzerman, A. P., and Heitman, L. H. (2014) Drug‐Target Residence 
Time—A Case for G Protein‐Coupled Receptors. Medicinal research reviews 34, 856-892 
53. Vauquelin, G. (2016) Effects of target binding kinetics on in vivo drug efficacy: koff, kon and 
rebinding. British journal of pharmacology 173, 2319-2334 
54. Vauquelin, G., and Charlton, S. J. (2010) Long-lasting target binding and rebinding as 
mechanisms to prolong in vivo drug action. British journal of pharmacology 161, 488-508 
55. de Witte, W. E., Danhof, M., van der Graaf, P. H., and de Lange, E. C. (2016) In vivo target 
residence time and kinetic selectivity: the association rate constant as determinant. Trends 
in pharmacological sciences 37, 831-842 
56. Copeland, R. A. (2016) The drug–target residence time model: a 10-year retrospective. 
Nature Reviews Drug Discovery 15, 87 
57. Sykes, D. A., Stoddart, L. A., Kilpatrick, L. E., and Hill, S. J. (2019) Binding kinetics of 
ligands acting at GPCRs. Molecular and cellular endocrinology  
58. Tautermann, C. S. (2016) Impact, determination and prediction of drug–receptor residence 
times for GPCRs. Current Opinion in Pharmacology 30, 22-26 
59. Abrahamsson, T., Karp, L., Brandt-Eliasson, U., Morsing, P., Renberg, L., and 
SJOeQUIST, P.-O. (2000) Candesartan Causes Long-lasting Antagonism of the 






Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174). Blood 
pressure 9, 52-52 
60. Hothersall, J. D., Brown, A. J., Dale, I., and Rawlins, P. (2016) Can residence time offer a 
useful strategy to target agonist drugs for sustained GPCR responses? Drug discovery 
today 21, 90-96 
61. Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., and Charlton, S. 
J. (2017) Extrapyramidal side effects of antipsychotics are linked to their association 
kinetics at dopamine D2 receptors. Nature Communications 8, 763 
62. Miller, D. C., Lunn, G., Jones, P., Sabnis, Y., Davies, N. L., and Driscoll, P. (2012) 
Investigation of the effect of molecular properties on the binding kinetics of a ligand to its 
biological target. Medchemcomm 3, 449-452 
63. Guo, D., Xia, L., van Veldhoven, J. P., Hazeu, M., Mocking, T., Brussee, J., IJzerman, A. 
P., and Heitman, L. H. (2014) Binding kinetics of ZM241385 derivatives at the human 
adenosine A2A receptor. ChemMedChem 9, 752-761 
64. Alonso, J. A., Andrés, M., Bravo, M., Buil, M. A., Calbet, M., Castro, J., Eastwood, P. R., 
Esteve, C., Ferrer, M., and Forns, P. (2014) Structure–activity relationships (SAR) and 
structure–kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent 
CRTh2 antagonists III: The role of a hydrogen-bond acceptor in long receptor residence 
times. Bioorganic & medicinal chemistry letters 24, 5127-5133 
65. Dror, R. O., Pan, A. C., Arlow, D. H., Borhani, D. W., Maragakis, P., Shan, Y., Xu, H., and 
Shaw, D. E. (2011) Pathway and mechanism of drug binding to G-protein-coupled 
receptors. Proceedings of the National Academy of Sciences 108, 13118-13123 
66. Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. 
I., Okada, T., Kobilka, B. K., and Haga, T. (2012) Structure of the human M2 muscarinic 
acetylcholine receptor bound to an antagonist. Nature 482, 547-551 
67. Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. 
F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., and Kobilka, B. K. 
(2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 
552-556 
68. Disse, B., Reichl, R., Speck, G., Traunecker, W., Rominger, K. L., and Hammer, R. (1993) 
Ba 679 BR, A novel long-acting anticholinergic bronchodilator. Life Sciences 52, 537-544 
69. Tautermann, C. S., Kiechle, T., Seeliger, D., Diehl, S., Wex, E., Banholzer, R., Gantner, F., 
Pieper, M. P., and Casarosa, P. (2013) Molecular Basis for the Long Duration of Action and 
Kinetic Selectivity of Tiotropium for the Muscarinic M3 Receptor. Journal of medicinal 
chemistry 56, 8746-8756 
70. Violin, J. D., and Lefkowitz, R. J. (2007) β-Arrestin-biased ligands at seven-transmembrane 
receptors. Trends in pharmacological sciences 28, 416-422 
71. Palanche, T., Ilien, B., Zoffmann, S., Reck, M.-P., Bucher, B., Edelstein, S. J., and Galzi, J.-
L. (2001) The neurokinin A receptor activates calcium and cAMP responses through distinct 
conformational states. Journal of Biological Chemistry 276, 34853-34861 
72. Swaminath, G., Xiang, Y., Lee, T. W., Steenhuis, J., Parnot, C., and Kobilka, B. K. (2004) 
Sequential Binding of Agonists to the β2 Adrenoceptor KINETIC EVIDENCE FOR 
INTERMEDIATE CONFORMATIONAL STATES. Journal of Biological Chemistry 279, 686-
691 
73. Kenakin, T. (2007) Collateral efficacy in drug discovery: taking advantage of the good 
(allosteric) nature of 7TM receptors. Trends in pharmacological sciences 28, 407-415 
74. Okude, J., Ueda, T., Kofuku, Y., Sato, M., Nobuyama, N., Kondo, K., Shiraishi, Y., 
Mizumura, T., Onishi, K., and Natsume, M. (2015) Identification of a Conformational 
Equilibrium That Determines the Efficacy and Functional Selectivity of the μ‐Opioid 
Receptor. Angewandte Chemie 127, 15997-16002 
75. Liu, J. J., Horst, R., Katritch, V., Stevens, R. C., and Wüthrich, K. (2012) Biased Signaling 
Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR. Science (New York, 
N.Y.) 335, 1106-1110 
76. Strachan, R. T., Sun, J.-p., Rominger, D. H., Violin, J. D., Ahn, S., Thomsen, A. R. B., Zhu, 






efficacies generate biased agonism at a G protein-coupled receptor (GPCR). Journal of 
Biological Chemistry 289, 14211-14224 
77. Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X.-P., Vardy, E., McCorvy, J. D., 
Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L., and Stevens, R. 
C. (2013) Structural Features for Functional Selectivity at Serotonin Receptors. Science 
(New York, N.Y.) 340, 615-619 
78. Bohn, L. M., Gainetdinov, R. R., Lin, F.-T., Lefkowitz, R. J., and Caron, M. G. (2000) μ-
Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not 
dependence. Nature 408, 720-723 
79. Viscusi, E. R., Webster, L., Kuss, M., Daniels, S., Bolognese, J. A., Zuckerman, S., 
Soergel, D. G., Subach, R. A., Cook, E., and Skobieranda, F. (2016) A randomized, phase 
2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous 
treatment of acute pain. Pain 157, 264-272 
80. Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. 
C., Bernat, V., and Hübner, H. (2016) Structure-based discovery of opioid analgesics with 
reduced side effects. Nature 537, 185-190 
81. Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., 
Cameron, M. D., Bannister, T. D., and Bohn, L. M. (2017) Bias factor and therapeutic 
window correlate to predict safer opioid analgesics. Cell 171, 1165-1175. e1113 
82. Hill, R., Disney, A., Conibear, A., Sutcliffe, K., Dewey, W., Husbands, S., Bailey, C., Kelly, 
E., and Henderson, G. (2018) The novel μ‐opioid receptor agonist PZM21 depresses 
respiration and induces tolerance to antinociception. British journal of pharmacology 175, 
2653-2661 
83. Kliewer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J., Levitt, E., Williams, J., 
Christie, M., and Schulz, S. (2019) Phosphorylation-deficient G-protein-biased μ-opioid 
receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nature 
communications 10, 1-11 
84. Kliewer, A., Gillis, A., Hill, R., Schmidel, F., Bailey, C., Kelly, E., Henderson, G., Christie, M. 
J., and Schulz, S. (2020) Morphine‐induced respiratory depression is independent of ß‐
arrestin2 signalling. British journal of pharmacology  
85. Michel, M. C., and Charlton, S. J. (2018) Biased agonism in drug discovery—is it too soon 
to choose a path? Molecular pharmacology 93, 259-265 
86. Black, J., and Leff, P. (1983) Operational models of pharmacological agonism. Proceedings 
of the Royal Society of London B: Biological Sciences 220, 141-162 
87. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., and Novick, S. (2012) A 
simple method for quantifying functional selectivity and agonist bias. ACS chemical 
neuroscience 3, 193-203 
88. Birdsong, W. T., Arttamangkul, S., Clark, M. J., Cheng, K., Rice, K. C., Traynor, J. R., and 
Williams, J. T. (2013) Increased agonist affinity at the μ-opioid receptor induced by 
prolonged agonist exposure. The Journal of Neuroscience 33, 4118-4127 
89. DeVree, B. T., Mahoney, J. P., Vélez-Ruiz, G. A., Rasmussen, S. G., Kuszak, A. J., 
Edwald, E., Fung, J.-J., Manglik, A., Masureel, M., and Du, Y. (2016) Allosteric coupling 
from G protein to the agonist-binding pocket in GPCRs. Nature 535, 182-186 
90. Paton, W. D. M. (1961) A theory of drug action based on the rate of drug-receptor 
combination. Proceedings of the Royal Society of London. Series B. Biological Sciences 
154, 21-69 
91. Sykes, D. A., Dowling, M. R., and Charlton, S. J. (2009) Exploring the mechanism of 
agonist efficacy: a relationship between efficacy and agonist dissociation rate at the 
muscarinic M3 receptor. Molecular pharmacology 76, 543-551 
92. Deng, H., Sun, H., and Fang, Y. (2013) Label-free cell phenotypic assessment of the 
biased agonism and efficacy of agonists at the endogenous muscarinic M 3 receptors. J. 
Pharmacol. Toxicol. Methods 68, 323-333 
93. Guo, D., Mulder‐Krieger, T., IJzerman, A. P., and Heitman, L. H. (2012) Functional efficacy 
of adenosine A2A receptor agonists is positively correlated to their receptor residence time. 






94. Hoeren, M., Brawek, B., Mantovani, M., Löffler, M., Steffens, M., van Velthoven, V., and 
Feuerstein, T. J. (2008) Partial agonism at the human α2A-autoreceptor: role of binding 
duration. Naunyn-Schmiedeberg's archives of pharmacology 378, 17 
95. Rosethorne, E. M., Bradley, M. E., Gherbi, K., Sykes, D. A., Sattikar, A., Wright, J. D., 
Renard, E., Trifilieff, A., Fairhurst, R. A., and Charlton, S. J. (2016) Long Receptor 
Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 
Adrenoceptor. Molecular pharmacology 89, 467-475 
96. Klein-Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., 
Scammells, P. J., Capuano, B., Sexton, P. M., and Charlton, S. J. (2016) The role of kinetic 
context in apparent biased agonism at GPCRs. Nature communications 7 
97. Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., Lansu, 
K., Schools, Z. L., Che, T., Nichols, D. E., Shoichet, B. K., Dror, R. O., and Roth, B. L. 
(2017) Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell 168, 377-
389.e312 
98. Kaiser, A., Wanka, L., Ziffert, I., and Beck-Sickinger, A. G. (2020) Biased agonists at the 
human Y 1 receptor lead to prolonged membrane residency and extended receptor G 
protein interaction. Cellular and Molecular Life Sciences, 1-17 
99. D’Souza, U. M. (2010) Gene and Promoter Structures of the Dopamine Receptors. in The 
Dopamine Receptors, Springer. pp 23-46 
100. Dal Toso, R., Sommer, B., Ewert, M., Herb, A., Pritchett, D. B., Bach, A., Shivers, B. D., 
and Seeburg, P. H. (1989) The dopamine D2 receptor: two molecular forms generated by 
alternative splicing. The EMBO journal 8, 4025 
101. Lindgren, N., Usiello, A., Goiny, M., Haycock, J., Erbs, E., Greengard, P., Hökfelt, T., 
Borrelli, E., and Fisone, G. (2003) Distinct roles of dopamine D2L and D2S receptor 
isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. 
Proceedings of the National Academy of Sciences 100, 4305-4309 
102. Namkung, Y., Dipace, C., Javitch, J. A., and Sibley, D. R. (2009) G Protein-coupled 
Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 
Dopamine Receptor. Journal of Biological Chemistry 284, 15038-15051 
103. Beaulieu, J.-M., and Gainetdinov, R. R. (2011) The Physiology, Signaling, and 
Pharmacology of Dopamine Receptors. Pharmacological reviews 63, 182-217 
104. Seeman, P. (2006) Targeting the dopamine D2 receptor in schizophrenia. Expert Opinion 
on Therapeutic Targets 10, 515-531 
105. Uitti, R. J., and Ahlskog, J. E. (1996) Comparative Review of Dopamine Receptor Agonists 
in Parkinson’s Disease. CNS Drugs 5, 369-388 
106. Hening, W. A., Allen, R. P., Earley, C. J., Picchietti, D. L., and Silber, M. H. (2004) An 
update on the dopaminergic treatment of restless legs syndrome and periodic limb 
movement disorder. Sleep 27, 560-583 
107. Tohen, M., and Vieta, E. (2009) Antipsychotic agents in the treatment of bipolar mania. 
Bipolar Disorders 11, 45-54 
108. Mansour, A., Meador-Woodruff, J., Bunzow, J., Civelli, O., Akil, H., and Watson, S. (1990) 
Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat 
brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. Journal of 
neuroscience 10, 2587-2600 
109. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998) Dopamine 
receptors: from structure to function. Physiological reviews 78, 189-225 
110. Jackson, D. M., and Westlind-Danielsson, A. (1994) Dopamine receptors: molecular 
biology, biochemistry and behavioural aspects. Pharmacology & therapeutics 64, 291-370 
111. Jang, J. Y., Jang, M., Kim, S. H., Um, K. B., Kang, Y. K., Kim, H. J., Chung, S., and Park, 
M. K. (2011) Regulation of dopaminergic neuron firing by heterogeneous dopamine 
autoreceptors in the substantia nigra pars compacta. Journal of neurochemistry 116, 966-
974 
112. Rubí, B., Ljubicic, S., Pournourmohammadi, S., Carobbio, S., Armanet, M., Bartley, C., and 
Maechler, P. (2005) Dopamine D2-like receptors are expressed in pancreatic beta cells and 






113. Li, Z. S., Schmauss, C., Cuenca, A., Ratcliffe, E., and Gershon, M. D. (2006) Physiological 
modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: 
analysis of dopamine receptor expression, location, development, and function in wild-type 
and knock-out mice. Journal of Neuroscience 26, 2798-2807 
114. Wang, Q., Ji, T., Zheng, L.-F., Feng, X.-Y., Wang, Z.-Y., Lian, H., Song, J., Li, X.-F., Zhang, 
Y., and Zhu, J.-X. (2012) Cellular localization of dopamine receptors in the gastric mucosa 
of rats. Biochemical and biophysical research communications 417, 197-203 
115. Liu, L., Yuan, G., Cheng, Z., Zhang, G., Liu, X., and Zhang, H. (2013) Identification of the 
mRNA expression status of the dopamine D2 receptor and dopamine transporter in 
peripheral blood lymphocytes of schizophrenia patients. PloS one 8 
116. Castellano, C., Cestari, V., Cabib, S., and Puglisi-Allegra, S. (1991) Post-training dopamine 
receptor agonists and antagonists affect memory storage in mice irrespective of their 
selectivity for D1 or D2 receptors. Behavioral and Neural Biology 56, 283-291 
117. Cunningham, C. L., Howard, M. A., Gill, S. J., Rubinstein, M., Low, M. J., and Grandy, D. K. 
(2000) Ethanol-conditioned place preference is reduced in dopamine D2 receptor-deficient 
mice. Pharmacology Biochemistry and Behavior 67, 693-699 
118. Trifilieff, P., Feng, B., Urizar, E., Winiger, V., Ward, R. D., Taylor, K. M., Martinez, D., 
Moore, H., Balsam, P. D., and Simpson, E. H. (2013) Increasing dopamine D2 receptor 
expression in the adult nucleus accumbens enhances motivation. Molecular psychiatry 18, 
1025-1033 
119. Ben-Jonathan, N., and Hnasko, R. (2001) Dopamine as a prolactin (PRL) inhibitor. 
Endocrine reviews 22, 724-763 
120. Baskerville, T. A., and Douglas, A. J. (2008) Interactions between dopamine and oxytocin in 
the control of sexual behaviour. Progress in brain research 170, 277-290 
121. Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., Newman, 
A. H., Javitch, J. A., and Cherezov, V. (2010) Structure of the human dopamine D3 receptor 
in complex with a D2/D3 selective antagonist. Science (New York, N.Y.) 330, 1091-1095 
122. Wang, S., Wacker, D., Levit, A., Che, T., Betz, R. M., McCorvy, J. D., Venkatakrishnan, A., 
Huang, X.-P., Dror, R. O., and Shoichet, B. K. (2017) D4 dopamine receptor high-resolution 
structures enable the discovery of selective agonists. Science (New York, N.Y.) 358, 381-
386 
123. Wang, S., Che, T., Levit, A., Shoichet, B. K., Wacker, D., and Roth, B. L. (2018) Structure 
of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 
555, 269 
124. Fan, L., Tan, L., Chen, Z., Qi, J., Nie, F., Luo, Z., Cheng, J., and Wang, S. (2020) 
Haloperidol bound D 2 dopamine receptor structure inspired the discovery of subtype 
selective ligands. Nature Communications 11, 1-11 
125. Lane, J. R., Abramyan, A. M., Adhikari, P., Keen, A. C., Lee, K.-H., Sanchez, J., Verma, R. 
K., Lim, H. D., Yano, H., and Javitch, J. A. (2020) Distinct inactive conformations of the 
dopamine D2 and D3 receptors correspond to different extents of inverse agonism. eLife 9, 
e52189 
126. Thomas, T., Fang, Y., Yuriev, E., and Chalmers, D. K. (2016) Ligand binding pathways of 
clozapine and haloperidol in the dopamine D2 and D3 receptors. Journal of chemical 
information and modeling 56, 308-321 
127. Javitch, J. A., Fu, D., Chen, J., and Karlin, A. (1995) Mapping the binding-site crevice of the 
dopamine D2 receptor by the substituted-cysteine accessibility method. Neuron 14, 825-
831 
128. Tresadern, G., Bartolome, J. M., Macdonald, G. J., and Langlois, X. (2011) Molecular 
properties affecting fast dissociation from the D2 receptor. Bioorganic & medicinal 
chemistry 19, 2231-2241 
129. Dyhring, T., Nielsen, E. Ø., Sonesson, C., Pettersson, F., Karlsson, J., Svensson, P., 
Christophersen, P., and Waters, N. (2010) The dopaminergic stabilizers pridopidine 
(ACR16) and (−)-OSU6162 display dopamine D2 receptor antagonism and fast receptor 






130. Fyfe, T. J., Kellam, B., Sykes, D. A., Capuano, B., Scammells, P. J., Lane, J. R., Charlton, 
S. J., and Mistry, S. N. (2019) Structure–Kinetic Profiling of Haloperidol Analogues at the 
Human Dopamine D2 Receptor. Journal of medicinal chemistry 62, 9488-9520 
131. Shi, L., and Javitch, J. A. (2004) The second extracellular loop of the dopamine D2 receptor 
lines the binding-site crevice. Proceedings of the National Academy of Sciences of the 
United States of America 101, 440-445 
132. Masuho, I., Ostrovskaya, O., Kramer, G. M., Jones, C. D., Xie, K., and Martemyanov, K. A. 
(2015) Distinct profiles of functional discrimination among G proteins determine the actions 
of G protein–coupled receptors. Sci. Signal. 8, ra123-ra123 
133. Obadiah, J., Avidor-Reiss, T., Fishburn, C. S., Carmon, S., Bayewitch, M., Vogel, Z., Fuchs, 
S., and Levavi-Sivan, B. (1999) Adenylyl Cyclase Interaction with the D2 Dopamine 
Receptor Family; Differential Coupling to Gi, Gz, and Gs. Cellular and Molecular 
Neurobiology 19, 653-664 
134. Stoof, J., and Kebabian, J. (1981) Opposing roles for D-1 and D-2 dopamine receptors in 
efflux of cyclic AMP from rat neostriatum. Nature 294, 366-368 
135. Cardozo, D. L., and Bean, B. P. (1995) Voltage-dependent calcium channels in rat midbrain 
dopamine neurons: modulation by dopamine and GABAB receptors. Journal of 
neurophysiology 74, 1137-1148 
136. Schinelli, S., Paolillo, M., and Corona, G. L. (1994) Opposing Actions of D1 and D2‐
Dopamine Receptors on Arachidonic Acid Release and Cyclic AMP Production in Striatal 
Neurons. Journal of neurochemistry 62, 944-949 
137. Cordeaux, Y., Nickolls, S. A., Flood, L. A., Graber, S. G., and Strange, P. G. (2001) Agonist 
Regulation of D2 Dopamine Receptor/G Protein Interaction: EVIDENCE FOR AGONIST 
SELECTION OF G PROTEIN SUBTYPE. Journal of Biological Chemistry 276, 28667-
28675 
138. Gazi, L., Nickolls, S. A., and Strange, P. G. (2003) Functional coupling of the human 
dopamine D2 receptor with Gαi1, Gαi2, Gαi3 and Gαo G proteins: evidence for agonist 
regulation of G protein selectivity. British journal of pharmacology 138, 775-786 
139. Lane, J. R., Powney, B., Wise, A., Rees, S., and Milligan, G. (2007) Protean agonism at the 
dopamine D2 receptor:(S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for 
activation of Go1 but an antagonist/inverse agonist for Gi1, Gi2, and Gi3. Molecular 
pharmacology 71, 1349-1359 
140. Jiang, M., Spicher, K., Boulay, G., Wang, Y., and Birnbaumer, L. (2001) Most central 
nervous system D2 dopamine receptors are coupled to their effectors by Go. Proceedings 
of the National Academy of Sciences 98, 3577-3582 
141. Sternweis, P. C., and Robishaw, J. D. (1984) Isolation of two proteins with high affinity for 
guanine nucleotides from membranes of bovine brain. Journal of Biological Chemistry 259, 
13806-13813 
142. Neer, E. J., Lok, J., and Wolf, L. (1984) Purification and properties of the inhibitory guanine 
nucleotide regulatory unit of brain adenylate cyclase. Journal of Biological Chemistry 259, 
14222-14229 
143. Albert, P. R. (2002) G protein preferences for dopamine D2 inhibition of prolactin secretion 
and DNA synthesis in GH4 pituitary cells. Molecular Endocrinology 16, 1903-1911 
144. Marcott, P. F., Gong, S., Donthamsetti, P., Grinnell, S. G., Nelson, M. N., Newman, A. H., 
Birnbaumer, L., Martemyanov, K. A., Javitch, J. A., and Ford, C. P. (2018) Regional 
heterogeneity of D2-receptor signaling in the dorsal striatum and nucleus accumbens. 
Neuron 98, 575-587. e574 
145. Kimple, M. E., Hultman, R. C., and Casey, P. J. (2010) Signaling through Gz. in Handbook 
of Cell Signaling, Elsevier. pp 1649-1653 
146. Farino, Z. J., Morgenstern, T. J., Maffei, A., Quick, M., De Solis, A. J., Wiriyasermkul, P., 
Freyberg, R. J., Aslanoglou, D., Sorisio, D., and Inbar, B. P. (2019) New roles for dopamine 
D 2 and D 3 receptors in pancreatic beta cell insulin secretion. Molecular psychiatry, 1 
147. Kimple, M. E., Nixon, A. B., Kelly, P., Bailey, C. L., Young, K. H., Fields, T. A., and Casey, 







148. Gonzalez-Iglesias, A. E., Murano, T., Li, S., Tomić, M., and Stojilkovic, S. S. (2007) 
Dopamine inhibits basal prolactin release in pituitary lactotrophs through pertussis toxin-
sensitive and-insensitive signaling pathways. Endocrinology 149, 1470-1479 
149. Ralph, R. J., Varty, G. B., Kelly, M. A., Wang, Y.-M., Caron, M. G., Rubinstein, M., Grandy, 
D. K., Low, M. J., and Geyer, M. A. (1999) The dopamine D2, but not D3 or D4, receptor 
subtype is essential for the disruption of prepulse inhibition produced by amphetamine in 
mice. Journal of Neuroscience 19, 4627-4633 
150. van den Buuse, M., Martin, S., Brosda, J., Leck, K.-J., Matthaei, K., and Hendry, I. (2005) 
Enhanced effect of dopaminergic stimulation on prepulse inhibition in mice deficient in the 
alpha subunit of Gz. Psychopharmacology 183, 358-367 
151. Leck, K. J., Blaha, C. D., Matthaei, K. I., Forster, G. L., Holgate, J., and Hendry, I. A. (2006) 
Gz proteins are functionally coupled to dopamine D2-like receptors in vivo. 
Neuropharmacology 51, 597-605 
152. Cabrera-Vera, T. M., Hernandez, S., Earls, L. R., Medkova, M., Sundgren-Andersson, A. 
K., Surmeier, D. J., and Hamm, H. E. (2004) RGS9-2 modulates D2 dopamine receptor-
mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. Proceedings of the 
National Academy of Sciences of the United States of America 101, 16339-16344 
153. Namkung, Y., Dipace, C., Urizar, E., Javitch, J. A., and Sibley, D. R. (2009) G Protein-
coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression 
and Signaling Independently of Receptor Phosphorylation. Journal of Biological Chemistry 
284, 34103-34115 
154. Skinbjerg, M., Ariano, M. A., Thorsell, A., Heilig, M., Halldin, C., Innis, R. B., and Sibley, D. 
R. (2009) Arrestin3 mediates D2 dopamine receptor internalization. Synapse (New York, 
NY) 63, 621 
155. Beaulieu, J.-M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R., and 
Caron, M. G. (2005) An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic 
neurotransmission and behavior. Cell 122, 261-273 
156. Namkung, Y., and Sibley, D. R. (2004) Protein Kinase C Mediates Phosphorylation, 
Desensitization, and Trafficking of the D2 Dopamine Receptor. Journal of Biological 
Chemistry 279, 49533-49541 
157. Jeanneteau, F., Diaz, J., Sokoloff, P., and Griffon, N. (2004) Interactions of GIPC with 
dopamine D2, D3 but not D4 receptors define a novel mode of regulation of G protein-
coupled receptors. Molecular biology of the cell 15, 696-705 
158. Nadine, K., Mathew, P. W., Jacob, C. N., and Robert, L. (2012) Dopamine Receptor 
Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor 
Interaction for Antipsychotic Drug Development. Current Drug Targets 13, 72-79 
159. Kabbani, N., Negyessy, L., Lin, R., Goldman-Rakic, P., and Levenson, R. (2002) Interaction 
with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine 
receptor. The Journal of neuroscience 22, 8476-8486 
160. Smith, F. D., Oxford, G. S., and Milgram, S. L. (1999) Association of the D2 dopamine 
receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. 
Journal of Biological Chemistry 274, 19894-19900 
161. Schmieg, N., Rocchi, C., Romeo, S., Maggio, R., Millan, M. J., and Mannoury la Cour, C. 
(2016) Dysbindin-1 modifies signaling and cellular localization of recombinant, human D3 
and D2 receptors. Journal of neurochemistry 136, 1037-1051 
162. Liu, Y., Buck, D. C., and Neve, K. A. (2008) Novel Interaction of the Dopamine D2 Receptor 
and the Ca2+ Binding Protein S100B: Role in D2 Receptor Function. Molecular 
Pharmacology 74, 371-378 
163. Saha, S., Chant, D., Welham, J., and McGrath, J. (2005) A systematic review of the 
prevalence of schizophrenia. PLoS medicine 2 
164. Messias, E. L., Chen, C.-Y., and Eaton, W. W. (2007) Epidemiology of schizophrenia: 
review of findings and myths. Psychiatric Clinics of North America 30, 323-338 
165. Andreasen, N. C., Arndt, S., Alliger, R., Miller, D., and Flaum, M. (1995) Symptoms of 







166. Howes, O. D., and Kapur, S. (2009) The dopamine hypothesis of schizophrenia: version 
III—the final common pathway. Schizophrenia bulletin 35, 549-562 
167. Kebabian, J. W., and Greengard, P. (1971) Dopamine-sensitive adenyl cyclase: possible 
role in synaptic transmission. Science (New York, N.Y.) 174, 1346-1349 
168. Kebabian, J. W., Petzold, G. L., and Greengard, P. (1972) Dopamine-sensitive adenylate 
cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”. 
Proceedings of the National Academy of Sciences 69, 2145-2149 
169. Carlsson, A., and Lindqvist, M. (1963) Effect of chlorpromazine or haloperidol on formation 
of 3‐methoxytyramine and normetanephrine in mouse brain. Acta pharmacologica et 
toxicologica 20, 140-144 
170. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. (1976) Antipsychotic drug doses and 
neuroleptic/dopamine receptors. Nature 261, 717-719 
171. Kebabian, J. W., and Calne, D. B. (1979) Multiple receptors for dopamine. Nature 277, 93-
96 
172. Seeman, P., Chau-Wong, M., Tedesco, J., and Wong, K. (1975) Brain receptors for 
antipsychotic drugs and dopamine: direct binding assays. Proceedings of the National 
Academy of Sciences 72, 4376-4380 
173. Roth, B. L., Sheffler, D. J., and Kroeze, W. K. (2004) Magic shotguns versus magic bullets: 
selectively non-selective drugs for mood disorders and schizophrenia. Nature reviews Drug 
discovery 3, 353-359 
174. Behere, P. B., Das, A., and Behere, A. P. (2019) Antipsychotics. in Clinical 
Psychopharmacology, Springer. pp 39-87 
175. Hippius, H. (1999) A historical perspective of clozapine. The Journal of clinical psychiatry  
176. Seeman, P. (2002) Atypical antipsychotics: mechanism of action. The Canadian Journal of 
Psychiatry 47, 29-40 
177. Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., and Morita, S. (1995) 
7-(4-[4-(2, 3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3, 4-dihydro-2 (1H)-quinolinone (OPC-
14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor 
agonistic activity and postsynaptic D2 receptor antagonistic activity. Journal of 
Pharmacology and Experimental Therapeutics 274, 329-336 
178. Inoue, T., Domae, M., Yamada, K., and Furukawa, T. (1996) Effects of the novel 
antipsychotic agent 7-(4-[4-(2, 3-dichlorophenyl)-1-piperazinyl] butyloxy)-3, 4-dihydro-2 
(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. 
Journal of Pharmacology and Experimental Therapeutics 277, 137-143 
179. Newman-Tancredi, A. (2010) The importance of 5-HT1A receptor agonism in antipsychotic 
drug action: rationale and perspectives. Current opinion in investigational drugs (London, 
England: 2000) 11, 802-812 
180. Mailman, R. B., and Murthy, V. (2010) Third generation antipsychotic drugs: partial agonism 
or receptor functional selectivity? Current pharmaceutical design 16, 488-501 
181. Beaulieu, J.-M., Sotnikova, T. D., Yao, W.-D., Kockeritz, L., Woodgett, J. R., Gainetdinov, 
R. R., and Caron, M. G. (2004) Lithium antagonizes dopamine-dependent behaviors 
mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the 
National Academy of Sciences of the United States of America 101, 5099-5104 
182. Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M., and Gogos, J. A. (2004) 
Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nature 
genetics 36, 131-137 
183. Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., and 
Caron, M. G. (2008) Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a 
common property of clinically effective antipsychotics. Proceedings of the National 
Academy of Sciences 105, 13656-13661 
184. Allen, J. A., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S., 
Yadav, P. N., Huang, X.-p., Feng, B., Jensen, N. H., Che, X., Bai, X., Frye, S. V., Wetsel, 
W. C., Caron, M. G., Javitch, J. A., Roth, B. L., and Jin, J. (2011) Discovery of β-Arrestin–






Antipsychotic Efficacy. Proceedings of the National Academy of Sciences 108, 18488-
18493 
185. Park, S. M., Chen, M., Schmerberg, C. M., Dulman, R. S., Rodriguiz, R. M., Caron, M. G., 
Jin, J., and Wetsel, W. C. (2016) Effects of β-arrestin-biased dopamine D2 receptor ligands 
on schizophrenia-like behavior in hypoglutamatergic mice. Neuropsychopharmacology 41, 
704-715 
186. Donthamsetti, P., Gallo, E. F., Buck, D. C., Stahl, E. L., Zhu, Y., Lane, J. R., Bohn, L. M., 
Neve, K. A., Kellendonk, C., and Javitch, J. A. (2018) Arrestin recruitment to dopamine D2 
receptor mediates locomotion but not incentive motivation. Molecular psychiatry, 1-15 
187. Kapur, S., and Seeman, P. (2001) Does fast dissociation from the dopamine D2 receptor 
explain the action of atypical antipsychotics?: A new hypothesis. American Journal of 
Psychiatry 158, 360-369 
188. Kapur, S., Zipursky, R., Jones, C., Remington, G., and Houle, S. (2000) Relationship 
between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET 
study of first-episode schizophrenia. American Journal of Psychiatry 157, 514-520 
189. Carboni, L., Negri, M., Michielin, F., Bertani, S., Delle Fratte, S., Oliosi, B., and Cavanni, P. 
(2012) Slow dissociation of partial agonists from the D2 receptor is linked to reduced 
prolactin release. International Journal of Neuropsychopharmacology 15, 645-656 
190. Mateus, C., and Coloma, J. (2013) Health economics and cost of illness in Parkinson’s 
disease. Eur Neurol Rev 8, 6-9 
191. Bohingamu Mudiyanselage, S., Watts, J. J., Abimanyi-Ochom, J., Lane, L., Murphy, A. T., 
Morris, M. E., and Iansek, R. (2017) Cost of living with Parkinson’s disease over 12 months 
in Australia: a prospective cohort study. Parkinson’s Disease 2017 
192. Schapira, A. H., Chaudhuri, K. R., and Jenner, P. (2017) Non-motor features of Parkinson 
disease. Nature Reviews Neuroscience 18, 435 
193. Surmeier, D. J., Obeso, J. A., and Halliday, G. M. (2017) Selective neuronal vulnerability in 
Parkinson disease. Nat Rev Neurosci 18, 101-113 
194. Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., 
and Spano, P. (2016) Review: Parkinson's disease: from synaptic loss to connectome 
dysfunction. Neuropathology and Applied Neurobiology 42, 77-94 
195. Halliday, G. M., Leverenz, J. B., Schneider, J. S., and Adler, C. H. (2014) The 
neurobiological basis of cognitive impairment in Parkinson's disease. Movement Disorders 
29, 634-650 
196. Freire, C., and Koifman, S. (2012) Pesticide exposure and Parkinson's disease: 
epidemiological evidence of association. Neurotoxicology 33, 947-971 
197. Scheperjans, F. (2018) The prodromal microbiome. Movement disorders 33, 5-7 
198. Ben-Joseph, A., Marshall, C. R., Lees, A. J., and Noyce, A. J. (2019) Ethnic Variation in the 
Manifestation of Parkinson’s Disease: A Narrative Review. Journal of Parkinson's Disease, 
1-15 
199. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., 
Root, H., Rubenstein, J., and Boyer, R. (1997) Mutation in the α-synuclein gene identified in 
families with Parkinson's disease. Science (New York, N.Y.) 276, 2045-2047 
200. Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., Van Der Brug, M., De 
Munain, A. L., Aparicio, S., Gil, A. M. n., and Khan, N. (2004) Cloning of the gene 
containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 
201. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., 
Hulihan, M., Uitti, R. J., and Calne, D. B. (2004) Mutations in LRRK2 cause autosomal-
dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 
202. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., Ali, 
Z., Del Turco, D., Bentivoglio, A. R., and Healy, D. G. (2004) Hereditary early-onset 
Parkinson's disease caused by mutations in PINK1. Science (New York, N.Y.) 304, 1158-
1160 
203. Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-






glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine 
361, 1651-1661 
204. Chaudhuri, K. R., and Schapira, A. H. (2009) Non-motor symptoms of Parkinson's disease: 
dopaminergic pathophysiology and treatment. The Lancet Neurology 8, 464-474 
205. Connolly, B. S., and Lang, A. E. (2014) Pharmacological treatment of parkinson disease: A 
review. JAMA 311, 1670-1683 
206. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., and Pezzoli, G. (2007) Valvular 
heart disease and the use of dopamine agonists for Parkinson's disease. New England 
Journal of Medicine 356, 39-46 
207. Andersohn, F., and Garbe, E. (2009) Cardiac and noncardiac fibrotic reactions caused by 
ergot‐and nonergot‐derived dopamine agonists. Movement Disorders 24, 129-133 
208. Hutcheson, J. D., Setola, V., Roth, B. L., and Merryman, W. D. (2011) Serotonin receptors 
and heart valve disease—it was meant 2B. Pharmacology & therapeutics 132, 146-157 
209. Stowe, R., Ives, N., Clarke, C. E., Ferreira, J., Hawker, R. J., Shah, L., Wheatley, K., and 
Gray, R. (2008) Dopamine agonist therapy in early Parkinson's disease. Cochrane 
Database of Systematic Reviews  
210. Glover, V., Sandler, M., Owen, F., and Riley, G. (1977) Dopamine is a monoamine oxidase 
B substrate in man. Nature 265, 80-81 
211. Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., 
Hibbert, S., Budnik, N., Zampedri, L., and Dickson, J. (2017) Exenatide once weekly versus 
placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The 
Lancet 390, 1664-1675 
212. Domenici, M. R., Ferrante, A., Martire, A., Chiodi, V., Pepponi, R., Tebano, M. T., and 
Popoli, P. (2019) Adenosine A2A receptor as potential therapeutic target in 
neuropsychiatric disorders. Pharmacological research 147, 104338 
213. Lang, A. E., and Espay, A. J. (2018) Disease modification in Parkinson's disease: current 
approaches, challenges, and future considerations. Movement Disorders 33, 660-677 
214. West, A. B. (2017) Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson 
disease. Experimental neurology 298, 236-245 
215. Stoker, T. B., Torsney, K. M., and Barker, R. A. (2018) Emerging treatment approaches for 
Parkinson’s disease. Frontiers in neuroscience 12, 693 
216. Palfi, S., Gurruchaga, J. M., Lepetit, H., Howard, K., Ralph, G. S., Mason, S., Gouello, G., 
Domenech, P., Buttery, P. C., and Hantraye, P. (2018) Long-term follow-up of a phase I/II 
study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease. Human Gene 
Therapy Clinical Development 29, 148-155 
217. Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., and Clarke, C. E. (2010) 
Systematic review of levodopa dose equivalency reporting in Parkinson's disease. 
Movement Disorders 25, 2649-2653 
218. Kapur, S., and Seeman, P. (2000) Antipsychotic agents differ in how fast they come off the 
dopamine D2 receptors. Implications for atypical antipsychotic action. Journal of Psychiatry 
and Neuroscience 25, 161 
219. Liggett, S. B. (2011) Phosphorylation Barcoding as a Mechanism of Directing GPCR 
Signaling. Science Signaling 4, pe36-pe36 
220. Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., 
Al-Lazikani, B., Hersey, A., and Oprea, T. I. (2017) A comprehensive map of molecular 
drug targets. Nature reviews Drug discovery 16, 19 
221. Motulsky, H. J., and Mahan, L. (1984) The kinetics of competitive radioligand binding 
predicted by the law of mass action. Molecular pharmacology 25, 1-9 
222. Disse, B., Speck, G. A., Rominger, K. L., Witek Jr, T. J., and Hammer, R. (1999) Tiotropium 
(Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life 
sciences 64, 457-464 
223. Silhavy, T. J., Szmelcman, S., Boos, W., and Schwartz, M. (1975) On the significance of 







224. Gopalakrishnan, M., Forsten-Williams, K., Cassino, T. R., Padro, L., Ryan, T. E., and 
Täuber, U. C. (2005) Ligand rebinding: self-consistent mean-field theory and numerical 
simulations applied to surface plasmon resonance studies. European Biophysics Journal 
34, 943-958 
225. García-Nafría, J., and Tate, C. G. (2019) Cryo-electron microscopy: Moving beyond x-ray 
crystal structures for drug receptors and drug development. Annual review of pharmacology 
and toxicology 60 
226. Söldner, C. A., Horn, A. H., and Sticht, H. (2018) Binding of histamine to the H1 receptor—
a molecular dynamics study. Journal of molecular modeling 24, 346 
227. Nguyen, A. T., Baltos, J.-A., Thomas, T., Nguyen, T. D., Muñoz, L. L., Gregory, K. J., 
White, P. J., Sexton, P. M., Christopoulos, A., and May, L. T. (2016) Extracellular loop 2 of 
the adenosine A1 receptor has a key role in orthosteric ligand affinity and agonist efficacy. 
Molecular pharmacology 90, 703-714 
228. Guo, D., Pan, A. C., Dror, R. O., Mocking, T., Liu, R., Heitman, L. H., Shaw, D. E., and 
IJzerman, A. P. (2016) Molecular basis of ligand dissociation from the adenosine A2A 
receptor. Molecular pharmacology 89, 485-491 
229. Bressan, R. A., and Crippa, J. A. (2005) The role of dopamine in reward and pleasure 
behaviour–review of data from preclinical research. Acta Psychiatrica Scandinavica 111, 
14-21 
230. Boulay, D., Depoortere, R., Perrault, G., Borrelli, E., and Sanger, D. (1999) Dopamine D2 
receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of 
dopamine D2/D3 receptor agonists. Neuropharmacology 38, 1389-1396 
231. Seeman, P. (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clinical 
schizophrenia & related psychoses 4, 56-73 
232. Lim, E. (2005) A walk through the management of Parkinson s disease. Ann Acad Med 
Singapore 34, 188-195 
233. Mansour, A., Meng, F., Meador-Woodruff, J. H., Taylor, L. P., Civelli, O., and Akil, H. (1992) 
Site-directed mutagenesis of the human dopamine D2 receptor. European Journal of 
Pharmacology: Molecular Pharmacology 227, 205-214 
234. Shi, L., and Javitch, J. A. (2004) The second extracellular loop of the dopamine D2 receptor 
lines the binding-site crevice. Proceedings of the National Academy of Sciences 101, 440-
445 
235. Klein Herenbrink, C., Verma, R., Lim, H. D., Kopinathan, A., Keen, A., Shonberg, J., 
Draper-Joyce, C. J., Scammells, P. J., Christopoulos, A., Javitch, J. A., Capuano, B., Shi, 
L., and Lane, J. R. (2019) Molecular Determinants of the Intrinsic Efficacy of the 
Antipsychotic Aripiprazole. ACS Chemical Biology 14, 1780-1792 
236. Zhou, Y., Cao, C., He, L., Wang, X., and Zhang, X. C. (2019) Crystal structure of dopamine 
receptor D4 bound to the subtype selective ligand, L745870. eLife 8, e48822 
237. Sykes, D. A., Lane, J. R., Szabo, M., Capuano, B., Javitch, J. A., and Charlton, S. J. (2018) 
Reply to ‘Antipsychotics with similar association kinetics at dopamine D2 receptors differ in 
extrapyramidal side-effects’. Nature Communications 9, 3568 
238. Harrison, T. S., and Perry, C. M. (2004) Aripiprazole. Drugs 64, 1715-1736 
239. Wadenberg, M.-L. G. (2007) Bifeprunox: a novel antipsychotic agent with partial agonist 
properties at dopamine D2 and serotonin 5-HT1A receptors.  
240. Parkes, D. (1979) Bromocriptine. New England Journal of Medicine 301, 873-878 
241. Möller, H.-J. (2005) Risperidone: a review. Expert opinion on pharmacotherapy 6, 803-818 
242. Janssen, P. A. (1974) Butyrophenones and diphenylbutylpiperidines. 
Psychopharmacological agents 3, 129-158 
243. Ballesteros, J. A., and Weinstein, H. (1995) [19] Integrated methods for the construction of 
three-dimensional models and computational probing of structure-function relations in G 
protein-coupled receptors. in Methods in neurosciences, Elsevier. pp 366-428 
244. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, 
T. S., Choi, H.-J., Kuhn, P., Weis, W. I., and Kobilka, B. K. (2007) High-resolution crystal 
structure of an engineered human β2-adrenergic G protein–coupled receptor. Science 






245. Sykes, D. A., Jain, P., and Charlton, S. J. (2019) Investigating the Influence of Tracer 
Kinetics on Competition-Kinetic Association Binding Assays: Identifying the Optimal 
Conditions for Assessing the Kinetics of Low-Affinity Compounds. Molecular pharmacology 
96, 378-392 
246. Swinney, D. C., Beavis, P., Chuang, K. T., Zheng, Y., Lee, I., Gee, P., Deval, J., Rotstein, 
D. M., Dioszegi, M., and Ravendran, P. (2014) A study of the molecular mechanism of 
binding kinetics and long residence times of human CCR 5 receptor small molecule 
allosteric ligands. British journal of pharmacology 171, 3364-3375 
247. Van Oijen, A. M. (2011) Single-molecule approaches to characterizing kinetics of 
biomolecular interactions. Current opinion in biotechnology 22, 75-80 
248. Gilman, A. G. (1987) G proteins: transducers of receptor-generated signals. Annual review 
of biochemistry 56, 615-649 
249. Gurevich, V. V., and Gurevich, E. V. (2019) GPCR signaling regulation: the role of GRKs 
and arrestins. Frontiers in pharmacology 10, 125 
250. Peterson, Y. K., and Luttrell, L. M. (2017) The diverse roles of arrestin scaffolds in G 
protein–coupled receptor signaling. Pharmacological reviews 69, 256-297 
251. Free, R. B., Chun, L. S., Moritz, A. E., Miller, B. N., Doyle, T. B., Conroy, J. L., Padron, A., 
Meade, J. A., Xiao, J., Hu, X., Dulcey, A. E., Han, Y., Duan, L., Titus, S., Bryant-Genevier, 
M., Barnaeva, E., Ferrer, M., Javitch, J. A., Beuming, T., Shi, L., Southall, N. T., Marugan, 
J. J., and Sibley, D. R. (2014) Discovery and Characterization of a G Protein–Biased 
Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor. Molecular 
Pharmacology 86, 96-105 
252. Bonifazi, A., Yano, H., Guerrero, A. M., Kumar, V., Hoffman, A. F., Lupica, C. R., Shi, L., 
and Newman, A. H. (2019) Novel and potent dopamine D2 receptor Go-protein biased 
agonists. ACS pharmacology & translational science 2, 52-65 
253. Waelbroeck, M., Boufrahi, L., and Swillens, S. (1997) Seven helix receptors are enzymes 
catalysing G protein activation. What is the agonist Kact? Journal of theoretical biology 187, 
15-37 
254. Kinzer-Ursem, T. L., and Linderman, J. J. (2007) Both Ligand-and Cell-Specific parameters 
control ligand agonism in a kinetic model of G protein–coupled Receptor signaling. PLoS 
computational biology 3 
255. Woolf, P. J., and Linderman, J. J. (2003) Untangling ligand induced activation and 
desensitization of G-protein-coupled receptors. Biophysical journal 84, 3-13 
256. Shonberg, J., Herenbrink, C. K., López, L., Christopoulos, A., Scammells, P. J., Capuano, 
B., and Lane, J. R. (2013) A Structure–Activity Analysis of Biased Agonism at the 
Dopamine D2 Receptor. Journal of medicinal chemistry 56, 9199-9221 
257. Masuho, I., Martemyanov, K. A., and Lambert, N. A. (2015) Monitoring G Protein Activation 
in Cells with BRET. in G Protein-Coupled Receptors in Drug Discovery: Methods and 
Protocols (Filizola, M. ed.), Springer New York, New York, NY. pp 107-113 
258. Hollins, B., Kuravi, S., Digby, G. J., and Lambert, N. A. (2009) The c-terminus of GRK3 
indicates rapid dissociation of G protein heterotrimers. Cellular signalling 21, 1015-1021 
259. Donthamsetti, P., Quejada, J. R., Javitch, J. A., Gurevich, V. V., and Lambert, N. A. (2015) 
Using Bioluminescence Resonance Energy Transfer (BRET) to Characterize Agonist‐
Induced Arrestin Recruitment to Modified and Unmodified G Protein‐Coupled Receptors. 
Current Protocols in Pharmacology, 2.14. 11-12.14. 14 
260. Lan, T.-H., Liu, Q., Li, C., Wu, G., and Lambert, N. A. (2012) Sensitive and High Resolution 
Localization and Tracking of Membrane Proteins in Live Cells with BRET. Traffic 13, 1450-
1456 
261. De Vries, L., Finana, F., Cathala, C., Ronsin, B., and Cussac, D. (2019) Innovative 
Bioluminescence Resonance Energy Transfer Assay Reveals Differential Agonist-Induced 
D2 Receptor Intracellular Trafficking and Arrestin-3 Recruitment. Molecular pharmacology 
96, 308-319 
262. Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., 






characterization of a novel serotonin-dopamine activity modulator. Journal of Pharmacology 
and Experimental Therapeutics 350, 589-604 
263. Calne, D., Teychenne, P., Claveria, L., Eastman, R., Greenacre, J., and Petrie, A. a. (1974) 
Bromocriptine in parkinsonism. Br med J 4, 442-444 
264. Scheller, D., Ullmer, C., Berkels, R., Gwarek, M., and Lübbert, H. (2009) The in vitro 
receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn-
Schmiedeberg's archives of pharmacology 379, 73-86 
265. Wood, M., Dubois, V., Scheller, D., and Gillard, M. (2015) Rotigotine is a potent agonist at 
dopamine D 1 receptors as well as at dopamine D 2 and D 3 receptors. British journal of 
pharmacology 172, 1124-1135 
266. Blackburn, T. (2017) Orally-active, highly effective, fast-onset, long-acting dopamine D3/D2 
agonists in translational experimental models of Parkinson’s disease displays specific 
biased agonism profile. in pA2 online - BPS Pharmacology 2017, London, UK 
267. Lane, J. R., Powney, B., Wise, A., Rees, S., and Milligan, G. (2008) G protein coupling and 
ligand selectivity of the D2L and D3 dopamine receptors. Journal of Pharmacology and 
Experimental Therapeutics 325, 319-330 
268. Lawler, C. P., Prioleau, C., Lewis, M. M., Mak, C., Jiang, D., Schetz, J. A., Gonzalez, A. M., 
Sibley, D. R., and Mailman, R. B. (1999) Interactions of the novel antipsychotic aripiprazole 
(OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 
20, 612-627 
269. Brandt, D., and Ross, E. (1986) Catecholamine-stimulated GTPase cycle. Multiple sites of 
regulation by beta-adrenergic receptor and Mg2+ studied in reconstituted receptor-Gs 
vesicles. Journal of Biological Chemistry 261, 1656-1664 
270. Klewe, I. V., Nielsen, S. M., Tarpø, L., Urizar, E., Dipace, C., Javitch, J. A., Gether, U., 
Egebjerg, J., and Christensen, K. V. (2008) Recruitment of β-arrestin2 to the dopamine D2 
receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. 
Neuropharmacology 54, 1215-1222 
271. Kim, K.-M., Valenzano, K. J., Robinson, S. R., Yao, W. D., Barak, L. S., and Caron, M. G. 
(2001) Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled 
Receptor Kinases and β-Arrestins. Journal of Biological Chemistry 276, 37409-37414 
272. Oakley, R. H., Laporte, S. A., Holt, J. A., Caron, M. G., and Barak, L. S. (2000) Differential 
affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled 
receptors delineate two major classes of receptors. Journal of Biological Chemistry 275, 
17201-17210 
273. Kenakin, T. (2009) Quantifying biological activity in chemical terms: a pharmacology primer 
to describe drug effect. ACS Publications 
274. Luttrell, L. M., Maudsley, S., and Bohn, L. M. (2015) Fulfilling the promise of" biased" G 
protein–coupled receptor agonism. Molecular pharmacology 88, 579-588 
275. White, K. L., Scopton, A. P., Rives, M.-L., Bikbulatov, R. V., Polepally, P. R., Brown, P. J., 
Kenakin, T., Javitch, J. A., Zjawiony, J. K., and Roth, B. L. (2014) Identification of novel 
functionally selective κ-opioid receptor scaffolds. Molecular pharmacology 85, 83-90 
276. McAnally, D., Siddiquee, K., Sharir, H., Qi, F., Phatak, S., Li, J.-L., Berg, E., Fishman, J., 
and Smith, L. (2017) A systematic approach to identify biased agonists of the apelin 
receptor through high-throughput screening. SLAS DISCOVERY: Advancing Life Sciences 
R&D 22, 867-878 
277. Frank, A., Kiss, D. J., Keserű, G. M., and Stark, H. (2018) Binding kinetics of cariprazine 
and aripiprazole at the dopamine D 3 receptor. Scientific reports 8, 1-9 
278. Packeu, A., De Backer, J.-P., Van Liefde, I., Vanderheyden, P. M., and Vauquelin, G. 
(2008) Antagonist-radioligand binding to D2L-receptors in intact cells. Biochemical 
pharmacology 75, 2192-2203 
279. Kessler, R. M., Votaw, J. R., de Paulis, T., Bingham, D. R., Ansari, M. S., Mason, N. S., 
Holburn, G., Schmidt, D. E., Votaw, D. B., and Manning, R. G. (1993) Evaluation of 5‐[18F] 
fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors. 






280. Zimmerman, B., Beautrait, A., Aguila, B., Charles, R., Escher, E., Claing, A., Bouvier, M., 
and Laporte, S. A. (2012) Differential β-Arrestin–Dependent Conformational Signaling and 
Cellular Responses Revealed by Angiotensin Analogs. Sci. Signal. 5, ra33-ra33 
281. Namkung, Y., LeGouill, C., Kumar, S., Cao, Y., Teixeira, L. B., Lukasheva, V., Giubilaro, J., 
Simões, S. C., Longpré, J.-M., and Devost, D. (2018) Functional selectivity profiling of the 
angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. Science 
signaling 11 
282. Gundry, J., Glenn, R., Alagesan, P., and Rajagopal, S. (2017) A practical guide to 
approaching biased agonism at G protein coupled receptors. Frontiers in neuroscience 11, 
17 
283. Onaran, H. O., Ambrosio, C., Uğur, Ö., Koncz, E. M., Grò, M. C., Vezzi, V., Rajagopal, S., 
and Costa, T. (2017) Systematic errors in detecting biased agonism: analysis of current 
methods and development of a new model-free approach. Scientific reports 7, 1-17 
284. Attramadal, H., Arriza, J. L., Aoki, C., Dawson, T. M., Codina, J., Kwatra, M. M., Snyder, S. 
H., Caron, M. G., and Lefkowitz, R. J. (1992) Beta-arrestin2, a novel member of the 
arrestin/beta-arrestin gene family. Journal of Biological Chemistry 267, 17882-17890 
285. Yano, H., Cai, N.-S., Xu, M., Verma, R. K., Rea, W., Hoffman, A. F., Shi, L., Javitch, J. A., 
Bonci, A., and Ferré, S. (2018) Gs-versus Golf-dependent functional selectivity mediated by 
the dopamine D 1 receptor. Nature communications 9, 1-11 
286. Bolognini, D., Moss, C. E., Nilsson, K., Petersson, A. U., Donnelly, I., Sergeev, E., König, 
G. M., Kostenis, E., Kurowska-Stolarska, M., and Miller, A. (2016) A novel allosteric 
activator of free fatty acid 2 receptor displays unique Gi-functional bias. Journal of 
Biological Chemistry 291, 18915-18931 
287. Inoue, A., and Nakata, Y. (2001) Strategy for modulation of central dopamine transmission 
based on the partial agonist concept in schizophrenia therapy. Japanese journal of 
pharmacology 86, 376-380 
288. McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., Dewey, W. L., 
Bailey, C. P., Rosethorne, E. M., and Charlton, S. J. (2010) μ-opioid receptors: correlation 
of agonist efficacy for signalling with ability to activate internalization. Molecular 
pharmacology 78, 756-766 
289. Beaulieu, J.-M. M., and Gainetdinov, R. R. (2011) The physiology, signaling, and 
pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217 
290. Seeman, P. (2006) Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther 
Targets 10, 515-531 
291. Namkung, Y., Dipace, C., Urizar, E., Javitch, J. A., and Sibley, D. R. (2009) G protein-
coupled receptor kinase-2 constitutively regulates D2 dopamine receptor expression and 
signaling independently of receptor phosphorylation. J. Biol. Chem. 284, 34103-34115 
292. Cho, D. I., Zheng, M., Min, C., Kwon, K. J., Shin, C. Y., Choi, H. K., and Kim, K. M. (2013) 
ARF6 and GASP‐1 are post‐endocytic sorting proteins selectively involved in the 
intracellular trafficking of dopamine D2 receptors mediated by GRK and PKC in transfected 
cells. Br. J. Pharmacol. 168, 1355-1374 
293. Allen, J. A., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S., 
Yadav, P. N., Huang, X.-p., Feng, B., Jensen, N. H., Che, X., Bai, X., Frye, S. V., Wetsel, 
W. C., Caron, M. G., Javitch, J. A., Roth, B. L., and Jin, J. (2011) Discovery of β-Arrestin–
Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for 
Antipsychotic Efficacy. Proc. Natl. Acad. Sci. U.S.A 108, 18488-18493 
294. Namkung, Y., Dipace, C., Javitch, J. A., and Sibley, D. R. (2009) G Protein-coupled 
Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 
Dopamine Receptor. J. Biol. Chem. 284, 15038-15051 
295. DeWire, S. M., Ahn, S., Lefkowitz, R. J., and Shenoy, S. K. (2007) β-Arrestins and Cell 
Signaling. Ann. Rev. Physiol. 69, 483-510 
296. Beaulieu, J.-M., Gainetdinov, R. R., and Caron, M. G. (2007) The Akt–GSK-3 signaling 






297. Peterson, S. M., Pack, T. F., Wilkins, A. D., Urs, N. M., Urban, D. J., Bass, C. E., Lichtarge, 
O., and Caron, M. G. (2015) Elucidation of G-protein and β-arrestin functional selectivity at 
the dopamine D2 receptor. Proc. Natl. Acad. Sci. U.S.A 112, 7097-7102 
298. Donthamsetti, P., Gallo, E. F., Buck, D. C., Stahl, E. L., Zhu, Y., Lane, J. R., Bohn, L. M., 
Neve, K. A., Kellendonk, C., and Javitch, J. A. (2018) Arrestin recruitment to dopamine D2 
receptor mediates locomotion but not incentive motivation. Mol. Psychiatry  
299. Porter-Stransky, K. A., Petko, A. K., Karne, S. L., Liles, L. C., Urs, N. M., Caron, M. G., 
Paladini, C. A., and Weinshenker, D. (2019) Loss of β-arrestin2 in D2 cells alters neuronal 
excitability in the nucleus accumbens and behavioral responses to psychostimulants and 
opioids. Addict. Biol., e12823 
300. Urs, N. M., Peterson, S. M., and Caron, M. G. (2017) New Concepts in Dopamine D2 
Receptor Biased Signaling and Implications for Schizophrenia Therapy. Biol. Psychiatry 81, 
78-85 
301. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., 
Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and 
Mailman, R. B. (2007) Functional Selectivity and Classical Concepts of Quantitative 
Pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 
302. Violin, J. D., Crombie, A. L., Soergel, D. G., and Lark, M. W. (2014) Biased ligands at G-
protein-coupled receptors: promise and progress. Trends Biochem. Sci. 35, 308-316 
303. Free, B. R., Chun, L. S., Moritz, A. E., Miller, B. N., Doyle, T. B., Conroy, J. L., Padron, A., 
Meade, J. A., Xiao, J., Hu, X., Dulcey, A. E., Han, Y., Duan, L., Titus, S., Bryant-Genevier, 
M., Barnaeva, E., Ferrer, M., Javitch, J. A., Beuming, T., Shi, L., Southall, N. T., Marugan, 
J. J., and Sibley, D. R. (2014) Discovery and Characterization of a G Protein–Biased 
Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor. Mol. 
Pharmacol. 86, 96-105 
304. Doll, C., Poll, F., Peuker, K., Loktev, A., Gluck, L., and Schulz, S. (2012) Deciphering micro-
opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br. J. Pharmacol. 
167, 1259-1270 
305. Mann, A., Mouledous, L., Froment, C., O'Neill, P. R., Dasgupta, P., Gunther, T., Brunori, 
G., Kieffer, B. L., Toll, L., Bruchas, M. R., Zaveri, N. T., and Schulz, S. (2019) Agonist-
selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals 
differential post-activation signaling by chemically diverse agonists. Sci. Signal. 12 
306. Tobin, A. B., Butcher, A. J., and Kong, K. (2008) Location, location, location…site-specific 
GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends 
Pharmacol. Sci. 29, 413-420 
307. Lehmann, A., Kliewer, A., Gunther, T., Nagel, F., and Schulz, S. (2016) Identification of 
Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking. Mol. Endocrinol. 
30, 645-659 
308. Hollins, B., Kuravi, S., Digby, G. J., and Lambert, N. A. (2009) The c-terminus of GRK3 
indicates rapid dissociation of G protein heterotrimers. Cell. Signal. 21, 1015-1021 
309. Günther, T., Culler, M., and Schulz, S. (2016) Research Resource: Real-Time Analysis of 
Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-
Based Membrane Potential Assay. Mol. Endocrinol. 30, 479-490 
310. Klein-Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., 
Scammells, P. J., Capuano, B., Sexton, P. M., and Charlton, S. J. (2016) The role of kinetic 
context in apparent biased agonism at GPCRs. Nature communications 7, 10842 
311. Donthamsetti, P., Quejada, J. R., Javitch, J. A., Gurevich, V. V., and Lambert, N. A. (2015) 
Using Bioluminescence Resonance Energy Transfer (BRET) to Characterize Agonist‐
Induced Arrestin Recruitment to Modified and Unmodified G Protein‐Coupled Receptors. 
Curr. Protoc. Pharmacol., 2.14. 11-12.14. 14 
312. Clagett-Dame, M., and McKelvy, J. F. (1989) N-linked oligosaccharides are responsible for 
rat striatal dopamine D2 receptor heterogeneity. Arch Biochem Biophys 274, 145-154 
313. Ikeda, S., Keneko, M., and Fujiwara, S. (2007) CARDIOTONIC AGENT COMPRISING 






314. Benovic, J. L., Strasser, R. H., Caron, M. G., and Lefkowitz, R. J. (1986) Beta-adrenergic 
receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-
occupied form of the receptor. Proc. Natl. Acad. Sci. U.S.A 83, 2797-2801 
315. Masuho, I., Ostrovskaya, O., Kramer, G. M., Jones, C. D., Xie, K., and Martemyanov, K. A. 
(2015) Distinct profiles of functional discrimination among G proteins determine the actions 
of G protein-coupled receptors. Sci.Signal. 8, ra123 
316. Lane, J. R., Powney, B., Wise, A., Rees, S., and Milligan, G. (2007) Protean Agonism at the 
Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for 
Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3. Mol.Pharmacol. 
71, 1349-1359 
317. Wood, M., Dubois, V., Scheller, D., and Gillard, M. (2015) Rotigotine is a potent agonist at 
dopamine D 1 receptors as well as at dopamine D 2 and D 3 receptors. Br. J. Pharmacol. 
172, 1124-1135 
318. Inoue, T., Domae, M., Yamada, K., and Furukawa, T. (1996) Effects of the novel 
antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-
quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. 
Pharmacol. Expt.Ther. 277, 137-143 
319. Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., 
and Mailman, R. (2003) Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique 
and Robust Pharmacology. Neuropsychopharmacology 28, 1400-1411 
320. Urs, N. M., Gee, S. M., Pack, T. F., McCorvy, J. D., Evron, T., Snyder, J. C., Yang, X., 
Rodriguiz, R. M., Borrelli, E., Wetsel, W. C., Jin, J., Roth, B. L., O’Donnell, P., and Caron, 
M. G. (2016) Distinct cortical and striatal actions of a β-arrestin–biased dopamine D2 
receptor ligand reveal unique antipsychotic-like properties. Proc. Natl. Acad. Sci. U.S.A 
113, E8178-E8186 
321. Ågren, R., Århem, P., Nilsson, J., and Sahlholm, K. (2018) The beta-arrestin-biased 
dopamine D2 receptor ligand, UNC9994, is a partial agonist at G-protein-mediated 
potassium channel activation. Int. J. Neuropsychopharmacol. 21, 1102-1108 
322. Black, J. W., and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. 
Soc. Lond. B. 220, 141-162 
323. Just, S., Illing, S., Trester-Zedlitz, M., Lau, E. K., Kotowski, S. J., Miess, E., Mann, A., Doll, 
C., Trinidad, J. C., Burlingame, A. L., von Zastrow, M., and Schulz, S. (2013) Differentiation 
of opioid drug effects by hierarchical multi-site phosphorylation. Mol. Pharmacol. 83, 633-
639 
324. Miess, E., Gondin, A. B., Yousuf, A., Steinborn, R., Mösslein, N., Yang, Y., Göldner, M., 
Ruland, J. G., Bünemann, M., Krasel, C., Christie, M. J., Halls, M. L., Schulz, S., and 
Canals, M. (2018) Multisite phosphorylation is required for sustained interaction with GRKs 
and arrestins during rapid μ-opioid receptor desensitization. Sci. Signal. 11, eaas9609 
325. Cho, D., Zheng, M., Min, C., Ma, L., Kurose, H., Park, J. H., and Kim, K.-M. (2010) Agonist-
Induced Endocytosis and Receptor Phosphorylation Mediate Resensitization of Dopamine 
D2Receptors. Mol. Endocrinol 24, 574-586 
326. Jeong, J., Park, Y.-U., Kim, D.-K., Lee, S., Kwak, Y., Lee, S.-A., Lee, H., Suh, Y.-H., Gho, 
Y. S., and Hwang, D. (2013) Cdk5 phosphorylates dopamine D2 receptor and attenuates 
downstream signaling. PloS one 8, e84482 
327. Namkung, Y., and Sibley, D. R. (2004) Protein Kinase C Mediates Phosphorylation, 
Desensitization, and Trafficking of the D2 Dopamine Receptor. J. Biol. Chem. 279, 49533-
49541 
328. Thibault, D., Albert, P. R., Pineyro, G., and Trudeau, L.-É. (2011) Neurotensin triggers 
dopamine D2 receptor desensitization through a protein kinase C and β-arrestin1-
dependent mechanism. J. Biol. Chem. 286, 9174-9184 
329. Morris, S. J., Itzhaki Van-Ham, I., Daigle, M., Robillard, L., Sajedi, N., and Albert, P. R. 
(2007) Differential desensitization of dopamine D2 receptor isoforms by protein kinase C: 







330. Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., Strachan, R. T., 
Huang, T.-Y., Bressler, E. A., Hara, M. R., Shenoy, S. K., Gygi, S. P., and Lefkowitz, R. J. 
(2011) Distinct Phosphorylation Sites on the β(2)-Adrenergic Receptor Establish a Barcode 
That Encodes Differential Functions of β-Arrestin. Science signaling 4, ra51-ra51 
331. Free, R. B., Chun, L. S., Moritz, A. E., Miller, B. N., Doyle, T. B., Conroy, J. L., Padron, A., 
Meade, J. A., Xiao, J., Hu, X., Dulcey, A. E., Han, Y., Duan, L., Titus, S., Bryant-Genevier, 
M., Barnaeva, E., Ferrer, M., Javitch, J. A., Beuming, T., Shi, L., Southall, N. T., Marugan, 
J. J., and Sibley, D. R. (2014) Discovery and Characterization of a G Protein–Biased 
Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor. Mol. 
Pharmacol. 86, 96-105 
332. Szabo, M., Klein Herenbrink, C., Christopoulos, A., Lane, J. R., and Capuano, B. (2014) 
Structure-activity relationships of privileged structures lead to the discovery of novel biased 
ligands at the dopamine D₂ receptor. J. Med. Chem. 57, 4924-4939 
333. Möller, D., Kling, R. C., Skultety, M., Leuner, K., Hübner, H., and Gmeiner, P. (2014) 
Functionally selective dopamine D₂, D₃ receptor partial agonists. J. Med. Chem. 57, 4861-
4875 
334. Hiller, C., Kling, R. C., Heinemann, F. W., Meyer, K., Hübner, H., and Gmeiner, P. (2013) 
Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. J. 
Med. Chem. 56, 5130-5141 
335. McCorvy, J. D., Butler, K. V., Kelly, B., Rechsteiner, K., Karpiak, J., Betz, R. M., Kormos, B. 
L., Shoichet, B. K., Dror, R. O., Jin, J., and Roth, B. L. (2017) Structure-inspired design of 
β-arrestin-biased ligands for aminergic GPCRs. Nat. Chem. Biol. 14, 126-134 
336. Bonifazi, A., Yano, H., Guerrero, A. M., Kumar, V., Hoffman, A. F., Lupica, C. R., Shi, L., 
and Newman, A. H. (2019) Novel and Potent Dopamine D2 Receptor Go-Protein Biased 
Agonists. ACS Pharmacol. Transl. Sci. 2, 52-65 
337. Shen, Y., McCorvy, J. D., Martini, M. L., Rodriguiz, R. M., Pogorelov, V. M., Ward, K. M., 
Wetsel, W. C., Liu, J., Roth, B. L., and Jin, J. (2019) D2 Dopamine Receptor G protein-
biased Partial Agonists Based on Cariprazine. J. Med. Chem. 62, 4755-4771 
338. Urban, J. D., Vargas, G. A., von Zastrow, M., and Mailman, R. B. (2007) Aripiprazole has 
Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways. 
Neuropsychopharmacology 32, 66-77 
339. Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., and 
Caron, M. G. (2008) Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a 
common property of clinically effective antipsychotics. Proc. Natl. Acad. Sci. U.S.A 105, 
13656-13661 
340. Chen, X., McCorvy, J. D., Fischer, M. G., Butler, K. V., Shen, Y., Roth, B. L., and Jin, J. 
(2016) Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists. J. Med. 
Chem. 59, 10601-10618 
341. Chun, L. S., Vekariya, R. H., Free, R. B., Li, Y., Lin, D.-T., Su, P., Liu, F., Namkung, Y., 
Laporte, S. A., Moritz, A. E., Aubé, J., Frankowski, K. J., and Sibley, D. R. (2018) Structure-
Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for 
Biased Signaling of the D2 Dopamine Receptor. Front. Synaptic. Neuroscience 10, 2 
342. Urs, N. M., Gee, S. M., Pack, T. F., McCorvy, J. D., Evron, T., Snyder, J. C., Yang, X., 
Rodriguiz, R. M., Borrelli, E., Wetsel, W. C., Jin, J., Roth, B. L., O'Donnell, P., and Caron, 
M. G. (2016) Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 
receptor ligand reveal unique antipsychotic-like properties. Proc. Natl. Acad. Sci. U.S.A 
113, E8178-E8186 
343. Scarduzio, M., Zimmerman, C. N., Jaunarajs, K. L., Wang, Q., Standaert, D. G., and 
McMahon, L. L. (2017) Strength of cholinergic tone dictates the polarity of dopamine D2 
receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia. Exp. 
Neurol. 295, 162-175 
344. Haga, K., and Haga, T. (1990) Dual regulation by G proteins of agonist‐dependent 






345. Haga, K., and Haga, T. (1992) Activation by G protein beta gamma subunits of agonist-or 
light-dependent phosphorylation of muscarinic acetylcholine receptors and rhodopsin. 
Journal of Biological Chemistry 267, 2222-2227 
346. Koch, W. J., Inglese, J., Stone, W., and Lefkowitz, R. (1993) The binding site for the beta 
gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. 
Journal of Biological Chemistry 268, 8256-8260 
347. Jiang, M., Spicher, K., Boulay, G., Wang, Y., and Birnbaumer, L. (2001) Most central 
nervous system D2 dopamine receptors are coupled to their effectors by Go. Proc. Natl. 
Acad. Sci. U.S.A 98, 3577-3582 
348. Rask-Andersen, M., Almén, M. S., and Schiöth, H. B. (2011) Trends in the exploitation of 
novel drug targets. Nature Reviews Drug Discovery 10, 579 
349. Hildebrandt, J. D., Sekura, R. D., Codina, J., Iyengar, R., Manclark, C. R., and Birnbaumer, 
L. (1983) Stimulation and inhibition of adenylyl cyclases mediated by distinct regulatory 
proteins. Nature 302, 706 
350. Pfaffinger, P. J., Martin, J. M., Hunter, D. D., Nathanson, N. M., and Hille, B. (1985) GTP-
binding proteins couple cardiac muscarinic receptors to a K channel. Nature 317, 536 
351. Sokolov, M., Lyubarsky, A. L., Strissel, K. J., Savchenko, A. B., Govardovskii, V. I., Pugh Jr, 
E. N., and Arshavsky, V. Y. (2002) Massive light-driven translocation of transducin between 
the two major compartments of rod cells: a novel mechanism of light adaptation. Neuron 
34, 95-106 
352. Kenakin, T. (2016) Theoretical aspects of GPCR–ligand complex pharmacology. Chemical 
reviews  
353. McCorvy, J. D., Butler, K. V., Kelly, B., Rechsteiner, K., Karpiak, J., Betz, R. M., Kormos, B. 
L., Shoichet, B. K., Dror, R. O., Jin, J., and Roth, B. L. (2017) Structure-inspired design of 
β-arrestin-biased ligands for aminergic GPCRs. Nature Chemical Biology 14, 126 
354. Masuho, I., Xie, K., and Martemyanov, K. A. (2013) Macromolecular Composition Dictates 
Receptor and G Protein Selectivity of Regulator of G Protein Signaling (RGS) 7 and 9-2 
Protein Complexes in Living Cells. Journal of Biological Chemistry 288, 25129-25142 
355. Sutor, B., and ten Bruggencate, G. (1990) Ascorbic acid: A useful reductant to avoid 
oxidation of catecholamines in electrophysiological experiments in vitro? Neuroscience 
Letters 116, 287-292 
356. Atwood, B. K., Lopez, J., Wager-Miller, J., Mackie, K., and Straiker, A. (2011) Expression of 
G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell 
lines as revealed by microarray analysis. BMC Genomics 12, 14 
357. Coldwell, M. C., Boyfield, I., Brown, T., Hagan, J. J., and Middlemiss, D. N. (1999) 
Comparison of the functional potencies of ropinirole and other dopamine receptor agonists 
at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. 
British journal of pharmacology 127, 1696-1702 
358. Jiang, L. I., Collins, J., Davis, R., Lin, K.-M., DeCamp, D., Roach, T., Hsueh, R., Rebres, R. 
A., Ross, E. M., Taussig, R., Fraser, I., and Sternweis, P. C. (2007) Use of a cAMP BRET 
Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 
Pathway. Journal of Biological Chemistry 282, 10576-10584 
359. Vilardaga, J.-P., Bünemann, M., Krasel, C., Castro, M., and Lohse, M. J. (2003) 
Measurement of the millisecond activation switch of G protein–coupled receptors in living 
cells. Nature Biotechnology 21, 807 
360. Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) Distantly related 
sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other 
ATP-requiring enzymes and a common nucleotide binding fold. The EMBO Journal 1, 945-
951 
361. Raw, A. S., Coleman, D. E., Gilman, A. G., and Sprang, S. R. (1997) Structural and 
Biochemical Characterization of the GTPγS-, GDP·Pi-, and GDP-Bound Forms of a 
GTPase-Deficient Gly42 → Val Mutant of Giα1. Biochemistry 36, 15660-15669 
362. Koelle, M. R., and Horvitz, H. R. (1996) EGL-10 regulates G protein signaling in the C. 
elegans nervous system and shares a conserved domain with many mammalian proteins. 






363. Sjögren, B. (2017) The evolution of regulators of G protein signalling proteins as drug 
targets – 20 years in the making: IUPHAR Review 21. British journal of pharmacology 174, 
427-437 
364. Rahman, Z., Schwarz, J., Gold, S. J., Zachariou, V., Wein, M. N., Choi, K.-H., Kovoor, A., 
Chen, C.-K., DiLeone, R. J., and Schwarz, S. C. (2003) RGS9 modulates dopamine 
signaling in the basal ganglia. Neuron 38, 941-952 
365. Kovoor, A., Seyffarth, P., Ebert, J., Barghshoon, S., Chen, C.-K., Schwarz, S., Axelrod, J. 
D., Cheyette, B. N., Simon, M. I., and Lester, H. A. (2005) D2 dopamine receptors 
colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and 
RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. Journal of 
Neuroscience 25, 2157-2165 
366. Wang, J., Tu, Y., Woodson, J., Song, X., and Ross, E. M. (1997) A GTPase-activating 
Protein for the G Protein Gαz: IDENTIFICATION, PURIFICATION, AND MECHANISM OF 
ACTION. Journal of Biological Chemistry 272, 5732-5740 
367. Mao, H., Zhao, Q., Daigle, M., Ghahremani, M. H., Chidiac, P., and Albert, P. R. (2004) 
RGS17/RGSZ2, a Novel Regulator of Gi/o, Gz, and Gq Signaling. Journal of Biological 
Chemistry 279, 26314-26322 
368. De Vries, L., Mousli, M., Wurmser, A., and Farquhar, M. G. (1995) GAIP, a protein that 
specifically interacts with the trimeric G protein G alpha i3, is a member of a protein family 
with a highly conserved core domain. Proceedings of the National Academy of Sciences 
92, 11916-11920 
369. De Vries, L., Elenko, E., Hubler, L., Jones, T. L. Z., and Farquhar, M. G. (1996) GAIP is 
membrane-anchored by palmitoylation and interacts with the activated (GTP-bound) form of 
Gα<sub>i</sub> subunits. Proceedings of the National Academy of Sciences 93, 15203-
15208 
370. Jeong, S.-W., and Ikeda, S. R. (1998) G Protein α Subunit Gαz Couples Neurotransmitter 
Receptors to Ion Channels in Sympathetic Neurons. Neuron 21, 1201-1212 
371. Doi, M., Murai, I., Kunisue, S., Setsu, G., Uchio, N., Tanaka, R., Kobayashi, S., Shimatani, 
H., Hayashi, H., Chao, H.-W., Nakagawa, Y., Takahashi, Y., Hotta, Y., Yasunaga, J.-i., 
Matsuoka, M., Hastings, M. H., Kiyonari, H., and Okamura, H. (2016) Gpr176 is a Gz-linked 
orphan G-protein-coupled receptor that sets the pace of circadian behaviour. Nature 
Communications 7, 10583 
372. Goto, K., Doi, M., Wang, T., Kunisue, S., Murai, I., and Okamura, H. (2017) G-protein-
coupled receptor signaling through Gpr176, Gz, and RGS16 tunes time in the center of the 
circadian clock [Review]. Endocrine Journal 64, 571-579 
373. Vancura, P., Abdelhadi, S., Csicsely, E., Baba, K., Tosini, G., Iuvone, P. M., and Spessert, 
R. (2017) Gnaz couples the circadian and dopaminergic system to G protein-mediated 
signaling in mouse photoreceptors. PloS one 12, e0187411 
374. Kelleher, K. L., Matthaei, K. I., Leck, K. J., and Hendry, I. A. (1998) Developmental 
expression of messenger RNA levels of the α subunit of the GTP-binding protein, Gz, in the 
mouse nervous system. Developmental brain research 107, 247-253 
375. Hinton, D., Blanks, J., Fong, H., Casey, P., Hildebrandt, E., and Simons, M. (1990) Novel 
localization of a G protein, Gz-alpha, in neurons of brain and retina. The Journal of 
Neuroscience 10, 2763-2770 
376. Hendry, I. A., Johanson, S. O., and Heydon, K. (1995) Retrograde axonal transport of the α 
subunit of the GTP-binding protein Gz to the nucleus of sensory neurons. Brain Research 
700, 157-163 
377. Crouch, M. F., Heydon, K., Garnaut, S. M., Milburn, P. J., and Hendry, I. A. (1994) 
Retrograde Axonal Transport of the α‐Subunit of the GTP‐binding Protein Gz in Mouse 
Sciatic Nerve: a Potential Pathway for Signal Transduction In Neurons. European Journal 
of Neuroscience 6, 626-631 
378. Wong, Y., Conklin, B., and Bourne, H. (1992) Gz-mediated hormonal inhibition of cyclic 






379. Curzon, P., and Decker, M. W. (1998) Effects of phencyclidne (PCP) and (+)MK-801 on 
sensorimotor gating in CD-1 mice. Progress in Neuro-Psychopharmacology and Biological 
Psychiatry 22, 129-146 
380. Serres, F., Li, Q., Garcia, F., Raap, D. K., Battaglia, G., Muma, N. A., and Van de Kar, L. D. 
(2000) Evidence that Gz-proteins couple to hypothalamic 5-HT1A receptors in vivo. Journal 
of Neuroscience 20, 3095-3103 
381. Garzón, J., Martínez-Peña, Y., and Sánchez-Blázquez, P. (1994) Dissimilar efficacy of 
opioids to produce μ-mediated analgesia: Role of Gx/z and G12 transducer proteins. Life 
Sciences 55, PL205-PL212 
382. Chan, A. S. L., Lai, F. P. L., Lo, R. K. H., Voyno-Yasenetskaya, T. A., Stanbridge, E. J., and 
Wong, Y. H. (2002) Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via 
pertussis toxin-sensitive and -insensitive G proteins. Cellular Signalling 14, 249-257 
383. Traynor, J. R., Clark, M. J., and Remmers, A. E. (2002) Relationship between Rate and 
Extent of G Protein Activation: Comparison between Full and Partial Opioid Agonists. 
Journal of Pharmacology and Experimental Therapeutics 300, 157-161 
384. Furness, S. G. B., Liang, Y.-L., Nowell, C. J., Halls, M. L., Wookey, P. J., Dal Maso, E., 
Inoue, A., Christopoulos, A., Wootten, D., and Sexton, P. M. (2016) Ligand-Dependent 
Modulation of G Protein Conformation Alters Drug Efficacy. Cell 167, 739-749.e711 
385. Nikolaev, V. O., Hoffmann, C., Bünemann, M., Lohse, M. J., and Vilardaga, J.-P. (2006) 
Molecular Basis of Partial Agonism at the Neurotransmitter α2A-Adrenergic Receptor and 
Gi-protein Heterotrimer. Journal of Biological Chemistry 281, 24506-24511 
386. Barr, A. J., Brass, L. F., and Manning, D. R. (1997) Reconstitution of Receptors and GTP-
binding Regulatory Proteins (G Proteins) in Sf9 Cells: A DIRECT EVALUATION OF 
SELECTIVITY IN RECEPTOR·;G PROTEIN COUPLING. Journal of Biological Chemistry 
272, 2223-2229 
387. Northup, J. K., Sternweis, P. C., Smigel, M. D., Schleifer, L. S., Ross, E. M., and Gilman, A. 
G. (1980) Purification of the regulatory component of adenylate cyclase. Proceedings of the 
National Academy of Sciences 77, 6516-6520 
388. Taylor, S. J., Smith, J. A., and Exton, J. H. (1990) Purification from bovine liver membranes 
of a guanine nucleotide-dependent activator of phosphoinositide-specific phospholipase C. 
Immunologic identification as a novel G-protein alpha subunit. Journal of Biological 
Chemistry 265, 17150-17156 
389. Hescheler, J., Rosenthal, W., Trautwein, W., and Schultz, G. (1987) The GTP-binding 
protein, Go9 regulates neuronal calcium channels. Nature 325, 445 
390. Lee, E., Taussig, R., and Gilman, A. G. (1992) The G226A mutant of Gs alpha highlights 
the requirement for dissociation of G protein subunits. Journal of Biological Chemistry 267, 
1212-1218 
391. Buhl, A. M., Johnson, N. L., Dhanasekaran, N., and Johnson, G. L. (1995) Gα12 and Gα13 
stimulate Rho-dependent stress fiber formation and focal adhesion assembly. Journal of 
Biological Chemistry 270, 24631-24634 
392. Fong, H., Yoshimoto, K. K., Eversole-Cire, P., and Simon, M. I. (1988) Identification of a 
GTP-binding protein alpha subunit that lacks an apparent ADP-ribosylation site for 
pertussis toxin. Proceedings of the National Academy of Sciences 85, 3066-3070 
393. Matsuoka, M., Itoh, H., Kozasa, T., and Kaziro, Y. (1988) Sequence analysis of cDNA and 
genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding 
regulatory protein alpha subunit. Proceedings of the National Academy of Sciences 85, 
5384-5388 
394. Strathmann, M., Wilkie, T. M., and Simon, M. I. (1989) Diversity of the G-protein family: 
sequences from five additional alpha subunits in the mouse. Proceedings of the National 
Academy of Sciences 86, 7407-7409 
395. Strathmann, M., and Simon, M. I. (1990) G protein diversity: a distinct class of alpha 
subunits is present in vertebrates and invertebrates. Proceedings of the National Academy 






396. Kimple, M. E., Joseph, J. W., Bailey, C. L., Fueger, P. T., Hendry, I. A., Newgard, C. B., 
and Casey, P. J. (2008) Gαz negatively regulates insulin secretion and glucose clearance. 
Journal of Biological Chemistry 283, 4560-4567 
397. Brill, A. L., Wisinski, J. A., Cadena, M. T., Thompson, M. F., Fenske, R. J., Brar, H. K., 
Schaid, M. D., Pasker, R. L., and Kimple, M. E. (2016) Synergy between Gαz deficiency 
and GLP-1 analog treatment in preserving functional β-cell mass in experimental diabetes. 
Molecular Endocrinology 30, 543-556 
398. Fenske, R. J., Cadena, M. T., Harenda, Q. E., Wienkes, H. N., Carbajal, K., Schaid, M. D., 
Laundre, E., Brill, A. L., Truchan, N. A., and Brar, H. (2017) The Inhibitory G Protein α-
Subunit, Gαz, Promotes Type 1 Diabetes-Like Pathophysiology in NOD Mice. 
Endocrinology 158, 1645-1658 
399. Ng, N. M., Littler, D. R., Paton, A. W., Le Nours, J., Rossjohn, J., Paton, J. C., and Beddoe, 
T. (2013) EcxAB is a founding member of a new family of metalloprotease AB5 toxins with 
a hybrid cholera-like B subunit. Structure 21, 2003-2013 
400. Endo, Y., Tsurugi, K., Yutsudo, T., Takeda, Y., Ogasawara, T., and Igarashi, K. (1988) Site 
of action of a Vero toxin (VT2) from Escherichia coli O157: H7 and of Shiga toxin on 
eukaryotic ribosomes: RNA N‐glycosidase activity of the toxins. European Journal of 
Biochemistry 171, 45-50 
401. Katada, T., and Ui, M. (1982) Direct modification of the membrane adenylate cyclase 
system by islet-activating protein due to ADP-ribosylation of a membrane protein. 
Proceedings of the National Academy of Sciences 79, 3129-3133 
402. Cassel, D., and Pfeuffer, T. (1978) Mechanism of cholera toxin action: Covalent 
modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. 
Proceedings of the National Academy of Sciences 75, 2669-2673 
403. Orth, J. H., Preuss, I., Fester, I., Schlosser, A., Wilson, B. A., and Aktories, K. (2009) 
Pasteurella multocida toxin activation of heterotrimeric G proteins by deamidation. 
Proceedings of the National Academy of Sciences 106, 7179-7184 
404. Katada, T., and Ui, M. (1982) ADP ribosylation of the specific membrane protein of C6 cells 
by islet-activating protein associated with modification of adenylate cyclase activity. Journal 
of Biological chemistry 257, 7210-7216 
405. Littler, D. R., Ang, S. Y., Moriel, D. G., Kocan, M., Kleifeld, O., Johnson, M. D., Tran, M. T., 
Paton, A. W., Paton, J. C., Summers, R. J., Schembri, M. A., Rossjohn, J., and Beddoe, T. 
(2017) Structure–function analyses of a pertussis-like toxin from pathogenic Escherichia 
coli reveal a distinct mechanism of inhibition of trimeric G-proteins. Journal of Biological 
Chemistry 292, 15143-15158 
406. Pedersen, M. H., Pham, J., Mancebo, H., Inoue, A., and Javitch, J. A. (2020) A novel 
luminescence-based β-arrestin membrane recruitment assay for unmodified GPCRs. 
bioRxiv  
407. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. 
C., and Ferrin, T. E. (2004) UCSF Chimera—a visualization system for exploratory 
research and analysis. Journal of computational chemistry 25, 1605-1612 
408. Bowin, C.-F., Inoue, A., and Schulte, G. (2019) WNT-3A–induced β-catenin signaling does 
not require signaling through heterotrimeric G proteins. Journal of Biological Chemistry 294, 
11677-11684 
409. Eden, R., Costall, B., Domeney, A., Gerrard, P., Harvey, C., Kelly, M., Naylor, R., Owen, D., 
and Wright, A. (1991) Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel 
dopamine D2 agonist. Pharmacology Biochemistry and Behavior 38, 147-154 
410. Hildebrandt, J., Hanoune, J., and Birnbaumer, L. (1982) Guanine nucleotide inhibition of 
cyc-S49 mouse lymphoma cell membrane adenylyl cyclase. Journal of Biological Chemistry 
257, 14723-14725 
411. Dearry, A., Gingrich, J. A., Falardeau, P., Fremeau Jr, R. T., Bates, M. D., and Caron, M. 
G. (1990) Molecular cloning and expression of the gene for a human D1 dopamine 






412. Zhou, Q.-Y., Grandy, D. K., Thambi, L., Kushner, J. A., Van Tol, H. H., Cone, R., Pribnow, 
D., Salon, J., Bunzow, J. R., and Civelli, O. (1990) Cloning and expression of human and 
rat Dt dopamine receptors. Nature 347, 76 
413. Seeman, P., and Niznik, H. (1988) Dopamine D1 receptor pharmacology. ISI Atlas Sci 
Pharmacol 2, 161-170 
414. Andersen, P. H., and Jansen, J. A. (1990) Dopamine receptor agonists: selectivity and 
dopamine D1 receptor efficacy. European Journal of Pharmacology: Molecular 
Pharmacology 188, 335-347 
415. Wu, T., Li, A., and Wang, H.-L. (1995) Neurotensin increases the cationic conductance of 
rat substantia nigra dopaminergic neurons through the inositol 1, 4, 5-trisphosphate-calcium 
pathway. Brain research 683, 242-250 
416. Wang, H.-L., and Wu, T. (1996) Gαq11 mediates neurotensin excitation of substantia nigra 
dopaminergic neurons. Molecular brain research 36, 29-36 
417. Besserer-Offroy, É., Brouillette, R. L., Lavenus, S., Froehlich, U., Brumwell, A., Murza, A., 
Longpré, J.-M., Marsault, É., Grandbois, M., and Sarret, P. (2017) The signaling signature 
of the neurotensin type 1 receptor with endogenous ligands. European journal of 
pharmacology 805, 1-13 
418. Vivaudou, M., Chan, K. W., Sui, J.-L., Jan, L. Y., Reuveny, E., and Logothetis, D. E. (1997) 
Probing the G-protein Regulation of GIRK1 and GIRK4, the Two Subunits of the KACh 
Channel, Using Functional Homomeric Mutants. Journal of Biological Chemistry 272, 
31553-31560 
419. Castro, M. G., McNamara, U., and Carbonetti, N. H. (2001) Expression, activity and 
cytotoxicity of pertussis toxin S1 subunit in transfected mammalian cells. Cellular 
microbiology 3, 45-54 
420. Shenoy, S. K., Drake, M. T., Nelson, C. D., Houtz, D. A., Xiao, K., Madabushi, S., Reiter, 
E., Premont, R. T., Lichtarge, O., and Lefkowitz, R. J. (2006) β-Arrestin-dependent, G 
protein-independent ERK1/2 activation by the β2 adrenergic receptor. Journal of Biological 
Chemistry 281, 1261-1273 
421. Quan, W., Kim, J.-H., Albert, P. R., Choi, H., and Kim, K.-M. (2008) Roles of G protein and 
β-arrestin in dopamine D2 receptor-mediated ERK activation. Biochemical and biophysical 
research communications 377, 705-709 
422. Hunton, D. L., Barnes, W. G., Kim, J., Ren, X.-R., Violin, J. D., Reiter, E., Milligan, G., 
Patel, D. D., and Lefkowitz, R. J. (2005) β-Arrestin 2-dependent angiotensin II type 1A 
receptor-mediated pathway of chemotaxis. Molecular pharmacology 67, 1229-1236 
423. Friedman, J., Babu, B., and Clark, R. B. (2002) β2-Adrenergic Receptor Lacking the Cyclic 
AMP-Dependent Protein Kinase Consensus Sites Fully Activates Extracellular Signal-
Regulated Kinase 1/2 in Human Embryonic Kidney 293 Cells: Lack of Evidence for Gs/Gi 
Switching. Molecular pharmacology 62, 1094-1102 
424. Wang, J., Hanada, K., Staus, D. P., Makara, M. A., Dahal, G. R., Chen, Q., Ahles, A., 
Engelhardt, S., and Rockman, H. A. (2017) Gα i is required for carvedilol-induced β 1 
adrenergic receptor β-arrestin biased signaling. Nature communications 8, 1706 
425. Nogueras-Ortiz, C., Roman-Vendrell, C., Mateo-Semidey, G. E., Liao, Y.-H., Kendall, D. A., 
and Yudowski, G. A. (2017) Retromer stops beta-arrestin 1–mediated signaling from 
internalized cannabinoid 2 receptors. Molecular biology of the cell 28, 3554-3561 
426. Grundmann, M., Merten, N., Malfacini, D., Inoue, A., Preis, P., Simon, K., Rüttiger, N., 
Ziegler, N., Benkel, T., and Schmitt, N. K. (2018) Lack of beta-arrestin signaling in the 
absence of active G proteins. Nature communications 9, 341 
427. Senogles, S. E. (1994) The D2 dopamine receptor isoforms signal through distinct Gi alpha 
proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. 
Journal of Biological Chemistry 269, 23120-23127 
428. Doi, M., Murai, I., Kunisue, S., Setsu, G., Uchio, N., Tanaka, R., Kobayashi, S., Shimatani, 
H., Hayashi, H., and Chao, H.-W. (2016) Gpr176 is a Gz-linked orphan G-protein-coupled 
receptor that sets the pace of circadian behaviour. Nature communications 7, 10583 
429. Reisine, T. (1990) Pertussis toxin in the analysis of receptor mechanisms. Biochemical 






430. Joshi, S. A., Fan, K. P., Ho, V. W., and Wong, Y. H. (1998) Chimeric Gαq mutants 
harboring the last five carboxy‐terminal residues of Gαi2 or Gαo are resistant to pertussis 
toxin‐catalyzed ADP‐ribosylation. FEBS letters 441, 67-70 
431. Bahia, D. S., Wise, A., Fanelli, F., Lee, M., Rees, S., and Milligan, G. (1998) Hydrophobicity 
of residue351 of the G protein Gi1α determines the extent of activation by the α2A-
adrenoceptor. Biochemistry 37, 11555-11562 
432. Rask-Andersen, M., Masuram, S., and Schiöth, H. B. (2014) The druggable genome: 
evaluation of drug targets in clinical trials suggests major shifts in molecular class and 
indication. Annual review of pharmacology and toxicology 54, 9-26 
433. Bonci, A., and Hopf, F. W. (2005) The dopamine D2 receptor: new surprises from an old 
friend. Neuron 47, 335-338 
434. Krasel, C., Vilardaga, J.-P., Bünemann, M., and Lohse, M. (2004) Kinetics of G-protein-
coupled receptor signalling and desensitization. Portland Press Ltd. 
435. Volavka, J. (2012) Clozapine is gold standard, but questions remain. International Journal 
of Neuropsychopharmacology 15, 1201-1204 
436. Mottola, D. M., Kilts, J. D., Lewis, M. M., Connery, H. S., Walker, Q. D., Jones, S. R., 
Booth, R. G., Hyslop, D. K., Piercey, M., and Wightman, R. M. (2002) Functional selectivity 
of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 
receptors linked to adenylate cyclase. Journal of Pharmacology and Experimental 
Therapeutics 301, 1166-1178 
437. Kilts, J. D., Connery, H. S., Arrington, E. G., Lewis, M. M., Lawler, C. P., Oxford, G. S., 
O'Malley, K. L., Todd, R. D., Blake, B. L., and Nichols, D. E. (2002) Functional selectivity of 
dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D 
cells and pituitary lactotrophs. Journal of Pharmacology and Experimental Therapeutics 
301, 1179-1189 
438. Urban, J. D., Vargas, G. A., Von Zastrow, M., and Mailman, R. B. (2007) Aripiprazole has 
functionally selective actions at dopamine D 2 receptor-mediated signaling pathways. 
Neuropsychopharmacology 32, 67 
439. Mailman, R. B. (2007) GPCR functional selectivity has therapeutic impact. Trends in 
pharmacological sciences 28, 390-396 
440. Tschammer, N., Bollinger, S., Kenakin, T., and Gmeiner, P. (2011) Histidine 6.55 is a major 
determinant of ligand-biased signaling in dopamine D2L receptor. Molecular pharmacology 
79, 575-585 
441. Conibear, A. E., and Kelly, E. (2019) A biased view of μ-opioid receptors? Molecular 
pharmacology 96, 542-549 
442. Wei, H., Ahn, S., Shenoy, S. K., Karnik, S. S., Hunyady, L., Luttrell, L. M., and Lefkowitz, R. 
J. (2003) Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II 
activation of extracellular signal-regulated kinases 1 and 2. Proceedings of the National 
Academy of Sciences 100, 10782-10787 
443. Saulière, A., Bellot, M., Paris, H., Denis, C., Finana, F., Hansen, J. T., Altié, M.-F., 
Seguelas, M.-H., Pathak, A., and Hansen, J. L. (2012) Deciphering biased-agonism 
complexity reveals a new active AT 1 receptor entity. Nature chemical biology 8, 622-630 
444. Herve, D., Levi-Strauss, M., Marey-Semper, I., Verney, C., Tassin, J., Glowinski, J., and 
Girault, J. (1993) G (olf) and Gs in rat basal ganglia: possible involvement of G (olf) in the 
coupling of dopamine D1 receptor with adenylyl cyclase. Journal of Neuroscience 13, 2237-
2248 
445. Taniguchi, M., Suzumura, K.-i., Nagai, K., Kawasaki, T., Saito, T., Takasaki, J., Suzuki, K.-
i., Fujita, S., and Tsukamoto, S.-i. (2003) Structure of YM-254890, a novel Gq/11 inhibitor 
from Chromobacterium sp. QS3666. Tetrahedron 59, 4533-4538 
446. Dai, S. A., Hu, Q., Gao, R., Lazar, A., Zhang, Z., von Zastrow, M., Suga, H., and Shokat, K. 






Molecular determinants of the intrinsic 
efficacy of the antipsychotic 
aripiprazole 
  






































































































































































































































Appendix 2: Distinct inactive 
conformations of the dopamine D2 and 
D3 receptors correspond to different 
extents of inverse agonism 
  




































































































































Appendix 2 – Distinct inactive conformations of the D2R and D3R 
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